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Analysis of Telomere Dynamics in Human Tissues
Boitelo Theresia Letsolo 
ABSTRACT
Human telomeres are DNA-protein structures that “cap” the chromosome 
termini. Once uncapped, telomeres can generate chromosome instability through 
breakage-fusion-bridge cycles, leading to large-scale genomic rearrangements 
such as non-reciprocal translocations [NRTs]; that typify human cancers.
High-resolution single-molecule analysis of telomere length and fusion in vitro 
has demonstrated that telomeres are subjected to mutational changes, which 
generate short telomeres that are capable of fusion. This knowledge of telomere 
dynamics in vitro was translated to human tissues in vivo.
Initially, the single-molecule telomere fusion technology was further developed 
to facilitate the detection of a broader range and potentially rare telomere fusion 
events. Subsequently, telomere length and fusion were investigated in normal 
and disease tissues including normal dermis, melanocytic naevi, Barrett’s 
metaplasia, normal oesophageal and gastric tissues. We have demonstrated that 
telomere dysfunction both in vitro and in vivo generated truncated telomeres that 
are capable of fusion. The molecular analysis of fusion events revealed that the 
fusion of critically short telomeres was accompanied by large deletion extending 
into the subtelomeric DNA up to 5.6kb; close to the limit of the assay and the 
presence of short patches of DNA sequence homology. Furthermore, complex 
fusion events that include fusion with interstitial non-telomeric loci, near sites 
implicated in skin cancer and other human cancers were detected.
In Barrett’s oesophagus, the metaplastic tissue displayed clonal growth 
characterised by very short homogenous telomere profiles compared to the 
adjacent normal tissue. Short telomeres and fusions were also detected in normal 
dermis and melanocytic naevi with evidence of clonal telomere fusion events. 
Such events can result in clonal expansion, which could confer selective 
advantage for other abnormalities that may drive neoplastic progression. These 
data are consistent with the view that telomere dysfunction in vivo may drive 
large-scale genomic instability of the type observed in early-stage neoplasia.
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1 Chapter 1: Introduction: Telomeres
1.1 The structure of the thesis
This thesis describes a detailed analysis of telomere dynamics and fusion in 
human tissues. This work required technology development to allow the 
detection of rare events, a large analysis of the spectrum of mutation that 
accompanies telomere fusion and the application of these assays for the analysis 
of both normal and diseased tissues in vivo.
The first part of the thesis [introductory chapter 1] includes the review of 
literature on telomeres in the context of mammals [including humans] with little 
reference to other organisms as required. Initially, the history of telomere biology 
research will be considered, after which the structure and function of telomeres, 
the consequence of telomere dysfunction and processes that affect telomere 
homeostasis will be discussed. Since telomeres are critical for maintaining 
genome integrity, the telomere length measurements are important in ageing, 
cancer and disease research. Thus, the final sections of this chapter will discuss 
the methods employed to determine telomere length and telomere-induced 
chromosome-instability. Finally, the aims of the project will be outlined.
The second part of the thesis (chapter 2) describes the equipment, materials and 
experimental procedures used. Whilst the third part of the thesis describes the 
technological improvement of the assays used during the study [Chapter 3]; 
analysis of telomere instability and fusion in human cells in vitro [chapter 4] and 
in vivo in human skin [Chapters 5] and premalignant Barrett’s oesophagus 
[Chapters 6]. Each result chapter is outlined such that it includes the brief 
introduction, the findings (results) and their implication (discussion).
Finally, chapter 7 summarises the main findings and discusses their implications. 
The possible limitations of the whole study are also considered and future 
research directions are suggested in this chapter.
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1.2 Brief history of telomere Biology
The importance of the natural chromosome ends, telomeres in maintaining 
genome integrity was first recognised by McClintock (1941) and Muller (1938) 
who independently defined telomeres as the functional ends of chromosomes that 
are distinct from X-ray-induced double-stranded breaks [reviewed in (Olovnikov 
1996; Bolzan and Bianchi 2006)].
In his experiments with fruit-fly, Drosophila melanogaster, Muller recognised 
that unlike internal double-stranded breaks, the natural chromosome ends had the 
protective cap against x-ray induced chromosome aberrations such as inversions, 
deletions and translocations [reviewed in (McKnight and Shippen 2004; Bolzan 
and Bianchi 2006). He later named the chromosome end “telomere” from two 
Greek words telos=Qnd and meros=part meaning end part [reviewed in (Bolzan 
and Bianchi 2006)]. During the same period, in her experiments with com (Zea 
Mays), Barbara McClintock discovered that unlike X-ray-induced chromosome 
breaks, natural chromosomes ends were concealed from fusing and forming 
dicentric chromosomes, and thus had “chromosome healing” properties 
(McClintock 1941).
About three decades later, the importance of telomeres in DNA replication and 
cell integrity was enhanced by the independent recognition of “end replication 
problem” [section 1.6] by Watson (Watson 1972) and Olovnikov (Olovnikov 
1973). They hypothesised that DNA polymerases failed to replicate the 3' ends of 
the chromosomes fully during semi-conservative replication. Consequently, the 
chromosomes shorten with each round of replication, a phenomenon called “end- 
replication” problem. The existence of a protective mechanism that prevents 
chromosome shortening was then postulated (Watson 1972). The link was also 
established between the “end-replication problem” and unlimited cell 
proliferation of cells in culture (Hayflick and Moorhead 1961; Olovnikov 1973).
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However, the solution to the “end-replication problem” remained a mystery until 
the discovery of telomeric repeat DNA (Blackburn and Gall 1978) and reverse 
transcriptase, telomerase [initially named telomere terminal transferase] in 
Tetrahymena thermophila (Greider and Blackburn 1985; Greider and Blackburn 
1987). The latter discovery was a major breakthrough in telomere biology and 
led to the trio; Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak 
being awarded the Nobel Prize in medicine in 2009 (Wolinsky 2010). 
Telomerase has since been discovered in other organisms including humans 
(Morin 1989).
Telomere biology has become an area of extensive research with a principal 
objective of understanding the function and structure of telomeres, and their role 
in important biological processes such as ageing, cancer and chronic diseases.
1.3 Telomeric DNA
In most eukaryotes, telomeres consist of tandem arrays of asymmetric double 
stranded short GC-rich repeats [reviewed in (Zakian 1989); Table 1.1], which 
end with a 3'-G-strand overhang (Makarov et al. 1997; McElligott and Wellinger 
1997). The exceptions to this general rule include telomeres of onion-related 
plants of the genus Allium, Drosophila and other dipterans. In the genus Allium, 
telomeres consist o f terminal 375bp satellite (Pich and Schubert 1998). Whilst in 
Drosophila and other dipterans, telomeres are composed of multiple copies of 
head-to-tail terminal arrays of non-LTR retro-transposable elements HeT-A and 
TART [(Biessmann et al. 1990a); also reviewed in (Mason et al. 2008)].
Apart from these exceptions, terminal repeats appear to be highly conserved such 
that telomeres in all vertebrates consist of simple sequence repeat motif, 
TTAGGG (Moyzis et al. 1988; Meyne et al. 1989). In addition, similar telomeric 
repeats occur among unrelated organisms, for instance, filamentous fungus, 
Aspergillus nidulans maintains short vertebrate-like TTAGGG repeats
3
Table 1.1 illustrates the different telomere repeats in different organisms
Organism Telomeric repeat References
Vertebrates (e.g Human) TTAGGG (Moyzis et al. 1988; Meyne et al. 1989)
Trypanosoma TTAGGG (Blackburn and Challoner 1984)
Tetrahymena, TTGGGG (Blackburn and Gall 1978)
Paramecium TTGGG(T/G) (Baroin et al. 1987)
Oxytricha, Euplotes TTTTGGGG (Klobutcher et al. 1981)
Plasmodium TTAGGG(T/C) (Ponzi et al. 1985)
Arabidopsis thaliana TTTAGGG (Richards and Ausubel 1988)
Chlamydomonas TTTTAGGG (Petracek et al. 1990)
Schizosaccharomyces pombe TTAC(A)(C)G(l-8) (Matsumoto et al. 1987)
Saccharomyces cerevisiae ( t g ),_6 t g 2_3 (Shampay et al. 1984; Wang and Zakian 1990)
Filamentous fungi, slime moulds TTAGGG (Forney et al. 1987; Schechtman 1990)
Candida albicans GGTGTACGGATGTCTAACTTCTT (McEachem and Hicks 1993)
Kluyveromyces lactis GGT GT ACGG ATTT GATT AGGT AT GT (McEachem and Blackburn 1994)
Caenorhabditis elegans TTAGGC (Wicky et al. 1996)
Bombyx mori TTAGG (Okazaki et al. 1993)
Ascaris lumbricoides TTAGGC (Muller etal. 1991)
4
Chapter 1: Introduction
(Bhattacharyya and Blackburn 1997) suggesting a common recent ancestry 
during eukaryotic evolution. However, telomeric repeats can vary in type and 
size, for example, telomeres of Saccharomyces cerevisiae consists of irregular 
repeats, (TG)i_6 TG2-3 (Wang and Zakian 1990). Furthermore, same chromosome 
within an individual can possess more than one type of telomere repeats as 
documented in Tetrahymena thermophila. in which micronuclear telomeres 
consist of internal G4T3 and external G4T2 (Kirk and Blackburn 1995).
1.3.1 Human telomeres
In human, telomeres consist of 9-25 kb of duplex non-coding TTAGGG tandem 
repeats in the germ-line and no more than several hundred nucleotides of single­
stranded 3' overhang [Figure 1.1; (Wright et al. 1997; Baird et al. 2006)]. The 
proximal region (0-3kb) is marked by interspersion of the canonical TTAGGG 
repeats, with telomere variants repeats such as TGAGGG (G-type), TCAGGG 
(C-type) and TTGGGG (J-type) among others [N-type; (Allshire et al. 1989; 
Varley et al. 2002)]. Whilst the distal region consists of a homogenous array of 
TTAGGG repeats (Allshire et al. 1989; Varley et al. 2002).
1.4 Telomeric Repeat-containing RNA (TERRA)
Until recently when two independent research groups reported that mammalian 
telomeres are transcribed into telomeric-repeat-containing RNA called TERRA 
or TelRNA (Azzalin et al. 2007; Schoeftner and Blasco 2008), telomeres were 
considered transcriptionally silent. Telomeres are transcribed by DNA-dependent 
RNA Pol II from multiple different sub-telomeric sites to generate heterogeneous 
lengths (lOObp to 9kb) of UUAGGG repeats with transcripts containing 
CCCUAA expressed at very low to undetectable levels (Schoeftner and Blasco
2008) in mammals, Zebrafish (Danio renio) and yeast (Luke et al. 2008; 
Schoeftner and Blasco 2008). However, it is not yet known if TERRA molecules 
are translated. However, TERRA molecules are found only in nuclear fractions 
but not in cytoplasm suggesting that they may not be translated.
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Figure 1.1 Telomere structure. An “open” linear structure of the chromosome termini. In humans, telomeres are composed of 
duplex TTAGGG repeats and several hundreds of TTAGGG overhang.
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The role of TERRA molecules in telomere structural stability (Deng et al. 
2009b), heterochromatin formation (Schoeftner and Blasco 2008) and telomerase 
regulation (Schoeftner and Blasco 2008) have been suggested. For instance, 
TERRA molecules interact with shelterin components TRF1/2 and their 
depletion induces telomere dysfunction characterised by increased frequency of 
telomere free ends, telomere doublets, telomere double minutes, chromatid 
duplications and 53BP1/ yH2 AX-associated telomere foci without significant 
telomere length changes (Deng et al. 2009b), indicating loss of telomere capping 
function. In addition, TERRA molecules have been reported to form G- 
quadruplex structures with telomeric DNA (Xu et al. 2008; Randall and Griffith 
2009).
In support of their role in telomerase regulation, TERRA containing oligo­
nucleotides hybridise to the catalytic subunit of telomerase in vitro thus inhibit 
telomerase activity (Schoeftner and Blasco 2008). Whilst the role of TERRA in 
heterochromatin formation is supported by the observation that TERRA 
associates with several heterochromatin-associated proteins, including methyl 
CpG binding protein (MeCP2) and heterochromatin protein 1 (HP1) at telomeres 
(Schoeftner and Blasco 2008; Deng et al. 2009b). TERRA also accumulates at 
the vicinity o f inactivated X-chromosome in female mouse cells (Schoeftner and 
Blasco 2008).
TERRA levels are regulated by several mechanisms, including developmental 
stage, cellular localisation and differentiation, telomere length and telomeric 
chromatin (Schoeftner and Blasco 2008; Caslini et al. 2009). For instance, 
TERRA localises to telomeres at different phases of the cell cycle, being 
detectable at telomeres during interphase and metaphase (Azzalin and Lingner 
2007; Azzalin et al. 2007). In addition, differential expression of TERRA is 
limited to adult cells in mice such that highest levels are detected in thymus, 
kidney, spleen and undetectable in embryonic mouse cells (Schoeftner and 
Blasco 2008). Furthermore, levels of TERRA are directly correlated with
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telomere length such that cells with longer telomeres express high levels of 
TERRA. Similarly, cells from laboratory mice exhibit higher levels of TERRA 
compared to human cells (Schoeftner and Blasco 2008). Likewise, diminished 
TERRA levels have been reported in ageing fibroblasts with shortened telomere 
repeat tracts (Caslini et al. 2009), further implicating direct correlation between 
telomere length and levels of TERRA molecules at telomeres. On the contrary, 
human cells derived from ICF syndrome patients exhibit elevated TERRA levels 
and shortened telomeres suggesting that TERRA expression cannot be simply 
correlated with telomere length (Yehezkel et al. 2008; Schoeftner and Blasco 
2009; Deng et al. in press).
1.5 Telomere length
The length of the telomere repeat arrays is not precise and varies considerably 
among species (Zakian 1995), in similar organisms as well as in different cells of 
the same organism (Schmitt et al. 1994; Londono-Vallejo et al. 2001; Baird et al. 
2003; Graakjaer et al. 2004; Londono-Vallejo 2004; Graakjaer et al. 2006b). For 
instance in humans, telomeres vary between 9-25kb in germ-line (Moyzis et al. 
1988; Baird et al. 2006) and are much shorter in somatic cells depending on the 
tissue type, age and replicative history (Lindsey et al. 1991). However, in cancer 
cells telomeres can extend beyond 20kb depending on the telomere maintenance 
mechanism employed (Schmitt et al. 1994). For example, long telomeres 
(70.2kb) have been reported in cells maintaining their telomeres through 
telomerase-independent recombination-based mechanisms collectively known as 
alternative lengthening of telomeres (Cesare and Griffith 2004).
In contrast, laboratory mice, Mus Musculus have very long telomeres exceeding 
50kb (Kipling and Cooke 1990) while wild-type mice have shorter telomeres 
(Zijlmans et al. 1997). In other organisms, telomeres are much shorter being as 
short as 20 base pairs in Oxytrichia (Klobutcher et al. 1981) and a few hundred 
bases long in Saccharomyces cerevisiae (Wang and Zakian 1990; Zakian 1995).
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In addition to being species-specific, telomere lengths vary greatly among 
telomeres within the same cell as well as among alleles of the same telomere 
(Lansdorp et al. 1996; Londono-Vallejo et al. 2001; Baird et al. 2003; Londono- 
Vallejo 2004; Britt-Compton et al. 2006; Capper et al. 2007). However, specific 
telomeres display similar length profiles in different cells of the same individual 
but varies between individuals (de Lange et al. 1990). For instance, different 
studies have demonstrated that telomeres on both arms of chromosome 17 are 
among the shortest in human cells while 4q telomere is among the longest of 
human telomeres (Martens et al. 1998; Pemer et al. 2003; Zou et al. 2004b).
The telomere length is paternally inherited (Nordfjall et al. 2005; Njajou et al. 
2007). In support of this, it has been reported that paternal age is an important 
determinant of telomere length in offspring, such that offspring of older fathers 
have longer telomeres, consistent with the notion that telomere length of human 
sperm cells increases with donor age (Allsopp et al. 1992; Unryn et al. 2005; De 
Meyer et al. 2007). In addition, the relative telomere length is established in the 
zygote and maintained throughout life (Graakjaer et al. 2004; Graakjaer et al. 
2006a; Graakjaer et al. 2006b) suggesting that telomere length detected in any 
tissue will be reflective of the length at birth, assuming similar telomere 
dynamics at all telomeres.
Moreover, variation in telomere length according to tissue and age of an 
individual has been reported (Takubo et al. 2002). For instance, the telomere 
length is typically 2-8kb in peripheral blood (Valdes et al. 2005) while in germ- 
line, it can extend beyond 20kb (Baird et al. 2006). In addition, the age- 
dependent decline in telomere length has been reported to occur more rapidly in 
peripheral blood lymphocytes (53bp/year) than in granulocytes (Hoffmann et al.
2009). The variation in telomere length among the different tissues from the 
same individual has been demonstrated previously (Friedrich et al. 2000; Takubo 
et al. 2002). For instance, shorter telomeres were reported in leukocytes (6.5kb) 
than in skin (7.8kb) and synovial tissues [7.9kb; (Friedrich et al. 2000)], whilst
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longer telomeres (>10kb) were reported in cerebral cortex, myocardium, liver, renal 
cortex and spleen regardless of the age of the subject (Takubo et al. 2002).
1.6 Telomere functions
Telomeres have a number of functions, which are dependent on both the telomere 
length as well as the telomere structure (Blackburn 2001).
1.6.1 Provide a solution to the “end-replication problem”
The unidirectional semi-conservative replication nature and inability of the DNA 
polymerases to initiate replication without a need for RNA pose a problem for 
replication of chromosome termini during lagging strand synthesis. Due to these 
features, the parental lagging strand of the newly synthesised molecule is not 
fully replicated such that when the terminal primer is removed the gap is left 
which is prone to nucleolytic processing and cleavage. Hence there is a loss of 
few nucleotides with each round of replication (Watson 1972). This phenomenon 
has been termed “end-replication problem” [(Olovnikov 1973); Figure 1.2]. 
Eukaryotes have evolved different mechanisms to compensate for the loss of 
DNA upon replication, some of which are discussed below.
1.6.1.1 Telomerase
Unlike in somatic cells where the telomeres erode as a function of time, in 
rapidly proliferating cells such as germ-line, lymphocytes, basal layer of the 
epidermis, some adult stem cells and most cancer cells, telomere attrition is 
counteracted by a reverse transcriptase telomerase, that de novo adds telomeric 
repeats to chromosome ends (Kim et al. 1994). Telomerase is fully discussed in 
section 1.11.
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Figure 1.2. Illustrating the “end-replication” problem. DNA polymerases require an RNA 
primer to intiate DNA synthesis. When the 5' terminal primer is removed from the lagging 
strand, a single-stranded DNA molecule is left. A. Outline of the double strand (ds) DNA 
prior to replication. B. Semi-conservative replication showing the direction of the replication 
fork, the leading strand (black arrow) and okazaki fragments of lagging strand synthesis (blue 
arrows). Primers are denoted by red lines at the start of newly synthesised strand. C. dsDNA 
with 3' single-stranded overhang on the parental strand of the lagging strand synthesis (black) 
as the newly synthesised strand is shorter (blue). D. Shortened chromosome termini after
replication of the newly synthesised strand.
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1.6.1.2 Recombination
The budding yeast Saccharomyces cerevesiae maintain telomeres by telomerase 
(Zakian 1989). However, in the absence of telomerase, yeast telomeres become 
critically short and most cells die but a few that survive maintain their telomeres 
through a recombination-based mechanism. The survivors fall into two types; 
Type I survivors maintain short telomeres but amplify their sub-telomeric Y' 
elements through Rad52 and Rad51 dependent pathways (Lundblad and 
Blackburn 1993; Le et al. 1999), while type II survivors maintain heterogeneous 
length of telomeres via Rad52 and Rad50 dependent pathway (Le et al. 1999; 
Lundblad 2002).
Similarly, human cancer cell lines and some tumours that do not express 
telomerase, maintain their telomeres through recombination-based mechanisms 
called Alternative lengthening of telomeres [ALT; (Bryan et al. 1997a; Henson et 
al. 2002)]. ALT is discussed in section 1.11. In addition, the recombination-based 
telomere maintenance mechanism have also been reported in mosquitoes (Roth et 
al. 1997).
1.6.1.3 T ransposition
Most insects maintain their telomeres by telomerase, however dipterans have lost 
the telomerase system. In Drosophila and related dipterans, progressive telomere 
erosion is counteracted by transpositions of head-to-tail arrays of non-LTR retro- 
transposable elements HeT-A and TART thereby forming a heterochromatin that 
protects the telomeres from degradation [(Biessmann et al. 1990b); also reviewed 
in (Mason et al. 2008)].
1.6.2 Telomere capping and Chromosome stability
The primary function of telomeres is to preserve the integrity of the 
chromosomes, prevent chromosome instability and allow cell cycle progression 
(McEachem et al. 2000b; Blackburn 2001). This telomere capping function
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depends largely on the minimum telomere length and integrity of multi-protein 
complex, “Shelterin’’ or “telosome” which together form a scaffold in which the 
end is sequestered within the duplex DNA. In this higher-order conformation, 
telomeres (unlike internal DSBs) are protected from nucleolytic attack, end-to- 
end fusions and illegitimate DNA damage checkpoints and repair mechanisms 
such as homologous recombination and non-homologous end-joining [(Griffith et 
al. 1999; de Lange 2005; Denchi and de Lange 2007); reviewed in (McEachem 
et al. 2000a)]. Telomeres are believed to be capped at all the times except during 
cell division (Smith and Blackburn 1999) indicating that the integrity of the 
telomere cap is essential for cell survival. In support of this, defects in shelterin 
component, TRF2 leads to rapid loss of overhang, cell cycle arrest, apoptosis and 
increased frequency of end-to-end chromosome fusions (van Steensel et al.
1998).
1.6.3 Chromosome healing
As early as the 1940s, Barbara McClintock demonstrated that telomeres have a 
potential of preventing the Breakage-Fusion-Bridging cycles thus healing 
chromosomes (McClintock 1941). It was only after the discovery of telomerase, 
that it became apparent that telomerase was capable of de novo addition of 
telomeric repeats to broken chromosome and maintain chromosome stability, a 
process termed “chromosome healing” (Mumane and Yu 1993; Flint et al. 1994; 
Melek and Shippen 1996; Slijepcevic and Bryant 1998). Direct addition of 
telomere repeats to broken chromosomes has been reported in humans (Flint et 
al. 1994; Wong et al. 1997; Fouladi et al. 2000; Varley et al. 2000) and mouse 
embryonic stem cells (Sprung et al. 1999; Gao et al. 2008). For example in 
human diseases such a-thalassaemia (16p) and mental retardation syndrome 
(22q), the breakage point within the sub-telomeric DNA (about 50kb-2Mb 
proximal to the telomeres) is stabilised by direct addition of telomeric DNA to 
the breakage point (Wilkie et al. 1990; Lamb et al. 1993). Similarly, de novo 
addition of telomere repeats to sites similar to those found at terminal deletion
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resulting in a-thalassaemia have been reported in extracts from human cancer 
cells (Morin 1991).
1.6.4 Telomeres and chromosome segregation
Telomeres have also been implicated in chromosome segregation. In support of 
this, telomeres cluster close to the inner nuclear envelope during meiotic 
prophase I in various organisms, suggesting a possible role of telomeres in 
facilitating homologous chromosome pairing during meiosis (de Lange 1992; 
Morin 1997; Harper et al. 2004). In addition, recent studies in human cells have 
suggested that degradation of a telomere-specific cohesion complex is necessary 
for sister telomere segregation during mitosis (Dynek and Smith 2004). 
Furthermore, the isoform of TIN2 (TIN2L), a central player in “shelterin’’ has 
been found to interact with the nuclear matrix suggesting the role of TIN2 in 
tethering the telomeres to nuclear matrix (Kaminker et al. 2009).
1.6.5 Telomere position effect
By virtue of being heterochromatic, telomeres have the potential to influence the 
transcription of genes located in their proximity by silencing them (Zakian 1995; 
Urquidi et al. 2000); the phenomenon termed telomere position effect (TPE). 
TPE is extensively documented in yeast (Tham and Zakian 2002) but it is not as 
dramatic in human cells (Baur et al. 2001; Baur et al. 2004). In S.cerevisiae, 
repressor activator protein 1 (Rapl) interacts with silent information regulator 
(Sir) 2, 3 and 4 proteins and deacetylate histone 3 and 4 thus facilitating the 
spread of telomeric heterochromatin. TPE is stronger closer to the telomeres but 
can extend extensively into the sub-telomere, such that genes located 10-40 kb 
upstream of telomeres are silenced in S. cerevisiae (Kyrion et al. 1993; Halme et 
al. 2004).
Consistent with being heterochromatic (Tommerup et al. 1994), human and 
mouse sub-telomeres are heavily methylated (Steinert et al. 2004) through the
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action of the DNA methyltransferases DNMT1, DNMT3a and DNMT3b (Brock 
et al. 1999; Gonzalo et al. 2006). In addition, the heterochromatin proteins HP1 
alpha and beta (Garcia-Cao et al. 2004) associate with telomeres. The sub- 
telomeric and telomeric heterochromatin is believed to be regulated by telomere 
length (Garcia-Cao et al. 2004); such that loss of telomeric repeats in telomerase- 
deficient (Terc_/_) mice leads to continuous loss of H3K9me3, H4K20me3 and 
HP1, significant reduction in sub-telomeric DNA methylation as well as increase 
in histone H3 and H4 acetylation at telomeres and sub-telomeres (Benetti et al.
2007).
1.7 Telomere structure
At least three factors are necessary for telomere protection: minimum telomere 
length, the integrity of the G-strand overhang and high-order telomere structure t- 
loop with associated telomere binding proteins (Griffith et al. 1999; Blasco 
2002).
1.7.1 Telomere-loop (t-loop)
Mammalian telomeres terminate with a 3' overhang, which is believed to loop 
back and invade the proximal part of the telomere to form a high order, lariat 
structure called the telomere loop [t-loop; Figure 1.3; (Griffith et al. 1999; 
Stansel et al. 2001; de Lange 2004)]. In this structure, the 3' overhang displaces 
the G-strand and base pairs with the C-strand thus creating a displacement loop 
[D-loop; Figure 1.3; (Griffith et al. 1999)]. The t-loop is stabilised by telomeric 
proteins especially TRF2 which binds at the t-loop junctions (Griffith et al.
1999). In addition to being a high order end-protection structure, t-loop might 
restrict access of telomerase to telomeres, thus prevents unnecessary telomere 
elongation.
The t-loops of varying size have also been observed in other organisms including 
trypanosomes (0.3kb), ciliates, plants (50kb in peas), C.elegans and some yeasts
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Telomere Variants
5'
TIN2
NBS1  nc,UJU
POT1&
MRE11 ^ --------  t p p i
Tankyrase 1
TRF1 homodimer 
Tankyrase 2
PINX
TIN2
Figure 1.3 Telomere-Ioop. The simplified telomere structure in a t-loop “closed” 
conformation with telomere binding proteins bound at telomeres. The 3' overhang 
has looped back and invaded the proximal telomere to form the t-loop structure. The 
t-loop is stabilised by a number of protein complexes. Two related factors, TRF1 and 
TRF2 bind duplex TTAGGG and recruit the other four subunits to the shelterin 
complex; single-strand binding protein, POT1 which is linked to the TRF1 and 
TRF2/RAP1 sub-complex by TIN2, TPPI (de Lange 2005a; Palm and de Lange
2008)]. Other proteins that bind on TRF2 such as BLM and WRN are not shown.
RAPl
TRF2 hom odim er
Rad50
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[excluding S. cerevisiae; (Munoz-Jordan et al. 2001; Cesare et al. 2003; de Lange 
2004; Cesare et al. 2008; Cesare and Reddel 2008)].
1.7.2 G-strand over hang
The 3' overhang which is several hundred of nucleotides long plays an important 
role in telomere structure and protection (Wright et al. 1997). It prevents 
formation of end-to-end fusions by sequestering the ends of the telomeres from 
DNA repair machinery, through formation of a t-loop (Griffith 1999). Evidence 
for the importance of overhang in preventing telomere fusions comes from the 
increased frequency of the fusions in the presence of any mutations that lead to 
overhang loss such as inhibition of TRF2 (van Steensel et al. 1998).
The overhang also forms a platform for single strand telomere binding proteins; 
TEBP in ciliates (Price and Cech 1987), Cdcl3p in S-cerevisiae (Lin and Zakian 
1996; Chandra et al. 2001) and POT1 in human, mouse, chicken and plants 
(Baumann and Cech 2001; Baumann et al. 2002; Wei and Price 2004).
1.8 Telomere associated proteins (shelterin)
The telomeric DNA forms a platform for binding of a multi-protein complex 
called “Shelterin” (de Lange 2005) or telosome (Liu et al. 2004a). These proteins 
play a role in structural capping of telomeres in which they shield the 
chromosome ends from DNA repair machinery (Karlseder et al. 2004; Celli and 
de Lange 2005; Denchi and de Lange 2007). They are also involved in telomere 
length regulation through either direct interaction with telomerase or through 
remodelling telomeric chromatin (Smogorzewska and de Lange 2004).
The shelterin complex consists of six factors; three [TRF1, TRF2, POT1] bind 
directly to the telomere DNA and recruit three others [RAP1 TIN2, TPPI] which 
links the shelterin into one complex (de Lange 2005).
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1.8.1 Telomere Repeat binding Factor 1 (TRF1)
TRFl is a small dimeric protein which consists of three domains; C-terminal 
DNA binding (Bianchi et al. 1999; Court et al. 2005; Hanaoka et al. 2005), 
dimerisation/TRF homology (TRFH) and the acidic N-terminal protein 
interacting domains (Smith and de Lange 1997). It is considered to be a principal 
negative regulator of telomere length as its over-expression induces gradual 
telomere shortening to a new telomere length range while inhibition of TRFl 
binding through expression of the dominant negative form (TRF166_439; lacks 
DNA binding domain) results in telomerase-mediated telomere elongation (van 
Steensel and de Lange 1997; Smogorzewska et al. 2000). TRFl interacts with a 
number of proteins (through its acidic N-terminal domain), including TIN2, 
tankyrasesl/2 and Pinxl, all of which control its telomere length regulatory role 
(Smogorzewska and de Lange 2004). In addition to its telomere length regulation 
function, TRFl may play a role in telomere protection by stabilising the 
“shelterin complex.” In fact TRFl can bend telomeric DNA (Bianchi et al. 1997; 
Griffith et al. 1998), and disruption of TRFl leads to decrease in TRF2 at 
telomeres (Iwano et al. 2004) and an increased association of remaining TRF2 
with TIN2/TPP1 (Houghtaling et al. 2004). TRFl may also be involved in cell 
survival as it has been demonstrated that its deletion in mice was lethal 
(Karlseder et al. 2003). In addition, TRFl is required for proper replication of 
telomeres (Sfeir et al. 2009).
1.8.2 Telomere Repeat binding Factor 2 (TRF2)
The duplex-binding TRF2 is a close relative of TRFl with similar architecture 
except that its N-terminal domain is guanine and arginine-rich (GAR) and hence 
was formerly called the N-terminal basic domain (Broccoli et al. 1997). Like 
TRFl, it binds DNA as homo-dimers and never hetero-dimerises with TRFl. It 
plays an important role in telomere “capping” and thus it is often referred to as a 
principal telomere “capping” protein. TRF2 has several properties that can 
potentially enable it to remodel TTAGGG-like containing DNA into t-loops in
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vitro (Griffith et al. 1999; Stansel et al. 2001). Its multimeric binding ability can 
promote unwinding and strand invasion (Amiard et al. 2007). Whilst, its GAR 
domain has sequence-independent affinity for DNA junctions including Holliday 
junctions. Evidently, the mutant TRF2 without this GAR domain results in 
increased frequency of telomeric t-loop size circular DNA, an observation 
consistent with processing of the junction (Wang et al. 2004). In addition, TRF2 
has been demonstrated to remodel the telomeric DNA into Holliday junctions 
and protects telomeres from DNA repair Holliday junction resolving activities 
(Poulet et al. 2009).
In support of its role in telomere capping, loss of TRF2 function destabilises the 
chromosomes, induces rapid loss of 3' single-strand G-overhang, senescence or 
apoptosis and increased frequency of NHEJ-dependent chromosome end-to-end 
fusions (van Steensel et al. 1998; Karlseder et al. 1999; Smogorzewska et al. 
2000; Smogorzewska et al. 2002; Zhu et al. 2003; Celli and de Lange 2005).
The role of TRF2 at telomeres is controlled by interacting factors, some of which 
are involved in DNA damage response and repair pathways (Zhu et al. 2000; 
Karlseder et al. 2004; de Lange 2005; Gomez et al. 2006; Lenain et al. 2006; van 
Overbeek and de Lange 2006; Buscemi et al. 2009). These factors form a sub­
complex that protects the 3' overhang from degradation and DNA repair 
activities thus preventing end-to-end fusions (Liu et al. 2004a; Ye et al. 2004a; de 
Lange 2005; Bae and Baumann 2007; Sarthy et al. 2009).
1.8.3 Repressor/Activator Proteinl (Rapl)
The human Rapl is a telomere-specific protein and a distant homologue of the 
budding yeast scRaplp (Longtine et al. 1989). Unlike its yeast orthologue, 
human Rapl lacks a DNA binding domain and therefore its localisation and 
recruitment to the telomeres is TRF2-dependent (Li and de Lange 2003). In 
support of this, hRapl has been isolated in a complex with TRF2 and other TRF2
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interacting proteins [Rad50, MRE11, ku70/86, PARP1; (O'Connor et al. 2004)]. 
Recently, it has been reported that human Rapl may protect telomeres from 
illegitimate non-homologous end-joining through interaction with TRF2, 
suggesting that the TRF2 recruitment of Rapl may be essential for preventing the 
type of chromosome fusions that occur in the absence of functional TRF2 at 
telomeres (Bae and Baumann 2007; Sarthy et al. 2009). However, interaction of 
hRapl and other TRF2-binding factors can be independent of its interaction with 
TRF2 (O'Connor et al. 2004).
hRapl acts as a negative regulator of telomere length through 1:1 interaction 
with TRF2 (Li and de Lange 2003). Evidently, over-expression of hRapl and its 
mutants [hRap^11 AM, hRaplACTand hRaplABR ACT] results in telomere elongation 
(Li et al. 2000; Li and de Lange 2003).
1.8.4 TRFl and TRF2-interacting protein 2 (TIN2)
TIN2 is a small protein that interacts with TRFl (Kim et al. 1999), TRF2 (Liu et 
al. 2004a; Ye et al. 2004a) and TPPI [(Xin et al. 2007) also called PTOP (Liu et 
al. 2004b), PIP1 (Ye et al. 2004b) or TINT1 (Houghtaling et al. 2004)]. It forms 
a bridge that brings the duplex binding and single-stranded binding components 
of the shelterin together (Liu et al. 2004a; Ye et al. 2004a; de Lange 2005). i.e. 
TIN2’s interaction with TPPI, TRF2 and TRFl brings POT 1/TPPI, TRFl and 
TRF2 complexes together (O'Connor et al. 2006). Although TIN2 can interact 
with three subunits of the shelterin, it is not known whether it is permanently 
bound to them or it switches between TRF1-TRF2 complex andI or TPPI-POT 1 
complex (Palm and de Lange 2008).
TIN2/TRF2 interactions stimulate telomere DNA interactions in vitro suggesting 
the role of the complex in modulating a tertiary telomeric structure (Kim et al. 
2003) and hence telomere capping (Kim et al. 2008). Whilst its interaction with 
TRFl stabilises TRFl-tankyrase interaction and protects TRFl from being
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ribosylated by tankyrases in vitro (Ye and de Lange 2004). Thus TIN2 plays a 
role in telomere capping and regulation of telomerase-mediated elongation 
(Smogorzewska and de Lange 2004; Ye and de Lange 2004).
1.8.5 Protection of Telomeres 1 (POT1)
POTl is a single-stranded DNA binding protein that was identified through its 
sequence similarity to ciliate TEBP subunits (Baumann and Cech 2001). It is 
recruited to telomeres by TRFl complex (Ye et al. 2004b) and binds specifically 
to the terminal 5'-TAGGGTTAG-3' sequence through its N-terminus folds (de 
Lange 2005). The binding of POTl to single-stranded 3' overhang in vitro and in 
vivo blocks telomerase access to the telomeres (Loayza and De Lange 2003; Liu 
et al. 2004b; Wang et al. 2007a), thus it is a regulator of telomere length. In 
support of this, the expression of a mutant POTl without telomere binding site 
(Loayza and De Lange 2003) and the over-expression of wild-type POTl result 
in telomerase-dependent telomere elongation (Armbruster et al. 2004).
POTl can also associate with telomeres without direct binding to the telomeric 
DNA but through interaction with TRF2 (Yang et al. 2005) and TRFl (Loayza 
and De Lange 2003) sub-complexes. The deletion of the N-terminal DNA 
binding domain of POTl only affects its DNA binding ability and not its 
association with telomeres through interaction with TRFl complex (Loayza and 
De Lange 2003). Over-expression of POTl protects the loss of overhang 
generated when the dominant negative TRF2 mutant is expressed (Yang et al. 
2005). Together these findings indicate that POTl plays a role in telomere 
capping and telomere length regulation.
1.8.6 TPPI, TINT1, PIP1, PTOP1
It consists of three domains: centrally located POTl-interacting domain, C- 
terminus TIN2-interacting domain and the OB (oligonucleotide/ oligosaccharide 
binding) fold with which it interacts with telomerase (Liu et al. 2004b).
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TIN2/TPPrs interaction with TRFl and TRF2 recruits POTl to telomeres (Ye et 
al. 2004b; Kibe et al. 2009). In addition, TPPI-POTl interaction is important for 
sub-cellular localisation of POTl as well as stabilising POTl on telomeres (Liu 
et al. 2004b). Furthermore, POT1/TPP1 hetero-dimerisation regulates 
recruitment of POTl to telomeres and telomere length (Liu et al. 2004b). In 
support of this, depletion of TPPI through expression of TPPI mutants that lack 
POTl-interacting domain results in reduction or total loss of POTl from 
telomeres. Furthermore, impaired TPPI function or disruption of TPP 1/POT 1 
interaction leads to telomere deprotection (Liu et al. 2004b; Xin et al. 2007).
1.8.7 Shelterin associated proteins
1.8.7.1 Pin2/TRF1 interacting protein 1 (Pinxl)
Pinxl interacts with TRFl and its isoform Pin2 (Shen et al. 1997) but has extra- 
telomeric roles which include ensuring faithful chromosome segregation during 
mitosis, plausibly through its interaction with Pin2 (Li et al. 2009; Yuan et al.
2009). It is believed that it acts in trans to regulate telomerase-mediated 
elongation. In support of this, silencing of Pinxl in telomerase-positive human 
cancer cells impaired telomere length maintenance whilst over-expression or 
reduction leads to telomere shortening or elongation respectively (Zhou et al. 
2003; Zhang et al. 2009). Pinxl also plays a role in telomere length regulation 
through mediating accumulation of TRFl in the nucleolus and enhancing TR Fl’s 
binding affinity at the telomeres (Yoo et al. 2009). Moreover, Pinxl interacts 
with (Banik and Counter 2004) and inhibit telomerase activity directly (Lin and 
Blackburn 2004) through sequestering the catalytic subunit of telomerase in an 
inactive complex without telomerase RNA subunit (Zhou and Lu 2001; Zhou et 
al. 2003).
1.8.7.2 ATM
ATM kinases are phosphoinositide-3-kinase related DNA signalling proteins, 
which are mutated in ataxia telangiecstasia (AT), a rare, autosomal recessive
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inherited disease characterised by immunodeficiency, chromosomal instability, 
premature ageing, cancer predisposition, lack of radio-resistant DNA synthesis, 
cell cycle-checkpoints impairment and shortened telomeres [reviewed in 
(Rotman and Shiloh 1999; Kastan and Lim 2000; Barzilai et al. 2002). ATM 
plays a central role in the signalling pathways leading to p53 activation in 
response to DSBs, through direct binding and phosphorylation of p53 (Banin et 
al. 1998; Canman and Lim 1998). ATM and its relative ATR associate with 
telomeres (Takata et al. 2004; Verdun et al. 2005). Thus, ATR and ATM play a 
role in both telomere length maintenance and telomere capping. Evidently, 
ATM-defective cells show accelerated telomere shortening, high levels of end- 
to-end chromosome fusions and the presence of extra-chromosomal telomeric 
fragments and circles (Metcalfe et al. 1996; Hande et al. 2001; Pandita 2001; 
Pandita 2002; Karlseder et al. 2004).
1.8.7.3 Tankyrase 1 and 2 (TRFl-interacting Ankyrin 
Related ADP-ribose polymerase)
Tankyrases 1 and 2 are two related poly ADP-ribose polymerases (PARPS) 
which have the ability to form both homo and heterodimers. Like other 
multifunctional PARPs, they have diverse functions in different subcellular 
compartments such as the Golgi, nuclear pore complexes and centrosomes 
(Smith et al. 1998; Chi and Lodish 2000; Kaminker et al. 2001; Chang et al. 
2005).
They ADP-ribosylate TRFl in vitro and once ribosylated, T R Fl’s DNA binding 
ability is diminished (Smith et al. 1998; Chiang et al. 2006). Consequently, TRFl 
dissociates from telomeres after which it is then ubiquinated and degraded by 
proteosomes (Smith et al. 1998; Smith and de Lange 2000; Cook et al. 2002; 
Chang et al. 2003; Ye and de Lange 2004). Once TRFl has dissociated from the 
telomeres, telomerase can then elongate telomeres (Seimiya et al. 2004). Thus, 
tankyrases are positive regulators of telomere length as they regulate telomere 
length indirectly by altering levels of TRFl bound at telomeres in telomerase-
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positive cells in vivo and in vitro thereby allowing telomerase-mediated telomere 
elongation (Smith et al. 1998; Smith and de Lange 2000; Seimiya et al. 2004; 
Chiang et al. 2006). In contrast, tankyrase 1 knockdown by siRNA interference, 
results in telomere shortening (Donigian and de Lange 2007), thus further 
supporting the role of tankaryses in telomere length regulation.
Apart from TRFl-mediated telomere length regulation, PARP activity of 
tankyrases is required for dissolving sister chromatid cohesion at telomeres and 
for separating sister chromatid telomeres during mitosis, indicating the role of 
tankyrases in ensuring proper chromosome segregation (Dynek and Smith 2004).
1.8.7.4 PARP1 and 2
Poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and 2) are proteins involved in 
base excision repair (BER) where they ribosylate other proteins (Ame et al. 1999; 
Schreiber et al. 2002). PARP-1 ribosylates TRF2 and tethers it from telomeres 
and thus allows access by DNA repair machinery (Gomez et al. 2006), whilst 
PARP-2 binds to TRF2 with high affinity (Dantzer et al. 2004) suggesting the 
role of both PARPs in telomere capping. Evidently, deficiency of PARP-1 in 
mice leads to an increased frequency of telomere fusions, abundant chromosomal 
breaks and telomere erosion (d'Adda di Fagagna et al. 1999). Similarly, cells 
from mice defective in PARP-2 display higher frequencies of individual 
chromosomes without detectable telomeric sequences (Dantzer et al. 2004).
1.8.7.5 Bloom syndrome protein (BLM)
BLM is a 3'-5' RecQ DNA helicase required for maintaining genome stability 
and suppression of sister chromatid exchanges. It is mutated in Bloom Syndrome 
(BS), a rare recessive disorder associated with growth retardation, 
immunodeficiency and increased risk of malignancy at an early age (Ellis et al. 
1995; Karow et al. 1997).
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Like other RecQ proteins, BLM participates in several diverse processes such as 
DNA repair, replication and homologous recombination (Karow et al. 1997). At 
telomeres, BLM plays a role in telomere length regulation through interaction 
with TRF1, TRF2 and POT1, all of which regulate its DNA unwinding activity 
(Lillard-Wetherell et al. 2004; Opresko et al. 2005b). In ALT+ cells, BLM 
interacts with TRF2 and together with WRN and RPA unwind TRF2-prebound 
telomeric DNA (Opresko et al. 2002) thus resulting in an increased telomeric 
length suggesting its role in recombination-mediated telomere elongation 
(Stavropoulos et al. 2002; Lillard-Wetherell et al. 2004). However, in 
telomerase-positive cells, loss of BLM result in increased telomere length 
suggesting the role of BLM in inhibiting activity of telomerase at telomeres 
(Schawalder et al. 2003). Thus BLM may play a role in both telomerase- 
dependent and independent telomere elongation.
1.8.7.6 Werner syndrome protein (WRN)
WRN is a 3'-5' RecQ helicase and 3-5 ' exonuclease (Gray et al. 1997; Huang et 
al. 1998; Kitao et al. 1998) which is mutated in Werner syndrome (WS); an 
autosomal recessive disease characterised by premature ageing, cancer- 
predisposition and genomic instability. Like BLM, it participates in replication, 
DNA repair, recombination and transcription (Bohr et al. 2002) and interacts 
with TRF2 and POT1 to unwind telomeric DNA (Opresko et al. 2002). WRN 
may also play a role in telomere capping as cells from WS patients display 
chromosomal abnormalities, accelerated telomere shortening and early entry into 
replicative senescence (Tahara et al. 1997; Opresko et al. 2002). Unlike in BS 
cells, expression of hTERT alone rescues cells from senescence without 
completely restoring the chromosomal instability observed in WS cells, 
indicating that other factors than telomere impairment are responsible for the 
elevated genomic instability in WS cells (Kruk et al. 1995; Schulz et al. 1996; 
Wyllie et al. 2000). Single molecule analysis of fibroblast cultures derived from 
Werner patients did not reveal any significant rate of telomere erosion compared
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to normal fibroblasts (Baird et al. 2004). Together these indicate an indirect 
effect of the absence of WRN on telomere dynamics that may be influenced by 
the kinetics of cell growth (Wyllie et al. 2000; Baird et al. 2004).
1.8.7.7 Non-homologous end-joining (NHEJ) and 
Homologous Recombination (HR) proteins
NHEJ is a mechanism that involves joining of DNA ends with the use of little or 
no sequence homology. It employs a number of proteins, which include Ku 
heterodimer, DNA-dependent protein kinase catalytic subunit (DNA-PKcs), 
XRCC4, Ligase IV, Artemis and XLF [also known as Cemunnos; (Kanaar et al. 
1998; Smith and Jackson 1999; Karran 2000)]. The key components of NHEJ do 
not only bind telomeres but are also essential for telomere length homeostasis 
and chromosome end protection (d'Adda di Fagagna et al. 2004; Lenain et al. 
2006; van Overbeek and de Lange 2006).
HR is a repair mechanism, in which a homologous chromatid serves as a 
template for repair of broken strand. HR is a predominant mechanism for DSB 
repair during the G2 phase of mammalian cell cycle when the sister chromatids 
are available (Karran 2000). HR consists of a number of proteins, like RAD50, 
RAD51, RAD52, RAD54, MRE11, RPA, BRCA1, RAD51B, RAD51C, 
RAD51D, XRCC2 and XRCC3 and BRCA2 etc [reviewed in (Karran 2000; Li 
and Heyer 2008)].
1.8.7.7.1 KU heterodimer
Ku heterodimer [Ku70 and Ku80 subunits] is a DSB recognition protein that has 
high affinity for DNA ends [reviewed in (Fisher and Zakian 2005). It binds to 
telomeres (Bianchi and de Lange 1999; Hsu et al. 1999; d'Adda di Fagagna et al.
2001) and plays a role in telomere length homeostasis and chromosome end 
protection through interaction with TRF1 and TRF2 (Kysela et al. 2003). Ku also
26
Chapter 1: Introduction
play a role in telomere length regulation through inhibiting telomerase access to 
telomeres (Slijepcevic and Bryant 1998; Espejel et al. 2002a).
In support of its capping function, Ku86 knockout mice exhibit elevated 
frequencies of end-to-end chromosomal fusions with telomeric sequences clearly 
detectable at fusion points indicating loss of telomere cap without telomere 
erosion (Bailey et al. 1999; Hsu et al. 1999; Hsu et al. 2000; Samper et al. 2000; 
d'Adda di Fagagna et al. 2001). Whilst its role as a negative telomere length 
regulator is supported by the studies in human cells, in which deletion of a single 
Ku allele or suppression of Ku by RNA interference (RNAi) resulted in severe 
telomere shortening and telomeric fusions (Jaco et al. 2004; Myung et al. 2004). 
This role is further supported by studies in yeast where, loss of ku functions 
resulted in telomere erosion (Boulton and Jackson 1998).
1.8.7.7.2 DNA Pkcs
DNA-dependent protein kinase catalytic subunit (DNA PKcs) is a member of 
phosphoinositide-3-kinase related family, which also include ATM and ATR 
kinases. Similar to Ku, DNA-PKcs localises to telomeres (d'Adda di Fagagna et 
al. 2001) where it plays a role in telomere capping. Its deficiency in mouse cells 
result in accumulation of telomere fusion events without evidence of change in 
telomere length (Gilley et al. 2001). Whilst, cells from severe combined 
immunodeficiency (SCID) mice (natural DNA-PKcs mutants) display telomere 
fusions and abnormal telomere elongation (Hande et al. 1999; Goytisolo et al.
2001) suggesting that DNA PKcs may be involved in regulation of telomerase- 
mediated elongation. Evidently, mouse cells doubly deficient in DNA-PKcs and 
telomerase show accelerated telomere shortening (Espejel et al. 2002b).
1.8.7.7.3 MRE11 complex (MSN)
The MRE11 complex consists of evolutionary conserved MRE11 and Rad50 and 
less conserved NBS1 [in mammals] /Xrs2 [yeast] protein (Haber 1998;
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D'Amours and Jackson 2002). MRE11 is a structure-specific nuclease, which 
exhibits 3-5' double-stranded exonuclease and single-stranded/ double-stranded 
DNA endonuclease activities (D'Amours and Jackson 2002). The MRN complex 
plays a role in DNA damage detection, signalling and repair through ATM kinase 
pathway, HR, NHEJ (Lee and Pauli 2005; Pauli and Lee 2005) and micro- 
homology-mediated end joining [MMEJ; (Ma et al. 2003)].
At telomeres, however the complex helps to distinguish telomeres from DSBs. It 
binds to telomeres at different stages of cell cycle through interaction with TRF2 
(Zhu et al. 2000). i.e. MRE11 and Rad50 are bound to TRF2 throughout cell 
cycle while NBS1 localises to telomeres only during G2 and S-phases indicating 
a role in telomeric replication or t-loop formation (Zhu et al. 2000; Verdun et al. 
2005).
Recently, it has been demonstrated that MRE11 plays several functions at 
uncapped telomeres, which include protective role in preventing NHEJ-mediated 
fusion of leading strand telomeric DNA and removal of the 3' telomeric overhang 
to promote chromosome fusions in the absence of TRF2 (Deng et al. 2009a; Zha 
et al. 2009). Thus, MRE11 plays an essential role in telomere capping.
The complex may also cooperate in telomerase-dependent and independent 
telomere maintenance. In fact, cells from NBS patients display 25% decline in 
telomere length and early onset of senescence, which could not be rescued by 
reintroduction of either hTERT or NBS1 alone. However, simultaneous 
expression of both hTERT and NBS1 restored proliferation capacity and 
increased telomere length (Ranganathan et al. 2001; Riha et al. 2006). In ALT 
cells, NBS1 interacts with TRF1 (Wu et al. 2000) and together with TRF2 
localises with PML bodies, structures characteristic feature of ALT cells (Zhu et 
al. 2000; Wu et al. 2007). Furthermore, knockdown of NBS 1 inhibits formation 
of PML bodies and thus prevent activation of ALT (Jiang et al. 2005), further 
suggesting the role of NBS 1 in suppressing recombination at telomeres.
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Deficiency of other HR components such as RAD54 (Jaco et al. 2003) and 
RAD51D (Tarsounas et al. 2004) result in telomere shortening and increase in 
frequencies of end-to-end chromosome fusions and cell death through apoptosis 
(in case of RAD51D) indicating loss of telomere-capping function (Tarsounas et 
al. 2004). Similarly, inhibition of BRCA1 localisation to telomeres results in 
telomere elongation in the presence and absence of telomerase activity (Ballal et 
al. 2009). Together these studies suggest that different HR components may play 
a role in telomere capping function.
1.9 Telomere evolution
In most eukaryotes, telomeres consist of TTAGGG-like repeats with the 
exception being budding yeasts; this is suggestive of the common evolutionary 
route from TTAGGG-containing recent ancestral eukaryotes [Figure 1.4; (Li et 
al. 2000)]. Li and colleagues have suggested a model for the evolution of the 
telomeric complex in which the ancestral eukaryotic telomeres were composed of 
TTAGGG repeats and were maintained by telomerase (Li et al. 2000). During 
evolution, mutations in telomerase activity could have given rise to different 
TTAGGG derivatives. In support of this, our recent study (Letsolo et al. 2009) 
and others (Allshire et al. 1989; Baird et al. 1995) analysis of the human 
telomeres have revealed that the proximal telomeres consists of at least 24 
different repeat types ranging from penta to octa repeats all with a TTAGGG- 
type mortif [also chapter 4 of this thesis]. Some of these repeat types are also 
found in other organisms, for example in plants, telomeres consist of 
TT(T/A)GGG (Richards and Ausubel 1988). In their model, Li and colleagues 
proposed that mutations within the RNA component of telomerase could have 
resulted in a departure of budding yeast telomeres from the TTAGGG motif 
resulting in different telomeric repeats of different length and sequence (e.g., 
ACGGATTTGATTAGGTATGTGGTGT in K. lactis (McEachem and 
Blackburn 1994).
29
C hapter 1: In troduction
Vertebrates TTAGGG
C. elegansTTAGGC
Ustilago TTAGGG 
S. pombe TTAC AGG[G]0-4 
Pneumocystis TTAGGG
Neurospora TTAGGG
Toma.oTTlWlG00
m c n a rrG G G G
Tetrad
lds TTAGGG
S i * * * * 1110 G
ttaggg
lastid*
GGG
Figure 1.4. Putative model for the Evolution of Eukaryotic Telomeres. 
TTAGGG-like repeats predominate at telomeres of most eukaryotes with 
the exception o f budding yeasts. For references on telomeric sequences, see 
(Zakian 1989). Line lengths do not represent evolutionary distances 
[modified from (Li et al. 2000)].
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In support of the view of TTAGGG-containing ancestor, most eukaryotes have 
TRF-like proteins that bind the telomeres. In mammalian cells, telomeres are 
bound by the multi-protein complex “Shelterin’’ which consists of at least six 
core components (de Lange 2005). Two-related proteins TRF1 and TRF2 bind 
duplex DNA whilst POT1 binds single-strand binding protein (de Lange 2005).
TRF homologues have been identified in other vertebrates [Xenopus (Nishiyama 
et al. 2006) and chicken (Okamoto et al. 2008)]. In S.pombe, TRF-homologue 
tazl binds double stranded DNA as a dimer, negatively regulates telomere length 
and is essential for telomere-end protection and recruits spRapl to telomeres 
(Kanoh and Ishikawa 2003). However, no TRF homologues have been identified 
in S. cerevisiae in which duplex DNA is bound by Rapl, a protein that in humans 
interacts with TRF2 at telomeres (Conrad et al. 1990; Li et al. 2000). Similarly, 
TIN2 and TPP1 have not been identified in yeasts, plants or worms, and are 
hypothesised to have evolved after vertebrate’s divergence.
In humans, sub-telomeric DNA has evolved through duplications, sequence 
exchanges and truncations from ancestral primates. Evidently, organisation of the 
satellite DNA within the sub-telomere is such that some sequences are abundant 
in gorillas and chimpanzees but undetectable in orang-utans and human 
telomeres (Royle et al. 1994). In addition, analysis of XpYp sub-telomeric DNA 
has revealed the SINE that is located immediately adjacent to the telomere which 
is truncated in humans, but full length in one allele of orang-utans and absent in 
another as well as in gorillas (Baird and Royle 1997). Similarly, the human 2q 
contain an interstitial telomeric DNA, which is believed to be a result of fusion 
between two arms of the ancestral chromosome 2 during evolution (JW et al. 
1991; Macina et al. 1994). Thus, closely related species such as humans, 
chimpanzees and gorillas have distinct telomeric sequence organisations, which 
are subjected to rapid evolution (Royle et al. 1994; Baird and Royle 1997).
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Further support for rapid evolution in human lineage comes from nucleotide 
substitution studies, which revealed higher frequency of base substitution within 
sequences immediately adjacent to the telomeres than the genome average at 
non-coding regions. For instance, the 850bp of the telomere-adjacent DNA of 
XpYp exhibits the rates of base substitution as high as 1 in 50-65bp. However, 
all the base substitutions are in complete linkage disequilibrium resulting in a 
small number of haplotypes within human populations (Baird et al. 1995; Baird 
et al. 2000). Linkage disequilibrium (LD) is a condition in which the haplotype 
frequencies in populations deviate from the values they would be under random 
segregation. The linkage disequilibrium coupled with high frequency of the base 
substitution have resulted in haplotypes that vary by 2.1% at XpYp indicating 
that the haplotypes are ancient and have been preserved in modem human 
populations (Baird et al. 1995). One of the processes that can give rise to linkage 
disequilibrium is the suppression of recombination. Linkage-map expansion and 
terminal chismata distribution indicated high rates of recombination in some 
terminal regions of human chromosomes (Hulten 1974). Such high rates of 
recombination could result in rapid evolution of the terminal regions. Indeed sub- 
telomeric exchanges between 4q and lOq have been reported with some people 
carrying a 4q/10q translocation (van Deutekom et al. 1996; Mefford and Trask
2002). In contrast, LD analysis at the telomere arrays indicated a suppression of 
meiotic recombination at telomeres (Baird et al. 1995; Baird et al. 2000).
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1.10 Telomere replication
Semi-conservation replication is achieved through cooperation of lagging and 
leading strand synthesis. While replication of telomeres by leading strand 
synthesis of telomeres is complete and results in blunt-ended molecules, the 
molecules synthesised by lagging strand synthesis is incomplete (Watson 1972). 
There is no known mechanism of synthesising DNA when the distal primer is 
removed thus a gap equivalent to the size of the terminal primers may be 
generated. However, in vitro studies have shown that due to randomness of 
priming, the lagging strand synthesis is halted within 500bp of the end resulting 
in gaps of up to 500bp when the primers are removed (Ohki et al. 2001). Thus 
with ongoing cell division telomeres can be lost, a phenomenon called end- 
replication problem [Figure 1.2; section 1.6].
It has become increasingly apparent that replication of telomeres and telomerase 
mediated telomere elongation are highly coordinated. For example, in ciliates 
Euplotes crassus (Fan and Price 1997) and yeast S.cerevesiae (Diede and 
Gottschling 1999), inhibition of activity of DNA polymerases a and 5 (C-strand 
synthesis) induces telomere elongation of the G-strand and inhibits G-strand 
polymerisation respectively, indicating that extension of 3' G-strand by 
telomerase and filling of gaps in C-strand by DNA primase are coordinated. It is 
not known whether replication is coordinated in mammalian cells, however, 
inactivation of the DNA polymerase in mouse cells induces elongation of the G- 
overhang implicating that DNA replication and telomerase elongation may be 
coordinated in mammals as well (Nakamura et al. 2005).
Whilst telomere replication of opposite telomeres of same chromosome is 
synchronised during late S-phase in yeast (Wellinger et al. 1993), mammalian 
telomere replication is asynchonised but timed and regulated (Zou et al. 2004a). 
The replication of telomeres is initiated from the sub-telomeric origin of 
replication (Verdun and Karlseder 2007) early in S-phase and continues
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throughout the S-phase. In addition, opposite telomeres of specific chromosome 
within the same cell are replicated at different but specific times during the S- 
phase. Furthermore, some specific telomeres are replicated at early stages of S- 
phase (Ten Hagen et al. 1990; Wright et al. 1999; Hultdin et al. 2001; Zou et al. 
2004a).
The repetitive GC-rich nature of telomeres complicates replication probably 
through formation of secondary structures like G-quadruplexes (Parkinson et al.
2002) and T-loop (Griffith et al. 1999). Evidently, studies have reported that 
TRF1 and TRF2 bound telomeric DNA stalls the replication fork in vitro and in 
vivo (Ohki and Ishikawa 2004). Consequently, efficient replication of telomeres 
requires resolution of stalled replication forks. Telomere proteins TRF1 and 
shelterin-associated protein WRN play an essential role in processing of stalled 
replication fork to allow efficient telomere replication (Crabbe et al. 2004; Sfeir 
et al. 2009). In support of this view, over-expression of WRN in mouse cells 
cause loss of telomeres generated by lagging strand synthesis in the absence of 
telomerase. However, expression of telomerase in these cells (expressing WRN) 
counteracts telomere loss (Crabbe et al. 2004).
In summary, whilst telomere replication may be problematic, telomere proteins 
play an essential role in regulating coordinated telomere replication and 
telomerase-mediated elongation.
1.11 Telomere maintenance
1.11.1 Human Telomerase
Human telomerase is a holoenzyme and ribonucleo-protein (RNP) complex 
consisting of two essential core components; the human telomerase RNA 
component [hTERC; CUAACCCUA...] and the human telomerase reverse 
transcriptase catalytic subunit [hTERT; (Morin 1989)]. hTERC acts as a template
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for de novo addition of the new telomeric repeats while hTERT synthesises 
telomeric repeats and catalyses telomere elongation (Nakamura et al. 1997).
Telomerase adds telomeric repeats to counteract telomere erosion due to end 
replication problem, and other processes including nucleolytic activity 
(Wellinger et al. 1996) and oxidative damage (von Zglinicki 2002). It specifically 
recognises the 3 -OH of the G-strand at the ends of the chromosomes (Nakamura 
and Cech 1998; Collins and Mitchell 2002) and preferentially elongates short 
telomeres in human cells (Kim et al. 1994; Britt-Compton et al. 2009) thus 
maintaining telomeres at a stable length.
The level of telomerase activity is regulated at different levels including 
transcriptional regulation, mRNA splicing and assembly of the hTERT and 
hTERC genes. hTERC and other telomerase-associated proteins are ubiquitously 
expressed in all human tissues (Feng et al. 1995) thus the level of hTERT is a 
major determinant of telomerase activity such that the steady-state levels of 
hTERT are elevated in cancer cells (Avilion et al. 1996; Yi et al. 1999) but not in 
most somatic cells. hTERT expression is regulated by several proteins which 
include c-myc, Smad3 and TGFp among others. For examples, c-myc binds on 
several locations on the promoter of hTERT gene to enhance transcription (Wu et 
al. 1999; Kyo et al. 2000) while interaction between TGFp, Smad3 and c-myc 
represses hTERT activity (Li et al. 2006). Post-transcriptional regulation includes 
alternative splicing of hTERT into hTERTa, which results in down-regulation of 
hTERT (Colgin et al. 2000).
1.11.1.1 Telomerase expression in human tissues
In humans, telomerase expression is restricted to male and female germ-line, 
some adult stem cells, 80-90% of human cancer tissues and immortalised cells 
(Kim et al. 1994; Kolquist et al. 1998). It is also expressed in cells of self­
renewal high-proliferative tissues such as haematopoietic system [e.g. CD34+ 
haematopoetic progenitor cells; (Broccoli et al. 1995)] and the basal layer of the
35
Chapter 1: Introduction
skin (Kolquist et al. 1998). Telomerase activity is also detectable in normal 
keratinocytes (Harle-Bachor and Boukamp 1996; Yasumoto et al. 1996); 
lymphocytes after mitogenic stimulation (Hiyama et al. 1995; Greider 1998; Liu 
et al. 1999); in normal mature T cells on entry into S-phase (Buchkovich and 
Greider 1996); leukocytes (Counter et al. 1995), normal human endothelial cells 
in culture (Hsiao et al. 1997), endometrial tissue (is correlated with proliferation 
during menstrual cycle), mitotically active regions of human hair follicles, 
proliferative zone of intestinal crypts (Ramirez et al. 1997) and normal human 
blood (Broccoli et al. 1995; Counter et al. 1995). In contrast, most normal human 
somatic tissues express undetectable to low-level telomerase activity (Kim et al. 
1994; Kolquist et al. 1998).
1.11.2 Telomerase and telomere length homeostasis
In most telomerase deficient cells telomeres erode as a function of a cell division, 
however in immortal cells such as germ line and cancer cells, telomerase activity 
elongates telomeres thus maintain them at stable length (Kim et al. 1994; 
Kolquist et al. 1998; Meyerson 2000). In other telomerase-positive cells, 
telomerase activity is insufficient to counteract telomere loss implicating a 
regulatory mechanism of telomerase activity in such cells. In support of this, 
studies have reported that limiting telomerase activity contributes to telomere 
homeostasis (Cristofari and Lingner 2006) such that in telomerase-positive yeast, 
telomere length homeostasis depends on a switch between telomerase-extendible 
and telomerase-nonextendible states (Teixeira et al. 2004). Telomerase access to 
telomeres is coordinated with cell cycle progression such that telomeres are 
elongated during S-phase following DNA replication (Masutomi et al. 2003). 
However, not all telomeres are elongated at each S-phase, only a subset of short 
telomeres that may display open telomere structure [where the G-overhang is 
accessible] are elongated in yeast (Teixeira et al. 2004) and human cells (Britt- 
Compton et al. 2009). Regulation of accessibility depends on the amount of 
telomeric proteins bound at the telomeres such that longer telomeres carry more
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TRF1 molecules and thus are not accessible and vice versa for short telomeres 
(de Lange 2005).
1.11.3 Alternative lengthening of telomeres (ALT)
ALT represents telomerase-independent mechanism(s) expressed in a subset of 
human cancer cells and tumours (Bryan et al. 1995; Bryan et al. 1997b; Henson 
et al. 2002). ALT is believed to be a recombination-based mechanism 
characterised by high rates of telomeric exchanges (Londono-Vallejo et al. 
2004), however the exact mechanism is not known. It is prevalent in tumours of 
mesenchymal origin such as osteosarcoma (35-47%), soft tissue sarcomas (35%) 
and liposarcomas [24-33%; (Henson et al. 2005; Johnson et al. 2005; Costa et al. 
2006; Johnson and Broccoli 2007; Jeyapalan et al. 2008)]. However, some 
exceptions to this trend have been documented. For example, Ulaner and 
colleagues have reported that majority of Ewing’s sarcoma tumours expressed 
telomerase as opposed to osteosarcomas which expressed ALT (Ulaner 2004). 
Moreover, telomerase activity has been documented in other sarcomas with low 
frequency of ALT, such as synovial sarcomas (Montgomery et al. 2004) 
implicating that in some tumours both ALT and telomerase are methods of 
telomere maintenance.
ALT-expressing cells (ALT+) are characterised by lack of telomerase activity, 
heterogeneous length of telomeres varying from undetectable to >20kb, presence 
of extra-chromosomal telomeric circular DNA (Cesare and Griffith 2004) and 
presence of ALT-associated promyelocytic leukaemia nuclear bodies (APBs) 
containing telomeric DNA and binding factors, TRF1 and TRF2 (Yeager et al. 
1999). However, PMLs have also been documented in the absence of either 
telomerase or ALT suggesting that their role in ALT cells may not be essential 
(Fasching et al. 2005).
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1.12 Telomere dysfunction triggers DNA damage response
As illustrated in section 1.8, several DNA repair factors localise to the telomere 
and participate in telomere maintenance. In mammalian cells, DNA damage 
lesions are detected by two related phosphatidylinositol 3-kinase proteins: ATM 
(DSBs) and ATR [for Single-stranded DNA breaks; (Zou 2007; Cimprich and 
Cortez 2008)] which are auto-phosphorylated at the site of the lesion. Once 
activated, they phosphorylate histone yH2AX on serl39, CHK1 and CHK2 (Liu 
et al. 2000) and through cascades of events activate p53/p21 pathways (Wang et 
al. 2007b). Unlike DSBs, telomeres are protected from these pathways by 
shelterin (de Lange 2005).
The loss of the telomere function due to either erosion, or loss of telomeric 
protein function, leads to a DNA damage response. In support o f this, cells 
without functional TRF2 display molecular markers characteristic of cells 
bearing DNA DSBs such as phosphorylated yH2AX, p53-binding protein 1 
(TP53BP1), NBS1 (also known as nibrin), MDC1 and CHK2 at the site of the 
lesion, forming telomere-induced foci [TIFs; (d'Adda di Fagagna et al. 2003; 
Takai et al. 2003)]. This indicates that TRF2-depleted telomeres are recognised 
as sites of DNA damage (van Steensel et al. 1998; Karlseder et al. 1999). 
Similarly, loss of both mouse Potls results in formation of TIFs and cell cycle 
arrest whilst POT 1-deficient cells contain phosphorylated CHK1 and CHK2 
consistent with ATR signalling (Denchi and de Lange 2007). TIFs have also been 
detected in senescent human diploid fibroblasts (d'Adda di Fagagna et al. 2003; 
Takai et al. 2003), indicating that senescent cells contain dysfunctional telomeres 
that induces DNA damage response and cell cycle exit.
1.13 Telomere dysfunction and Genomic instability
Chromosomes that have lost the telomere function through either progressive 
erosion or uncapping are highly unstable, i.e. Critically short or uncapped 
telomeres are “sticky” and tend to fuse forming dicentric chromosomes among
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others (Mumane and Sabatier 2004). With subsequent divisions when the 
centromeres are pulled apart during anaphase, the fused chromosomes may form 
a bridge and break not necessarily at the original fusion point. The broken 
fragments can then fuse to other uncapped chromosomes and initiate another 
cycle of breakage-fusion-bridge cycle and hence genomic instability [Figure 1.5; 
(DePinho and Wong 2003)]. The consequence of genomic instability is the loss 
of genome integrity, which in turn may leads to mis-regulation of genes involved 
in growth control and tumour suppression (Mumane and Sabatier 2004). Thus 
through accumulation of additional abnormalities loss of genomic stability can 
promote tumourgenesis (Artandi et al. 2000; Artandi and DePinho 2000; 
DePinho 2000).
Several studies have demonstrated that disruption of the telomere cap such as 
through loss of TRF2 (van Steensel et al. 1998; Cell! and de Lange 2005), POT1 
(Hockemeyer et al. 2005) and/ or RAP1 (Bae and Baumann 2007; Sarthy et al.
2009) functions, induce widespread NHEJ-mediated /ligase IV-dependent 
telomere fusions, consisting of long tracts of TTAGGG repeats. In addition, loss 
of POT 1 (He et al. 2006; Wu et al. 2006) or TRF2 and ku increases the frequency 
of sister telomere exchanges, a form of homologous recombination predominant 
in ALT. Moreover, mutant TRF2 lacking the DNA-binding domain (AB) 
represses NHEJ but result in rapid erosion of telomeres as well as formation of t- 
loop sized telomere circles implicating the XRCC3-dependent processing of the 
Holliday junction at the t-loop (Wang et al. 2004), an intermediate stage in 
homologous recombination. Similarly, perturbation of the shelterin stability 
through loss of interacting factors such as PARP1 (d'Adda di Fagagna et al. 
1999) or Ku (Samper et al. 2000) in knock-out mice exhibit elevated frequency 
of telomere fusions, abundant chromosomal breaks and aneuploid cells compared 
to the wild type mice. Taken together these studies support the view that loss of 
telomere function triggers DNA repair at telomeres.
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[reviewed in (Campisi et al. 2001)]. Senescence can also be triggered by 
telomere uncapping without telomere erosion as indicated previously (Blackburn 
2001; Karlseder et al. 2002). In support of this, loss of telomere cap through 
depletion of TRF2 in vitro (Karlseder et al. 1999), ablation of TIN2 (Chiang et al. 
2004; Kim et al. 2008) and conditional deletion of mPotla (Wu et al. 2006), all 
induce p53-dependent cell cycle arrest. Similarly, telomere dysfunction in 
telomerase-deflcient mouse cells and human cells expressing a mutant hTERT 
induce apoptosis in the presence and absence of functional p53 (Chin et al. 1999; 
Hahn et al. 1999; Zhang et al. 1999; Guiducci et al. 2001; Kim et al. 2001); 
indicating that telomere dysfunction induces both p53-dependent and 
independent apoptosis in mammalian cells.
1.14.1 Ageing
In long-lived species such as humans, senescence whether telomere-dependent 
(Harley et al. 1990; Wright and Shay 1992) or telomere-independent [e.g. 
oncogene-induced (Serrano et al. 1997)] plays two antagonistic roles in ageing 
and cancer (Campisi 1997). By limiting the cell proliferation, senescence can 
contribute to ageing by accumulation of changes that may alter 
microenvironment thus leading to disruption of tissue homeostasis. These 
changes include secretion of extracellular matrix as well as matrix-degrading 
enzymes, inflammatory cytokines and growth factors [reviewed in (Campisi et al. 
2001), all of which may alter tissue homeostasis. Accumulation of senescent cells 
may therefore impair tissue function and contribute to ageing. Indeed, senescent 
cells accumulate with age in human tissues and mice, especially at sites of age- 
related pathologies such as skin ulcers and osteoarthritic joints, as well as 
premalignant tumours (Dimri et al. 1995; Price et al. 2002; Collado et al. 2005). 
Accumulation of senescent cells has also been reported in skin of ageing baboons 
(Herbig et al. 2006; Jeyapalan et al. 2007).
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Figure 1.5. Schematic representation of dual antagonistic role of telomeres in cancer. 
When the telomeres become uncapped, they are detected by cell machinery as damaged 
DNA and triggers cell cycle exit, a mechanism that is believed to be a barrier to 
uncontrolled proliferation and hence tumour suppressive. However if DNA repair 
machinery is impaired, uncapped telomeres can fuse with each other, forming dicentric 
chromosomes. The fused chromosomes form a bridge when the two centromeres are 
pulled to opposite poles. With subsequent cell divisions, fused chromosomes could 
result in extensive chromosome instability, as the breakage does not occur at the 
original fusion site.
1.14 Telomere dysfunction may contribute to Ageing and 
tumourigenesis
In most somatic cells, telomeres erode as a function o f age due to the “end 
replication” problem, insufficient telomerase activity and post replicative 
processing until they reach the telomere length at which they undergo replicative 
senescence, often termed mortality stage I [(Wright and Shay 1992; Wei and 
Sedivy 1999); M l; Figure 1.6). Senescence (biological ageing) is a state of 
permanent cell-cycle arrest in which cells stop dividing but remain viable
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While it is clear that telomere dysfunction, may contribute to ageing by virtue of 
its ability to trigger senescence (biological ageing), the direct biological link 
between telomere dysfunction and organismal ageing is very tantalising, but 
remains to be proven. However, several studies have reported telomere erosion 
with age in human tissues including blood cells, lymphocytes (Weng et al. 1995; 
Elwood 2004), kidney epithelium (Melk et al. 2000) and intestinal epithelium 
(Jiang et al. 2007). It is not known whether telomere dysfunction contributes to 
complex process of organismal ageing.
The possible role of telomere dysfunction in organismal ageing is studied in 
mouse model. Laboratory mice have long telomeres (Kipling and Cooke 1990) 
and cellular and organismal ageing in mice is believed to be telomere- 
independent. Consistent with this, telomerase knockout did not induce any 
ageing phenotype in first generation mice, at which their telomeres have not 
eroded to the length at which telomeres may be dysfunctional. However late 
(sixth) generation telomerase knockout mice displaying short telomere profiles, 
also showed degeneration of proliferative lymphoid, haematopoietic and gonadal 
cells in generation consistent with ageing (Blasco et al. 1997; Lee et al. 1998). 
Whilst these mice also displayed ageing phenotype such as grey hair, alopecia, 
delayed healing etc, deletion of WRN protein in these mice displaying short 
telomeres induced phenotypes that resemble those of premature ageing human 
Werner syndrome such as premature death, osteoporosis, type II diabetes and 
cataracts (Chang et al. 2004), implicating that telomere dysfunction may play a 
role in ageing. Again, studies of human genetic diseases, such as premature 
ageing, telomerase-deficiency disorder, dyskeratosis congenital (DKC) have 
provided insights into the link between telomere biology and ageing. Like 
telomerase knockout mice, DKC pedigrees display decline in telomere length 
distributions from one generation to the next (Diaz de Leon et al. in press), 
defects in proliferative tissues such as the bone marrow and signs of premature 
ageing such as alopecia, grey hair and cancer predisposition [reviewed in 
(Armanios 2009)].
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In summary, telomere dysfunction may contribute to ageing by triggering 
senescence. By secreting growth factors, cytokines, extracellular matrix and 
degradative enzymes, all of which can alter tissue microenvironments, 
accumulation of senescent cells may contribute to ageing. Because tissue 
microenvironments is crucial for suppressing growth and progression of cells 
carrying oncogenic mutations, changes in microenvironment may favour 
neoplastic progression in cells that carry oncogenic mutations (Park et al. 2000). 
Thus, senescence may contribute to the exponential rise in cancer that occurs 
with age (DePinho 2000; Krtolica et al. 2001). Senescence represents an example 
of a phenomenon called antagonistic pleiotropy [reviewed in (Kirkwood and 
Austad 2000)], in which one trait can benefit an organism’s fitness early in life 
while at the same time can be detrimental in ageing organisms, i.e. Early in life, 
cell cycle arrest, senescence, prevents unlimited cell proliferation required for 
malignancy, i.e. senescence can benefit the organism’s fitness by suppressing 
tumour formation. However, accumulation of senescent cells with age, may 
promote neoplastic progression of neighbouring cells [that carry mutations] as 
evident from studies by Krtolica and colleagues, in which they demonstrated that 
senescent human fibroblasts did stimulate growth and progression of 
preneoplastic, epithelial cells carrying p53 mutations but not normal 
keratinocytes (Krtolica et al. 2001). In summary, because mutations accumulate 
with age, it is possible that cells carrying mutations in growth control genes will 
lie in close proximity to senescent cells in ageing organisms. Thus, changes in 
microenvironment may drive neoplastic progression in vivo.
1.14.2 Tumourigenesis
As discussed in previous section, telomere dysfunction triggers p53/pRb- 
dependent cell cycle arrest, called replicative senescence (d'Adda di Fagagna et 
al. 2003; Takai et al. 2003); barrier that cells must overcome to allow the cell 
proliferation necessary, to progress to malignancy. Thus, senescence represents a 
potential tumour suppressive mechanism. In support of the role in tumour
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suppression, studies in mice without telomerase activity showed that Burkitt’s 
lymphoma mouse models (accomplished by interbreeding terc-/- mice with Ep- 
myc tumour prone mice) displayed short telomeres, reduced tumour formation, 
increased levels of senescence-associated p-galactosidase and senescence- 
associated kinase inhibitors p i6 and p i5, indicating induction of senescence 
(Feldser and Greider 2007). Similarly, telomerase-deficient mice with short 
telomeres are resistance to tumourigenesis in the presence of functional 
checkpoints (Gonzalez-Suarez et al. 2000; Rudolph et al. 2001; Qi et al. 2005; 
Cosme-Blanco et al. 2007). Further evidence comes from mice carrying a mutant 
p53 (Trp53515C/515C) which can induce senescence but not apoptosis (Liu et al. 
2004c). Unlike Trp53-null mice, which succumb to early thymic lymphoma 
tumourigenesis (Donehower et al. 1992; Jacks 1996), these mice [carrying 
Trp53515C/515C] were resistant to early tumour formation (Liu et al. 2004c) even in 
response to telomere dysfunction as with terc-/-, Trp53515C/515C mice (Cosme- 
Blanco et al. 2007). Together these studies implicate that senescence but not 
apoptosis suppresses tumourigenesis.
However, when the DNA checkpoints are defective, telomere dysfunction can 
result in critically short telomeres that are capable of fusion. In culture, cells 
displaying critically short telomeres enter the second checkpoint, which is p53- 
independent called “crisis” or mortality stage II (M2; Figure 1.6). M2 is 
characterised by increased cell mortality and chromosome instability (Wright and 
Shay 1992). The cells that emerge from crisis activate one or both of the telomere 
maintenance mechanisms; telomerase (Counter et al. 1992; Bodnar et al. 1998) 
and alternative lengthening of telomeres (Ducray et al. 1999; Dunham et al.
2000).
As discussed in section 1.13, telomere dysfunction can lead to loss of genomic 
integrity and hence promote the tumourigenic process by increasing the rate of 
mutation of oncogenes and tumour-suppressor genes (Maser and DePinho 2002). 
Supporting evidence comes from studies in which late generation terc'A, p53+/‘
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mice with short telomeres showed a shift in tumour spectrum from lymphomas 
and sarcomas to accumulation of carcinomas, such as colorectal cancer with 
characteristic chromosome instability and complex rearrangements similar to 
those of human epithelial cancers (Artandi et al. 2000). Similarly, telomere 
dysfunction in late generations of APCmul Terc'7' led to increased onset of 
microscopic adenomas with the early adenoma-carcinoma transition being 
marked by increased frequency of anaphase bridges, surrogate markers of 
telomere dysfunction (Rudolph et al. 2001). In contrast, in the presence of 
functional p53-signaling pathway, Terc-7- mice with critically shortened 
telomeres are highly resistant to tumour development (Greenberg et al. 1999; 
Gonzalez-Suarez et al. 2000). This dual role of telomere biology in 
tumourgenesis, which is such that telomere dysfunction promote tumour 
initiation while at the same time tumour progression is limited by cell cycle arrest 
(Rudolph et al. 2001; Lechel et al. 2007) is another example of antagonistic 
pleiotropy. In this case, loss of telomere function in proliferating cells induces 
cell cycle exit in the presence of functional DNA damage machinery while 
progressive telomere attrition in cells with defective checkpoints can initiate 
chromosome instability and ultimately loss of genome integrity, which could 
drive malignant progression if genes involved in growth control are switched on 
or off.
1.15 Telomere biology in human diseases
Several genetic disorders are associated with telomere shortening through loss of 
telomerase function via mutations in hTERT/hTERC genes or defects in specific 
components of DNA repair or defects in telomere proteins. Below I discuss 
briefly some of these human disorders.
1.15.1 Diseases associated with telomerase insufficiency
Dyskeratosis congenital (DKC) is a rare syndrome of premature ageing 
characterised by the abnormalities of the oral mucosa known as leukoplakia, skin
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hyper-pigmentation and nail dystrophy/ridging (Dokal and Vulliamy 2003). DKC 
is both an autosomal and X-linked disease. The familial Dyskeratosis congenital 
(DKC) is linked to mutation in dyskerin gene (DKC1), a nucleolar protein that 
stabilises hTERC. These mutations impair telomerase activity through either 
reduced ability of dyskerin to stabilise hTERC or disrupting the holoenzyme 
assembly (Bessler et al. 2004). The autosomal dominant form of the disease 
results from mutations in hTERC gene (Vulliamy et al. 2001), which frequently 
result in low hTERC expression in patients, compared to siblings. Affected 
individuals have low telomerase activity and short telomeres as well as increased 
chromosome end-to-end fusions, indicating telomere dysfunction (Dokal 2000). 
The X-linked DC patients have lower levels of telomerase and short telomeres 
(Heiss et al. 1998). Some cases are characterised by a functionally null allele in 
hTERT (Armanios et al. 2005), mutations in NOP 10 and NHP2 [components of 
the holoenzyme; (Walne et al. 2007; Vulliamy et al. 2008)]. In addition to 
telomerase mutations, mutations in TIN2, a component of shelterin have been 
identified in severe cases of DKC (Savage et al. 2008).
Aplastic anaemia is a serious bone marrow disorder that is characterised by low 
blood cell count (Young 2002). Sufferers have short telomeres compared to 
controls probably due to insufficient telomerase activity. The patients carry 
heterozygous mutations in hTERT, hTERC, TRF1, TRF2 and TIN2 (Savage et 
al. 2006; Walne et al. 2008).
Other blood diseases such as myelodysplatic syndromes (MDS), a group of 
clonal diseases in which the bone marrow fails to produce blood cells and are 
characterised by low blood cell counts, only hTERC mutations but no mutations 
in hTERT or dyskerin have been identified (Yamaguchi et al. 2003). Short 
telomeres in MDS are associated with development of acute myeloid leukaemia 
[AML; (Boultwood et al. 1997)].
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Similarly, mutations in telomerase components have been reported in non-blood 
conditions such as Cri du chat syndrome (CdCS) and idiopathic pulmonary 
fibrosis. Cri du chat syndrome (CdCS) is characterised by a distinct cat-like cry, 
microcephaly, widely spaced eyes, low set ears, a low broad nasal bridge and 
palmar creases in infants (Cerruti Mainardi 2006; Laczmanska et al. 2006). The 
characteristic cat-like cry has been linked to terminal deletion at 5p (5pl5.3- 
5pter), encompassing the hTERT gene [5p 15.33; (Zhang et al. 2003; Laczmanska 
et al. 2006)].
Idiopathic pulmonary fibrosis (IPF) is a rare non-neoplastic pulmonary disease 
that is characterised by the scarring of the lung tissues without any known cause 
[reviewed in (Meltzer and Noble 2008)]. Similar to other conditions already 
discussed, in IPF, mutations in telomerase components, hTERT and hTERC, 
underlie inheritance of familial IPF in 8-15% of individuals. Heterozygous 
carriers of all of the mutations in TERT or TERC display shorter telomeres than 
age-matched family members without mutations (Armanios et al. 2007; Tsakiri et 
al. 2007). However, short telomeres but not mutations in telomerase components 
are the risk factor for development of sporadic IPF (Alder et al. 2008).
1.15.2 Human cancer
One of the earliest neoplastic changes that occur in most cancers is genomic 
instability (Hanahan and Weinberg 2000). It is clear from discussion of in vitro 
studies and mouse models that telomere dysfunction can be the key driving force 
in generating genomic instability which in turn may lead to mis-regulation of 
genes involved in growth control, and tumour suppression and hence promotes 
cancer development (DePinho 2000; Maser and DePinho 2002). In this section, 
telomere dysfunction is discussed in premalignant conditions and human 
tumours.
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Several human premalignant precursor lesions termed intraepithelial neoplasia 
that predispose to development of cancer display short telomeres, increased 
frequency of anaphase bridges and end-to end fusions, markers of telomere 
dysfunction, expression of telomerase or recombination-based telomere 
maintenance mechanism (Meeker et al. 2002b; Meeker et al. 2004). For instance, 
telomerase activity is expressed early during carcinogenesis of the gastric, 
oesophageal, liver, pancreas, cervix, colorectal and oral cavity etc (Meeker et al.
2004). While telomerase does not induce genomic instability, it is essential for 
maintaining the telomeres to ensure continued proliferation that cells require to 
accumulate more abnormalities that could drive neoplastic progression (Bodnar 
et al. 1998; Morales et al. 1999). In Barrett’s oesophagus, a premalignant 
condition that predispose to oesophageal adenocarcinoma, telomerase activity 
increases gradually at all precancer stages being high in dysplasia and carcinoma 
in situ (Lord et al. 2000). Similarly, telomerase is expressed in intestinal 
metaplasia of the stomach which became elevated in adenomas and gastric 
cancers; regardless of whether nodal metastases, peritoneal metastases and 
recurrent gastric tumours (Tahara et al. 1995a; Maruyama et al. 1997). Similar 
patterns o f telomerase activation, increased chromosome instability and telomere 
erosion have been reported in other conditions of the gastrointestinal tract such as 
liver cirrhosis-hepatocellular carcinoma transition (Tahara et al. 1995b); 
pancreatic intraepithelial neoplasia-pancreatic ductal adenocarcinoma transition 
(Hiyama et al. 1997) and ulcerative colitis-colorectal cancer transition (Hastie et 
al. 1990; Tahara et al. 1995a; Engelhardt et al. 1997).
Telomere dysfunction and chromosomal instability are believed to pose clonal 
advantage in the absence of functional DNA checkpoint, which through 
accumulation o f more mutations have potential to initiate cancer, i.e. cells that 
have lost telomere function can dominate the culture and result in clonal 
expansion, and allow for accumulation of more abnormalities that may drive 
neoplastic progression. Clinical evidence demonstrates the clonal heterogeneity 
of telomeres and telomerase activity in tumour cells. For instance, telomere
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length in colorectal carcinoma have been reported to be shorter than in normal 
controls and polyps, without any correlation between the telomere length and 
telomerase activity (Kim et al. 2002).
In addition, losses of p53 and p i6 function are some of the early lesions in non­
neoplastic epithelium of ulcerative colitis and Barrett’s oesophagus with telomere 
dysfunction, as marked by short telomeres and increased frequency of anaphase 
bridges (O'Sullivan et al. 2002; Finley et al. 2006; O'Sullivan et al. 2006; Risques 
et al. 2008), occurring at advanced stages.
Telomere length has been suggested in prognosis of numerous cancers. For 
instance, telomere erosion in peripheral blood lymphocytes increases the risk of 
gastric cancers (Liu et al. 2009). Again, short telomeres and increased frequency 
of telomere fusion is associated with disease progression and poor outcome in 
chronic lymphocytic leukaemia (Lin et al. 2010).
1.16 Telomere length Dynamics and homeostasis
Telomere length homeostasis depends on a balance between the processes that 
result in telomere attrition or telomere elongation. It also depends on shelterin 
complex that work in cis to control access of telomerase to telomeres 
(Smogorzewska and de Lange 2004).
1.16.1 End-replication losses and post-replicative 
processing.
The majority of somatic cells do not express any telomere maintenance 
mechanism thus, their telomeres erode as a function of cell division with age 
(Harley et al. 1990). Following replication, the telomere created during the 
lagging strand synthesis is shorter than the parent telomere by the size of the 
terminal primer (Watson 1972). Thus the lagging strand synthesis result in 
telomere erosion with each round of cell division. The leading strand on the other
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hand is fully replicated resulting in blunt ended molecules, which are then 
processed by putative nucleases to create the overhang necessary for t-loop 
formation (Makarov et al. 1997; Wright et al. 1997; Bailey et al. 2001; Sfeir et al.
2005). Although the nucleases that process the telomeres to generate overhangs 
are not known, they may include endonucleases such as FEN-1 (Liu et al. 2004d; 
Saharia and Stewart 2009) and ERCC/XPF1 (de Laat et al. 1998; Hoeijmakers
2001) or exonucleases such as Apollo (Lenain et al. 2006; van Overbeek and de 
Lange 2006), WRN (Li and Comai 2001), MRE11 (D'Amours and Jackson 2002) 
and EXOl (Sharma et al. 2003; Schaetzlein et al. 2007), all of which play a 
direct or indirect role in telomere homeostasis. For example loss of FEN1 has 
been reported to induce telomere instability in ALT expressing cells (Saharia and 
Stewart 2009). The end-replication problem and post-replicative processing 
result in 50-15Obp losses per cell division in human fibroblasts (Harley et al. 
1990; Makarov et al. 1997).
1.16.2 Oxidative damage
By virtue of being dithymidine and triple-Guanine-containing structures, 
telomeres are highly sensitive to damage by oxidative stress (Henle et al. 1999), 
alkylation (Petersen et al. 1998) or ultraviolet (UV) irradiation (Oikawa and 
Kawanishi 1999; Jin and Ikushima 2004; Kawanishi and Oikawa 2004). On 
exposure to UV, adjacent thymines tend to form an unusual covalent bond to 
generate thymine dimers which when excised by base excision repair may create 
single-stranded breaks [SSBs] on the G-strand. Similarly, guanine has low 
oxidation potential, which is even lower on tri guanines. Generation of the 8-oxo 
guanines can be very mutagenic if unrepaired, as 8-oxoG base pairs with adenine 
resulting in a GC to AT transversion just after two replication cycles (Boiteux 
and Radicella 1999). These mutations can lower the affinity of the telomere 
binding proteins (Opresko et al. 2005a) and result in telomere uncapping and/ or 
increased rate of recombination.
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Alternatively, excision of the 8-oxoG can generate the single stranded break on 
the G-strand and single strand DNA on the C-strand which may be cleaved and 
lead to telomere shortening. In support of this, studies have reported detectable 
SSBs in human cells (von Zglinicki et al. 2000) and mouse cells (Wang et al.
2010) under high oxygen tension. All these studies suggest that oxidative damage 
may result in a substantial loss of telomere repeats and thus an increase in the 
rate of telomere erosion (Oikawa and Kawanishi 1999; von Zglinicki 2002; 
Kawanishi and Oikawa 2004; Houben et al. 2008). Indeed, UVA exposure, 
which can generate oxidative stress via reactive oxygen species (ROS) such as 
H20 2, 0 2‘ and NO-, which have been implicated in accelerated telomere 
shortening of cultured fibroblasts (Oikawa et al. 2001; Kawanishi and Oikawa
2004). In addition, it has been shown that chronic oxidative stress compromises 
the telomere integrity and accelerates the onset of senescence in endothelial cells 
(Kurz et al. 2004). Similarly, AT cells display sensitivity to oxidative stress such 
that mild chronic oxidative stress increased the rate of telomere shortening in AT 
cells (Metcalfe et al. 1996; Tchirkov and Lansdorp 2003).
1.16.3 Telomere Capture
Telomere capture is a non-reciprocal process in which telomere repeats are added 
to DSB creating sub-telomeric translocations (Meltzer et al. 1993; Fouladi et al. 
2000; Lo et al. 2002). The process has been observed in human cancer cells such 
as malignant melanoma cells, and chronic lymphocytic leukaemia cells (Meltzer 
et al. 1993; Fouladi et al. 2000; Amiel et al. 2005). Since it is a non-reciprocal 
process, it results in short telomeres on the donor chromosome and longer 
telomeres on recipient. Telomere capture of sequences from another chromosome 
has been shown to stabilise the chromosomes, following terminal deletions in 
human malignant and normal cells (Meltzer et al. 1993).
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1.16.4 Telomeric sister-chromatid exchange
Recombination events between sister chromatid telomeres can be detected 
cytogenetically with a characteristic reciprocal pattern of hybridisation during 
CO-FISH (Bailey et al. 2004c). Elevated frequency of sister chromatid 
exchanges have been observed at sub-telomeres [210 x 10~9 SCE/(bp x cell 
generation] compared to the genome average [1.3 x 10-9 SCE/(bp x cell 
generation; (Rudd et al. 2007)]. In contrast, meiotic recombination is suppressed 
at telomeres (Baird et al. 1995; Baird et al. 2000). However, high frequency of 
the T-SCE has been documented in immortalised and cancer cells that maintain 
their telomeres by telomerase-independent methods (Bechter et al. 2004; 
Londono-Vallejo et al. 2004), implicating increased recombination. Furthermore, 
it has been shown that both human and murine cells that are telomerase-deflcient 
and /or have impaired DNA repair proteins exhibit spontaneous T-SCE (Bailey et 
al. 2004a; Londono-Vallejo et al. 2004). Moreover, embryonic stem cells with 
critically short telomeres and lack telomerase activity have been shown to exhibit 
high levels of telomere sister chromatid exchanges (Wang et al. 2005a; Wang et 
al. 2005b); implicating that this recombination-based process can be utilised by 
cells to compensate for telomere loss in the absence of telomerase. In support of 
this view, telomere sister chromatid exchanges are only elevated after telomerase 
inactivation in human cells and reactivation of telomerase abolishes these events 
(Bechter et al. 2004). Whilst telomere sister chomatid exchanges do not result in 
loss of genetic material per se, unequal T-SCE can result in telomere erosion and 
elongation on donor and recipient respectively (Muntoni and Reddel 2005; 
Muntoni et al. 2009).
1.16.5 Stochastic telomere deletion events
The analysis of telomeres at single molecule level has revealed that in addition to 
gradual telomere erosion due to end-replication and post replicative processing, 
telomeres are subjected to processes that generate truncated telomeres (Baird et 
al. 2003; Baird et al. 2006; Baird 2008). In addition, high frequency of extra
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chromosomal telomere repeat DNA, consistent with telomere breakage, has been 
reported in Fanconi anaemia lymphocytes (Callen et al. 2002) and ATM deficient 
mouse cells as well as in cells derived from AT patients (Hande et al. 2001). 
These events are similar to the telomere rapid deletion events described in yeast 
(Lustig 2003) and plants (Watson and Shippen 2007). However, in yeast and 
plants over-elongated telomeres are truncated to the genetically determined 
average telomere length through an intra-chromatid recombination process 
(Bucholc et al. 2001; Lustig 2003; Watson and Shippen 2007). In contrast, in 
human cells, the telomeres are truncated from genome-average to critically short 
telomeres regardless of telomerase status of the cell (Mumane et al. 1994; Baird 
et al. 2003; Baird et al. 2006). These telomeres have potential to fuse with other 
telomeres or double strand breaks and initiate chromosome instability. In fact, we 
have demonstrated that short telomeres below a certain threshold are capable of 
fusion (Capper et al. 2007; Letsolo et al. 2009). In MRC5 clone where the longer 
and shorter telomere alleles could be distinguished by polymorphisms in the 
telomere adjacent DNA, it was apparent that both alleles were involved in fusion, 
an observation consistent with gradual end-replication losses coupled with 
stochastic deletions resulting in short telomeres (Capper et al. 2007). Similarly, 
studies in immortal cell line (KB 319), have reported random rapid changes in 
telomere length which result in short telomeres that lack telomere signal 
(Mumane et al. 1994). However, no change in polymorphism in the sub- 
telomeric DNA was observed (Mumane et al. 1994), consistent with our studies, 
indicating that telomeres are not lost but random deletions generate short 
telomeres that are capable of fusion. Indeed the frequency of these shorter than 
average telomeres was correlated with increase in chromosomal fusions 
(Mumane et al. 1994).
The mechanism that generates human telomere rapid deletion events is not 
known. However, like in yeast, they could be a by-product of activity of the 
MRN complex and/or other repair proteins (Bucholc et al. 2001; Lustig 2003), 
which in humans could be resulting from resolution of the Holliday junctions at
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the t-loop. Supporting evidence comes from the observation that t-loop size 
extra-chromosomal telomere repeat containing circular DNA are frequent in 
human cells that maintain telomeres by recombination (Cesare and Griffith 2004; 
Wang et al. 2004). In addition such short telomeres and circular DNA has been 
reported in normal fibroblasts (Vidacek et al. in press). Alternatively, these 
events could be generated by spontaneous chromosome breakages that may occur 
when the stalled replication fork (on encountering telomere proteins such as 
TRF1 or TRF2) is resolved (Ohki and Ishikawa 2004). Another mechanism, 
oxidative damage which is known to be elevated at telomeres (von Zglinicki
2002) could lead to stochastic large telomere deletions through generation of SI 
nuclease-sensitive sites which could break creating single stranded breaks which 
are known to accelerate telomere shortening (von Zglinicki et al. 2000). In 
addition, oxidation may result in generation of double strand breaks. Evidently, 
mouse cells deficient from one of the base excision repair proteins that excise 
oxidised guanines (Oggl), display moderate telomere erosion at low oxygen 
tension levels (3%) but accelerated telomere erosions, high frequency of SSBs 
and DSBs under high oxygen tension [20%; (Wang et al. 2010)]. Another 
possible mechanism that could generate the events is unequal sister chromatic 
exchanges (SCE). As explained in section 1.16.4, unequal SCE can result in both 
telomere elongation and truncation. Indeed both longer and shorter than genome- 
average telomere lengths have been detected in human cells (Britt-Compton and 
Baird 2006). The short telomeres are of interest because they are capable of 
fusion and through cycle of breakage-fusion-bridging cycles can fuel large-scale 
rearrangements such as non-reciprocal translocations, amplifications and 
deletions (Mumane 2006) . Indeed studies have shown that short telomeres fuse 
with other telomeres as well as with other non-telomeric interstitial loci some of 
which are near fragile sites (Capper et al. 2007).
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Figure 1.6. Telomere hypothesis of cell ageing. The telomere length changes as a 
function of number of cell division. Germ cells are telomerase positive (Tel+) and 
maintain their telomere length with each cell division. Unlike germ cells, somatic cells 
are telomerase-negative, so their telomeres shorten with each cell division. Short 
telomeres signal cell cycle arrest and activation of senescent phenotype (Ml/Hayflick 
limit checkpoint). Cells can bypass Ml through oncogenic transformation events, but 
their telomeres continue to shorten until the chromosome function is impaired. Then 
cells enter crisis/M2 where most cells die. A few that emerge from crisis maintain 
length of telomeres by activating either telomerase or ALT and are thus immortal.
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1.17 Methods for determining telomere length
Several methods are employed to determine the telomere length as well as for 
detecting chromosomal aberrations resulting from telomere dysfunction. Some of 
these methods, their advantages and limitations are discussed below.
1.17.1 Terminal restriction fragment (TRF) analysis
TRF analysis employs the principle of Southern blotting analysis, which was first 
described by Southern in 1974 [(Sambrook et al. 1989); reviewed in (Saldanha et 
al. 2003)]. In humans, the genomic DNA is usually digested with frequent- 
cutters, Hinfl and/or Rsal; which digest the majority of the genomic DNA 
without cutting within the telomere repeat region (Moyzis et al. 1988; Allshire et 
al. 1989). The restriction fragments are then resolved by agarose gel 
electrophoresis and transferred to the membrane where they are detected by 
telomere-repeat containing probe [(Sambrook et al. 1989); review in (Baird 2005; 
Lin and Yan 2005); Figure 1.7].
TRF analysis has advantages that make it the most popular method for telomere 
length analysis. For example, it utilises standard molecular biology techniques, 
reagents and equipment and provides genome-wide telomere-length. However, it 
has several drawbacks. The requirement for concentrated DNA (microgram 
concentrations) limits the technique use to analysis of large number of cells or 
tissue samples. Furthermore, the TRFs contain an unknown length of the highly 
variable sub-telomeric sequences and proximal regions (l-3kb) of the human 
telomeres (Allshire et al. 1989; Mefford and Trask 2002), thus TRFs do not 
represent the accurate telomere length [reviewed in (Saldanha et al. 2003; Baird
2005). Moreover, the TRF represents the mean telomere length of all 
chromosomes not specific chromosomes, which may not be very informative as 
it is the shortest chromosome that triggers senescence (Zou et al. 2004b). 
Importantly, the key limitation is that: because TRF analysis is a hybridisation- 
based method, there is a threshold length below which telomere cannot be
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detected (Baird 2005). Thus, very short telomere lengths at which telomere 
dysfunction can occur may not be detected by TRF analysis. Despite these 
limitations, TRF analysis is widely used, and provides a good comprise between 
the accuracy and speed; thus has been successfully used in many epilogical 
studies (Valdes et al. 2005; Bataille et al. 2007).
-9.4kb
-4.4kb
-2.0kb
JL
\ X
Figure 1.7. Telomere restriction analysis gel, illustrating the smears that represent 
telomere length range in young and senescent fibroblasts. DMB unpublished.
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1.17.2 Slot blots and Hybridisation protection assay 
(HP A)
Unlike TRF analysis, slot blot measures the ratio of telomere to centromere 
content and requires the minimum of 9ng of purified DNA; thus abolishing the 
requirement for at least a microgram of DNA (Norwood and Dimitrov 1998).
The hybridisation protection assay (HPA) measures the ratio of telomere to Alu 
sequences up to the ratio of 0.01, which corresponds to approximately 2kb of 
mean TRF. Like slot blots, it requires low amounts of genomic DNA [10- 
3000ng; (Nakamura et al. 1999)]. In HP A, the need for unsheared pure DNA is 
abolished. Unlike TRF analysis, HPA is rapid and simple requiring 
approximately 45min and does not include the length of the sub-telomeric 
regions (Nakamura et al. 1999).
However, HPA and slot bots have the drawback of not measuring the actual size 
of the telomeres directly but the ratio of telomere to Alu repeats or centromere 
respectively. In addition, the large inter-individual variation in copy number of 
Alu sequences limits the use of these assays. Furthermore, like TRF analysis, 
HPA and slot blots cannot measure telomere length at the single-molecule level 
(Nakamura et al. 1999; Saldanha et al. 2003; Lin and Yan 2005). Consequently, 
the use of these techniques is rarely reported.
1.17.3 Fluorescence in situ hybridisation (FISH)
FISH has several advantages over TRF analysis, which make it suitable for 
telomere dynamics estimations: the requirement for isolating highly concentrated 
DNA is abolished as FISH uses metaphase chromosomes. It employs small size, 
single-stranded, synthetic telomeric-specific fluorescein isothiocyante (FITC)- 
conjugated or Cy3-labelled oligonucleotide (TTAGGG or CCCTAA) probes, 
which can easily penetrate the cells (McNeil and Ried 2000). In addition, the
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signal is visualised by fluorescence microscopy, which makes the procedure 
time-efficient, as the need for washing off unbound radioactive probes is 
abolished (Lansdorp et al. 1996; McNeil and Ried 2000).
FISH can be widely used with several adaptations for detecting chromosomal 
aberrations such as acentric fragments using a telomere probe (Hultdin et al. 
1998; Natarajan and Boei 2003).
1.17.3.1 Quantitative-FISH
The quantifying of telomere length by FISH method is called quantitative FISH 
[Q-FISH; (Hultdin et al. 1998; Martens et al. 2000)]. Unlike conventional FISH, 
Q-FISH utilises the peptide nucleic acid (PNA) oligonucleotides probes. PNAs 
are synthetic molecules that mimic DNA but their backbone sugar-phosphate 
molecule has been replaced by an uncharged flexible polyamide molecule 
(Pellestor and Paulasova 2004a; Pellestor and Paulasova 2004b). The PNA-FISH 
has the advantage of forming more stable complex than those formed by 
conventional DNA-DNA or DNA-RNA duplexes. In addition, the probes are 
more resistant to proteases and nuclease degradation. Furthermore, PNA-FISH 
procedure can be as short as two hours with the commercial kits, making it the 
preferred method for analysis of human telomeres (Lansdorp et al. 1996). In 
addition, PNA probes produce intense staining which improves sensitivity 
(Lansdorp et al. 1996). Unlike TRF analysis which require large amount of cells 
(>100000 cells), very few metaphase cells (<30 cells) are required for Q-FISH 
analysis. It can also be used to measure telomere length in cells that possesses the 
interstitial telomeres without overestimating telomere length as with TRF 
analysis. However it use metaphase spreads and thus requires cell culture and can 
only analyse proliferating cells (McNeil and Ried 2000).
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1.17.3.2 Flow-FISH
It is an adaptation of Q-FISH, in which the interphase cells are analysed by FISH 
coupled with flow cytometry (Ishikawa 1998; Rufer et al. 1998; Baird 2005). It 
provides the genome-wide telomere length assessment for single cells thus is 
more informative than use of TRF analysis (Baerlocher et al. 2002; Baerlocher et 
al. 2006). Flow-FISH has several advantages over FISH alone: several 
subpopulations of cells can be analysed at the same time (Brummendorf et al. 
2000; Brummendorf et al. 2001; Schmid et al. 2002). It can also be used to 
analyse telomeres in cells at different stages of the cell cycle without a need for 
metaphase spread preparation (Rufer et al. 1998; Baerlocher et al. 2002). FLOW- 
FISH has been employed extensively in studies of telomere length in blood cells 
(Rufer et al. 1998; Rufer et al. 1999; Brummendorf et al. 2000; Rufer et al.
2001).
1.17.3.3 Other FISH adaptations
Telomere/Immunostaining-FISH (TELI-FISH) combines the principles of FISH 
and immuno-staining techniques to measure telomere length. It requires fewer 
number of cells (10-15 cells) thus can be widely applied to several samples and it 
also gives telomere length estimates comparable to the mean TRF (Meeker et al. 
2002a).
The telomere/centromere-FISH on the other hand, measures the telomere length 
of every single chromosome arm in metaphase cells relative to the centromere of 
chromosome 2. The ratio of centromere to absolute telomere length is correlated 
with mean TRF to determine the telomere length. Since the method still employs 
TRF, it suffers similar drawbacks to those described with TRF analysis (section 
1.17.1). In addition, the requirement for capturing and karyotyping of metaphase 
images limit the application of the method to proliferating cells (Pemer et al.
2003).
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Finally, the fibre-FISH, a method that involves measuring telomeres on 
chromatin/DNA fibres is described in (Heiskanen et al. 1996). It determines 
telomere length of individual telomeres relative to the sub-telomeric probe of lq  
[lOOkb; (Heiskanen et al. 1996; van de Rijke et al. 2000)].
1.17.3.4 Chromosome-orientation FISH
CO-FISH is a strand-specific hybridisation method that is used for discriminating 
between different types of telomere fusions and for detection of telomere sister- 
chromatid exchanges [T_SCE; (Bailey et al. 2004a; Bailey et al. 2004c)]. The 
procedure involves growing cells in 5-bromodeoxyuridine (BrdUrd) and/or 
bromodeoxycytidine (BrdC) for one replicative cycle. Once cultured, cells are 
prepared by standard cytogenetic techniques and then cells are exposed to UV 
light in the presence of Hoechst dye. The UV exposure generates the breaks at 
the sites of BrdU/BrdC incorporation, which can serve as substrates for 
Exonuclease III, which will in turn remove all the newly synthesised strands 
leaving parental strands intact. The single-stranded sister chromatids can then 
hybridise to the DNA or PNA probe, producing two signals, one at either end 
corresponding to the leading-strand [(TTAGGG)n probe] and lagging-strand 
synthesised [(CCCTAA)n probe] telomeres (Bailey et al. 2004c). Thus this 
method can be utilised to distinguish different types of telomere fusions: 
telomere-telomere fusions, telomere-DSB fusions and telomere sister chromatid 
exchanges (Bailey et al. 2004b).
1.17.4 Primed in situ labelling (PRINS)
It involves the in situ annealing of synthetic oligonucleotide (CCCTAA)n for 
telomere detection, followed by primer extension in the presence of 
fluorochrome-labelled nucleotides (Therkelsen et al. 1995; Lavoie et al. 2003). 
This method offers several advantages in terms of sensitivity and specificity, 
owing to the use of PNA primers and to the fast kinetics of annealing and 
elongation reactions in situ. This in situ hybridisation technology is a faster
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alternative to conventional FISH for studying chromosomal aneuploidy and 
rearrangements, gene localisation and expression, and genomic organisation. In 
addition, it is fast, cost-effective, and produces intense and clearer signal (Lavoie 
et al. 2003; Yan et al. 2004). Furthermore, the conditions employed in PRINS 
prevent telomere reannealing. However, PRINS is not as appropriate for analysis 
of human telomeres which are short as it is, for detecting long repeat sequences 
such as those of mouse telomeres (Lavoie et al. 2003). However, like HPA and 
slot blotting, the use of this technique has not been reported extensively in the 
literature.
1.17.5 Quantitative polymerase chain reaction (Q-PCR).
The measurement of telomere length using Q-PCR was first described by Cawton 
(Cawthon 2002). Q-PCR measures the ratio of the telomere repeat copy to single 
copy gene number such that this ratio is proportional to average telomere length 
(Cawthon 2002). This method benefits from increased sensitivity and use of 
lower DNA concentrations compared to TRF analysis. Additionally, unlike TRF 
analysis, the estimated ratio does not include the variable sub-telomeric DNA 
[(Cawthon 2002); also reviewed in (Lin and Yan 2005)]. Furthermore, use of 
single gene copy avoid the problem of large inter-individual variation in copy 
number of Alu repeats, during the estimation of ratio of telomere length to Alu 
with HPA assays (Nakamura et al. 1999; Cawthon 2002).
Like slot blots, Q-PCR estimates relative telomere ratio but not the actual 
distributions of the telomere length. Nonetheless, this technique has been widely 
used for large epidemiological studies (Cawthon et al. 2003; Njajou et al. 2007; 
Shen et al. 2007; Zhang et al. 2007).
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1.17.6 Single Telomere Length Analysis (STELA)
STELA is a single-molecule PCR-based technique that determines the full 
spectrum of telomere length of the double-stranded telomere repeat region of a 
specific telomere [(Baird et al. 2003); reviewed in (Baird 2005); (Figure 1.8)]. 
First, the single stranded linker oligonucleotide called telorette, that targets the 3' 
overhang is ligated to the 5' end of the telomere. Then the telomere length of a 
given sample is determined through this simple procedure: multiple PCR 
reactions containing 4-10 amplifiable (250pg) molecules each are carried out 
with the linker, teltail and chromosome-specific telomere-adjacent 
oligonucleotide primer (Figure 1.8). The molecules are detected by Southern 
hybridisation with the chromosome-specific telomere adjacent probes and/or 
TTAGGG-containing probes after resolving by gel electrophoresis (Baird et al.
2003). The STELA was originally developed for analysis of XpYp telomere 
(Baird et al. 2003) and has since been extended for analysis of autosomal 
telomeres; 2p, 1 lq, 12q and 17p (Britt-Compton et al. 2006) as well as C.elegans 
(Cheung et al. 2004). Recently an adaptation of the STELA technique called 
“universal STELA” has been reported (Bendix et al. 2010). Unlike chromosome- 
specific STELA, this universal method estimates the telomere length from almost 
all chromosomes (Bendix et al. 2010). However, the discussion in this section 
will be limited to chromosome-specific STELA.
STELA exhibits several advantages over TRF analysis: with STELA very short 
telomeres that have potential to trigger replicative senescence or initiate genomic 
instability can be detected. In addition, STELA requires very low concentrations 
of DNA (in picograms) thus can be applicable to a broad spectrum of samples 
(Baird et al. 2003; Baird et al. 2006; Britt-Compton et al. 2006). In addition, the 
telomere length of specific telomeres in base pairs can be measured instead of the 
overall mean for all telomeres. Furthermore, STELA does not suffer from a 
lower length detection threshold thus STELA show a broader range of telomere 
distribution. For instance, using STELA large telomere variation up to and
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Figure 1.8. Single telomere length Analysis (STELA) at XpYp telomere. A. 
Outline of the assay with oligonucleotide primers indicated, [Reproduced from 
(Baird et al. 2003)]. B. STELA at XpYp in young and senescent HCA2 cells, each 
fragment represents a single telomere molecule (DMB unpublished). C. Allele- 
specific STELA in Clonal fibroblast cell line (MRC5), illustrating telomere 
distributions with narrow variance superimposed by sporadic short telomere 
molecules (indicated with red markers), modified from Baird et al 2003.
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beyond 20kb have been reported (Baird et al. 2006). Furthermore, by utilising the 
extensive sequence polymorphism within the telomere-adjacent DNA, each allele 
can be analysed separately thus revealing large allelic variation at the same 
telomere [Figures 1.8A and 1.8C; (Baird et al. 2003)]. Moreover, the length of 
the telomere-adjacent DNA can be compensated for by determining the distance 
(in nucleotides) between the oligonucleotide primer and start of telomere. Thus 
telomere length estimated by STELA does not include the sub-telomeric 
sequences (Baird et al. 2003). In addition, by combining STELA with telomere 
variant repeat PCR, the actual telomere lengths comprising homogeneous arrays 
of TTAGGG repeats can be determined after correction for the proximal variable 
telomere variant repeat region, which is considered to be the non-functional 
telomere repeat region (Baird et al. 1995; Capper et al. 2007). In addition, a 
single STELA experiment yields a massive dataset, thus it is more informative 
than TRF analysis. Again, unlike TRF analysis, it does not suffer hybridisation 
inefficiency as the small molecules can be detected (Baird et al. 2003).
The STELA has disadvantages of being laborious, as it requires several PCRs for 
each telomere. In addition, it requires good quality DNA, which limits its 
applicability to non-degraded and non-fixed material (Baird 2005). Furthermore, 
it does not give histological information and the complex hyper-variability of the 
sub-telomeric DNA limit the assay to a subset of telomeres (Mefford and Trask 
2002; Riethman et al. 2005).
Using STELA, it has been shown that some senescent cells have telomere length 
distributions as small as 0.3kb (Baird et al. 2003; Baird 2005; Britt-Compton et 
al. 2006). In addition, STELA can detect broad range of telomeres from very 
short to very long telomeres, which is an important aspect for in vivo studies 
where large heterogeneity in telomere length is expected. Importantly STELA 
can detect telomeres within the length range at which telomere dysfunction and 
fusion occurs, these telomeres cannot be detected with any other assay. It is thus
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a powerful technique for assessing the full extent of telomere erosion, deletion 
and dysfunction in human cells.
1.17.7 Telomere fusion assay
Telomere fusion assay is a PCR-based assay that allows the detection of the 
telomere-telomere fusion molecules between specific chromosomes (Capper et 
al. 2007; Letsolo et al. 2009). It can detect the fusion events including sister- 
chromatid-type fusion when there is a deletion in at least one of the ends creating 
an imperfect inverted repeats. It can also detect sister-chromatid-type fusion 
between heterologous chromosomes containing substantial arrays of head-to- 
head repeats as in cells with TRF2 knockdown (Capper et al. 2007). However, it 
cannot detect sister-chromatid type fusions that create perfect inverted repeats as 
in fusion between two homologous chromosomes without any deletion; as such 
events have potential to form palindromes (Capper et al. 2007; Letsolo et al. 
2009).
The procedure involves DNA amplification using the oligonucleotide PCR 
primers designed on the sub-telomeric telomere adjacent of the specific 
chromosome ends that are orientated 5 -3 ' towards the chromosome termini 
(Figure 1.9). To detect the fusion events, multiple PCR reactions containing 10- 
lOOng of DNA are carried out. Following amplification, the products are 
resolved by gel electrophoresis and the products are detected by Southern 
hybridisation with chromosome-specific telomere-adjacent probe. The putative 
fusion molecules are then re-amplified in semi-nested PCR reactions with one in 
twenty dilutions (1 in 20) of the original fusion PCR product. Following 
successful re-amplification the molecular structure of the fusion events and 
chromosomes involved in fusion are confirmed by direct sequence analysis 
(Capper et al. 2007). The telomere fusion assay was originally developed for two 
chromosomes, XpYp and 17p (Capper et al. 2007) and has since been extended 
to include at least 43% of the human genome (Capper et al. 2007; Letsolo et al.
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Figure 1.9. Telomere fusion assay. A. Schematic representation of the telomere fusion 
assay with oligonucleotide primers orientated 5-3' towards the telomeres for XpYp (top 
panel) and 17p (middle panel). The amplification can only occur when there is a fusion 
between the two chromosome ends (bottom panel). B. Telomere fusion gel illustrating 
fusion bands representing fusion events between XpYp and 17p telomeres in MRC5 cells 
undergoing crisis. Molecules were detected with telomere-adjacent XpYp probe. 
XpYp:XpYp, XpYp:17p and 17p:17p assays are shown. MW represents molecular 
weight while PD is population after which cells were harvested
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2009). Using this assay, we have shown that fusion of short dysfunctional 
telomeres is accompanied by large deletion events extending into the sub- 
telomeric region, short patches of micro-homology nucleotides and lack of 
TTAGGG repeats at fusion junction (Capper et al. 2007; Letsolo et al. 2009).
1.18 Aims of the project
The main objective of this study was to translate the knowledge of telomere 
dynamics obtained in vitro using the single-molecule telomere assays, to human 
tissues in vivo. To accomplish this, several aims of the project were proposed:
i. First part of the study was aimed at technological development and 
improvement of the two high-resolution PCR-based techniques, STELA and 
telomere fusion assays.
❖ STELA has been previously developed for analysis of XpYp (Baird et 
al. 2003) and four autosomal telomeres, 2q, llq , 12q and 17p (Britt- 
Compton et al. 2006). Thus, the present study was aimed at developing 
the STELA assay to include additional human telomeres, especially 
those with relevance to human cancers.
❖ The telomere fusion assay was originally developed for the analysis of 
fusion events between telomeres of XpYp and 17p (Capper et al. 
2007). Analysis of two telomeres was limiting, as it required analysis 
of several thousands of cells to detect what appeared to be rare events. 
Given the number of different chromosomes involved in chromosome 
instability in cancer and other diseases, it was essential to extend the 
assay to include additional telomeres.
❖ Using STELA and telomere fusion assay it has been demonstrated that 
telomeres are subjected to processes that generate short telomeres that
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are capable of fusion (Capper et al. 2007). It is known that telomere 
dysfunction can initiate genomic instability through anaphase-bridge- 
breakage cycles that can result in large-scale rearrangements such as 
non-reciprocal translocations (Artandi et al. 2000; Feldser et al. 2003). 
However, the mechanisms that underlie the fusion of short 
dysfunctional telomeres are unknown. Thus in an attempt to 
understand the mechanism that underlies these events, molecular 
structure of fusion events was characterised using the extended and 
improved assays. The data set collected with this study will be used as 
a reference for the experimental models that are aimed at 
understanding the mechanistic basis of fusion.
ii. The second aim was to utilise the improved assays to investigate telomere 
instability and fusion in normal human tissues. Telomere dynamics were 
investigated in human melanocytic naevi and surrounding dermal samples. 
The naevi represent a good model for study of telomere dynamics in 
senescent cells in vivo as cells remain senescent and dormant for years even 
though the naevi predispose to the deadly melanoma in susceptible 
individuals (Robinson et al. 1998). Melanocytic naevi consist of functionally 
viable melanocytes (Bandyopadhyay et al. 2001; Bennett and Medrano 2002; 
Bennett 2003; Mooi and Peeper 2006) which have undergone senescence 
following oncogenic mutations (Michaloglou et al. 2005). They can remain 
dormant for many years yet they predispose to melanoma in susceptible 
individuals (Skender-Kalnenas et al. 1995; Bennett and Medrano 2002).
iii. One of the biological processes than may drive neoplastic progression is 
telomere dysfunction (Artandi et al. 2000; Rudolph et al. 2001), thus another 
aim of the study was to investigate telomere erosion, instability and fusion in 
preneoplastic condition, Barrett’s oesophagus. Barrett’s oesophagus is the 
premalignant and metaplastic condition that predisposes to oesophageal 
adenocarcinoma [reviewed in (Wild and Hardie 2003; Maley 2007). It is a
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good model for carcinogenesis studies of solid tumours for a number of 
reasons: first, unlike other benign tumours such as adenomatous polyp in the 
colon, Barrett’s oesophagus tissue is not removed upon detection because of 
the low number of progressions to adenocarcinoma (Jenkins et al. 2002; 
Maley 2007). Secondly, it is easily visualised by endoscopes. In addition, it is 
easily and safely biopsied to track the progression overtime. Furthermore, the 
genetic changes associated with progression from Barrett’s metaplasia to 
oesophageal adenocarcinoma are universal in most human cancers, e.g. LOH 
at p53, pl6, aneuploidy etc (Gonzalez et al. 1997; Jenkins et al. 2002; Maley 
2007). Although periodic endoscopy surveillance are suggested for people 
with Barrett’s oesophagus, the question for cost-effectiveness and time 
remains controversial due to low percentage of progression to 
adenocarcinoma (van der Burgh et al. 1996; Sampliner 2002). In addition, 
some patients diagnosed with the putative high-risk histological stage, 
dysplasia revert (Reid et al. 2000). Finally, the large inter-observer variation 
among pathologists and histologists when identifying the histological stage 
dysplasia from Barrett’s oesophagus mucosa, complicates the diagnosis such 
that some individuals that are diagnosed as having dysplasia are already 
having carcinoma in situ (Reid et al. 1988). Thus, identification of more 
biomarkers that may be used for identifying patients at highest risk of 
progression is essential.
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2 Materials and Methods________________________
2.0 Chemicals and Molecular Biology reagents
Chemicals were obtained from Fisher Scientific (part of thermo fisher scientific, 
Loughborough, UK) and molecular biology reagents obtained from Gibco 
BRL/invitrogen Ltd (Paisley, UK), Stratagene (La Jolla, California), ABgene 
(Surrey, UK), Promega (Southampton, UK), New England Biolabs (UK) Ltd 
(Herts, UK), Roche Products Ltd (Hertfordshire, UK).
Radiochemical reagents were obtained from Amersham biosciences/GE 
Healthcare UK Limited (Bucks, UK) and PerkinElmer Life and Analytical 
Sciences (Milano, Italy). Whilst cell culture reagents were obtained from 
Invitrogen Ltd/Gibco (Paisley, UK), Sigma-Aldrich Company Ltd (Dorset, 
England) and Autogen Bioclear Ltd (Wiltshire, UK). Liquid nitrogen tanks were 
supplied by BOC cryospeed (Manchester, UK).
2.1 Plastic labware
Cell culture labware, all other plastics and glassware were obtained from Becton 
Dickson labware (Franklin, USA), Gilson (Middleton, USA), thermo electron 
corporation (Gormley) and Eppendorf (Cambridge, UK).
2.2 Equipment
Specialised equipment was obtained from Bio-RAD (Hertfordshire, UK), MJ 
Research (USA), MSE (UK) Limited (London,UK), Hybaid (Teddington, UK), 
Bioquell Ltd (Hampshire, UK), DJB Labcare Ltd/Heraeus (England, UK), 
Labcold (formerly Borolabs, Bakingstoke, UK), Patterson scientific (Cambridge, 
UK), GRANT instruments Ltd (Cambridge, UK), Thermo electron corporation 
(Gormley), Amersham biosciences (Buckinghamshire, UK), IBS integrated 
biosciences (Lewisberry, USA), Jencons-PLS (West Sussex, UK), Molecular 
dynamics (American laboratory trading, Groton), Qiagen (West Sussex,UK) and
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scientific laboratory supplies Ltd (Nottingham, UK). Microscopes were supplied 
by Olympus UK Ltd (Hertfordshire, UK).
2.3 Oligonucleotides
The oligonucleotide primers were designed using the human DNA sequences 
obtained from the databases, http://www.wistar.upenn.edu/Riethman/, National 
Centre for Biotechnology Information (NCBI) and UCSC human genome 
bioinformatics. The oligos were then synthesised by MWG-Biotech AG 
(Ebersberg, Germany). All oligonucleotide primers used during this study are 
shown in Table 2.1.
Table 2.1 Oligo nucleotide primers used in the study. The distance from start of 
telomere tracts for STELA primers is shown in parenthesis. While * denotes first-round 
PCR telomere fusion primers and ** for Semi-nested PCR primers. XpYp, 1 lq and 17p 
primers have been described in (Baird et al., 2003; Britt-Compton et al., 2006; Capper 
et al., 2007).
Primer name 17p primer Sequence
17p2 5'-GAG TCA ATG ATT CCA TTC CTA GC-3’
17p5 5'-TTT TCA TTA GGA TCC AGT TTG-3’
17p6* 5'-GGC TGA ACT ATA GCC TCT GC-3'(3078bp)
17p6B**A 5'-CTG AAC TAT AGC CTC TGC AAT G-3'
17p6C**A 5'-TGA ACT ATA GCC TCT GCA ATG GAT-3’
17p7** 5'-CCT GGC ATG GTA TTG ACA TG-3' (301 lbp)
17PSEQ1 5-CCT CAG CCT CTC AAC CTGCTT-3'
17pseqlA 5-CCT CAG CCT CTC AAC CTC GTT-3'
17pseqlrev 5-GAA TCC ACG GAT TGC TTT GTG TAC-3' (313bp)
17pseq2 5’-CCT CAG CCT CTC AAC CTC GTT-3’
17pseq3 5'-AGA ATC CTG TCC TCA ACA AGT-3'
Primer name 1 lq  Primer Sequence
1 lq l2 5'-CCC TGA TTA TTC AGG GCT GCA AAG-3'
1lql3B 5'-CAG ACC TTG GAG GCA CGG CCT TCG-3’ (105bp)
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Primer STELA universal primers sequences
Teltail 5-TGC TCC GTGCAT CTG GCA TC-3'
Telorette2 5'-TGC TCC GTG CAT CTG GCA TCT AAC CCT-3’
Primer name XpYp Primer Sequence
XpYp 433AT 5-GGT TAT CGA CCA GGT GOT CT-3'
XpYp 433GC 5-GGT TAT CGA CCA GGT GCT CC-3'
XpYp-427A/415T 5-GGTTATCAACCAGGTGCTCT-3'
XpYp-427G/415C 5-GGTTATCGACCAGGTGCTCC-3'
XpYpB2 5 -TCT GAA AGT GGA CC(A/T) ATC AG-3'
XpYpC 5 -CAG GGA CCG GGA CAA ATA GAC-3'
XpYpE 5-TTG TCT CAG GGT CCT AGT G-3'(406bp)
XpYpG 5'-AAT TCC AGA CAC ACT AGG ACC CTG A-3'
XpYpJ 5'-CTA ATC TGC TCC CWC CCA C-3'
XpYpM* 5'-ACC AGG TTT TCC AGT GTG TT-3'
XpYpMB**A 5'-AGG TTT TCC AGT GTG TTA TC-3'
XpYpMC**A 5'-CCA GTG TGT TAT CTA TCT AC-3’
XpYpO** 5'-CCT GTA ACG CTG TTA GGT AC -3'
XpYpP 5'-ACC AGG GGC TGA TGT AAC G-3'
XpYpQ 5'-CCA TGA GAC ACA AAG GAC TC-3'
A Duncan Baird (unpublished)
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Primer name 17q Primer Sequence
17qlREV 5'-TAA ACA TCT GTT GGT GCT TGT GG-3'
17q2 5'-AGA TAA CAG ACG TCT ACA CAG CTC G-3'
17q3 5'-CAA ACT CCT GAG ATC CAT GTG TC-3'
17q4 5'-CGT GGA GAG GGT CAC TGT GCA CGT G-3’
Primer name 21q Group primer Sequence
lOqASF 5-GCT CTG ACTTTA AGTGGTGC-3'
10Q1 5-AGG TTC CAC TCG TCT CTG CG-3'
lOqlA 5'-TGC AGC CAC GAC AAT GGC AG-3'
10q2 5’-TGC AAT GTC CCT AGC TGC CAG(C)-3'
10q3 5'-AG(C)A CAC AGG ATA GTG GGC TCT G -3'
10q4rev 5-TGC ACG CGC AGA GAC ACA CG-3'
lOqA 5'-GAA ACA CCC TAG AAC TTC TCT TG-3'
lOqFMS 5'-CTT AAC AAG GTC TCT TCC AGA G-3'
10qSTEL3 5'-CTA ATG CAC ACA TGA CAC CCT-3'
10qt21 5'-GTA CTG CCT GCC TTT GGG AT-3' (277bp)
19pl 5'-AGC AGA GTT CTC CTC AGG TC-3'
21Q1* 5-CTT GGT GTC GAG AGA GGT AG-3'
21qlB**A 5'-TTG GTG TCG AGA GAG GTA GC-3'
21qlC**A 5'-GTG TCG AGA GAG GTA GCT TTT AAA TG-3'
21Q2CT 5'-AGT AGC ATC TC(CT) AGT GCT GGA G-3'
21q3 5-CTG CAG TTG TCC TAG TCG C-3'
21q5rev 5'-GGT GTG TGC TAA AGA GAA CG-3'
21qA 5-GTA CTG CAT GGC TTT GGG AC-3'(277bp)
21qB 5'-GTT GCT GCC CTG AAT AAT CAA GGT CAC-3'
21qBTl 5'-TTT GGG AGG CCA AGG CGG GC-3'
21qBT2 5'-TTT GGG AGG CCG AGG CGG GT-3'
21qC 5'-AGA GTT CTT CTC AGG TCA GAC CTG-3'
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Primer name 21 q Group primer Sequence
21qD 5'-GGC GAG GGG CTG TAT TGC AC-3'
21qE 5'-GCG AGG GGC TGT ATT GCA CG-3’
21qseql** 5'-TGG TCT TAT ACA CTG TGT TC-3'
21qseqlrev 5'-AGC TAG CTA TCT ACT CTA ACA GAG C-3'
21qseq2 5'-TGC CCC AAT CAT CAT TCA CTC TGC-3'
21qseq2rev 5'-CTC GAT CTC CTG ACC TCA TGA TC-3’
5qlA 5'-AGC ACC TCT GGC AGT TTG-3'
6pl 5'-CTG CAC AGG ACT CCT AGG ATG-3'
6p2REV 5'-CGA CAG ACT GAC GCG ACG TG-3'
6qlA 5-TCA TGA TGC ATG CTG TGT GTC-3'
6q2A 5'-TCT TAC ACT GTC TCT CTG GC-3'
8pl 5-TGC ACA GGA CTC TTA GGC TG-3'
Subtel 3b 5-GTA CGC TGT CTTCAT GGC AG-3'
SubtellA 5-AAG GCG GAG CAG CAT TCT TCT CAG -3'
Subtel2A 5'-GAA TCC TGC GCA CCG AGA TTC TC-3'
SUBTEL2rev 5'-GAG AAT CTC G(GC)T GC (AGC) CAG (GC)AT TC-3'
SUBTEL3REV 5'-GTG CTT AGG AAT GCT GCA TTT G-3'
A Duncan Baird (unpublished)
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Primer name 16p Group Primer Sequence
15qA 5'-ATC GGA ACG CAA ATG CAG CAG-3' (73bp)
15qSEQl 5'-TGT CGG ATC TCT TCA ACA AGC-3'
16pl* 5'-TGG ACT TCT CAC TTC TAG GGC AG-3'
16plB** 5'-ACT TCT CAC TTC TAG GGC AGA G-3'
16p2** 5-CTA GAG AGG AAG CAG GGA GTA TC-3'
16p2BTL 5'-TCA CTG CTG TAT CTC CCA GTG-3'
16p5 5-TAG CAT GTG TCT CTGCGC CTG-3’
16p6 5'-CTC CAC TCC AGT GCT CAG CTT G-3'
16pBT 5'-AGT GAA GCT TTC CTC TCT AAG C-3'
16pseql 5'-TGC CTC ACC TCT CTG GGC CAG -3'
16pseqlrev 5 -GCT GGG TGA GCT TAG AGA GGA AAG C-3'
16pseq2 5 -CTT GCC AGA GCT CCT CTC CAG-3'
16pseq2B 5'-GCT CCA GAT GAC ATC ACA GGG -3'
16pseq3 5'-TCC AGG GCT TCA CCT GT( C) TAG -3’
16pseq4 5-TGG GTC CTG GCA ACA CTC TG-3'
16pseq4rev 5'-CTA GGT GGG ATC TCT GAG C-3'
16pseq5rev 5’-TGC TTG TGC TCA TCT CCT TGG C-3'
lpseqlA 5'-TCA GTG ACA GAC ACA GGG TCT C-3'
lpseq2BT 5'-TGC AGC TGC CTG TCA GGA AG-3'
SUBTEL 3a 5'-GCC GTG CGA CTT TGC TCC TG-3'
9pl 5'-TGC GTT CTC GTC AGC ACA GAC CC-3'
9p2 5'-CAC ATT CCT CAT GTG CTT ACG-3'(16bp)
9p3 5'-AAA CAG GCA CTC CTA GAC ATT GG-3'
XqYqseql 5'-TGC ACA GAT TTC G(A)G TGG TAC-3'
XqYqseq2 5'- GTT GCT CTG ACA TGG ACA CAG-3'
XqYqseq4 5'-TCT CTA GCT GTG CAG GAT GC-3'
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2.4 Samples
Patient-matched oesophageal and gastric epithelial tissue samples were obtained 
from Dr Gareth Jenkins (University of Wales, Swansea, Table 2.2) and Professor 
Nicol Keith (Centre for Oncology & Applied Pharmacology, Glasgow; Table 2.3 
and appendix) for collaborative work. The tissue samples obtained from Swansea 
were composed of squamous epithelium, Barrett’s metaplasia and gastric mucosa 
(Table 2.2). However, no data was provided (by collaborators) regarding the 
composition and quality of these samples.
Tissue samples obtained from patients undergoing endoscopy at the Glasgow 
royal infirmary were derived 2cm above the Z-line and every 2cm below the Z- 
line at the distal oesophagus. These samples were taken in triplicate; one for 
histopathology, one for telomerase activity analysis (Going et al., 2004), the 
remaining material following telomerase extracts was used for STELA and 
fusion analysis. Additional samples were derived from the oesophago-gastric 
junction as well as the gastric body and antrum (Table 2.3). The presence or 
absence of the different mucosal types was recorded for each biopsy as outlined 
in (Going et al., 2004). However, that data was not supplied with the samples 
used for this study, thus it may be difficult to comment on the quality and purity 
of these samples at present.
Skin samples were obtained from Professor Tim Spector (Twin Research & 
Genetic Epidemiology Dept, King's College London, St Thomas’ Hospital 
Campus; Table 2.4). The skin samples were obtained from dissected melanocytic 
naevi from female patients recruited for the twin study at St Thomas’ Hospital 
Campus. The melanocytic naevi was macro-dissected and separated from the 
surrounding dermis with the clean scalpel. However the actual cell composition 
of each sample was not verified. Thus it is possible that the melanocytic naevi 
preparations also contained epidermal keratinocytes and some cells from the 
dermis and vice versa for the dermal preparations.
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Ethical approval for use of human tissues was obtained as follows: for skin 
samples from Guy's and St Thomas NHS Trust ethics committee, oesophago- 
gastric samples from Glasgow Royal Infirmary Research Ethics committee 
(Going et al., 2004) and by Dyfed Powys LREC in Aug 2006 (ref no. 
06/WMW01/28) at Singleton and Morrison Hospital, Swansea, with written 
permission from participating patients.
Table 2.2 Oesophageal and gastric tissue sample obtained from 14 patients undergoing 
periodic endoscopy for Barrett’s oesophagus at Morrison hospital Swansea, UK.
Key: x-sample present, No DNA-means DNA extraction failed, None-no sample 
provided.
Patient ID
Squamous
Mlucosa Barrett's tissue Gastric Mucosa
144321 X X X
867688 X X X
814850 X X X
723792 X X X
753522 X X X
266355 X X X
744342 X X X
408975 X no DNA X
172729 X X X
345077 none X X
409390 none X X
218883 none X X
148058 none X X
21616 none X X
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Table 2.3 Oesophageal and gastric tissue samples taken from 26 patients undergoing 
periodic endoscopy for Barrett’s oesophagus at the Glasgow royal Infirmary, UK. Key: * 
Minimal dysplasia: ** Severe dysplasia: ***Patient with Tumour: for Tumour that was not 
classified i.e. either from oesophagus or gastric tissue, assumed was oesophageal tumour; 
none=no tissue sample provided. Normal represents the normal oesophageal squamous 
epithelial tissue.
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P a tien t ID
Norm al
Z-line
B a rre tt's  o e so p h a g u s  s e g m e n t -d is tan ce  (cm into  th e  o e so p h a g u s O-G
Junction Body A ntrum23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
600426L 113 114 107 108 109 110 112 111 106
600822W 124 125 116 117 118 119 120 121 123 122 115
608163H 132 133 127 128 129 131 130 126
648384K 140 141 135 136 137 139 138 134
701142B NONE 151 143 144 145 146 147 148 150 149 142
718557V 158 159 153 154 155 157 156 152
736499H 165 166 161 162 164 163 160
772131M 173 174 168 169 170 172 171 167
777314L 184 185 176 177 178 179 180 181 183 182 175
823098V 193 NONE 187 188 189 190 191 NONE 192 186
828803R 202 203 200 195 196 197 198 201 199 194
892847L 209 210 205 206 208 207 204
977002H 216 217 212 213 215 214 211
998755H * 227 NONE 219 220 221 222 223 224 225 228 226 218
3006544L** 237 238 230 231 232 233 234 236 235 229
41198R 336 338 333 334 337 335 332
484438X 348 349 340 341 342 343 344 345 347 346 339
312135E 57 58 52 53 54 56 55 51
454788X 64 65 60 61 63 62 59
482970M 71 72 67 68 70 69 66
492062K 81 82 74 75 76 77 78 80 79 73
507097W NONE NONE 84 85 86 87 88 90 89 83
591099E 97 98 92 93 94 96 95 91
594360R 104 105 100 101 103 102 99
Tissue A djacen t to  T um our OESOPHAGEAL TUMOUR GASTRIC TUMOUR
891759L*** 301 NONE 302 303 300 299 298
464583W *** 316 NONE 313 3 1 7 $ NONE 315 314
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Table 2.4. The melanocytic naevi and the surrounding dermal tissue from 19 patients 
* denotes same patient but two naevi samples.
Patient ID
Melanocytic
naevi Dermis
98592 X X
95981 X X
32811A* X
3281 IB* X X
20561 X X
20562 X X
32812 none X
52894 X X
17442 none X
93941 none X
93942 X X
2492 X X
2493 X X
94041 X X
97051 X X
18261 X X
93983 X X
06651 X X
06652 X X
98591 X X
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2.5 Cell culture
All cell culture work was carried out in a suitable Microflow Advanced 
Biological Safety Cabinets category class II flow hood (Bioquell).
The cells were incubated in 5% CO2 at 37°C and sub-cultured when confluent 
using standard techniques. Human embryonic kidney cell line, HEK293 (Graham 
et al., 1977) and human breast cancer cell line, MCF7 (Soule et al., 1973) were 
cultured in 88% Dulbecco's Modified Eagle's Medium (DMEM) containing 
4,500 mg/L D-glucose 110 mg/L sodium pyruvate, and non-essential amino acids 
but no L-glutamine (Invitrogen), supplemented with 10% (v/v) Foetal Calf 
Serum (FCS; Invitrogen), lx l0 5 IU/L penicillin (Sigma), 100 mg/L streptomycin 
(Sigma) and 2 mM glutamine (Sigma). The human fibroblast MRC5 (mixed 
population; Rebecca Capper, personal comm.) and MRC5 (Jacobs et al., 1970) 
cells expressing the human papilloma viral oncoproteins E6E7 were cultured in 
Eagle’s minimum essential medium supplemented with Eagle’s salts containing 
2x nonessential amino acids (Sigma), G418 (0.4mg/ml), HEPES (Sigma), sodium 
bicarbonate (7.5% solution, Gibco), 15% Foetal Calf serum, 1 x 105 IU/L 
penicillin (Sigma), 100 mg/L streptomycin (Sigma) and 2 mM glutamine 
(Sigma).
The cells were fed regularly and reseeded until confluent. For re-plating, cells 
were passed by removing the medium with the aspirator. The cells were then 
washed with l-2ml of trypsin (0.05% trypsin and 0.02% EDTA (Autogen 
Bioclear, biomedia). Once washed, cells were then trypsinised at 37°C with 1- 
2ml (1 for T25 and 2 for T75) of fresh trypsin until cells were detached. 
Trypsinisation was stopped by addition of medium to make the final volume of 
10ml after which the cells were counted on haemocytometer.
Depending on the number of cells, a fraction of cells was resuspended in medium 
and replated.
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2.5.1 Cells freezing and thawing
Some cells were frozen in liquid nitrogen to enable long-term storage for future 
experiments. To minimise ice damage, cells to be freezed were resuspended in 
equal amounts of medium and freezing mix (1:4 dimethyl sulphoxide (DMSO): 
foetal calf serum) prior to transferring to the ampoule. The ampoules were then 
stored in isopropanol at -80°C prior to transferring into liquid nitrogen.
Whenever required, frozen cells were quickly thawed at 37°C and transferred to 
centrifuge tube, into which 9ml of medium was added drop-wise to minimise 
osmotic shock. The cell suspensions were then centrifuged at 1000 rpm for 5 
minutes and the supernatant removed. Fresh medium was added prior to re­
plating.
2.6 DNA extraction and quantification.
2.6.1 Cells
When confluent, cells were treated with trypsin and washed in lx  phosphate- 
buffered saline (PBS). The cells were then pelleted by centrifuging at 1000 rpm 
for 5 minutes. The cell pellet was resuspended in 1.5ml of fresh lx PBS and 
pelleted again by centrifuging at 6000 rpm for 5 minutes. The pellet was then 
stored at -20°C until required for DNA extraction.
The DNA was extracted from the cells using phenol/chloroform extraction 
method (Sambrook et al., 1989). The procedure involved lysing the cells with 
300-500pl lysis buffer (lOmM Tris-HCl pH8.0, lOOmM NaCl, 5mM EDTA pH 
8.0, 0.5% SDS). The lysis buffer and cells were mixed thoroughly by flicking 
until the solution was clear. The RNA was degraded by the addition of 3 pi 
RNase A (Sigma; stock, lOmg/ml) and the proteins were digested using 60 pg 
proteinase K (Sigma: stock, 20mg/ml). The cell solution was then incubated at 
45°C overnight after which DNA was extracted by addition of 300-500pl of
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phenol: chloroform: isoamyl alcohol (25:24:1) to the cell solution mixing 
thoroughly but gently by rotating solution on tube rotator for atleast 2 x 30 
minutes. The cell debris and proteins were separated from DNA by 
centrifugation at 13000 rpm for 5 minutes on Heraeus Biofuge Pico 
microcentrofuge (DJB labcare). The aqueous layer containing DNA was then 
removed and DNA was ethanol-precipitated using 1/10* 3M sodium acetate 
(pH5.3; Sigma) and 4x the volume of iced-cold absolute ethanol (Fisher) at -20°C 
for atleast an hour. The DNA pellet was desalted by quick wash with 70% ice- 
cold ethanol and air-dried in the micro-flow hood. The air-dried DNA was either 
resuspended in 10 mM Tris-HCl, pH 8.0 (Sigma) or in lx  Ecorl or Notl buffer 
(Promega).
The high molecular weight DNA was solubilised by digesting with either EcoRI 
or Notl (Promega) for atleast 8 hours at 37°C, followed by enzyme inactivation at 
65°C for 10 (Ecorl) to 15 (Notl) minutes, or serially diluted in lOmM Tris prior 
to quantifying.
2.6.2 Tissues
Frozen tissues were disrupted with a tissue ruptor homogeniser (Qiagen) in lysis 
buffer and genomic DNA was extracted by standard proteinase K, RNase A and 
phenol/chloroform protocols (Sambrook et al., 1989) as outlined in section 2.6.1 
except that the lysis time was reduced to 6 hours at 45°C.
High molecular weight DNA was solubilised as outlined in Section 2.6.1.
2.6.3 DNA Quantification
The DNA concentration was estimated in triplicate using Hoechst 33258 
fluorometry (BioRad) and / or Nanodrop ND-1000 system (Thermo scientific).
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2.7 DNA Amplification and Enzymatic manipulation
All genomic DNA manipulation was carried out in either microflow category II 
advanced biosafety class II hood (Bio-quell) or in PCR-clean environment 
designated for that work to minimise contamination risk. All PCR reactions were 
cycled on MJ PTC-225 thermocycler (MJ Research).
2.7.1 Single TElomere Length Analysis (STELA)
The genomic DNA for telomere length analysis was first diluted to lOng/pl with 
lOmM Tris (pH8.0, Sigma). The diluted DNA was then diluted to 250pg/pl 
containing 0.25 pM telorrette 2 (Tel 2) primer.
Replicates/ Multiple (typically 6-8) PCR reactions containing lx  Taq reaction 
buffer (75mM Tris-HCl (pH 8.8), 20mM (NH4)2S04, 0.01 % Tween-20:Abgene), 
2.0mM MgCl2) 250pg DNA-tel2 mix, 0.5 pM telomere adjacent primer, 0.5 pM 
teltail primer, 1.2mM dNTPs, and 1 U Taq/Pwo (Abgene or CRuk/Roche) at the 
unit ratio of 10:1 were carried out as follows: 20sec at 94°C, 30sec at 65°C 
(XpYpE2, XpYp-427G/-415C, XpYp-427A/-415T (Baird et a l, 2003), 59°C 
[17pseqlrev or 17p7; (Britt-Compton et a l, 2006)], 61°C (9p2), 67°C (10q21T 
and 21qD), 63°C (15qA) and 66°C [llq l3B ; (Britt-Compton et a l, 2006)] and 8 
minutes at 68°C for 22 (XpYpE2& 17pseqlrev) or 24 (9p2 & 1 lql3B) cycles.
2.7.2 Telomere Fusion Assay
Multiple 10 pi PCR reactions (typically 7-18 per sample) containing: 10-100ng 
genomic DNA, lx Taq reaction buffer (ABgene), 2.0mM MgCl2; 0.5 pM each of 
XpYpM, 17p6 and 16pl or 21ql, 1.2mM dNTPs, and 0.5 U Taq/Pwo (ABgene 
or CRuk/Roche) at the unit ratio of 10:1 were carried out as follows: denaturation 
for 20 sec at 94°C, annealing for 30sec at 59°C (Britt-Compton et a l, 2006) and 
extension for 8minutes at 68°C for 25 cycles.
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First-round PCR reactions containing putative fusion molecules were diluted 
1:20 with double distilled water. Then 3pL of the diluted PCR reaction was used 
in a 30pL reaction containing 0.5 pM nested primers (XpYpO, 17p7, 21qseql, 
21q2CT, 16p2, 16pseql, 16plB, 21qlB, 17p6B, 17p6C, XpYpMB, XpYpMC), 
in the buffering system similar to above. The reactions were cycled as above but 
for 33cycles.
2.7.3 Telomere Variant Repeat-PCR (TVR-PCR)
Separate PCR reactions containing: lOOng genomic DNA, lx  Taq reaction buffer 
(ABgene), 3.0mM MgCl2, 1.0 pM telomere adjacent primer (XpYpE2, 
17pseqlrev, 9p2, 10q21T, 21qA), 1.0 pM TVR primers Tel-X, Tel-W, or Tel-Y, 
1.2mM dNTPs, and 0.5 U Taq/Pwo (ABgene or Cancer Research UK/Roche) at 
the unit ratio of 10:1 were carried out as follows: 20 cycles of 20sec at 96°C, 
30sec at 67°C and 3 minutes at 70°C.
2.7.4 Probe synthesis
The 50pL PCR reactions containing 200ng genomic DNA (MRC5, MCF7 or 
HEK293), lx  Taq reaction buffer (ABgene), 3.mM MgCl2, 1.0 pM primer, 
1.2mM dNTPs, and 0.5 U Taq/Pwo (ABgene or CRuk/Roche) at the unit ratio of 
10:1 were carried out as follows: 33 cycles of 96°C for 20 sec, 67°C for 30 sec 
and 3 minutes at 70°C.
Telomere adjacent probes for detection of telomere fusion products were made 
by PCR amplifications with the following oligonucleotide primers: XpYpO & 
XpYpG for XpYp; 17p7&17p2/17pseq3 for 17p; 21ql/21qseql&21qseqlrev for 
21q group; and 16p2&16pseqlrev for 16p group. While telomere adjacent probes 
for detection of STELA products were generated by amplification with the 
following oligonucleotides: XpYpE2 & XpYpB2 for XpYp (Baird et al., 2003);
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17pseqlrev &17pseql for 17p; and llq l3 B & llq l2  for l lq  (Britt-Compton et 
al., 2006); 10q21T &subtel2(3) rev for lOq and 21qA & subtel2(3) rev for 21q.
2.8 GEL electrophoresis
Amplified products were resolved by submarine agarose gel electrophoresis 
using lx  tris acetate buffer (TAE), unless stated otherwise.
2.8.1 STELA, TVR-PCR and telomere fusion assay products
The amplified products (4-5 pL) containing lx  Ficoll based loading buffer (5% 
bromophenol, 5% Xylene and 15% Ficoll) were loaded on the 40cm long gel 
alongside 0.5pi of each l.Okb (Stratagene) and 2.5kb (Biorad) ladder. The 
amplified products were resolved by 0.5% (STELA products) or 0.75% (first- 
round telomere fusion products) Seakem Gold agarose (Cambrex) or 
multiabgarose (ABgene) at 120-140 volts for 14-18 hours (STELA & TVR-PCR 
products) or 50-65volts for 16 hours (telomere Fusion products): under the 
circulating, cooling system at 4°C.
2.8.2 Gel electropheresis for other PCR products
The amplified probe products containing lx  ficoll-based loading dye were 
resolved on 0.8-1.0% electrophoresis grade agarose (Invitrogen) in lx  trisborate 
buffer (TBE; probes) for 1-2 hours at 120 volts or lx TAE (nested-PCR 
products) overnight at 50 volts.
2.9 Southern blotting and Hybridisation
2.9.1 Alkaline Southern Transfer of DNA
The resolved products (STELA, TVR and telomere fusions) were depurinated by 
washing the gel in 0.25 M hydrochloric acid (HC1) for 2 x 6 minutes. Following 
depurination, the gel was denatured in 1.5M NaCl/0.5M NaOH buffer for 15
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minutes. The DNA was then transferred to positively-charged membrane 
(Hybond XL; Amersham) by alkaline Southern blotting with denaturation buffer 
for 4-6 hours, after which the membrane was hybridised to the 33P a dCTP- 
labelled probe.
2.9.2 Probe labelling and Southern hybridisations
25ng of the probe and ladder (1:1 of l.Okb: 2.5kb) in TE buffer (Tris-HCl and 
ImM EDTA) was labelled in rediprime II reaction (contains exonuclease-free 
Klenow fragment and buffered ddNTPs; Amersham) by the random oligo- 
labelling method (Feinberg and Vogelstein, 1984), that involved use of klenow 
fragment of DNA polymerase I to incorporate radioactive “dCTP into 
synthesised DNA for at least 30 minutes.
After Southern blotting, the membranes were rinsed in water and left to air-dry 
for 5-10 minutes. The membranes were then prehybridised in 15ml modified 
church buffer [0.5M, pH 7.2 sodium phosphate buffer (1M disodium hydrogen 
phosphate and 1M sodium dihydrogen phosphate), ImM EDTA, 1% BSA and 
7% SDS] at 60°C for 30 minutes. The hybridisations were then carried out with 
same buffer at 60°C.
2.9.3 Removal of unbound probes
The southern hybridisation washes to remove unbound probe were carried out 
with O.lx sodium chloride sodium citrate (SSC)/0.1% Sodium Dodecyl Sulphate 
(SDS) at 60°C as follows: three quick washes followed by two thirty minutes 
washes. The washed blots were dried in the hybridisation oven at 60°C for 20 
minutes. The dried blots were placed against the molecular dynamics 
phosphoimager screen (Amersham) for at least 24 hours, after which blots were 
then stripped with boiling 0.1% SDS prior to reprobing with the second probe.
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2.9.4 Visualisation
The gel-resolved fragments were visualised by UV-transluminator (UVP Biodoc- 
IT™system) at 256nm and the picture taken with video graphic printer UP 
895MD (Sony). The fragments were then cut with clean scalpel and gel extracted 
using Alquick gel extraction kit (Qiagen) according to manufacturer’s 
instructions.
2.10 PCR product recovery and DNA sequencing
The PCR product to be sequenced was purified from the agarose gel slices using 
QIAquick gel extraction kit (Qiagen). The purified DNA was then resuspended 
in Qiagen’s elution buffer (Qiagen). The sequencing reaction was set up with 
4.4pl of recovered DNA, 0.16 pM sequencing primer, and 4.0pl BigDye® 
Terminator v3.1 Cycle Sequencing mix or dGTP BigDye® vl.O Terminator 
Cycle Sequencing mix (Applied Biosystems) for G-rich sequence. The reactions 
were cycled for 25 cycles as follows: 96°C for 30 seconds, 50°C for 15 seconds 
and 60°C for 4 minutes.
The amplified products were purified by Dye Ex™ 2.0 spin kit (Qiagen) 
according to manufacturer’s instructions prior to direct sequence analysis. The 
sequencing gels were run and data obtained by staff in Central Biotechnology 
Service (CBS), School of Medicine, Cardiff University.
The sequences were analysed and edited in sequence scanner vl.O (Applied 
biosystems). The edited sequences were then blasted in NCBI blastN and 
reference sequence(s) with the highest match (99-100%) was (were) considered 
significant.
2.11 Computer and Statistical analysis
The STELA and telomere fusions image signal was detected by phosphor- 
autoradiography using Molecular Dynamics Storm 860 Scanner (GE health). The 
images were then analysed in Molecular dynamics Image Quant 5.0 (GE Health).
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The molecular weight of each fragment on the STELA gel was determined using 
Phoretix ID quantifier in TotalLab TL120 v 2006 (Nonlinear dynamics) such 
that each fragment represented a single telomere molecule. Fragment size data 
was exported to excel, and the actual telomere length represented by each 
fragment was determined by subtracting the distance between the primer site on 
telomere-adjacent DNA and the start of the telomere repeat arrays.
The mean telomere length and accompanying descriptive statistics which 
included standard deviation (measure of how widely the values are dispersed), 
standard error of the mean and 95% confidence intervals within which the mean 
can be obtained, were calculated from telomere length estimated for all 
fragments in all experiments for each sample (4-8 reactions, repeated until 
representative molecules was obtained) in Microsoft Excel 2003/2007 (Microsoft 
Corporation), SPSS 14.0 and PRISM TRIAL 5.0 (Graphpad). The mode, the 
highest frequency of measurements (lots of deletions or telomere length) was 
estimated from the histogram for telomere length or calculated by counting the 
deletion values or number of TTAGGG repeats or number of micro-homology 
nucleotides. The histograms were drawn after binning values against telomere 
length in O.lkb intervals from 0 to 20kb. The telomere fusion frequency was 
estimated as described in box 2.1 in the appendix.
The D’Agostino-Pearson omnibus normality test was undertaken to determine if 
the distribution of telomere length follow Gaussian distribution. For those that 
passed the normality test the parametric ANOVA with Tukey-Kramer Multiple 
Comparisons Test and Student t-test were used. Whilst for those that failed the 
normality test, the Kruskal-Wallis Test (Nonparametric ANOVA) with Dunn’s 
comparison test was used to determine if the differences in telomere distributions 
were due to chance. The Bartlett statistic was used to test if the standard 
deviations were significantly different. The chi-square test was used to determine 
if any bias in the GC/AT micro-homology content was due to chance. Further 
statistical analysis for each dataset is described in relevant chapters.
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3 Chapter 3: Technological improvement of telomere 
fusion analysis and Single Telomere Length
Analysis [STELA]____________________________
3.0 Summary
The aim of the work described in this chapter was to extend telomere fusion 
assay by encompassing more chromosome ends, with the expectation that this 
would improve the sensitivity of the assays as well as the scope of the events that 
could be detected. An additional aim was to develop STELA at additional human 
telomeres.
The telomere fusion assay was originally developed to detect fusion events 
between the telomeres of XpYp and 17p (Capper et al. 2007); and has revealed 
that, unlike deprotected telomeres in the absence of TRF2, the fusion of short 
dysfunctional telomeres is accompanied by a distinct mutational spectrum. 
However, this assay could not be used across multiple chromosome ends and was 
thus limiting. Improving the assay will determine whether the events observed 
between telomeres of XpYp and 17p are a reflection of the mutational spectrum 
underlying fusion of short telomeres. This would also allow further study into the 
mechanistic basis of fusion events between dysfunctional telomeres. Importantly 
the increased sensitivity of the fusion may allow the detection of rare telomere 
fusion events in normal and diseased tissues. Using the sub-telomeric repeat 
sequence families shared amongst multiple chromosomes, the telomere fusion 
assay was extended to cover at least 43% of telomeres in the human genome.
STELA determines the length at specific telomeres, extending the STELA assay 
to additional chromosome ends could facilitate an examination of the role that 
specific telomeres may play in driving genomic instability during the progression 
to malignancy. STELA was developed successfully at 9p.
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3.1 Introduction
3.1.1 Human sub-telomeric DNA
The human sub-telomeres are hyper-variable, dynamic and rearrangement-prone 
regions near the chromosome ends. They are hotspots for DNA breaks and repair 
(Mefford and Trask 2002; Riethman et al. 2003; Linardopoulou et al. 2005; 
Riethman et al. 2005) and consist of repetitive sequences, large inter- 
chromosomal segmental duplications and segments that vary in size and copy 
number. The sub-telomeric DNA accounts for over 40% of inter-chromosomal 
duplication since the divergent evolution of human from great apes 
(Linardopoulou et al. 2005). Furthermore, higher rates of recombination have 
been reported within the sub-telomeric DNA. For example, 17% of all sister 
chromatid exchanges (SCE) occurs in the terminal 0.1% of the chromosome 
(Rudd et al. 2007). Such sub-telomeric dynamics are important as they can 
disrupt the gene function through amplifications and deletions. Indeed, the sub- 
telomeric regions contain multiple gene families with varying copy number and 
chromosome distribution. These gene families include, amongst others, the 
cytokine receptors, zinc finger homeo-domain proteins, secretoglobins, 
immunoglobulin heavy chain and olfactory receptor genes (Trask et al. 1998a; 
Trask et al. 1998b; Linardopoulou et al. 2005; Riethman et al. 2005).
The TTAGGG-adjacent sequence is related to the families of telomere-associated 
repeat (TAR) sequences defined by the half-YAC clones originally described by 
Brown and colleagues (Brown et al. 1990). The sequences of the TAR vary 
among different chromosomes, allowing PCR-based techniques such as allele- 
specific STELA and telomere fusion assay at different chromosomes (Riethman 
et al. 2003; Riethman et al. 2004; Riethman et al. 2005).
The discovery that human telomeres could be cloned by complementation in 
yeast artificial chromosomes (YACs) enabled the molecular characterisation of 
sub-telomeric repetitive regions (Brown 1989; Brown et al. 1990). Using the 
YACs containing different restriction fragments, Brown and colleagues isolated
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four telomere-associated sequences of which two mapped to single, different 
telomeres while the other two (Telbam 3.4 and Telbaml 1) hybridised to multiple 
telomeres (Brown 1989; Brown et al. 1990). In order to expand the telomere 
fusion assay, I took advantage of the sub-telomeric repeat sequences to design 
primers that will amplify multiple chromosome ends simultaneously. Two 
families (Telbam 3.4 and Telbaml 1) of related telomeres, which share between 
90 to 99% sequence homology were identified (Riethman et al. 2003; Riethman 
et al. 2005; Riethman 2008). Based on this variation, I designed primers for the 
telomere fusion assay to target Telbam 3.4 and Telbaml 1 families of telomeres 
which I renamed 16p and 21q families respectively.
3.1.1.1 16p family
The members of this family share the sub-telomeric repeat block that hybridise to 
TelBam3.4 cosmid (Brown et al. 1990; Riethman et al. 2005), these include 16p, 
XqYq, 9p, lp, 12p, 15q and the interstitial 2ql3-14 (Brown et al. 1990; Riethman 
et al. 2004). They carry the most terminally located class of newly discovered 
subclass of the Wiskott-Aldrich syndrome Protein (Linardopoulou et al. 2005; 
Linardopoulou et al. 2007) gene family, called Wiskott-Aldrich Syndrome 
Protein and SCAR homologues (previously named MGC52000, WASH). The 
truncated copy of the WASH gene (MGC52000) was first annotated on pseudo- 
autosomal region of XqYqtel (Ciccodicola et al. 2000). These genes are 
conserved from Entamoeba to human (Linardopoulou et al. 2007) and terminate 
within less than 5kb of the start of telomere tracts (Riethman 2008). Like their 
sister subclasses, Wiskott-Aldrich syndrome Protein (WASP) and suppressor of 
c-AMP receptors (SCAR), WASH genes recognise and co-localise with actin at 
the cell periphery and promote actin polymerisation in vitro.
Several members of the 16p family have been implicated in human diseases 
especially cancer. Thus in the next sections, the telomere-related chromosomal 
abnormalities involving some members of the family in different human cancers 
and/or disease will be discussed.
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3.1.1.1.1 Short arm of chromosome 1
The loss of heterozygosity (LOH) at short arm of chromosome 1 (lp) has been 
suggested to be one of the adverse prognostic features in Wilm’s tumour (Grundy 
et al. 1994) and endometrial cancer (Arlt et al. 1996). Furthermore, frequent 
deletion of lp is an early step in the progressive loss of chromosomal material in 
histological atypical and malignant meningiomas (Sawyer et al. 2000). These 
losses are probably a consequence of defective or impaired telomere function as 
lp has been found to be involved in recurring telomere fusions and forms 
dicentric chromosomes with 1 lp, 19q and 22q (Sawyer et al. 2003).
3.1.1.1.2 Short arm of chromosome 9
The locus, 9p21 carries two very important cell control cycle genes INK4b 
(pl5/CDKN2B) and INK4a/ARF (pl6/CDKN2A and pl4/ARF). CDKN2A is 
part of the Gr S cell cycle checkpoint mechanism that involves the 
retinoblastoma-susceptibility tumour suppressor protein [pRb; (Weinberg 1995)]. 
Germ-line mutations at the INK4a/ARF predisposes to familial melanoma, a very 
deadly form of skin cancer (Hussussian et al. 1994; Hewitt et al. 2002). Whilst, 
frequent LOH at this locus is documented in most human cancers including 
oesophageal squamous carcinoma (Hu et al. 2006), lung cancers (Merlo et al. 
1994) and melanoma, among others (Coleman et al. 1994). Moreover, expansion 
of clones with LOH at 9p has been implicated as one of the early events in 
Barrett’s oesophagus, a premalignant condition known to predispose to 
oesophageal adenocarcinoma (Galipeau et al. 1999; Jenkins et al. 2002).
3.1.1.1.3 Long arm of chromosome 15
Losses of 15q have been reported in oesophageal squamous carcinoma and 
exocrine pancreatic cancers (Hu et al. 2006). Additionally, Zheng and colleagues 
have reported a significant association between telomere erosion in lymphocytes 
from oesophageal squamous cell carcinoma patients and chromosome instability 
at 15q (Zheng et al. 2009). It is however not yet known if there are any tumour
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suppressor genes located on 15q. Interestingly all cases of mental/growth 
retardation arising from the terminal deletions of insulin-like growth factor 
receptor (IGF1R) gene (15q26.3) also involve the 15q26.2—»qter deletion 
(Walenkamp et al. 2008).
3.1.1.2 21q family
The members of this family of telomeres constitute a subset of the chromosomes 
that share the sub-telomeric repeat region that hybridised to the TelBam 11 
cosmid. The TelBam 11 class is a low-copy repeat sequence that is found in 10- 
20 telomeres and 2ql2-14 interstitial loci; which share 90-98% nucleotide 
identity (Brown et al. 1990; Riethman et al. 2004; Riethman et al. 2005). Of 
these TelBam 11 members, only those chromosomes which further have the 
region that hybridise to HC 1208 probe were targeted (Brown et al. 1990; 
Riethman et al. 2004). These include lq, 2q, 5q, 6p, 6q, 8p, lOq, 13q, 17q, 19p, 
19q, 21q, 22q and interstitial 2ql3.
Below I give examples of the different events involving some members of 21q 
family in different diseases. For example, several chromosomal losses at 
members of 21q family such as 13q, 21q, 6q, and 17p have been reported in 
exocrine pancreatic cancers with high frequency LOH in oesophageal squamous 
carcinoma documented at 3p, 4p, 4q, 5q, 9q, 13q (Hu et al. 2006).
3.1.1.2.1 Long arm of chromosome 1
One of the chromosome abnormalities that involves telomeres is the jumping 
translocation (Hatakeyama et al. 1998). The jumping translocation is a very rare 
chromosome abnormality in which the segment of the specific chromosome 
translocates to various chromosomes. One of the most common jumping 
translocations is that involving the distal region of the long arm of chromosome 1 
(lq), which has been described in acute lymphoblastic leukaemia (Pelz et al. 
2005). Furthermore, fusion events involving lq21-ter and the telomeres of a 
variety of chromosomes (3q, 4p, 5q, 7p, 8q, 9q, 13q, 21q, 7p and 22q) have been
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described in acute myelomonocytic leukaemia (Hatakeyama et al. 1998). 
Frequent gains of chromosome lq  is a typical feature in many solid tumours 
including breast carcinoma (Tsukamoto et al. 1999), cervical cancers (Kloth et al. 
2007) and endometrial cancers among others (Suzuki et al. 1997). Interestingly, 
in a subset of breast tumours (25%), lack of telomerase is correlated with 
amplification of the lq31 loci, suggesting the presence of putative telomerase 
repressors in the region (Loveday et al. 1999). Thus chromosome instability at lq  
extending internally could result in telomerase misregulation and hence telomere 
instability at other telomeres.
3.1.1.2.2 Long arm of chromosome 5
The chromosome arm 5q carries the APC/MCC gene (5q21), that is often 
mutated or deleted in colorectal and lung cancers (Ashton-Rickardt et al. 1991). 
The germ-line mutations in APC gene result in familial adenomatous polyposis, a 
dominantly inherited colorectal tumour predisposition syndrome (Konishi et al.
1996). The site 5q34-qter is one of the most commonly deleted in testicular 
germ-cell cancer (Peng et al. 1999).
3.1.1.2.3 Short arm of chromosome 8
The chromosomal changes on the short arm of chromosome 8 (8p) are associated 
with different malignancies. For example, chromosomal deletion of 8p is a 
prognosis marker in papillary bladder carcinoma and 8p deletions are strongly 
correlated with invasive tumour growth and papillary growth pattern in patients 
with invasive bladder cancer (Stoehr et al. 2004; Stoehr et al. 2005). In addition, 
dicentric chromosomes with 8 p l2 -llq l3  fusion (8qter>8pter::llql3>llqter), a 
potential consequence of telomere dysfunction, has been reported in a subset (5- 
7%) of breast cancer (Bautista and Theillet 1998; Bimbaum et al. 2003).
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3.1.1.2.4 Long arm of chromosome 10
The long arm of chromosome 10 carries a tumour suppressor gene that encodes 
for a phosphatase PTEN/MMAC1 (10q23); a protein of which its deletion in 
mice results in cancer-prone phenotypes (Di Cristofano et al. 1998). PTEN is 
often mutated or deleted in several cancers including acute leukaemia, 
endometrial, brain, breast and prostate cancer (Li et al. 1997; Tashiro et al. 1997; 
Dahia et al. 1999). It is a cell cycle protein that is involved in modulating G] cell 
cycle progression through interaction with the cyclin-dependent kinase inhibitor 
p27(KIPl) thus negatively regulating the PI3K/Akt signaling pathway (Li and 
Sun 1998). Interestingly, studies with p53/ATM/telomerase triple null mice with 
dysfunctional telomeres revealed that murine lymphomas possessed complex 
abnormalities similar to those of human carcinoma such as deletion of the PTEN 
locus (Deng and Chang 2007). The authors suggested that telomere dysfunction 
may impact upon pathways that would allow stepwise carcinogenesis (Deng and 
Chang 2007). In fact, inactivation of PTEN in mice activates a p53-dependent 
growth arrest and promotes development of prostate cancers (Chen et al. 2005).
3.1.1.2.5 Long arm of chromosome 13
The long arm of the largest acrocentric chromosome 13 (13q), carries the genes 
involved in cancer and other human diseases; breast cancer type 2 (BRCA2) and 
tumour suppressor gene retinoblastoma (RBI) genes (Dunham et al. 2004). In 
patients with a history of familial upper gastrointestinal cancer, the predominant 
LOH is at 13q, with the gene that may predispose to upper gastrointestinal 
cancers being mapped to 13ql4 (Champaigne et al. 2009). It is however not 
known whether such locus is same as the pRb gene (13ql3). In addition, 
telomere length in carcinoma-associated fibroblasts and lymphocytes from 
oesophageal squamous cell carcinoma is associated with increased chromosome 
instability on 4q and 13q (Zheng et al. 2009). Moreover, LOH at 13q is frequent 
in human prostrate carcinomas (Cooney et al. 1996; Melamed et al. 1997) and 
lymphoid malignancies, with different loci often deleted or re-amplified. For 
example, homozygous deletion of the 13ql4.3 is found in 10-44% of B-cell
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chronic lymphocytic leukaemia, 25% of non-Hodgkin’s lymphoma and 28% of 
acute lymphocytic leukaemia [ALL; (Liu et al. 1995; Dunham et al. 2004)].
3.1.1.2.6 Long arm of acrocentric chromosome 21
The loss of heterozygosity (LOH) on the long arm of chromosome 21 (21q) is 
observed in several human malignancies such as squamous cell carcinomas. LOH 
is often associated with presence of tumour suppressor genes. The chromosome 
arm 21q, carries a putative tumour suppressor gene, ANA gene which is 
associated with oral squamous cell carcinomas [OSCCs; (Yamamoto et al. 
2001)]. In children, acute lymphoblastic leukaemia is associated with intra- 
chromosomal amplifications of 21q and deletions of 21q telomere have been 
reported in a subset of individuals (Kuchinskaya et al. 2007). Other studies have 
shown that the dinucleotide repeat, which is interspersed by a LINE very close to 
the telomere of 21q, renders the terminal very recombinogenic, with higher 
recombination rates observed in males than females (Blouin et al. 1995; Lynn et 
al. 2000).
Recently, it has been shown that the overall telomere length from peripheral 
blood of older mothers is linked to types of chromosome 21 non-disjunction and 
subsequent Down syndrome births at an advanced maternal age (Ghosh et al. 
2010). This finding is in contrast to the notion that telomere length is paternally 
inherited (Nordfjall et al. 2005; Njajou et al. 2007).
3.1.1.2.7 Long arm of the acrocentric chromosome 22
Unbalanced translocations such as 46, XX, der(21)t(21;22) (pl3;ql3.2), 46, XY, 
der(21)t(21;22)(pl0;ql3.3) resulting in 22qter duplications have been associated 
with birth defects (Feenstra et al. 2006). Additionally, a complex unbalanced 
chromosomal event arising from the transposition of the distal part of 6p and 20q 
to 22q telomere have been reported in children with birth defects. It is however 
not yet known if such event is a result of telomere dysfunction (Bonaglia et al. 
2003; Bonaglia et al. 2008). Telomeric deletions of 22q on the other hand are
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associated with hypotonia, developmental delay, and absence of speech in 
affected infants (Precht et al. 1998) and ovarian endometriomas [22ql2.3-qter; 
(Gogusev et al. 1999)].
3.1.1.3 Chromosome 17
Telomeres on both arms of the chromosome 17 have been implicated as some of 
the short telomeres in human cells (Martens et al. 1998; Pemer et al. 2003; Zou et 
al. 2004). The short arm of chromosome 17 is often lost in many cancers. It 
carries a gene (at 17pl3) that encodes for the tumour suppressor p53; which 
plays a crucial role in DNA damage response and apoptosis (Lane 1992; Levine
1997). The region 17pl3.3-ter (distal to p53) is often deleted in sporadic breast 
cancer (Liscia et al. 1999; Johnson et al. 2002). Furthermore, LOH at 17p is 
believed to convey growth advantage and hence clonal expansion in Barrett’s 
oesophagus (FitzGerald et al. 1996; Galipeau et al. 1999).
Rashid-Kolvear and colleagues have reported a greater erosion rate at 17q 
telomere relative to other telomeres (Rashid-Kolvear et al. 2007). Interestingly, 
17q carries BRCA1, a breast cancer gene which when mutated pose the life time 
risk of familial breast and ovarian cancers in women carriers (Simard et al. 
1994). In oesophageal squamous carcinoma, LOH at both arms of chromosome 
17 is a frequent event (Hu et al. 2006). Interestingly the loss of 17q23-qter is 
frequent in carcinomas of the kidney, ovary, head and neck, and testicular germ 
cell (Mertens et al. 1997).
3.2 This study
As indicated in the previous sections, human chromosomal deletions or 
amplifications are frequent in human cancers. Although some are intra- 
chromosomal deletion/amplifications, it has been suggested that they might be a 
result of breakage-fusion-breakage cycles; a consequence of telomere 
dysfunction (Sabatier et al. 2005). Indeed, Kuchinskaya and colleagues have 
shown that frequent 21q amplification associated with acute lymphoblastic
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leukaemia in children are linked to 21q telomere deletion in some individuals 
(Kuchinskaya et al. 2007).
The aim of the work described in this chapter was to improve the telomere fusion 
assay and expand the telomere length analysis (STELA) to include additional 
telomeres. Telomere fusion assay is a PCR-based assay that allows the detection 
of the telomere fusion molecules between specific chromosomes. It was 
originally developed for two chromosomes, XpYp and 17p. The sub-telomeric 
sequence of these chromosomes is sufficiently unique to allow telomere-specific 
STELA and telomere fusion assays (Capper et al. 2007; Letsolo et al. 2009). 
However, analysis of two telomeres was limiting as it required the analysis of 
several million cells to detect rare fusion events in normal cells, thus increasing 
the scope may improve sensitivity. The improved assay will also allow the 
detection of broader range fusions and indicate whether the type of fusions 
observed between XpYp and 17p was a reflection of the chromosome instability 
generated by eroded telomeres. This may provide further mechanistic insights 
into the fusion of short dysfunctional telomeres. Furthermore, the extended assay 
will also be important when determining the telomere fusion events in human 
tissues derived from normal and disease contexts (Capper et al. 2007; Letsolo et 
al. 2009).
STELA has several key strengths over other telomere length analysis assays; 
with STELA, the full spectrum telomere lengths ranging from short to longer 
than 20kb can be detected (Baird et al. 2006). In addition, STELA requires very 
low concentrations of DNA thus can be applicable to a broad spectrum of 
samples (Baird et al. 2003; Baird et al. 2006; Britt-Compton et al. 2006). STELA 
was originally developed for analysis of XpYp telomere (Baird et al. 2003) and 
then later for analysis of autosomal telomeres; 2p, l lq  12q, and 17p (Britt- 
Compton et al. 2006) and C.elegans (Cheung et al. 2004). Recently an adaptation 
of the STELA technique called “universal STELA” has been described (Bendix 
et al. 2010). Unlike chromosome-specific STELA, this “universal” method
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estimates the telomere length from almost all chromosomes (Bendix et al. 2010). 
However, it has a disadvantage compared to chromosome-specific STELA of 
low amplification efficiency for molecules with telomere length greater than 7kb, 
presence of unknown length of subtelomeric DNA and non-linear correlation 
with TRFs. Thus for this study, only chromosome-specific STELA which can 
detect the full spectrum of human telomere length range (0-25kb) was considered 
(Baird et al. 2003; Baird et al. 2006; Britt-Compton et al. 2006). Since it is the 
shortest telomere not the average length of all telomeres that triggers senescence 
and fusion (Baird et al. 2003; Baird et al. 2006; Britt-Compton et al. 2006), 
developing STELA at additional telomeres, especially those of chromosomes 
carrying the tumour suppressor genes, will allow the examination of whether 
such ends have potential to drive genomic instability in human disease.
Therefore, extending the assays to include additional ends will enable further 
understanding of the role of telomere erosion, instability and fusion in human 
cells and tissues derived from normal and disease context.
3.3 Sample preparation, Data manipulation and Statistical 
analysis
HEK293, MCF7 and MRC5 cells were cultured until confluent (Chapter 2) and 
DNA obtained by standard methods (Sambrook et al. 1989). HEK293 is the 
human embryonic kidney cell line that has been transformed by Adenovirus type 
5 which its oncoproteins El A and E1B inactivate pRb and p53 respectively 
(Graham et al. 1977; Yew and Berk 1992; Bischoff et al. 1996). MCF7 is a cell 
line that was first isolated in 1970 from the breast tissue of a 69-year old 
Caucasian woman (Soule et al. 1973). Both HEK293 and MCF7 cells exhibit 
telomerase activity (Bryan et al. 1998) while MRC5, a human fibroblast derived 
from normal lung tissue of a 14-week-old male foetus, is telomerase-negative 
(Jacobs et al. 1970).
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The telomere lengths were estimated by fragment analysis in TotalLab from 
STELA blots of all experiments for each sample (6-8 reactions). The mean 
telomere length and accompanying statistics [including the arithmetic mean, the 
mode (highest frequency at which a specific variable occurs), standard deviation 
(extend of the dispersion of values from the mean), median (middle value when 
data points are arrange in other from smallest to largest) and confidence intervals 
(interval range within which the mean value can be found)] were calculated in 
Microsoft excel 2007. To accurately determine the telomere length, the distance 
between the telomere-adjacent primer and the start of the telomere repeat array 
was deducted from estimated lengths; XpYp [406bp; (Baird et al. 2003)]; allele- 
specific XpYp [433bp; (Baird et al. 2003)]; 17p [311 bp; (Britt-Compton and 
Baird 2006)] and 9p (Obp).
The telomere fusion frequency were estimated from the number of amplifiable 
input molecules based on the concentration of single diploid human DNA 
molecule (6 picograms) relative to the amplified molecules (box 2.1; in chapter 
2).
For pair-wise comparison, it was essential to determine whether the data was 
normally distributed, thus the D’Agostino-Pearson omnibus test (Graphpad 5.0) 
was carried out to acertain this. The unpaired two-tailed student’s t-test and the 
Bartlett’s F-test determined the statistical significance of the difference in the 
telomere length means and variances respectively. While the Pearson's chi-square 
test (Microsoft Excel 2007) was used to investigate the significance of the 
deviation from the expected data. For all tests, the differences were considered 
significant enough (i.e. not due to chance) at P<0.05, while P0 .001 was 
considered very significantly different.
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3.4 Results
3.4.1 Development of STELA at additional chromosome ends
STELA was previously developed at XpYp and four autosomal telomeres 2p, 
17p, l lq  and 12p (Baird et al. 2003; Britt-Compton et al. 2006). The sub- 
telomeric sequence of these chromosome arms is sufficiently unique to enable 
telomere-specific STELA. Given the repetitive nature of sub-telomere sequence 
and the fact that similar sequences are shared amongst multiple chromosome 
ends it was difficult to obtain telomere-adjacent sequence that was sufficiently 
unique to allow chromosome specific amplification (Brown et al. 1990; 
Riethman et al. 2005). However, utilising the single-base variation between 
different ends, the sequence specific primers could be designed based on the 
putative sequences of 21q, lOq, 9p and 15q [Figure 3.1 A and 3.IB; (Riethman et 
al. 2004)]. The 21q and lOq represented the telomeres of the 21q family, a sub- 
telomeric repeat family that share 90-98% homology. The telomere-adjacent 
DNA of 21q and lOq contains less than 600bp between the start of the telomere 
repeat array and the GC-rich dinucleotide repeat interspersed by a LINE (Blouin 
et al. 1995; Lynn et al. 2000). This satellite is refractory to PCR thus primer 
design was limited to the <600bp region [Appendix, Figure 3A-1].
The 16p family is represented by 9p and 15q, which share 97-99% sequence 
homology (Riethman et al. 2003; Riethman et al. 2004). The telomere adjacent 
DNA of 15q share 99.2% sequence homology with lp, thus primers for 15q were 
designed utilising the single-base variation that distinguish 15q sequence from lp 
and other members of the 16p family. Similarly, primers for 9p were designed 
utilising the single-base variation that distinguish 9p from other members of 16p 
family. However, the primer design at chromosome 9p was limited to the <300bp 
region between the GC-rich minisatellites (37bp-29bp-61bp; Appendix, Figure 
3A-2) and the start of the telomere repeat array (Brown et al. 1990). The STELA 
was carried out as outlined in (Baird et al. 2003) using HEK293 DNA with 
modifications outlined in chapter 2. The specificity of the primers was 
determined by utilising clonal MRC5 in STELA experiments, it was not possible
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Figure 3.1 A. Sequence alignments for telomeres of the 16p family, lp, 9p, 12p, 15q, 
16p, XqYq, and interstitial 2ql4. The regions of homology are indicated by *, gaps 
indicate mismatch. The hyphen (-) has been inserted to improve the alignment. The 
oligonucleotide primers used for telomere fusion assay and STELA are highlighted 
in grey and yellow respectively, with the arrows indicating the 5'-3' orientation of the 
primers relative to the telomere. The telomere fusion oligo primers were designed on 
the putative sequence of 16p, thus the distances (nucleotide) from the repeat array of 
16p are indicated on the right of each alignment. The 16pl was used for telomere 
fusion PCR, while 16plB or 16p2 was used for making the probe with 16pseqlrev 
and for nested-PCR during re-amplification of the putative fusion molecules. 15qA 
and 9p2 primer were used for 15q and 9p STELAs respectively.
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1 6 p l 16plB
—
l p  GTTTTCAAACTGTAGAGCTCTGG C C /C C  CTAGGGCAGAGGGAGCCTGAACAAGT 6 0 2 3
1 2 p  GCTTTCAAACTGTAGAGCTCTGGACTTCTCACTTCTAGGGCAG; .GGGAGCCTGAACAAGT 
1 6 p  GCTTTCAAACTGTAGAGCTCTGGACTTCTCACTTCTAGGGCAG/-GGGAGCCTGAACAAGT 
1 5 q  GCTTTCAAACTGTAGAGCTCTGGACTTCTCACTTCTAGGGCAGAGGGAGCCTGAACAAGT 
9 p  GCTTTCAAACTGTAGAGCTCTGGACTTCTCACTTC7AGGGCAG.-GGGAGCCTGAACAAGT 
Xq GCTTTCAAACTGTAGAGCTC|,GGACTTCTCACTTCTAGGGCAG--GGG.AACCTGAACAAGT
Yq g c t t t c a a a c t g t a g a g c t c I g g a c t t c t c a c t t c t a g g g c a g a g g g a a c c t g a a c a a g t
2 q l 4 GCTTTCAAACTGTAGAGCTCTGGACTTCTCACTTCTAGGGCAG-.GGGAGCCTGAACAAGT 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * *
16p2
 >
l p  TACAGCAACACATTTTTCATTTCAGCTTCACTGCTGTGTCTCCCAGTGTAACCCTAGCAT 5 8 7 3  
1 2 p  TACAGCAACACATTTTTCATTTCAGCTTCACTGCTGTATCTCCCAGT^TAACCCTAGCAT 
1 6 p  TACAGCAACACATTTTTCATTTCAGCTTCACTGCTGTATCTCCCAGTGTAACCCTAGCAT 
1 5 q  T AC AGC AAC AC AT T T T T CAT T T C AGC T T C ACT GCT GT AT CT C C C AGT (§T AAC CC T AGC AT 
9 p  TACAGCAACACATTTTTCATTTCAGCTTCACTGCTGTATCTCCCAGTGTAACCCTAGCAT
Xq t a c a g c a a c a c a t t t t t c a t t t c a g c t t c a c t g c t g t a t c t c c c a g t g t a a c c c t a g c a t  
Yq t a c a g c . a a c a c a t t t t t c a t t t c a g c t t c a c t g c t g t a t c t c c c a g t g t a a c c c t a g c a t  
2 q l 4  t a c a g c a a c a c a t t t t t c a t t t c a g c t t c a c t g c t g t a t c t c c c a g t g t a a c c c t a g c a t  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * *
16pseq lrev  
<---------------------
l p  GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTGGAGCTTTCCTCTCTAAGCTC 5 1 8 7  
1 2 p  GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTGGAGCTTTCCTCTCTAAGCTC 
1 6 p  GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTGGAGCTTTCCTCTCTAAGCTC 
1 5 q  GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTGGAGCTTTCCTCTCTAAGGTC 
9p  GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTGGAGCTTTCCTCTCTAAGCTC
x q  g c c t g g g c t a t g g c t c c t t c c t g g t t t g g g a g c c a t a g t g a a g c f t t c c t c t c t a a g c t c
Yq GCCTGGGCTATGGCTCCTTCCTGGTTTGGGAGCCATAGTG --- g c t t t c c t c t c t a a g c t c  
2 q l 4  g c c t g g g c t a t g g c t c c t t c c t g g t t t g g g a g c c a t a g t g g a g c t t t c c t c t c t a a g c t c  
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * *
l p  ACCCAGCTCAAACTG— ACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 5 1 2 7
1 2 p  ACCCAGCTCAAACTGTGACAGGAGAATCTTCTTCGACAGCCAAGAGCGGTCCAAGGCAAT 
1 6 p  ACCCA.GCTCAAACTGTGACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 
1 5 q  ACCCAGCTCAAACT— GACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 
9 p  ACCCAGCTCAAACTGTGACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 
Xq ACCCAGCCCAAACTGTGACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 
Yq ACCC,‘GCCCAAACTGTGACAGGAGAATCTTCTTCGACTGCCAAGAGCGGTCCAAGGCAAT 
2 q l 4 a c c c a g c t c a a a c t g t g a c a g g a g a a t c t t c t t c g a c t g c c a a g a g c g g t c c a a g g c a a t
★ ★ ★ ★ ★ ★ ★  ' k ' k ' k - k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k i e i e i e ' k ' k ' k ' k
_____ 15qA___________
l p  --------------------------------------------------------------------------------------    2 3
1 2 p  ------------------ — •---------------------------------------------------------------------------------------------------------------
1 6p  a g g g t c c a g t t g c a g c g t t g a a a c a c a a a t g c a g c a t t c c t a a t g c a c c c a t g a c a g c t a
1 5 q  AGGGTCCAGTTGCAGCATCGGAACGC/AAATGCAGC.-.GTCCTAATGCACACATGATACCCA 
9p  AGGGTCCACTTGCAGCGTCGGAACGCAAATGCAGCATTCCTAATGCACACATGATACCCA 
Xq AGGGTCCACTTGCAGCGTCGGAACGCAAATGCAGCATTCCTAATGCACACATGATACCCA 
Yq AGGGTCCACTTGCAGCGTCGGAACGCAAATGCAGCATTCCTAATGCACACATGATACCCA
2 q l 4  AGGG-----------------------------------------------------------------------------------------------------------------------------
* * * * * * * *  * * * * * * *  * * *  * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * *
9P2
I p  -------------------------------------------------------------- TTAGGGTTAGGGTTAGGGTTAGGGGTTAGGGT
12 p  --------------------------------------------------------------TT AGGGTT AGGGT T AGGGTTGGGGT T GGGGTT
1 6p AAATATAACACCCACATTGCTCATGTGGTTAGGGTGAGGGTGAGGGTC— GGTTAGGGTT 
1 5  q AAATATAACACCCACGTTGCT CATGTGGTTAGGGTTAGGGTCAGGGT CGGGGT CGGGGT C 
9p  AAATATAACACCCACATTCCTCATGTGCTTACGGTGAGGGTGAGGGTGAGGGTGGGGGTG 
Xq AAATATAACACCCACATTCCTCATGTGCTTAGGGTGAGGGTGAGGGTTGGGGTTGGGGTT 
Yq AAATATAACACCCACATTCCTCATGTGCTTAGGGTGAGGGTGAGGGTTGGGGTTGGGGTT
2 q l 4  --------------------------------------------------------------TGAGGGTGAGGGTTAGGGTTTGGGTTGGGTTT
★★★★★★★★★★★★★★★ ★★ ★★★★★★★★ ★ ★ ★★★ ★★★★★ ★★★★★
 4 ______
Start o f  t e lo m e r e
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2 1 q l
 >
2 1 q  AGTGATTTAGTTATCCTTCTCTTCrTGGTGTCGAG G G G T A G C 777; GG7GATTT 3 6 3 3
1 9 q  AGTGATTTAGTTATCC C C CTTGGTGTCG G G GG GC GGI G . 7 7
8 p  AGTGATTTAGTTATCCTTCTCTTCTTGGTGTCG G G GG7AGCTTTTAAATGGTGATTT
1 9 p  AGTGATTTAGTTATCCTTCTCTTCTTGG~G7CG G G GGTAGC77 7 TAAATGGTGATTT
1 3 q  AGTGATTTAGTT CC  CTTGGTGTCG G G GG. G7 GG G
lO q AGTGATTTAGTTATCCTTCTC77 CTTGGTGTCG G G GG' -G C ' : : . ' GG" G ~ 7 7
2 q  AGTGATTTAGTTATCCTTCTCTTCTTGGTGTCGAGAGAGGTAGCTTTTAAATGGTGATTT
2 2 q  AGTGA7T7AG 77A 7CC77 CTC77CTTGGTGTCGAG G GG. GC .TGGTGATTT
l q  G G G ;7  7 7 c :  ; GG: G CG G G GG. G7 GG G
2 q l 3  AGTGi G 77 7 7 C GGCGTCG G G GG. GC GG G
5 q  a g t g a t t t a g t t a t c c t t c t c t t c t t g g t g t c g a g a g a g g t a g c t t t t a a a t g g t g a t t t
6p AGTGATTT 7 7 7 C GG G G G G GG: GC G GGGG
1 7 q  AGTGATTTAGTTATCCTTCTCTTCTTGGTGTTG G G GG GC GG G 77
6q  AGTGATTTAGTTATCCTTCTCTTCTTGTTGTCGAGAGAGGTAGCTTTTAAATGGTGATTT
2 1 q seq l
 >
2 l q  TGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAC 3 3 9 6
1 9 q  TGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
8p  TGGTCTTATACACTGTGTTCCACCGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
1 9 p  TGGTCTTA7 C C G:G: 7CC .CCGGC .. G G G7 7C77G 7 7777C C 7C C  GC
1 3 q  T G G 7C I. C C .G  G CC CCGGC G G G 7 G 7 7 7 7 G7
lO q  TGG C C C G G C .7 GGC G G G C G CC CC GC .
2 q  TGGTCTTATACACTGTGTTCTACTGGC.AATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
2 2 q  TGGCC CAC7G7G CC C GGC . G GAGTTCTTGTTTTTCCTCCAGC
l q  TGGTCT1 C C G GTTCCACCGGCAATG . G G CTTGTTTTTCCTCCAGCAAT
2 q l 3  TGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGGTTTTCCTCCAGCAAT
5 q  TGGTCTTATACACTGTGTTCTACTGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
op .‘ GG C : C G G C7 CCGGC. C- GAGTTCTTGTTTTTCCTCCAGCAAT
1 7 q  TGGTCTTATACACTGTGTTCCACTGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
6q  TGGTCTTATACACTG7G7TCCACCGGCAATGAAAAGAGTTCTTGTTTTTCCTCCAGCAAT
21q seq lrev
<------------------------------
2 l q  CTCACTAT7". . GGG G C C GG . G GGGC C G G G G 7 GC GC G 2 7 8 9
1 9 q  C7C ACC AC 7 7 ~ 7 GGG . C- C C GG I G:GGGC7C~G77 GAGT lGAT GC GC G
8p  CTCACTATTTTTGGGAAAGACACAGGATAGT GGGCTCTGTT AGAGTAGATAGCT AGCTAG
1 9 p  C7C. C GGG . G C C GG . G GGGC C G G G G GC GC G
1 3 q  C C 7 GGG GAC CAGGAT AGT GGGCTCTGTT AGAGT AG G C  G
lO q  CTCACTATTTTTGGG AAAGACACAGGATAGTGGGCTCTGTT AGAGT AGAT AGCT A.GCT AG
2 q  C T C AC T ATT T T T GGG AAA.GAC AC A.GG AT AGT GGGCT CT (JTT AGAGT AG GC GC. TG
2 2 q  CTCACT ATTTTTGGGAAAGACACAGGAT AGT GGGCT CT GTT AGAGT AGAT AGCT AGCSAG
l q  CTCACT ATTTTTGGGAAAGACACAGGAT AGT GGGCTCTGT1 G G  C- 7 GC . GC 1.  G
2 q l  3 CTCACT ATTTTTGGGAAAGACACAGGAT AGT GGGCT CT GC 7 AGAGT AGAT AGCT AGCT AG
5 q   —    ----------------------------------------------
6p 7 7 GGG 7 ' 3 7-7- G GGGCT C G G GG G G GC 7
1 7 q  -------------------------------------------------------------------------------------------------------------------------------------
6q   CTATTTCTGGG G 7 7 GG G GGGC C G  G G G  GATAGCTAG
21q3
 >
2 l q  CACCACTGT AAACAAGAGGGCCC7GC AGTTGTCC7 AGTCGCC AGT AGGGGGCGCAAT GGC 1 3 3 3
1 9 q  CACCACTGT AAGCAAGAGGGCCCT GCA.GT 7 GTCC7 AGT CGCC AGT AGGGGGCGCAAT GGC
8p  CACCACTGT AAGGAAGAGGGCCCTG.AAGTTGCCCTAGTTGCCAGCAGGGGGCGCAATGGC
1 9 p  CACCACTGT AAGGAAGAGGGCCCTGCAGTTGCCCT.-.GTCGCCAGCAGGGGGCGC.AATGGC
1 3 q  CACCACTGTAAGCAAGAGGGCCCTGCAGTTGTCCT.--C7CGCCAGTAGGGGGCGAAATGGC
lO q  CACCACTGT 7A.GCAAGAGGGCCCTGCAGTTGTCCTAGTCGCCAGTAGCGGACGCAA.TGGC
2 q CAGCACTGT AAGCAAGAGGGCCCTGC AGTTGTCCT AGTCGCC AGT AGGGGACGCAATGGC
2 2 q  CACCACTGTAAACAAGAGGGCCCTGC.AGTTGTCCT .AGTCGCC AGT A.GGGGGCGCAATGGT
l q  CACCACTGT.AAACAAGAGGGCCCTGCAGTTG CC GTCGCC AGT AGGGGGCGCAAT GGC
2 q 13  CAGCACTGT AAGCAAGAGGGCCCTGT AGT TGTCC7 AGTCGCC AGT AGGGGGCGCAATGGC
5q --------------------------------------------------------------------------------------------
6p CTACACTGTGAGCGAGAGG7T CCTGT. G7GCCCCCAGGGGCCAGAAGAGGGCG7GCCCCC
i7q --------------------------------------------------------------------------------------------
6q -------------------------------------------------------------------------------------------------------------------------------------
★ ★★★★★★ ★ ★★★★ ★★★ ★★ ★★ ★★★★★ ★★ ★★ ★★ ★★★*
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10q21T
2 l q  T AAAGGCGGAGCAGCATTCTT CTCAGCACAGACGT T GGGGGT ACT GC AT GGCT T T GGGAC 2 5 8
1 9 q  ---------------------------------------------------------------------------------------------------------------------------------------
8p  TAAAGGTGGAGCAGCATTCTCCTAAGCACAGACGTTGGGGGCACTGCCTGGCTTTGGGAC
1 9p  TAAAGGTGGAGCAGCATTCTCCTAAGCACAGACGTTGGGGGCACTGCCTGGCTTTGGGAC
1 3 q  T AAAGGCGGAGCAGCATTCTT CT CAGCACAGAC GT T GGGGGT ACT GCCTGCCTTTGGGAG
lO q  T AAAGGCGGAGC AGC ATTCTT CTCAGC AC AGACGT T GGGGjST ACT GCC T GCCI : GGG/
2 q  TAAAGGCGGAGCAGCATTCTTCTCAGCACAGACGTTGGGGGTACTGCCTGCCTTTGGGGT
2 2 q  TAAAGGCGGAGCAGCATTCTTCTCAGCACAGACGTTGGGGGTACTGCATGGCTTTGGGAC
l q  TAAAGGCGGAGCAGCATTCTTCTCAGCACATACGTTGGGGGTACTGCATGGCTTTGGGAC
2 q 1 3  TAAAGGCGGAGCAGCATTCTT CTCAGCACAGACGTT GGGT-T AGGGT GAGGGTGAGGGTT
5q ----------------------------------------------------------------------------------------------
6p  ---------------------------------------------------------------------------------------------------------------------------------------
1 7 q  ---------------------------------------------------------------------------------------------------------------------------------------
6q ----------------------------------------------------------------------------------------------
21qD
 >
2 i q  g c a a | g c g a g g g g c t GTATTGCACGGTTCAACTGCAGCGTCGCAACTCAAATGCAGCATT 52
1 9 q  ------------------------------------------------------------------------------ --------------------------------------------------------
8 p  ---------------------------------------------------------------------------------------------------------------------------------------
1 9 p  ---------------------------------------------------------------------------------------------------------------------------------------
1 3 q  ---------------------------------------------------------------------------------------------------------------------------------------
lO q  --------------------------------------------------------------------------------------------------------------------------------------
2 q  ---------------------------------------------------------------------------------------------------------------------------------------
2 2 q  --------------------------------------------------------------------------------------------------------------------------------------
l q  ---------------------------------------------------------------------------------------------------------------------------------------
2 q l 3  --------------------------------------------------------------------------------------------------------------------------------------
5 q  --------------------------------------------------------------------------------------------------------------------------------------6p ----------------------------------------------------------------------------------------------
1 7 q  --------------------------------------------------------------------------------------------------------------------------------------
6q -----------------------------------------------------------------------------------------
Figure 3.1B. Sequence Alignment from telomeres of the 21 q family, lq, 2q, 5q, 6p, 
6q, 8p, lOq, 13q, 17q, 19p, 19q, 21 q, 22q and interstitial 2ql3. The regions of 
homology are indicated by *, gaps indicate mismatch. The hyphen (-) has been 
inserted to improve the alignment. The oligonucleotide primers used for telomere 
fusion assay and STELA are highlighted in grey and yellow respectively, with the 
arrows indicating the 5'-3' orientation of the primers relative to the telomere. The 
21 q 1 was used for telomere fusion PCR, while 21qseql was used for making the 
probe with 21qseqlrev and for nested-PCR in reamplification of the putative fusion 
events involving members of the 21 q family. 21q3 is upstream of the satellite DNA, 
which may be refractory to PCR. Downstream of the satellites lies the 10q21T and 
21qD primer used for lOq and 21 q STELAs respectively. The numbers indicated on 
the right side of each alignment are the distances (nucleotide) from the start of the 
telomere repeat array of 21q. The perfect alignment is shown by * and gaps indicate 
mismatch.
108
Chapter 3: Technology development
to use sub-telomeric probes to determine specificity for the following reasons: 
First, given the high sequence homology among the members of the sub- 
telomeric repeat families, the sub-telomeric probes would not distinguish the 
specific telomere from its relatives. Secondly, in some ends, notably 9p (16bp), 
there was insufficient telomere-adjacent DNA between the oligonucleotide 
primer and the telomere to generate telomere-specific probes (Figure 3.1 A); thus 
the STELA molecules were detected with the TTAGGG-containing probe. The 
heterogeneity in telomere length profiles of cultured fibroblast strains often 
confounds the interpretation of the specificity of the STELA profile of a 
particular telomere, when developing the STELA at additional telomeres. 
However, clonal derivatives derived from single cells exhibit homogeneous 
telomere profiles (Baird et al. 2003; Britt-Compton et al. 2006). Thus, the clonal 
derivatives are suitable for validating the specificity of STELA products (Baird et 
al. 2003; Britt-Compton et al. 2006).
Out of the five STELA assays I developed, only 9p showed homogeneous 
distributions that are typical of those observed in clonal populations (Baird et al. 
2003; Britt-Compton et al. 2006); this suggested that the assay was specific for 
the telomere being investigated. However, due to the sequence constrains in 
primer positioning at 9p (Figure 3.1 A), STELA amplification at this telomere 
was of lower efficiency relative to that of telomeres of XpYp and 17p. 
Interestingly 9p could not be amplified in MCF7 (data not shown), an 
observation consistent with the presence of the polymorphism in the primer. The 
existence of null alleles has been reported with other successful STELAs; notably 
MRC5 contains one amplifiable allele at 17p and two at other ends, whilst the 
1 lq  telomere could not be amplified in IMR90 (Britt-Compton et al. 2006).
The STELA reactions for telomeres of 21q (Appendix, Figure 3A-3), lOq and 
15q readily amplified telomere molecules that could be detected by telomere 
repeat containing probes (Figure 3.2). These distributions showed clear evidence 
of telomere erosion with ongoing cell division and, as observed previously at
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Figure 3.2. Single telomere length analysis (STELA) for the telomeres of 9p, lOq and 15q in HEK293 and MRC5 expressing E6E7 oncoproteins. 
Multiple (typically 6 per sample) long-range single-molecule PCR reactions were carried out with oligonuclotide primers targeting telomeres 
of 9p, lOqand 15q. The bands were detected by Southern hybridisation with TTAGGG-containing probe. The number of population doublings 
after which the MRC5 cells were harvested is indicated above MRC5 gels. Molecular weight marker (MW) is shown.
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XpYp, the lOq assay had evidence of the complete loss of a telomere length 
distribution as the cells approach crisis (Figure 3.2). Moreover, the characteristic 
short telomere length profile of HEK293 cells that was apparent in all the assays 
has been identified at XpYp and 17p (Capper et al. 2007) as well as in the new 
9p assay (Figure 3.2; Figure 3.3). However, the telomere length distributions in 
MRC5 clones were more heterogeneous than observed from DNA derived from 
the clonal cell populations. These distributions appear to be composed of three to 
four distributions. This was indicative of more than one telomere being amplified 
simultaneously. Thus whilst these assays do provide an indication of telomere 
length, at the chromosome ends of interest, the fact that they might be detecting 
more than one end lessened the utility of these assays. Thus, they were not used 
for subsequent analysis (Figure 3.2: Figure 3.3).
3.4.1.1 Telomere length in HEK293
Telomere length in HEK293 was estimated for XpYp, 17p and 9p telomeres. 
Previous analysis of XpYp has revealed inter-allelic telomere length variation, 
which was particularly apparent in analysis of clonal populations; this variation is 
established in the zygote and maintained throughout development (Baird et al. 
2003). However, the telomere length profile of HEK293 did not suggest the 
existence of allelic-variation, thus it was essential to determine whether the 
population was homogeneous for any of the telomere-adjacent XpYp alleles. 
Direct sequence analysis of the XpYp telomere-adjacent DNA of HEK293 cells 
(Figure 3.3A) and allele-specific STELA analysis revealed two XpYp variant 
alleles (-427G/-415C or GC allele and -427A/-415T or AT allele). The two 
alleles exhibited identical telomere length distributions (t-test, P=0.3052; F-test, 
P=0.3850; Figure 3.3B and 3.3C) which are super-imposed on one another in a 
mixed HEK293 cell population. Interestingly, the AT-allele was under­
represented with the population consisting of 75% GC and 25% AT allele not the 
expected 50:50 ratio (chi-square, P<0.000013; Figure 3.3B). To rule out the 
possibility of the lower amplification efficiency with AT allele-specific STELA, 
direct sequence analysis of the telomere-adjacent DNA of XpYp revealed the
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Figure 3.3. Telomere length analysis at XpYp, 17p and 9p telomeres in HEK293. A. The
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telomere adjacent polymorphism at the XpYp telomere. The allelic variation at XpYp was 
based on the polymorphism at -427 (G/A) and -415 (C/T). B. Gels illustrating the telomere 
distributions at the three telomeres. C. The modal distribution of the telomere length at the 
three telomeres; XpYp, 17p and 9p (left to right).
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difference in peak height at several well-documented XpYp-SNP sites (Baird et 
al. 1995). The peak height for SNPs identifying the AT allele were shorter than 
those of GC allele thus further confirming that the population consists of fewer 
cells that carry AT allele of XpYp telomere [(Baird et al. 1995; Baird et al. 
2003); Figure 3.3A].
The analysis of 17p and 9p telomeres in HEK293 cells revealed telomere length 
distribution profiles comparable to that at XpYp (Figure 3.3B and C; F-test, P= 
0.8857). However, the mean telomere lengths (Figure 3.3B) were slightly 
different between the XpYp and 17p telomeres (F-test, P=0.7893, t-test, 
P=0.0424). Interestingly, the mean telomere at 9p was significantly longer than 
that of XpYp (F-test, P=0.8806; t-test, PO.OOOl) and 17p (F-test, P=0.6962; t- 
test, P=0.0013).
3.4.1.2 Telomere length in MRC5
In order to study the telomere dynamics in cells that had escaped senescence, the 
human foetal lung diploid fibroblast cell line (MRC5) was used. MRC5 displays 
large inter-allelic variation and homogenous telomere length profiles in its clonal 
derivatives, thus was an ideal candidate for this study (Baird et al. 2003; Capper 
et al. 2007). MRC5 is telomerase-negative and thus have a limited cell 
proliferation capacity after which cells undergo replicative senescence (Harley et 
al. 1990). Thus, to extend their life span, human papilloma 16 viral oncoproteins, 
E6 and E7 (Capper et al. 2007) which block p53 (Crook et al. 1991) and Rb 
(Heck et al. 1992) pathways respectively were expressed in MRC5 clone 1; a 
clone that displayed widely divergent allele length distributions at XpYp and 
short telomere length at 17p (Capper et al. 2007). The expression of the 
oncoproteins extended the replicative life span of these cells by 26-28 PDs 
beyond senescence and cells continued dividing until crisis (Capper et al. 2007; 
Letsolo et al. 2009). To investigate telomere dynamics in these cells, STELA was 
carried out for telomeres of XpYp, 17p and 9p in differing cell populations of 
MRC5; proliferating mixed population (PD 26.2), young presenescent clone 1
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(PD 19.3), post-senescent (PDs 32.2, 46.1) and from cells undergoing crisis 
(PD52.5). The proliferating MRC5 cells displayed heterogeneous length of the 
telomere at XpYp and 17p. Consistent with previous studies, the clonal 
populations exhibited homogeneous telomere length profiles characterised by 
bimodal distribution at XpYp telomere and a single distribution with narrow 
variance at 17p suggesting that it contains one amplifiable allele at 17p telomere 
[(Britt-Compton et al. 2006; Capper et al. 2007); Figure 3.4A; Figure 3.5]. 
Analysis of 9p revealed heterogeneous and homogeneous telomere length 
profiles in proliferating and clonal cells respectively (Figure 3.4C; Figure 3.5).
The apparent bimodal distribution in clones was similar to that observed in XpYp 
and was consistent with MRC5 containing two amplifiable alleles at 9p telomere. 
Like 17p and XpYp telomere, 9p telomere erodes as the cells continue 
proliferating beyond senescence to crisis. In addition, the telomere length 
variance increases i.e. distributions become wider as cells approach crisis. 
Interestingly, like XpYp, the shorter allele in 9p began to disappear as cells 
approach crisis (PD52.5; Figure 3.4A and C; Figure 3.5). We have previously 
demonstrated that at crisis, the shortest telomere consists of nine and three 
repeats in XpYp and 17p respectively (Capper et al. 2007). Similarly, the shortest 
telomere consists of approximately five repeats at 9p. However, due to close 
proximity of the 9p primer to the telomere, some shorter molecules might have 
not been detected.
The erosion rate due to end-replication losses, was estimated by determining the 
difference as a function of population doubling (PD) between modes of telomere 
length distribution plotted as histograms (Britt-Compton et al. 2006). The 
telomere erosion rates at 9p telomeres were comparable to those at XpYp and 
17p. The erosion rates at the longer alleles of XpYp and 9p were 77bp/PD and 
81bp/PD respectively, while the short 9p allele and that of the single 17p allele 
were both 48bp/PD. This observation is consistent with previous studies, in 
which the telomere erosion rates within individual clones were conserved among
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different termini (Britt-Compton et al. 2006). Thus, the telomere dynamics at 9p 
is similar to those observed at other human telomeres.
3.4.2 Development of the Telomere fusion assay at additional 
ends.
Telomere fusion assay is a PCR-based assay that allows the detection of the 
telomere fusion molecules between specific chromosomes. It was originally 
developed for two chromosomes, XpYp and 17p. Given the magnitude and the 
diversity of the chromosome instability in human malignancy, analysis of two 
telomeres was limiting: we have demonstrated that using this assay analysis of 
several million cells to detect rare fusion events in normal cells was required 
(Capper et al. 2007). To expand the scope of the assay, several oligonucleotide 
primers were designed within the sub-telomeric repeat sequences shared amongst 
multiple chromosome ends [(Riethman et al. 2004; Riethman et al. 2005); Figure 
3.6A-D]. This will allow the amplification of many different chromosomes in a 
single reaction. I took advantage of the sub-telomeric repeat families identified 
by half yeast artificial chromosomes (half-YACs) containing the BamHl human 
fragment with telomeric DNA. The oligonucleotide primers were targeted within 
the region that is shared amongst chromosomes that hybridised to human 
telomere cloning half YACs-containing the BamHl fragment (Brown 1989; 
Brown et al. 1990). Two sub-telomeric repeat families were selected to expand 
the telomere fusion assay to cover at least 43% of the human genome (Figure 
3.6B-D): one family included telomeres of lq, 2q, 5q, 6p, 6q, 8p, lOq, 13q, 17q, 
19p, 19q, 21q, 22q and 2ql3 interstitial locus (Figure 3.IB; Figure 3.6C-D). This 
represents a subset of telomeres detected with the TelBam 11 probes (Brown et 
al. 1990; Riethman et al. 2005). The second family represents telomeres detected 
by TelBam 3.4 probes (Brown et al. 1990; Riethman et al. 2005); these include 
16p, XqYq, 9p, lp, 12p, 15q and the interstitial 2ql3-14 [Figure 3.1 A; (Brown et 
al. 1990; Riethman et al. 2004)]. The primers for the Telbam 11 and Telbam 3.4 
telomeres were designed within the putative telomere adjacent sequences of 21q
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and 16p telomeres respectively (Figure 3.1 A and B; Appendix Figures 3A-1 and 
Figure 3A-2). Thus the two families have been referred to as 21q and 16p 
families respectively (Letsolo et al. 2009). Originally the telomere fusion assay 
was limited to detecting deletions up to 3.Okb of the telomere adjacent DNA of 
17p. While the improved assay, extended up to 3.5 kb and 6.0 kb proximal to the 
start of the telomere repeat array of the telomeres of 21q and 16p families 
respectively (Figure 3.7; Appendix, Figures 3A-1 and 3A-2).
The specificity of the primers was tested by PCR amplification of the telomere 
adjacent DNA and products validated by direct sequence analysis. Once 
appropriate primers were obtained, the telomere fusion assays were carried out as 
outlined in (Capper et al. 2007) with different two primer combinations (X:17, 
X:16, X:21, 17:21, 17:16, 16:21, 16:16, 17:17, 21:21 and X:X; Figure 3.8) in 
HEK293; a cell line in which we have demonstrated that it exhibited high 
frequency of fusion events between XpYp andl7p (Capper et al. 2007). To 
ensure the specificity of the analysis, the fusion products for all primers were 
detected by sequential Southern hybridisations with the chromosome-specific 
telomere adjacent (XpYp, 17p) and family-specific (21q and 16p) probes (Figure
3.8). The products were detected with all probes indicating that the assay was 
capable of detecting specific telomeres being investigated. However, cross­
hybridisation with 17p probe was expected as 21q family share some sequence 
homology with the 17p telomere-adjacent DNA (Figure 3.8, panel with ***). In 
addition to molecules detected by all probes corresponding to each combination, 
it was apparent that some molecules were detected with only one probe. For 
instance, in panel for X:17 of Figure 3.8, one molecule was detected with XpYp 
probe (indicated by an arrow) but not with 17p probe. Similar pattern is indicated 
in X:16 panel in which the arrowed molecule was not detected with XpYp probe 
but with 16p probe. This pattern of hybridisation is consistent with intra-allelic 
event such as sister chromatid exchange or the large deletion within the telomere 
adjacent DNA of either of the ends involved in the fusion events. This possibility
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is also confirmed in the assay carried out with a single primer (e.g. 17:17; Figure
3.8).
However, in assays involving detection of members of a family (e.g. arrowed 
molecules in X:21 or 16:21 assays), such hybridisation pattern could represent 
either intra-allelic events or fusion events between the members of the same 
family. To identity the chromosome ends involved in the fusion events, putative 
single fusion molecules were re-amplified by nested PCR and the chromosome 
ends verified by multiple direct sequence analysis of individual fusions followed 
by alignment (NCBI blast) against available near complete database human 
sequences. However since the sub-telomeric region of the telomeres within the 
family share high homology, it was difficult to determine the identity of the 
chromosomes involved in a fusion events between members of the same family 
(Letsolo et al. 2009).
In addition to specific fusion events, 21q and 16p probes produced several non­
specific fragments that could not be isolated by nested PCR. These molecules are 
potentially PCR artefacts or cross-hybridisation of the 21q or 16p probe with 
interstitial loci that share homology with families. Furthermore, assays that 
involved 17p with either 16p and/or 21q i.e. 17:16, 17:21, generated a product at 
2.5-3kb that was detected by 16p and 21q probes (Figure 3.8). Despite several 
attempts to characterise these molecules, it was not possible to isolate them thus 
their identities remained unknown. It is however possible that the molecule 
represented an amplification of the interstitial locus that contains a repetitive 
sequence such as a satellite that shares the sequence homology with the sub­
telomere of the two families, which is characteristic of human genome. In 
support of this view, this pattern of hybridisation was observed in several other 
human samples analysed (data not shown, LR, TL, NH personal comm.).
The telomere fusion frequencies were estimated from the number of amplifiable 
input molecules based on the concentration of single diploid human DNA
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molecule (6 picograms) relative to the amplified molecules, as measured by 
number of bands detected by individual probes. However, 21q and 16p probes 
produced non-specific bands and thus could not be used to provide reliable 
estimates of fusion frequencies; these probes are however useful for identifying 
the chromosome ends involved in each fusion event, which is informative for the 
subsequent analysis (Figure 3.8). Thus the frequencies of fusions were estimated 
from bands detected with either the XpYp or 17p probes (Figure 3.9 A and B). 
Combining XpYp, 17p and 21q primers, the frequency increased by 2.9x and 
2.7x with XpYp and 17p probes respectively (Figure 3.9A and B). Similar 
increment was observed with X:17:16 and 17:16:21 assays (Figure 3.8). The 
diversity of the fusion events was confirmed by direct sequence analysis, which 
indicated that different additional ends were involved in fusion events. The 
combination of all the four primers; XpYp, 17p, 21 q and 16p resulted in a further 
increase (4x) in number of detectable fusion events compared to XpYp and 17p 
alone [Figure 3.9; (Letsolo et al. 2009)].
Given the apparent success of the assay with HEK293, the improved assays were 
applied to the clonal MRC5, the telomerase-negative human fibroblast cell line 
expressing HPV 16 E6/E7 onco-proteins (Capper et al. 2007; Letsolo et al. 
2009). We have demonstrated that these cells suffer extensive telomere erosion 
as the cells enter crisis in culture with evidence of complete telomere loss at 
XpYp, 17p and 9p [(Capper et al. 2007; Letsolo et al. 2009); Figure 3.4A-C]. 
Interestingly, as the cells continue to divide towards crisis the frequency of 
telomere fusion events increased. Similar to HEK293, the frequency of fusions 
increased accordingly with three and four primer assays relative to XpYp:17p 
alone. However, the frequency of fusions in MRC5 was so great that it seemed to 
interfere with the amplification creating smears on the gels (Figure 3.9A and 
3.9B). The improved assay have also been applied to investigate telomere fusions 
in B-cells derived from chronic lymphocytic leukaemia patients supplied by Dr 
Chris Pepper, Cardiff university [Approved by South East Wales Research Ethics 
Committee (#02/4806)]. However, due to time limitation, this part of the project
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Figure 3.9. Telomere fusion assay in HEK293 and MRC5 cells. The telomere fusion gels 
indicating the improved assay from two primers (XpYp:17p) to 4 primers (XpYp:17p:21q:16p). 
The primer combinations used are indicated on the left while the probe used to detect the 
molecules are indicated above each gel. X for XpYp, 17 for 17p and 21 represents the 21q 
family of telomeres (lq, 2q, 5q, 6p, 6q, 8p, lOq, 13q, 17q, 19p, 19q, 21q and 22q) and 2ql3 
intestitial locus. Whist 16 represents 16p family of telomeres (lp, 9p, 12p, 15q, 16p and XqYq) 
and 2q 14 intestitial locus. The telomere fusion frequency as estimated from the number of 
amplifiable input molecules based on the concentration of single diploid human DNA molecule 
(6 picograms) relative to the amplified molecules, as measured by number of bands detected 
by either XpYp (A) or 17p (B) probes are indicated below each gel. The molecular weight 
markers (MW) are indicated on the right of each gel.
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was handed-over to a colleague. Data derived during this part has contributed to 
our recent publication (Lin et al. 2010).
3.4.2.1 The upper limit for the detection of telomere fusion 
events.
Several studies have reported presence of sporadic telomere deletion events in 
normal human cells and tissues expressing telomerase (Baird et al. 2006; Britt- 
Compton et al. 2006). Such events could result in dysfunctional telomeres that 
are capable of fusion, which may contribute to genomic instability in human 
tissues. Indeed we have demonstrated that telomeres below the specific threshold 
of 12 repeats are capable of fusion (Capper et al. 2007). Given the low frequency 
(8x 10'5) of fusions in any cell, detection of telomere fusion events in normal cells 
and tissues would require large-scale analysis. In fact, in its original 
manifestation with XpYp and 17p, lOng of DNA (1667 Molecules) per reaction, 
and several hundred PCR reactions were required to detect rare sporadic fusion 
events in normal cells (Capper et al. 2007). Thus there was a requirement to 
increase the efficiency of the fusion assay, by determining the maximum number 
of DNA (genome equivalents) molecules that could be analysed in a single 
fusion PCR without inhibiting the ability of the PCR to amplify what may be 
complex structures. We have detected higher frequency of telomere fusions 
between XpYp:17p in HEK293 than other telomerase-expressing cell lines such 
as W12 and Caski (Capper et al. 2007) but did not detect any fusions with MCF7 
(Capper et al. 2007), despite both MCF7 and HEK293 cells expressing 
telomerase activity and maintaining their telomeres at a very short length (Capper 
et al. 2007). Thus, MCF7 and HEK293 were selected for an experiment aimed at 
determining the maximum amount of DNA that could be analysed in a single 
fusion PCR without inhibiting PCR. To achieve this, first I undertook an 
extensive analysis with increasing amount of diploid genome equivalents [1,667 
(lOng) to 66, 667 (400ng)] per reaction (Figure 3.10A), to determine if 
XpYp:17p fusion events could be detected in MCF7. The telomere fusion events 
were not detected even with analysis of up to 2 533 346 diploid genome
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Figure 3.10. Illustrates the telomere fusion gels with increasing amounts of 
MCF7 either unspiked (A) or spiked (B) with equal amounts of HEK293 DNA. 
X pYp:17p telomere fusion assay was carried out with increasing amounts of 
MCF7 spiked with HEK293 (10 ng) DNA. C. The telomere variant map of the 
XpYp telomere in MCF7 and HEK293, V represents telomere variant repeat, 
and T represents TTAGGG repeat.
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equivalents in a single experiment (400ng per reaction with 38 reactions). 
However, with this number of input DNA, the assay produced some background 
amplification products, which despite several attempts could not be isolated and 
were deemed to be artifactual products that are apparent with increased amounts 
of input DNA.
Given the absence of detectable fusion events after extensive analysis of MCF7,1 
carried out experiments whereby the increasing concentrations of MCF7 DNA 
was spiked with lOng (1667 genome equivalents) per reaction of HEK293 DNA 
in a XpYp:17p telomere fusion reactions (Figure 3.1 OB). The frequency of the 
telomere fusions (6.4x1 O'4) with this increasing number of genome equivalents 
remained comparable to that in the control HEK293 (lOng or 1667 diploid 
genome equivalents) up to the concentration of 310ng (300ng MCF7 + lOng 
HEK293)/reaction. i.e. number of fusions observed in HEK293 (lOng) was 
similar to same amount when spiked into 300ng of MCF7 DNA. However, at the 
concentrations of DNA greater than 310ng up to 1.01 pg [168333 cells] per 
reaction, the fusion molecules could still be readily detected, however there was 
an increase in the background bands which made the estimation of the frequency 
difficult (data not shown). The putative fusion molecules from HEK293 were re- 
amplified and direct sequencing analysis revealed that indeed the molecules 
represented the fusion events between telomeres of XpYp and 17p.
The start of the human telomeres consists of the region often referred to as 
telomere variant repeat region (TVR) in which telomere variants are interspersed 
with TTAGGG repeats. The pattern of interspersion varies among different 
telomeres of the same individual as well as across the population (Baird et al. 
1995; Coleman et al. 1999; Letsolo et al. 2009). Similarly, the analysis of the 
TVR regions of XpYp and 17p telomeres in HEK293 and MCF7 TRF2 
knockdown cells (Capper et al. 2007) displayed distinct profiles [(Capper et al. 
2007); Figure 3.11C]. Thus for the fusion events that showed a deletion on one 
side of the fusion point, the TVR pattern did confirm that the fusion events were
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indeed from HEK293 but not MCF7; implicating that the fusion events could be 
detected even at higher input DNA concentration. However, too much DNA 
could result in the generation of artifactual bands. Therefore, I concluded that the 
highest concentration for detection of fusions was determined to be 310ng per 
PCR reaction [approximately 52000 diploid genome equivalents per reaction; 
(Figure 3.1 OB)].
3.4.2.2 Fusion frequency in MCF7 and normal MRC5
We have previously demonstrated that the cells that maintain telomere length 
distributions that extend to below a critical value of 12 TTAGGG repeats can be 
subjected to telomeric fusions (Capper et al. 2007). However, most normal 
human cells maintain their telomeres at longer length than this critical value. The 
analysis of normal cells has revealed that although telomeres are maintained at 
longer lengths in the normal cells, these profiles are superimposed by rare 
stochastic events which generate short telomeres that are capable of fusion (Baird 
et al. 2006; Britt-Compton et al. 2006). Such events have been detect in the 
young proliferating and senescent cells, as well as in cells expressing telomerase 
(Baird et al. 2006). The fusion of these truncated telomeres could be catastrophic 
as they may lead to large-scale genomic rearrangements through BFB cycles 
(Artandi et al. 2000). It is therefore essential to determine whether the rate of 
telomere fusion in normal human cells is similar to that in cancer cell lines using 
the improved telomere fusion assays. Two cell lines were selected, normal 
telomerase-negative human fibroblast cell line MRC5 and telomerase-positive 
breast cancer cell line MCF7. MRC5 displays two distinct allelic variation at 
XpYp, the two alleles differ in length as well as in the polymorphism of the 
telomere-adjacent DNA. This would allow the differentiation of the telomeres 
involving either of the XpYp alleles. We have detected an increased frequency of 
telomere fusion events in MRC5 expressing HPV16 E6E7 oncoproteins as cells 
continue proliferating to crisis. However, telomere fusion frequency was 
independent of the HPV status but appeared to be dependent on the telomere 
length distributions. Using the well-documented SNPs within the telomere-
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Figure 3.11. Telomere length distributions and telomere fusion frequencies in HEK293, 
MCF7 and MRC5. A) STELA gels illustrating the telomere length distribution at XpYp 
telomere detected by TTAGGG-containing probe. The distal end of the highly variable 
telomere variant region (TVR) for the longest allele is indicated by dashed line across 
each gel. The TVR for shorter alleles may be less extensive. The TVR and TTAGGG 
repeat regions are shown on the right Blue boxes represent TVRs and blank boxes 
represent TTAGGG repeats. B) Telomere fusion gels between 21q, XpYp and 17p 
telomeres. The number of input molecules used in each experiment is shown above gels 
while telomere fusion frequencies based on XpYp probe are shown below the gels. The 
putative fusion molecules in MRC5 and MCF7 are very weak thus have been indicated 
with arrows. C) TVR map of one allele of XpYp telomere, V represents telomere variant 
repeats whileTrepresents TTAGGG repeats.
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adjacent DNA of XpYp (Baird et al. 1995), we have shown that in addition to the 
telomere fusion events involving the short allele, some events were derived from 
the longer allele (Capper et al. 2007; Letsolo et al. 2009). These events are 
consistent with stochastic deletion events that generate telomeres that are capable 
of fusion.
MCF7 cells exhibited no telomere fusions between XpYp and 17p regardless of 
the short telomere length at these telomeres [section 3.3.4.1 and our original 
publication of telomere fusion (Capper et al. 2007)]. The proximal part of the 
human telomeres consists of the telomere variant repeats (TVR) and we have 
shown that in MCF7, the TVR region was longer than that of the cells (such as 
HEK293) that displayed telomere fusions, thus the cells exhibiting shortest 
TTAGGG repeats were displaying fusion events (Capper et al. 2007).
The improved assays were utilised to investigate telomere fusion events between 
telomeres of XpYp, 17p, and/or the 21q and 16p families. The telomere fusion 
frequencies were estimated from molecules detected with XpYp or 17p probes as 
the 21q or 16p probes produced non-specific bands (Figure 3.9). I analysed a 
total of 4.83 x 107 of diploid genome equivalents in MRC5 (n=3.3xl06) and 
MCF7 (n=4.5xl07). Similar to the early study (Capper et al. 2007), no telomere 
fusion events between XpYp and 17p telomeres were detected in MCF7 
(n=4.09xl07) and MRC5 (n=3.5xl05). In contrast, analysis with XpYp, 17p and 
21q primers revealed the fusion events between XpYp or 17p and 21q family in 
both cell lines [Figures 3.11A and B). The average frequency of the fusion events 
in MCF7 (n=2.8xl06) was undetectable and 3.7xl0'6 for XpYp and 17p probe 
respectively (see Table 3A-1 in appendix). In MRC5 (n=1.7xl06), the fusion 
frequencies were undetectable and 3.3x1 O'6 for XpYp and 17p probes 
respectively. In addition analysis with XpYp, 17p, 21q and 16p primers showed 
an increase in frequency for MRC5 (XpYp=3.3xl0‘6; 17p=5.2xl0'6). To confirm 
that the molecules detected represented the telomere fusion events, the putative 
single telomere fusion molecules were isolated with nested PCR primers and the
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identity of the chromosomes involved in a fusion event confirmed by direct 
sequence analysis. Despite several attempts, most of these molecules could not 
be isolated for characterisation, however one that was fully sequenced from 
MCF7 did represent the fusion event between 17p and lOq, with deletion on the 
telomere fusion adjacent DNA of both telomeres. Thus from these data, I 
concluded that the telomere fusion events could occur in normal cells although at 
a very low frequency despite maintaining their telomeres at a stable length. It 
will therefore be interesting to determine if these events occur in human tissues 
in vivo.
3.5 Discussion
In this chapter, I have described the development of STELA and fusion assays at 
additional telomeres, together with an analysis of base-line fusion frequencies in 
human cells. These will provide powerful tools for the analysis of telomere 
erosion, instability and fusion in human cells both in vitro and in vivo.
3.5.1 Telomere Length
STELA is a robust assay that allows the analysis of the telomere length of 
specific telomeres (Baird et al. 2003; Britt-Compton et al. 2006). However, the 
high sequence homology and variability of the sub-telomeric DNA pose a 
challenge during the development of the telomere specific primers. In addition, 
the variation among the sub-telomeric repeat families is not absolute thus 
targeting sequence differences between members of one family could still detect 
another telomere in a different family. For example, 6p telomere-adjacent DNA 
has the regions that hybridise weakly to the telbam3.4 probes and strongly to 
Telbam 11 probes (Brown et al. 1990). To compensate for these problems, 
“universal STELA” has been developed by others. It is based on similar principle 
as chromosome-specific STELA but estimates telomere length at almost all 
chromosomes (Bendix et al. 2010). However, unlike chromosome-specific 
STELA, the amplification efficiency is reduced for molecules greater than 7kb 
(Bendix et al. 2010). In addition telomere length estimated by this method
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include variable length of sub-telomeric DNA (depending on the restriction site 
utilised), thus like TRF analysis the telomere length estimated by this “universal 
STELA” may be greater than the actual telomere length. Whilst “universal 
STELA” may be ideal for detection of very short telomeres (Bendix et al. 2010), 
it is not suitable for analysis of samples in which large variability in telomere 
length may be expected. Again since some chromosome such as lOq and 21q are 
not amplified by the universal method (Bendix et al. 2010), it was important to 
develop the chromosome-specific STELA at specific ends. It remains to be 
determined if the “universal STELA” can be improved further. Taking into 
consideration the limitations of the “universal STELA” and other methods as 
described in Chapter 1 of this thesis, chromosome-specific STELA which can 
detect broader range telomere length [0-25kb; (Baird et al. 2006)] was deemed to 
be the suitable method for this study.
Here, I have shown that the telomere length of specific autosomal telomeres can 
be analysed by STELA despite the high sequence homology among the multiple 
sub-telomeric families. Using single nucleotide variation, I have developed the 
STELA at 9p telomere. The telomere adjacent DNA of 9p shares 97-99% 
sequence homology with other telomeres that hybridise to the Telbam 3.4 probes 
(lp, 12p, 15q, XqYq, 16p and interstitial locus 2ql4), which in the study have 
been named 16p family. The successful 9p assay will allow the investigation of 
whether the frequent LOH at 9p in premalignant conditions such as Barrett’s 
oesophagus is related to telomere dynamics at this end (Galipeau et al. 1999). As 
shown by others, loss of telomere function can result in chromosomal 
rearrangements and LOH via BFB cycles (Gisselsson et al. 2001; Hemann et al. 
2001). In addition, the chromosome instability in pre-malignant conditions such 
as ulcerative colitis and Barrett’s oesophagus has been linked to loss of telomere 
function resulting from telomere erosion (O'Sullivan et al. 2002; Finley et al. 
2006).
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I have also attempted to develop the STELA for analysis of telomeres of lOq, 
21q and 15q, however these assays failed to produce homogenous telomere 
distributions, characteristic of clonal populations in MRC5 clones, thus were 
considered not relevant for further analysis. Interestingly, the telomere length 
profile at these telomeres was similar to that of successful assays; XpYp, 17p and 
9p in HEK293. In addition, in MRC5 cells undergoing crisis, these assays 
revealed that the telomere length were eroding as a function of cell division with 
evidence of complete loss of shorter molecules especially at lOq. The 
development of chromosome-specific STELA was more difficult at these ends 
because in addition to falling into different families, the sub-telomeric DNA of 
these ends is also shared with other telomeres that are not within the 21q and 16p 
family. For instance, 20q telomere shares sequence homology with some 
members of the 21q family. In addition, the design of STELA primers was 
restricted to within 300bp region from the start of the telomere repeat array, as 
upstream to these region (>300bp) lies the hyper-variable minisatellite in some 
members of the 16p family. While in 21q family, the region (>600bp) consists of 
the GC-rich dinucleotide repeat that is interspersed by the LINE and this could be 
refractory to PCR (Brown et al. 1990; Blouin et al. 1995). Similarly 21q and lOq 
could not be amplified by “universal STELA” (Bendix et al. 2010). Thus analysis 
of the telomeres of 21q and lOq may be carried out with other methods such as 
FISH.
I have shown that HEK293 exhibits a characteristic short telomere distribution at 
9p telomere, similar to that reported at XpYp and 17p, indicating that the 
telomeres in this cell line are maintained within a similar range at which 
telomeres are capable of fusion despite expressing telomerase activity. Bryan and 
colleagues have shown that HEK293 cells exhibit variable telomerase activity 
with some cells showing no detectable telomerase activity. Thus, such cells 
exhibit short telomeres while cells with high telomerase activity tend to maintain 
longer telomeres (Bryan et al. 1998).
133
Chapter 3: Technology development
In MRC5, bimodal distribution at 9p was observed, suggesting that MRC5 
contains two differently lengthed alleles at the 9p telomere, a type of distribution 
similar to that of the telomeres of XpYp, 12q, 2p and 1 lq  (Britt-Compton et al.
2006). This bimodal distribution is consistent with allelic variation resulting from 
maternal and paternal telomeric contributions in the zygote that is maintained 
throughout life (Baird et al. 2003).
Previous studies revealed that as the cells divide towards crisis, the telomeres of 
XpYp, 17p and other autosomal telomeres were eroding with the evidence of 
complete loss of the telomeres (Britt-Compton et al. 2006). In this study, a 
similar pattern of erosion was observed at 9p telomere suggesting that these 
telomeres are subjected to similar telomere dynamics.
3.5.2 Telomere fusion assay
The human sub-telomeric regions are highly dynamic and variable regions that 
consist of duplications and sub-telomeric repeat sequences of varying size and 
composition (Brown et al. 1990; de Lange et al. 1990). I have taken advantage of 
this sub-telomeric variability and developed the telomere fusion assay at 
additional telomeres. The telomere fusion assay was originally developed for 
detection of telomere fusion events between XpYp and 17p (Capper et al. 2007). 
The analysis of two chromosome ends required analysis of several tens of 
thousands cells to detect such rare events in normal cells, thus was limiting. I 
have extended the telomere fusion assay to include at least 43% of the human 
genome. More telomeres with homology to the 21q and 16p families may 
become apparent as the sequence of all human telomeres is completed. These 
new assays will allow the detection of fusion events in samples derived from 
normal and diseased human tissues where the events could be very rare. 
Furthermore, the expanded assay will allow the analysis of broader range fusion 
structures and thus enhance further understanding of the mechanistic basis of 
short dysfunctional telomeres. In addition, using the improved assay, I have 
demonstrated that telomere fusion events can be detected between XpYp or 17p
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and other telomeres in samples that we have detected no fusion events with the 
original assay (Capper et al. 2007). Thus the improved assay appears to be more 
robust in detecting what may be rare fusion events.
Although not always involved in human tumourigenesis, cryptic telomere 
deletions/amplifications are associated with idiopathic mental retardation and 
birth defects. Such terminal deletions or duplications may result in unbalanced 
translocations (Precht et al. 1998; Bonaglia et al. 2003; Feenstra et al. 2006; 
Bonaglia et al. 2008), one of the consequences of telomere dysfunction. For 
instance, terminal deletion of 2q and duplication of 15q resulting in partial 
monosomy 2q (2q37-2qter) and trisomy 15q (15q24-15qter) was observed in the 
foetus with facial dysmorphism, clenched hands and malpositioned toes (Chen et 
al. 2009). The development of the telomere fusion assay to cover a large majority 
of the human genome would facilitate the better understanding of the 
chromosome instability initiated by dysfunctional telomeres in a variety of 
disease settings.
Despite extensive analysis of telomere fusion events between telomeres of XpYp 
and 17p in MCF7 and MRC5, no telomere fusion events were detected. In 
contrast, the analysis in HEK293 has revealed high frequency of telomere fusion 
events. Unlike MCF7 and HEK293 cells which express telomerase activity (Kim 
et al. 1994), MRC5 cells exhibit no detectable telomerase activity (Harley et al. 
1990). However, the young proliferating cells show longer telomere length 
profiles and thus telomere fusion events between these two telomeres could be so 
low that it was effectively difficult to detect. Indeed the shortest telomere in 
MRC5 at XpYp is several magnitudes longer than the threshold below which the 
telomeres are capable of fusion [(Capper et al. 2007); 12 TTAGGG repeats]. 
Additionally, we (Capper et al. 2007) and others (Ducray et al. 1999) have shown 
that MRC5 cells that have escaped senescence showed an increased frequency of 
end-to-end fusions once their telomeres have eroded to length at which they are 
capable of fusion. In contrast to the low frequency of fusions in normal
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fibroblasts described in this study, higher frequency of fusions was described by 
karyotype analysis (Takubo et al. 2010). The difference between the data 
described in this study and data by Takubo et al may be due to differences in 
telomere length profiles of cells analysed. The data described in this thesis was 
derived from MRC5 cells displaying long telomere profiles while in TIG cells 
analysed by Takubo and colleagues, the shortest telomeres were 1.3 and 2.4kb 
(Takubo et al. 2010). It is possible that analysis of MRC5 displaying shorter 
telomere length may reveal comparable frequency of telomere fusions to those 
described by Takubo and colleagues.
However, lack of fusion events in MCF7 cannot be explained on the basis of 
telomere length and telomerase activity (Capper et al. 2007). We have 
demonstrated that one XpYp allele of MCF7 contains an extensive telomere 
variant repeat region (TVR), which is such that the pure TTAGGG repeats begin 
at 1.3kb while in HEK293 cells, the pure TTAGGG starts at about 400bp. By 
taking into account the TVR region, we have also shown that the cell line with 
the shortest telomere range also displayed fusion events (Capper et al. 2007). 
Apart from telomere length distribution, the status of p53, a tumour suppressor 
that protects the cells from physiology and environmental stress such as telomere 
dysfunction could account for the differences in telomere fusion frequency in the 
two cell lines. Although telomeres are short in MCF7, the presence of the wild- 
type p53 (Zhan et al. 1994) in these cells could be inhibiting the propagation of 
genomic instability by ensuring that cells with dysfunction telomeres exit the cell 
cycle. Evidently, disruption of the p53 function by expression of the HPV16’s E6 
oncoprotein, impaired the cells’ response to y-ray-induced p53 cell cycle arrest 
(Fan et al. 1995). Furthermore, induction of DNA damage at telomeres of MCF7 
through use of T-oligos; molecules that mimic the 3' overhang led to p53- 
dependent apoptosis and senescence (Yaar et al. 2007). Moreover, our recent 
work has demonstrated that disruption of the telomere structure through siRNA- 
mediated knockdown of TRF2 increased the frequency of telomere fusions 
between XpYp and 17p (Capper et al. 2007). Knockdown of TRF2 has been
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shown to induce formation of telomere-induced foci, a marker of DNA damage 
resulting from telomere dysfunction and these are accompanied by p53- 
dependent apoptosis or senescence (van Steensel et al. 1998; Karlseder et al. 
1999). Similarly, disruption of telomere structure through knockdown of POT 1 
induced p53-dependent apoptosis in MCF7 cells (Yang et al. 2005).
In contrast, in HEK293 the p53 pathway has been impaired during 
transformation with adenovirus 5 (Graham et al. 1977). Thus, the cells with 
dysfunctional telomeres can continue proliferating and accumulate chromosome 
aberrations. Evidently, the primary cells that are deficient in p53 and /or pRb 
continue dividing beyond senescence, with subsequent severe telomere erosion 
and genetic instability. In vivo, p53 deficiency has been reported to rescue the 
adverse effects of telomeres by cooperating with telomere dysfunction to 
accelerate carcinogenesis (Chin et al. 1999; Artandi et al. 2000). Furthermore, 
mice without telomerase activity experience extensive telomere shortening and 
accumulation of chromosome end-to end fusions. However, in the presence of 
functional p53, these mice (mTR_/‘) exhibit a low rate of telomere fusions 
compared to mice without functional p53 [mTR'A p53'7'; (Chin et al. 1999; 
Cosme-Blanco et al. 2007)]. In addition, it has been shown that the level of 
telomerase is variable at the cellular level in HEK293 cells, where 
subpopulations with undetectable to very low activity and subpopulations with 
high telomerase activity are detected. Furthermore, clonal populations with 
longer and shorter telomeres have also been detected in these cells (Bryan et al. 
1998). Thus, p53 deficiency in those clones without telomerase activity could 
lead to telomere erosion and thus account for increased frequency of telomere 
fusions. To support this, recent work in our laboratory has isolated HEK293 
subpopulations with longer telomeres that exhibited no telomere fusions and 
clones with shorter telomeres that exhibited fusion events (DMB personal 
comm.). Thus, the difference in telomere fusion frequencies between MRC5, 
MCF7 and HEK293 can be explained on basis of telomere length, telomerase 
activity as well as the intact p53 pathway.
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3.6 Key findings
• Telomere fusion assay has been expanded to cover at least 43% of the 
human genome and this will allow the understanding on the mechanistic 
basis of the genomic instability generated by short telomeres.
• These will provide tools to study potentially rare fusion events in human 
tissues.
• The assay have also been extended to detect the events involving deletions 
of up to 6kb of the telomere adjacent DNA.
• Using the expanded assay, I have defined the fusion frequency in normal 
human cells in vitro.
• I have defined the upper limit at which the rare telomere fusion events can 
be detected, as 31 Ong per reaction.
• Despite extensive analysis of MCF7, the telomere fusion frequency 
remained very low.
• I have successfully developed STELA at an additional autosomal end, 9p. 
Using this assay, I have demonstrated that the telomere distribution at 9p 
is similar to that of other telomeres in HEK293 and MRC5.
138
Chapter 4: Telomere fusion in vitro
4.1 Introduction
4.1.1 Telomere dysfunction
The primary function of the telomeres is to preserve genomic integrity and to 
prevent genomic instability arising from degradation, recombination or end-to- 
end fusions, thus telomeres distinguish the natural chromosome ends from the 
double-stranded breaks [DSBs; (Blackburn 1991; De Lange 2005)]. The loss of 
telomere function could result from gradual telomere erosion or stochastic 
telomere deletion events generating short dysfunctional telomeres (Capper et al.
2007). In addition, destabilisation of the telomere structure through experimental 
disruption of the telomere binding proteins such as TRF2 can lead to full length 
but dysfunctional telomeres (van Steensel et al. 1998).
Normal human somatic cells do not express telomerase and thus display a limited 
replicative capacity in culture (Hayflick and Moorhead 1961; Harley et al. 1990). 
According to the telomere hypothesis of ageing, this finite proliferative capacity 
is correlated with telomere length such that cells with longer telomeres would 
exhibit a longer replicative capacity (Allsopp et al. 1992). In addition, the 
replicative capacity of normal diploid cells can be extended by expression of 
hTERT the catalytic component of telomerase (Bodnar et al. 1998). In the 
presence of functional p53/Rb DNA damage response machinery, cells at the end 
of their replicative capacity enter replicative senescence; an irreversible cell cycle 
arrest which is believed to be a barrier to tumourigenesis (Karlseder et al. 2002; 
d’Adda di Fagagna et al. 2003; Choudhury et al. 2007). However, in the absence 
of a functional DNA damage response, cells with shortened/dysfunctional 
telomeres fail to undergo senescence and continue to proliferate until their 
telomeres become critically short (Chin et al. 1999). Critically short telomeres 
are capable of fusion and may form dicentric chromosomes (amongst others). 
During anaphase, dicentric chromosomes can form bridges, which in turn can 
break when the sister chromatids are pulled to opposed poles of the cell. If the 
breakage occurred at a different site from the original fusion point, this would
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result in the loss or gain of genetic material in the daughter cells. The subsequent 
double-stranded breaks could drive successive cycles of fusion-bridge-breakage 
(Mumane and Sabatier 2004) and thus genomic instability. Hence, loss of 
telomere function can create chromosome instability such as non-reciprocal 
translocations (NRTs) and genetic amplifications/losses (Meltzer et al. 1993). 
Indeed, Artandi and colleagues have demonstrated that telomere dysfunction in 
ageing telomerase-negative mice results in NRTs, a typical feature of human 
carcinomas (Artandi et al. 2000). Anaphase bridges are surrogate markers of 
telomere instability and have been observed in early stages in human cancer cells 
and mouse cells. Furthermore, the frequency of anaphase bridges have been 
correlated with abnormal karyotypes in sarcomas, pancreatic and colon 
carcinomas (Gisselsson et al. 2001; Rudolph et al. 2001). Moreover, mice with 
knockouts in NHEJ proteins ligase IV and p53 exhibit lymphomas with 
chromosome rearrangements consistent with breakage-fusion-breakage cycles 
(Frank et al. 2000).
4.1.2 Intact shelterin complex inhibit telomere fusion
The loss of shelterin integrity or function induces inappropriate chromosome 
fusions through non-homologous end-joining and homologous recombination 
(van Steensel et al. 1998; Ferreira et al. 2004; Celli and de Lange 2005; Denchi 
and de Lange 2007; Verdun and Karlseder 2007).
Non-homologous end-joining is an error-prone repair mechanism in which 
broken ends are joined together after minimal processing. It depends upon the 
activities of ligase IV, XRCC4 and Ku/DNA PKcs (Kanaar et al. 1998; Smith 
and Jackson 1999; Karran 2000) and is the predominant repair mechanism that 
can operate at any phase of cell cycle. Another mechanism of DNA repair, 
homologous recombination; is mainly for repair of sister chromatids (Celli et al.
2006).
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Several experiments aimed at investigating the consequence of loss of telomere 
function arising from loss of shelterin components, have revealed that telomere 
dysfunction induces DNA damage response and repair at telomeres (van Steensel 
et al. 1998; Hockemeyer et al. 2007). Thus, below I discussed briefly the role of 
specific shelterin components in inhibiting illegitimate repair and formation of 
end-to-end fusions.
4.1.2.1 TRF2 and Telomere fusions
TRF2, the shelterin component that plays a crucial role in telomere capping 
represses illegitimate NHEJ and HR at telomeres thus functional TRF2 is 
essential at all stages of the cell cycle. During Gi phase, TRF2 is a main 
repressor of NHEJ thus allowing DNA replication to proceed while, post­
replication at G2, TRF2 cooperates with POT1 to repress NHEJ (Celli and de 
Lange 2005; Hockemeyer et al. 2006; Konishi and de Lange 2008). Evidently, 
TRF2 deficiency results in fusions at Gi phase (Konishi and de Lange 2008). The 
role of TRF2 in inhibiting inappropriate chromosome fusions is further enhanced 
by studies, which show that disruption of the TRF2 sub-complex i.e. TRF2 and 
its interacting partners, induces chromosome fusion (van Steensel et al. 1998; 
Bae and Baumann 2007). For instance, human RAP1; a TRF2-interacting factor 
protects telomeres from illegitimate non-homologous end-joining through 
interaction with TRF2 (Bae and Baumann 2007; Sarthy et al. 2009). In addition, 
knockout of another TRF2-interacting factor, PARP-1 in mice results in elevated 
frequency of telomere fusions, abundant chromosomal breaks and aneuploid cells 
compared to the wild type mice (dAdda di Fagagna et al. 1999). Furthermore, 
loss of Ku, a TRF2-interacting factor in mouse embryonic fibroblasts results in 
increased telomere fusions with long tracts of telomere repeats, consistent with 
telomere uncapping without telomere shortening (Samper et al. 2000).
Moreover, TRF2 cooperates with Ku to repress HR at the telomeres. Evidently, 
mouse cells lacking Ku70 [Ku70("A)] have normal telomeres and do not activate 
DNA damage response. However, in the absence of functional TRF2, these
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KuVO^ mouse cells exhibit increased frequency of telomere sister chromatid 
exchanges, a form of homologous recombination, predominant in cells 
maintaining their telomeres through telomerase-independent mechanism(s) called 
alternative lengthening of telomeres [ALT; (Celli et al. 2006)]. Furthermore, 
mutant TRF2 lacking the DNA-binding domain (AB) represses NHEJ but results 
in rapid erosion of telomeres as well as formation of t-loop sized telomere circles 
implicating the processing of the Holliday junction at the t-loop. Indeed such 
deletions were dependent upon the action of XRCC3, a nuclease involved in 
processing of Holliday junctions (Wang et al. 2004), an intermediate stage in 
homologous recombination.
4.1.2.2 POT1 and telomere fusions
The single-stranded binding protein, POT1 is essential for maintaining telomere 
integrity and genome stability by repressing NHEJ and HR at telomeres. In 
support of this, loss of POT1 function results in loss of overhang, TTAGGG- 
containing fusions, anaphase bridges, ring and dicentric chromosomes 
(Hockemeyer et al. 2005; He et al. 2006; Hockemeyer et al. 2007); suggesting 
that loss of POT1 function may result in recognition of telomeres as sites of 
DNA damage.
In addition, deficiency of Pot la  in mouse cells induced telomere elongation, 
increased frequency of telomere sister chromatid exchanges and telomere circles 
(t-circles); characteristic features of ALT, a homologous recombination-based 
telomere maintenance mechanism (Cesare and Griffith 2004; Wu et al. 2006). 
Similarly, a mutant mouse pot lb results in increased frequency of both leading 
and lagging strand telomeric sister chromatid exchanges (T SCE) in MEFs (He 
et al. 2006). Likewise, loss of potl in S.pombe results in telomeric loss and cell 
death, with survivors having circularised chromosomes, a potential processing of 
t-loops (Baumann and Cech 2001). Together these findings suggest that POT1 is 
essential for repressing inappropriate repair at telomeres.
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4.1.3 This study
The end-capping function of telomeres is mediated by TRF2 and associated 
proteins (van Steensel et al. 1998). Inhibition of TRF2 in human and mouse 
telomeres through expression of dominant mutant TRF2 induces Ligase IV- 
mediated chromosomal fusions (van Steensel et al. 1998; Smogorzewska et al. 
2002; Celli and de Lange 2005). These fusions are characterised by long tracts of 
TTAGGG repeats, and are a result of covalent linkage of the G-strand to the C- 
strand (Smogorzewska et al. 2002).
In contrast to TRF2-deficient cells, the telomere fusion events have been 
observed in mammals in the absence of NHEJ components, implicating the 
existence of an alternative mechanism that is employed during repair of short 
dysfunctional telomeres (Maser et al. 2007). Evidently, in telomerase-deflcient 
mutants of yeast and plants, dysfunctional telomeres result in fusion events 
independent of ku70, DNA PKcs and Ligase IV (Baumann and Cech 2000; 
Heacock et al. 2004; Maser et al. 2007). Thus to investigate the mechanism that 
underlies the fusion of short telomeres, a PCR-based telomere fusion assay was 
developed for analysis of telomere fusion events between the telomeres of XpYp 
and 17p (Capper et al. 2007). The advantage of the assay is the ability to isolate 
individual fusion events and examine their molecular structure using direct 
sequence analysis. Using this assay, we have demonstrated that the fusion of 
short telomeres is accompanied by large sub-telomeric deletions, short patches of 
micro-homology and minimal telomere repeats at the fusion point (Capper et al.
2007). The assay has since been extended to include at least 43% of the human 
genome [chapter 3: (Letsolo et al. 2009)]. Thus, the aim of the work described 
here was to isolate and characterise the telomere fusion events generated by short 
telomeres and investigate whether the chromosome instability we have observed 
between XpYp and 17p was typical of dysfunctional telomeres in the human 
genome. The study will detect broader range fusion events and possibly assist in 
the understanding of the mechanism that underlies the repair of short 
dysfunctional telomeres. The data can also be used to compare fusion profiles
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generated from human tissues, specific disease situations and importantly 
experimental systems testing the mechanistic basis of fusion.
4.1.4 Sample Preparation and Statistics
The HEK293 and MRC5 cells have been discussed in chapter 3. The statistical 
analysis was carried out as described in chapter 3.
4.2 Results
4.2.1 Telomere fusion analysis
The improved telomere fusion assay was used to isolate and characterise fusion 
events in HEK293, a telomerase-positive epithelial cell line that maintains short 
telomere length distributions (Figure 3.3B-C) and has been shown to exhibit 
increased frequency of fusions between XpYp and 17p (Capper et al. 2007). 
Telomere fusion events were also characterised from MRC5, telomerase-negative 
human fibroblast cell line expressing HPV16 E6E7 onco-proteins. These cells 
suffer extensive erosion of telomeres as the cells enter crisis in culture (Capper et 
al. 2007), with evidence of complete telomere loss at XpYp, 17p and 9p (Figure 
3.4A-C; Figure 3.5).
The DNA was analysed with multiple PCR reactions, typically 7-18 each 
containing 1667 diploid genome equivalent. The amplified products were 
detected by sequential Southern hybridisation with telomere-adjacent probes. 
After which the putative fusion molecules were isolated by PCR with nested 
primers prior to direct sequence analysis. The direct sequence analysis of the 
putative telomere fusion events verifies the chromosome ends involved in the 
fusion events and allows the examination of the molecular structure of fusion 
events as well as the investigation of the underlying mechanistic basis of fusion. 
However, fusion events between members of the 16p or 21 q telomere families 
only could result in the formation of palindromic sequences making the sequence
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analysis technologically challenging. Therefore, for the initial analysis, fusion 
events were investigated between 21q family of telomeres (lq, 2q, 5q, 6p, 6q, 8p, 
lOq, 13q, 17q, 19p, 19q, 21q and 22q and interstitial 2ql3), XpYp and/or 17p 
and then XpYp, 17p and/or 16p family (lp, 9p, 12p, 15q, 16p, XqYq and 
interstitial 2ql4) and between telomeres of the 21q and 16p families. I have 
shown that using the modified assays, the number of detectable molecules were 
increased, indicating that the assays were capable of detecting fusion events 
between additional telomeres (Letsolo et al. 2009).
Initially, 298 fusion events between XpYp or 17p and 21q and 16p families were 
sequenced; 125 from HEK293 [n=84 and n=41 for 21 q and 16p families 
respectively], 173 in MRC5 (n=102 and n=71 for 21q and 16p families 
respectively). An additional 10 events involving fusion between the telomeres of 
16p and 21q family were sequenced in HEK293, making a total of 308 
sequenced fusion events. I have detected fusion events between XpYp or 17p 
with telomeres of 21q and 16p families, and fusion events between members of 
21q and 16p families indicating that the assay was capable of detecting fusion 
events between multiple chromosome ends being targeted.
The telomerase-positive cell line HEK293, cells display uniformly short telomere 
length distributions at all the telomeres analysed with STELA (Figure 3.2; 3.3B- 
C). This appears to be reflected in the fusion analysis where it was apparent that 
several members of 21q and 16p families were involved in fusion events [Figure 
4.1 A and B]. In contrast, fusion events in MRC5 were limited to a subset of 
chromosome ends. Notably, within the 16p family [Figure 4.1 A] several 
members were detected in telomere fusion events while only 21q and lOq, 
representing the 21q family were detected. This suggests that in the telomerase- 
negative MRC5 E6E7 cells, a subset of telomeres have eroded to within the 
telomere length range at which fusion occurs (Figure 4.IB).
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Figure 4.1. Histograms illustrating the different ends that were detected in fusion 
events for 16p (A) and 21q (B) families in HEK293 (blank boxes) and MRC5 cells 
expressing HPV16 E6 E7 onco-proteins (black boxes)
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4.2.2 Internal structure of telomere fusion events 
4.2.2.1 Clonal events
The fusion events are amplified from single molecules, thus presence of same 
fusion in separate reactions from the same DNA sample would suggest that 
fusion events have been derived from separate cells and hence is a clonal event. 
In HEK293, all the 84 events derived from 21q family were unique while 15% 
(6/41) events derived from 16p family were sequenced more than once [Table
4.1]. In contrast, 25% of fusion events in MRC5 [(26/102 for 21q family; 17/71 
for 16p family] were sequenced more than once and the remaining 75% were 
unique. Interestingly, in MRC5, each event sequenced more than once was 
derived from cells within the same sample i.e. an event that is detected more than 
once within the same sample of MRC5 expressing E6E7 (PD46.1). In addition, it 
was apparent that some events were occurring in several cells, such that they 
were sequenced lOx. Such events were occurring in cells undergoing crisis [PD 
52.5; Table 4.1], implicating that once formed, fusion events can be stable 
throughout cell cycle. The specific clonal fusion events could dominate the 
culture and result in clonal expansion. Clonal expansion has been implicated as 
one of the early lesions that may predict progression to malignancy (Maley et al. 
2006). These data is consistent with the observation that non-reciprocal 
translocations in carcinomas and early stage neoplasia are clonal (Artandi et al. 
2000).
4.2.2.2 Subtelomeric deletions
A striking feature of all the 308 fusion events sequenced was that fusion was 
accompanied by the deletion of either one or both telomeres. The deletion events 
included the proximal telomere variant repeat region, extending into the 
telomere-adjacent DNA close to the limit of the assay (6.1 kb). In this section, I 
discuss the nature of the deletion events involving 21q and 16p families, XpYp 
and 17p.
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Table 4.1. Details of the fusion events that were detected more than once in HEK293 and MRC5
H E K 2 9 3
Chromosomes
involved
Number
of
TTAGGG
Deletion
size
21q/16p
Deletion
size
XpYp/17 
P
Microhomology
Nucleotides
(number) Insertion
Population
doubling
Microhomology
nucleotide
(sequence)
Number 
of events
9p;17p 0 883 0 0 0 n/a none 2
15q;17p 0 1925 2244 0 4 n/a none 2
1 4 8
MRC5
Chromosomes
involved
Number
of
TTAGGG
Deletion
size
21q/16p
Deletion
size
XpYp/17 
P
Microhomolo
gy
Nucleotides
(number) Insertion
Population
doubling
Microhomology
nucleotide
(sequence)
Number 
of events
15q;XpYp 0 4107 950 3 0 46.1 CAG 2
16p; 17p 0 2285 1737 4 0 46.1 ACAA 3
16p; 17p 0 1839 248 2 9 52.5 TC 2
16p;17p 0 3642 248 0 0 52.5 none 2
lp;XpYp 0 1199 1464 3 0 46.1 AAA 2
21q;17p 3.5 1486 0 0 0 46.1 none 2
21q;XpYp 0 2078 500 4 0 46.1 CTGG 4
21q;XpYp 0 1320 986 4 0 52.5 GGGC 10
21q;XpYp 0 1607 301 0 0 52.5 none 3
21q;XpYp 0 1299 1205 3 0 52.5 AGC 3
21q;XpYp 2.5 1237 0 0 no 46.1 none 2
XqYq;XpYp 0 2187 314 2 0 52.5 AG 3
XqYq;XpYp 14 5601 0 4 0 52.5 CCCT 3
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4.2.2.2.1 21q and 16p Families
The 21q family consists of lq, 2q, 2ql3 (interstitial), 5q, 6q, 6p, 8p, lOq, 13q, 
17q 19p, 19q, 21q, 22q and other ends that may be apparent with further 
sequencing of human genome. In HEK293, several of these ends were detected in 
telomere fusion events (Figure 4.IB). The mean sub-telomeric deletion was 
1.19kb ±0.53 (SD), with the largest and the minimum deletions being 2.79kb and 
0.24kb respectively (Table 4.2). In MRC5 on the other hand only two telomeres, 
21q and lOq within this family were detected during direct sequencing analysis.
Whilst the deletion profiles in MRC5 cells appeared to be similar to that 
observed in HEK293, the means and variances of the two profile were different 
(P<0.0001; Figure 4.2A; Figure 4.3, panel A) with the mean deletion size (±SD) 
being 1.50kb±0.35 and 1.19kb ±0.53 in MRC5 and HEK293 respectively (Table
4.2). The combined mean deletion (±SD) for telomeres of 21q family for both 
MRC5 and HEK293 was 1.34kb ±0.44.
Notably, in MRC5 cells, the frequency of deletion events was less in the region 
around lkb from the telomere (Figure 4.2A). This may be due to the presence of 
a satellite repeat interspersed with a LINE in that region in some members of the 
family, namely, 22q, 21q, lq, 2q and lOq (Blouin et al. 1995). This was more 
apparent in MRC5 where only 21q and lOq were detected in fusion events 
(Figure 4.2A). Thus to examine if the satellite was refractory to PCR, the assay 
was carried out with the oligonucleotide [subtel2], downstream of the satellite. 
Subtel 2 is an oligonucleotide that is shared amongst the members of 16p and 
21q families [appendix figures 3A-1 and 3A-2]. Despite several attempts, the 
amplification across the satellite DNA failed (data not shown). These data 
suggest that the satellite sequence located on 22q, 21q, lq, 2q and lOq could be 
refractory to PCR. However, using the subtel2 assay, the fusion frequency was 
1.8x lower than that of the 21ql [appendix Figure 4A-1A and 4A-1B, panels 1 
and 2]. It was however not known whether the frequency was reflective of the 
ends that have eroded beyond the subtel2 primer site or the low amplification
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Figure 4.2. Histograms illustrating the deletion size from the start of telomere 
repeat array of telomeres of 21q (A) and 16p (B) families, in telomerase-positive 
HEK293 (open bars) and telomerase-negative MRC5 expressing E6E7 (solid bars). 
The limit of the assay is indicated with the dotted line. Means±SD are shown for 
each data set.
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deletion sizes from the telomeres of 21 q family, 16p family, 17p and XpYp 
respectively . The P-values for pair-wise comparison of the data are shown 
for each data set
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efficiency of the primer. Within the 21 q family, the deletion events extended 
close to the limit of the assay, of 3.4kb from the start of the telomere repeat array. 
However, the distribution was random with no clear correlation between the 
distance from the start of the repeat array and the frequency of fusion events. The 
highest frequency of telomere fusions was at 1.1 kb and 1.3kb in MRC5 and 
HEK293 respectively, however the deletion events in both cell lines were not 
normally distributed [Figure 4.3A; D'Agostino & Pearson omnibus normality 
test, P=0.0460 (HEK293); P=0.002 (MRC5)] and there was no region that 
appeared to be a hotspot for fusions.
The 16p family consists of lp, 2ql4 (interstitial locus), 9p, 12p, 15q, 16p and 
XqYq (Riethman et al. 2004). The sequence analysis of fusion events involving 
the 16p family revealed extensive deletions extending close to limit of the assay 
(6.1kb). The maximum deletion sizes were 4.99kb and 5.70kb [Table 4.2; Figure 
4.2B; Figure 4.3B]. Both MRC5 and HEK293 cells displayed similar deletion 
profile [P=0.65; (Letsolo et al. 2009)] with the mean deletions (±SD) being 
2.40±1.54 and 2.53±1.23 respectively [Table 4.2; Figure 4.2B; Figure 4.3B].
However, the highest frequencies of deletion (mode) occurred at distinct 
distances from start of telomere repeat array [MRC5, 2.2kb; HEK293, 0.88kb] 
with the data derived from HEK293 being normally distributed [P=0.2561] 
whilst that from MRC5 was not [P=0.0072]. Interestingly, the frequency of the 
fusion events distal to the mode appeared to remain constant per unit length 
[Table 4.2; Figure 4.2B]. Thus, the data derived from fusion events involving 
telomeres of 16p show that the subtelomeric deletion can be very extensive and 
may extend beyond the limit of the assay.
Within the telomere-adjacent DNA of telomeres of 16p family lies the 29bp 
repeat array, which terminates 515bp from the start of the telomere array (Brown 
et al. 1990; de Lange et al. 1990). The 29bp repeat is a minisatellite that has 85% 
GC content. Downstream of the minisatellite lies another 37bp repeat array
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Table 4.2 Descriptive statistics summary of deletion size from telomere fusion data derived from HEK293 and MRC5.
Mean
16p group 21q group XpYp 17p
MRC5 HEK293 MRC5 HEK293 MRC5 HEK293 MRC5 HEK293
2395 2525 1496 1190 772 609 715 1680
Standard Error 183 191 34 58 52 78 166 287
Median 1839 2328 1386 1180 756 540 289 1879
Mode 2187 883 1320 1180 986 853 248 2244
Standard
Deviation 1540 1225 347 528 390 341 864 1034
Minimum 556 586 826 235 62 126 2 33
Maximum 5696 4986 2633 2790 1543 1198 2737 2938
Count 71 41 102 84 56 19 27 13
Confidence Level 
(95.0%) 364 387 68 114 104 164 342 625
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(Brown et al. 1990; de Lange et al. 1990). These satellites could be refractory to 
PCR. Consistent with this view, the minimal deletion size observed in fusion 
events involving the telomeres of the 16p family was 586bp and 556bp in 
HEK293 and MRC5 respectively [Figure 4.2B; Figure 4.3B]. The presence of the 
minisatellite in this region could also account for failure to detect the fusion 
events containing telomeric repeats from the 16p family.
To explore if the minisatellite was refractory to PCR, the fusion assay was 
carried out with oligonucleotide primers [subtel2; subtell; appendix Figure 3A-2] 
that were located downstream of both repeat arrays. Subtel 2 detects fusion 
events involving telomeres of 21q and 16p families while subtel 1 detects fusion 
events that involve the telomeres of the 16p family only [appendix Figure 4A-1, 
panels 3 and 4]. The putative fusion molecules detected with subtell could not be 
isolated and characterised as semi-nested PCR amplification failed.
We have previously illustrated that the analysis of fusion events between 17p and 
XpYp telomeres in MCF7 TRF2-knockdown cells resulted in fusion events that 
contained extensive TTAGGG repeats on both sides of the fusion junction 
(Capper et al. 2007). Thus, analysis of these cells was undertaken with the 
expectation of detecting fusion events that contain TTAGGG repeats from 
members of the 21q or 16p families. Despite multiple attempts, fusion events 
involving these ends were not detected in these cells. However, it was not known 
if the fusion events generated between these ends were too large to be resolved 
by gel electrophoresis or could not be amplified with the assays. Thus it remains 
to be determined if the assays are capable of detecting fusion events that contain 
telomere repeats from the telomeres of 16p family. As mentioned previously, the 
amplification of the fusion events containing telomere repeats from the telomeres 
of 16p family could be inhibited by the presence of the minisatellite mentioned 
above.
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4.2.2.2.2 XpYp and 17p telomere
The deletion events extending into the sub-telomeric DNA of XpYp and 17p 
have been described previously for fusion events that involve XpYp with 17p 
(Capper et al. 2007). The analysis of fusion events involving telomeres of XpYp 
and 17p has revealed that the fusion events were accompanied by large deletions 
extending to the limit of the assay [3kb (at 17p) and 1.7kb (at XpYp); (Capper et 
al. 2007)]. In this study, sub-telomeric deletions for fusion events involving 17p 
or XpYp with telomeres of the 21q and 16p families are described. A total of 191 
[HEK293, n=73; MRC5, n=118]; and 107 [HEK293, n=52; MRC5, n=60] fusion 
events involving XpYp and 17p respectively were sequenced. Notably, only 39% 
[MRC5, n=56/118; HEK293, n=19/73] of the telomere fusion events that 
involved XpYp showed a deletion extending into the telomere-adjacent DNA 
[Table 4.2].
Both MRC5 and HEK293 cells displayed similar deletion profiles at the XpYp 
telomere [P=0.1019] with a combined mean deletion (±SD) of 0.69±0.37kb 
[Table 4.2]. The highest frequency of deletion (mode) in both cell lines [0.986kb 
(MRC5); 0.853kb (HEK293)] was occurring around same distance, with data 
being normally distributed [Figure 4.3D; Figure 4.4A; HEK293, P=0.1970; 
MRC5, P=0.2570]. Interestingly 91% (MRC5) to 100% (HEK293) were 
clustered within 1200bp of the telomere repeat array [Figure 4.3D; Figure 4.4A] 
with distributions beyond 1200bp appearing to be randomly distributed extending 
to the maximum deletion of 1.198kb and 1.543kb in HEK293 and MRC5 
respectively, very close to the limit of the assay, 1627bp.
Similarly, the deletion profile at 17p was extending close to the limit of the assay 
3.1kb [HEK293, 2.9kb; MRC5, 2.7kb]. However, only 36% of fusion events 
[MRC5, n=27/60; HEK293, n= 13/52] involved a deletion extending into the 17p 
telomere-adjacent DNA [Figure 4.3C; Figure 4.4B]. In 17p, the deletions were 
randomly distributed with the minimal and maximum deletion being 
33bp/2938bp and 2bp/2737bp; and the highest frequency (mode) of deletion
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being at 2.244kb and 0.248kb in HEK293 and MRC5 respectively [Table 4.2; 
Figure 4.3C; Figure 4.4B].
In HEK293, despite the expression of telomerase activity, the telomeres were 
consistently short at all the chromosome ends analysed [Figure 3.3B-C]. At 
XpYp, the two alleles can be discriminated by the numerous well-documented 
single nucleotide polymorphisms [SNPs] within the 850bp of XpYp telomere 
adjacent DNA that are linked to specific sub-telomeric alleles (Baird et al. 1995). 
In HEK293, two haplotypes linked to SNPs at -427/-415 GC/AT alleles were 
identified; this showed similar telomere length distribution profiles [Figure 3.3A- 
C; (P=0.97)]. Interestingly, the HEK293 sample analysed in the study consisted 
of 75% GC and 25% AT alleles [Figure 3.3C]. In addition each allele exhibited 
distinct pattern of the telomere repeat variants (Baird et al. 1995). Thus using the 
SNP analysis and the pattern of the variant for each allele for those fusion events 
that contained the proximal region, it was apparent that the GC allele is involved 
in more fusion events (67%) than AT allele, indicating that both alleles are 
equally susceptible to fusion. However, some deletion events were occurring 
beyond the 850bp [well-documented SNPs region] from the start of the telomere 
repeat array thus could not be included in the estimation of the frequency of 
fusion events involving either allele, thus this data could represent an 
underestimate of the fusion events that involve either of the XpYp alleles in 
HEK293 cells.
STELA and analysis of the telomere-adjacent DNA at XpYp in MRC5 cells have 
revealed two length alleles, which are linked to specific SNPs. We have 
previously reported that as the MRC5 cells expressing E6E7 onco-protein 
continue dividing towards crisis, the telomere of the short allele starts to 
disappear and the frequency of fusions increases (Capper et al. 2007). However, 
there was no evidence of loss of heterozygosity at the SNPs associated with the 
short allele indicating that the telomere did not erode into the telomere-adjacent
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DNA but was involved in fusion events with other telomeres (Capper et al. 
2007).
Consistent with this, two alleles were involved in fusions with 17p (Capper et al. 
2007). The current data has further revealed that indeed the short and the longer 
length alleles were involved in fusion events with the members of the 21q and 
16p families. However, due to frequent deletions some of which were extending 
beyond the well-documented 850bp telomere adjacent DNA of XpYp, the ratio 
of events that involve either allele was not determined. The observation that both 
long and short XpYp alleles are involved in fusion events is consistent with 
large-deletion events at the longer allele resulting in short dysfunctional 
telomeres that are capable of fusion (Capper et al. 2007) coupled with telomere 
erosion at the short allele to range at which telomeres may be subjected to fusion.
4.2.2.3 TTAGGG and Micro-homology
In addition to large deletion events, the fusion events were characterised by 
limited TTAGGG repeats at the fusion point, with 38% to 60% of fusions in 
HEK293 and MRC5 respectively, containing no TTAGGG repeats at the fusion 
junctions [Figure 4.4C; Table 4.3; Figure 4.5A]. Of those that did contain 
TTAGGG repeats, the highest was 26.3 and 43 repeats in HEK293 and MRC5 
respectively [Figure 4.4C; Table 4.3; Appendix Figure 4A-2A]. However, the 
mean (±SE) TTAGGG repeats was similar in both cell lines (5.7±0.6; 5.8±0.7), 
with the minimum being 0.3 and 0.2 respectively. In HEK293 cells, 80-90% of 
the fusion events that had TTAGGG repeats were occurring at the proximal part 
of the telomere that contains telomere variant repeats [TVRs; Figures 4.5C and 
4.5G]. This proximal l-3kb of human telomeres is highly variable and consists of 
canonical telomere repeat sequences, TTAGGG, interspersed with telomere 
variant repeats (Allshire et al. 1989; Baird et al. 1995). The telomere variant 
repeats are not bound by the telomere binding proteins TRF1 and TRF2 (Bianchi 
et al. 1999; Baumann and Cech 2001). This coupled with extreme variability of 
TVR, indicates that the TVR region is non-functional. This data is consistent
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with this view, as it appears that telomeres that have eroded to within the TVR 
region are capable of fusion.
The fusion events that contained the longest TTAGGG tracts in MRC5 were 
observed in cells that have continued to proliferate for 6-8PDs beyond 
senescence, i.e. The two fusion events that contained long tracts of telomere 
repeats (21 and 43) were detected at PD32.2 where the telomere repeat arrays 
were longer, whilst fusion events derived from cells undergoing crisis (PD52) 
were characterised by large deletions on both sides of the fusion junction.
Out of the 308 fusion events sequenced, only one event revealed telomere repeats 
on each side of the fusion point, in this case 6.5 repeats from 17p and 3.5 repeats 
from lOq [Figure 4.5B]. This indicates that the assays are not refractory to 
inverted repeats on either side of the fusion point, consistent with our previous 
study (Capper et al. 2007).
Table 4.3. Descriptive statistical data of number of TTAGGG repeats and 
microhomology sequences at fusion point for fusion events derived from HEK293 and 
MRC5. S.E is standard error; S.D is standard deviation of the mean.
Mean
Number of 
TTAGGG at fusion 
point
Micro-homology at fusion point
HEK293 MRC5
data excluding zero
HEK293 MRC5 HEK293 MRC5
5.7 5.8 1.2 2.0 2.0 2.7
SE 0.6 0.7 0.1 0.1 0.1 0.1
Median 3.8 4.4 1.0 2.0 2.0 2.0
Mode 1.0 1.0 0.0 0.0 2.0 1.0
SD 5.5 6.1 1.2 1.8 1.0 1.6
Minimum 0.3 0.2 0.0 0.0 1.0 1.0
Maximum 26.3 43.0 5.0 12.0 5.0 12.0
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In addition to the characteristic large sub-telomeric deletions and lack of 
TTAGGG repeats at fusion junctions, the majority of fusion events [60-74% in 
HEK293 and MRC5 respectively] exhibited short patches of nucleotide 
homology at the fusion point between the participating telomeres [ l -12nt, mean 
1.7nt; Table 4.3; Figure 4.4D; Figure 4.5A-D and 4.5F-H]. These micro­
homologies at fusion point showed a significant bias towards a G:C content of 
39% A:T, 61% G:C (chi square, P= 0.002) in comparison to the A:T/G:C content 
of the telomere-adjacent sequences being investigated which consist of 48% A:T 
and 52% G:C.
4.2.2.4 Insertions and complex events
In addition to the fusion events between the chromosome ends described above, 
it was apparent that complex events could accompany the fusion of short 
dysfunctional telomeres. A subset of the fusion events (34/298) comprising 11% 
were characterised by an insertion of genomic sequences at the fusion junction 
between the chromosomes being studied. All of these insertions except six were 
made up of the simple insertions of 1-34 nucleotides [Figure 4.5E]; these 
insertions were too small for their origin to be identified. Four insertions that 
were large enough to be identified were mapped to interstitial sites in the human 
genome, near documented fragile sites. One was derived from 7p22.1, one from 
8q24.3 [Figure 4.5H] and the other two from Xp22.1 [appendix Figure 4A-2F; 
(Chen et al. 1998; Debacker and Kooy 2007)]. Two additional fusion events 
contained an insertion between the partner chromosomes. These were distinct 
however because they involved fusion of one telomere to telomere-adjacent 
DNA of same telomere in reverse orientation. In MRC5, where two XpYp alleles 
can be distinguished by the SNPs within the telomere adjacent DNA, it was clear 
that these insertions were derived from the same allele as the one fused to it, and 
were therefore intra-allelic [Figure 4.5G].
In addition, fusion events were detected between XpYp and/ or 17p and the 
interstitial loci adjacent to the ancestral telomere-telomere fusion locus, 2ql4; a
161
^  Chapter 4: Telomere fusion in vitro
. . . acc: cc-.ccca&agagggctt6Tcc: : c: :  e -jgcatgcagc gc ctgaca. . .
A-2121 bp: 4 ---------------  A -2117 bp: 21q
9p
B)
. . . c : GGGCI GGGC GGGG f GGGC ~.-.GGG GGG GGGTTAGGGTTAGGGTTAACCCT COT CCCTG CCCTT CCC CCC C C ...
(V+T)x30 Tx63/e 17p « = _ iQq Tx33/6 (V+T) x 23
C)
...AGGAGC GGTG GCGGQCOCT ' .-.CCCTA-.CCCTG.-.CCCT.-G.CCCT.-.-.CCC:' CCC CCC G . . .
A-5601 bp: XqYq X PY P Tx14 (V+T)x27
D)
. . . CCCTCACTCAGCCTTTTCCCTCCAGGCTAACCCTMCCTA.-.CCT CCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTGA. . .
A -4071 bp: 2q14 Tx14/6 Vx2 T x 7
(intestitial) (V +  T)x30
E)
. . .G  3GG 3GG G GGGG C GCGCC GCTCATC GGCTGTG • GGG G A T ...
A-853 bp: XpYp Insertion: "A-2071 bp: XqYq
8 nucleotides
F)
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G) | f
. . . GGCTGACGGCAAGTTAAC^ AAA GACGCGGAACCTCGCGGTGAGTGTTACAGTTCTTAAAGGTGGCGCGTCCGGAGTTTGTTTCTTCTGATGTTCAGATGTGTTCTGA
A-1260bp A-356bp XpYp -176 (short telomere) -146
I X
GTTTCTTCTTTCTGGTGGGGTTGTGGTCTCCTGGCTCAGGAGTGAAGCTGCAGACCTTTGCGGTGAGTGTCACAGCTCATAAAGGCAGTGTGGACCCAAAGAGTGAGCAATA 
GCAAGATTTATTGCAAAGAGTGAAAflA g C 3 G C  CC' GST: GT C : G G GGGG GGG C GGGCCTTCTgTC GGG C . . .
A-111 bD XdYd 4 -^ - *  A-596bp XpYp TDp A prp  < _  -652 (short telomere)
H)
. . . ggg: :  : ggg:: ggg.'  ggg : ggg GGG gggg: gggg: :  gggtc^ ttgaggggaagtcaccgggccctgcatcctcatcagcaaccaggtctaa
Vx28 Tx83/6 X p Y p « -= " " *  8q24.3
TAACCCCTGGCCAGAAGTGAGAGAGTCTGGCATGCGGTGTGAGCTCAGGAACTGTGAGCTCTCCAAATCTGTGCTTCTGAGGGCTOCCTTGGGAGCCCCAGAGTGGAGGCAG 
GGAGGCCAGGGGCGAGGCTGGTTCCTTTGCCCATAAGAAGGCTCAGCCAGGCAAGGGGAGAGGGCACTGAGGGAGGGGGAATGGATCCAGAGATGCTCTGCCTTCCTGGAGA 
AGGAGAGAGTGTGGGCAGTTCCCCAGCACCTGTCTCACTTCCCTGGATGAGGCTACATGGCCTCAGCTTCCCCTCCCCCAACTGTCCTGGGGCTGCGCCCATTCCCAGAAGC 
TTTGCAGGGAGGTAAGGAGGGGCCGATGCGGGGCAGAGCCCCCACTCGTCCTATCTCATATCCCCAAGCTCTGCCGGGTGTCACAAGGCCTCTCAGCTGCAGTATCCCCACT 
CCACCCTGACCCCAGGCCCATCCATCCTGCCTGTACCTTCCTAGTGCAGCAGGGCCCTGGTATTTTCAGGTAGTCAGTTTCTGCTCTTTTGGGACATATGCTCTGTTTTGCA 
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Figure 4.5. Examples of DNA sequences for the telomere fusion events. A) 16p:21q group fusion.
B) 17p:10q showing a fusion with TTAGGG on either side of the fusion point.C) XpYp:XqYq showing 
large deletion event in XqYq telomere-adjacent DNA. D) fusion of 17p to the intestitial locus 2q14.
E) XpYp:XqYq with a simple insertion. F) XpYp:8p showing fusion at the proximal part of the telomere 
G) 1p:XpYp, an example of an event with insertion from same telomere (XpYp) in reverse orientation, 
SNPs identifying the short allele are indicated with arrows.H) XpYp:10q, an event with large insertion 
from non-telomeric locus 8q24.3. large insertions are shown in brown. The TTAGGG (T) and variants 
(V) are indicated for each sequence. Microhomology nucleotides are bolded and underlined
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locus located about 130Mb from the telomere of 2q (JW et al. 1991). It was 
however, not clear if such a fusion event represented an interstitial breakage prior 
to fusion or a large-scale sub-telomeric deletion [Figure 4.5D].
Furthermore, the fusion events involving the opposite arms of same 
chromosomes were detected in 23 out of the 112 fusion events involving 
telomeres of 16p family fused to 17p and/or XpYp [21%; 9/41 in HEK293; 14/71 
in MRC5; Figures 4.5C and 4.5E]. These events are consistent with the formation 
of ring chromosomes. These datasets indicate that dysfunctional telomeres can 
initiate chromosome instability that can extend into non-telomeric loci.
4.2.3 Mutations within the proximal part of the telomere.
Unlike the distal regions of the telomere, that are composed of homogenous 
tracts of TTAGGG repeats, the proximal regions of the human telomeres consist 
of l-3kb of TTAGGG interspersed by telomere-variants repeats (TVR), which 
include TTGGGG (J-type), TGAGGG (G-type), TCAGGG (C-type) and others 
[N-type; (Allshire et al. 1989; Baird et al. 1995; Baird et al. 2000; Varley et al. 
2002)]. The distribution pattern of these repeats is usually determined by 
telomere variant repeat PCR [TVR-PCR; (Baird et al. 1995)]. However, in this 
study, the TVR region was characterised by direct sequencing analysis of those 
fusion events without a deletion of the telomere DNA (Baird et al. 1995; 
Coleman et al. 1999; Baird et al. 2000). Unlike the population studies where the 
TVR maps were derived for individuals, the TVR maps reported in this study are 
derived from single cells. Thus the deviation of the TVR distribution from the 
parental as determined by aligning all the TVR maps, would imply a mutation 
within a specific cell. In addition, the presence of the same pattern of deviation 
from the putative parental TVR pattern in more than one event derived from 
same cell strain would imply that such mutation was stably maintained through 
cell division. Detailed analysis of XpYp telomere and other autosomal telomeres 
16p, 16q and 12q in different populations have revealed extensive allelic
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Figure 4.6. Telomere variant repeat structure derived from telomeres o f XpYp and 17p in HEK293 and MRC5 E6E7 cells. The key 
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variation and hypervariability at the proximal end of the repeat array (Baird et al. 
1995; Coleman et al. 1999; Baird et al. 2000). Thus, to investigate whether such 
variability was reflective of the mutational spectrum at a single-cell level, a 
detailed analysis of the TVR region of the XpYp and 17p telomeres was 
undertaken. The large dataset of the single-molecule fusions gave comprehensive 
distribution of the TVRs and thus the TVR maps for each cell strain were 
produced [Figure 4.6]. The results revealed that the previously named N-type 
consists of many different repeat types ranging from five nucleotide repeat to >9- 
nucleotide repeats; interspersed with TTAGGG in single-repeats and/or varying 
blocks (3-16 repeats) of repeats within same allele. At least 24 different types of 
repeats were documented from XpYp and 17p telomeres. Furthermore, each 
variant was subjected to single nucleotide insertion or deletion e.g. TTAGGG to 
TAGGG or TTAGG and vice visa. In addition to simple deletion/insertion 
events, there were transitional/transversional changes within the repeat array 
resulting in a change of a repeat type without change in size. e.g. TTAGGG to 
TCAGGG.
From these detailed TVR maps, it was apparent that the fusion events that 
contained the TTAGGG repeats at the fusion junction were derived from within 
TVR region; this region is considered non-functional as far as the capping of 
telomeres is concerned (Capper et al. 2007). In only 14% (29) of the 201 fusion 
events in which the TVR region could be documented, the fusion point was 
located distal to the TVR regions [Figure 4.6; appendix Figure 4A-3].
Combining the TVR analysis and the SNPs within the telomere-adjacent DNA, 
the allelic variation at each telomere was determined in HEK293 and MRC5. In 
MRC5, one allele at XpYp and 17p was characterised while in HEK293, the two 
XpYp alleles displayed different repeat distributions. Similarly, at 17p telomere, 
two alleles that exhibited differences in repeat distributions were characterised. 
Allelic analysis of the same telomere e.g. XpYp in HEK293 has revealed the 
mutational changes in the pattern of variants distribution. There was evidence of
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contractions/expansions of the repeat blocks resulting from deletions/insertions 
of single or blocks of repeats. In addition, duplications of up to 12 repeats were 
also observed. Within a specific allele, the variation in the distribution profile 
could be attributed to simple events such as single nucleotide additions or 
deletions, converting one repeat type to another. Furthermore, the size of the 
repeat block was either contracting or expanding. Some of these events were 
detected more than once, indicating that the event was derived from more than 
one cell. This data suggested that once the event occurred, it can be stably 
maintained through cell division and thus result in clonal expansion. This is 
consistent with the clonal fusion events described in the study. However, the 
mutation events within the TVR region are unlikely to arise as a consequence of 
the fusion events as they were detected in independent and unrelated fusion 
events.
In addition to simple events, complex events involving insertion of the block of 
repeats with no obvious origin were characterised immediately adjacent to the 
fusion point in two fusion events [Figure 4.6; appendix Figure 4A-3]. It was 
however not clear whether they represented a mutational event resulting from the 
processing of sequences at the fusion junction or the insertion from another 
telomere.
4.3 Discussion
4.3.1 Telomere fusion analysis
Human cancers arise through accumulation of genetic alterations. One of the 
mechanisms that may confer tumourigenic potential is the state of the telomere, 
thus telomere-induced chromosome instability is a subject of extensive research 
in cancer studies. Telomere dysfunction through loss of the telomere cap or 
telomere attrition has been shown to result in telomere fusions (van Steensel et 
al. 1998). The fused chromosomes can break and fuse again fuelling large-scale 
chromosome instability such as amplifications, deletions and complex
167
Chapter 4: Telomere fusion in vitro
rearrangements, which are some of the early lesions that drive tumourigenesis in 
epithelial cancers (Artandi et al. 2000; Rudolph et al. 2001). Previous studies 
have shown that telomeres are subjected to processes that generate short 
telomeres (Mumane et al. 1994; Baird et al. 2006; Capper et al. 2007). Thus to 
determine the fate of the critically short telomeres, the PCR-based technique that 
detect fusion events between XpYp and 17p telomeres was developed. That 
study revealed that fusion of dysfunctional telomeres was accompanied by large 
sub-telomeric deletions, lack of TTAGGG and short patches of nucleotide 
homologies at the fusion point (Capper et al. 2007). The assay has since been 
extended to include at least 43% of the human genome (Letsolo et al. 2009). 
Here, I have described a comprehensive analysis of the telomere fusion events 
between telomeres of XpYp, 17p, 16p family [lp, 9p, 12p, 15q, 16p, XqYq and 
interstitial 2ql4] and 21q family [lq, 2q, 5q, 6p, 6q, 8p, lOq, 13q, 17q, 19p, 19q, 
21q, 22q and interstitial 2ql3] in HEK293 and MRC5 cells that have escaped 
senescence. In telomerase-positive cell line, HEK293, all telomeres analysed 
displayed short length profile with increased frequency of telomere fusions. It 
appears that telomerase in this cell line is not sufficient to counteract the effect of 
telomere erosion. Indeed it has been shown that some of the clones within 
HEK293 lack detectable telomerase activity and thus maintain short telomeres 
(Bryan et al. 1998). Interestingly recent work in our lab has isolated clones that 
maintained longer telomeres and did not display any telomere fusions (DMB 
personal comm.).
In the absence of telomerase gradual telomere loss in human fibroblasts as a 
function of replicative age could contribute to cell senescence (Harley et al. 
1990; Levy et al. 1992). However, inactivation of the p53/Rb pathways by 
oncogenic transformation extends the replicative capacity of fibroblast for 
several PDs. This extended life span results in further telomere erosion until cells 
reach crisis, the state characterised by extensive chromosome instability and cell 
death. However, cells that survive are generally aneuploid, maintain stable 
telomere lengths and express telomerase activity or a recombination-based
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mechanism (Wright and Shay 1992; Ducray et al. 1999). To investigate the 
chromosome instability in cells that have bypassed senescence and continued 
proliferating to crisis, we have extended the replicative life span of the human 
lung fibroblast cell line, MRC5 through forced expression of HPV16 E6E7 
oncoproteins (Capper et al. 2007). The analysis of these cells has revealed that as 
the cells continue dividing towards crisis, the telomere erosion was inversely 
proportional to frequency of fusion events. The longer alleles were becoming 
shorter while eroded shorter length alleles were actual disappearing. The short 
telomeres that are disappearing tend to fuse with other telomeres. Because the 
longer alleles are subjected to random deletions, they could become uncapped 
and are involved in telomere fusions. This was apparent in analysis of MRC5 
cells, which have two different lengthed XpYp alleles that could be distinguished 
by SNPs within the telomere-adjacent DNA. It was apparent that both alleles 
were involved in fusion events; consistent with the data that in addition to end- 
replication losses resulting in gradual telomere erosion as a function of time, 
telomeres were also subjected to random deletion events, both generating short, 
dysfunctional telomeres capable of fusion (Capper et al. 2007).
Unlike in HEK293, where several ends were involved in fusion events, in MRC5, 
two ends, lOq and 21q representing the members of 21q family were detected in 
fusion events with XpYp or 17p. Absence of other ends in fusion events could 
suggest that in MRC5, only a subset of chromosome ends have eroded to within 
the length range at which fusion is detected. In support of this, STELA at the 
telomeres of 2p, 1 lq and 12q have revealed that MRC5 exhibited longer 
telomeres at these ends compared with XpYp and 17p, with none of the 
telomeres exhibiting length within the range that yields telomere fusions (Britt- 
Compton et al. 2006; Capper et al. 2007). In addition, telomere fusion analysis 
did not reveal any fusion events involving XpYp, 17p and these ends [(Capper et 
al. 2007); DMB personal comm.]. These data is consistent with the view that 
telomeres need to erode to critical threshold prior to being subjected to fusion. 
An alternative explanation could be the existence of large allelic variation at sub­
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telomeres, extending beyond the scope of our assays, i.e. if the cells are carrying 
longer sub-telomeric alleles, the positions of the oligonucleotide primers used in 
these assays could be located several kilobases away from the start of the 
telomere repeat array and thus the size of fusion molecules could be beyond the 
amplifiable range of PCR products. Large allelic variation at sub-telomeres has 
been described at 16p telomere in which its several alleles vary by as much as 
260kb (Wilkie et al. 1991), thus involvement of such large alleles in fusion 
events would be beyond the scope of these assays.
The minimum deletion size in telomeres of 16p and 21q families was restricted to 
the regions proximal to the GC-rich satellite DNA. This could be refractory to 
PCR, several attempts were employed to examine these possibilities and it was 
found that at the telomeres of 21 q family, notably 21q and lOq, the telomere 
fusion events that contain telomeric repeats could be detected. However, the 
frequency of such events was very low regardless of the oligonucleotide primers 
used for detecting the telomeres of both families simultaneously. Therefore, I 
concluded that the extended assays [3.5kb at 21q family and 6.1 kb at 16p] could 
be limited to detecting the fusion events with deletions upstream of the satellite 
DNAs.
4.3.2 Mechanistic basis of telomere fusions
The comprehensive analysis of the telomere fusion events between multiple 
chromosomes described here indicated that fusion of short dysfunctional 
telomeres is accompanied by deletion of telomeric and sub-telomeric DNA; this 
is consistent with our previous study of fusion events between XpYp and 17p 
(Capper et al. 2007; Letsolo et al. 2009). The large deletions of up to 5.6kb are of 
interest especially in telomeres of the 16p family, in which the deletions occur 
within the Wiskott-Aldrich syndrome protein and SCAR homologue (WASH) 
gene family (Linardopoulou et al. 2007; Riethman 2008b; Riethman 2008a). 
Although their function is not yet known, the data indicates that the deletion
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within the sub-telomeric region can be very extensive extending to coding DNA 
within the region. This could create significant mutational burden that may result 
in misregulation of sub-telomeric genes thus leading to diseases. Indeed several 
terminal deletions have been associated with many human diseases, for instance, 
terminal deletions of 16p result in alpha-thalassemia (Hatton et al. 1990; Wilkie 
et al. 1990; Flint et al. 1994); terminal lOq deletion syndrome is associated with 
typical craniofacial appearance and varying degrees of psychomotor retardation 
found in patients with lOq-syndrome (Petersen et al. 1998).
Whilst the mechanism that underlies this type of event is not yet known, the 
characteristic profile consisting of large deletions at telomeric loci is consistent 
with other observations: for example, the repair of I-scel-induced double strand 
breaks near telomeres generated large deletions (Zschenker et al. 2009). In 
addition, in cdcl3 mutants of Saccharomyces cerevisiae, the processing of 
single-stranded DNA can result in telomere and sub-telomeric deletions 
extending up to 8kb from the start of the telomere repeat array (Maringele and 
Lydall 2002).
In addition to deletions, the fusion events lacked telomeric TTAGGG repeats on 
either or both side of the fusion point. Consistent with data described here, 
chromosome fusions that lack telomere repeats at fusion junction have been 
described in normal (Takubo et al. 2010) and transformed (Zou et al. 2009) 
human fibroblasts. Furthermore, more than 70% of fusions contained patches of 
homology nucleotides at the fusion point, of these 7% contained five nucleotides 
or more at the fusion point. Such fusion events are distinct from those generated 
through LIG4-mediated non-homologous end joining (TRF2-dependent); a 
mechanism involved in repair of long unprotected telomeres (van Steensel et al. 
1998). The fusion events generated when the function of TRF2 is inhibited are 
characterised by long tracts of the TTAGGG repeats on either side of the fusion 
point (van Steensel et al. 1998). The mechanism that underlies fusion events 
described here is consistent with some form of an error-prone processing that is
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facilitated by GC-rich micro-homologies. Alternative NHEJ pathways have been 
described in mammalian cells and tumours (Wang et al. 2003; Wang et al. 2006) 
as well as in class switch recombination in lymphocytes during synthesis of the 
immunoglobins in the absence of Ku70 and ligase 4 (Boboila et al. 2010). Such 
mechanisms are independent of DNA-PKcs and Ku, and may rely on the GC-rich 
micro-homologies to stabilise the complex prior to ligation of the ends together 
(Wang et al. 2003; Wang et al. 2006). The well-characterised alternative 
mechanism to NHEJ, which operates as a backup to NHEJ is micro-homology- 
mediated end-joining (MMEJ). Whether MMEJ represents one mechanism or 
several alternative mechanisms to NHEJ is controversial, such that the clear 
distinction need be made when discussing MMEJ and alternative NHEJ 
mechanisms. It is clear however that not all alternative end-joining events are 
MMEJ and similarly, some alternative end-joining events are distinct from 
MMEJ (Mcvey 2008).
MMEJ is an error-prone, ku-independent repair than involves (Use of micro­
homologies, which has been described in yeast and Xenopus (Ma et al. 2003). It 
is characterised by the use of 5-25bp micro-homology sequences during the 
repair of double-stranded breaks. In addition, such repair is accompanied by 
deletion of the DNA flanking the break (Yu and Gabriel 2003). A subset of the 
fusion events described here is consistent with micro-homology mediated end 
joining that involves use of 5-25 nucleotides (micro-homology sequences). More 
fusion events (93%) contained less than five nucleotide micro-homologies. 
Although the fusion events have two subsets (i.e. micro-homologies greater than 
or less than 5 nucleotides) of micro-homologies, the mechanism is consistent 
with some form of error-prone DNA repair mechanism which as yet is unknown 
whether is distinct from MMEJ or represents an alternative or subtype of MMEJ. 
In support of this, DSBs induced by the yeast site-specific homing endonuclease 
l-Scel in KU70-/~ mammalian cells are repaired via MMEJ. However, some 
breaks are repaired using micro-homology-independent pathways (Bennardo et 
al. 2008). Like the repair of I-Scel-induced DSBs, which consists primarily of
172
Chapter 4: Telomere fusion in vitro
large deletions, the mutational profile of the fusions described here is similar to 
that involving an alternative mechanism to NHEJ (Richardson and Jasin 2000; 
Zschenker et al. 2009).
In mammals, MMEJ has been associated with large deletions, complex 
rearrangements, translocations and cancer (Weinstock et al. 2007). For instance 
mice lacking functional p53 and NHEJ components, ku or lig4 develop pro b-cell 
lymphomas with multiple translocations characterised by presence of 2-8 
nucleotide micro-homologies (Difilippantonio et al. 2000; Ferguson et al. 2000). 
The chromosome fusion events that are consistent with MMEJ have been 
observed in tert_/7Ku+/+ mutants of Arabidopsis (Heacock et al. 2004; Heacock et 
al. 2007), Drosophila and yeast (Ma et al. 2003). In addition, telomere fusions 
that are independent of the NHEJ component, DNA PKcs has been described in 
mice without telomerase (Maser et al. 2007). This pathway is error-prone 
resulting in large deletions and is characterised by patches of micro-homologies 
at the fusion point with a bias towards G:C content (Audebert et al. 2008).
4.3.3 Telomere fusion has potential to form ring 
chromosomes
The fusion events involving the XpYp and XqYq were frequently detected, these 
events have a potential to form ring chromosomes. Formation of ring 
chromosomes is often accompanied by loss of chromosome ends, enabling the 
arms to fuse together (Miller and Therman 2001). However, ring formation can 
also occur with only one end being lost as in a case where the broken 
chromosome fused with the opposite telomere region (Amedo et al. 2005). The 
ring chromosomes can also form without loss of genetic information as in case of 
telomere-telomere fusion. Although, they do not result in loss of genetic 
information, ring chromosomes have been observed in many human diseases. For 
instance, ring chromosome 20 is associated with epileptic seizures, behaviour 
disorders and mental retardation (Schinzel and Niedrist 2001), ring chromosome 
14 (Schmidt et al. 1981) is associated with mental retardation, while ring X
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chromosome is associated with turner syndrome (Dennis et al. 1993; Miller and 
Therman 2001). It has been postulated that while they do not result in loss of 
genetic material, the ring syndromes are a result of the instability of the ring 
during mitosis. Indeed, it has been shown that the ring chromosomes can form 
anaphase-bridges, which could induce continuous rearrangement through 
breakage-fusion-bridge cycles (Gisselsson et al. 2001; Miller and Therman 
2001). Ring chromosomes are frequently detected in tumour cells and sarcomas, 
however the frequency of ring chromosomes is lower (<10%) for carcinomas 
(Gisselsson 2002). One of the mechanisms that generate ring chromosomes is 
loss of telomere function resulting in fusion of the two arms of the same 
chromosomes. Such ring chromosomes are unstable during mitosis (Miller and 
Therman 2001; Sumner 2003). The chromosomal breakage-fusion-bridge events 
have been implicated as mechanisms that increase the genetic heterogeneity of 
tumours (Gisselsson et al. 2000).
4.3.4 Telomere dysfunction can induce complex
rearrangements
This study has also detected the fusion events that contained an insertion of the 
telomere-adjacent DNA derived from one of the ends involved in a fusion event. 
Using the informative SNPs in the telomere-adjacent of XpYp, it was apparent 
that the inserted DNA was derived from the same allele as the one involved in a 
fusion event in reverse orientation; these are consistent with intra-allelic events. 
The mechanism by which the segment of the same chromosome fuse in reverse 
orientation is not known but could include a sister chromatid exchange resulting 
in inverted repeats at the fusion point; which have been shown to be unstable 
thus creating a fragile site that could break in successive cell divisions. Once 
broken an uncapped chromosome can then fuse to another telomere resulting in 
the type of fusion event described (Lo et al. 2002). It was however, not possible 
to verify the intermediate type of fusion using our assays, as the assays can only 
detect sister chromatid-type fusions when at least one of the telomere repeats has 
been deleted creating an imperfect repeat (Capper et al. 2007). In our recent
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publication, we have proposed an alternative mechanism, in which the telomeres 
are processed by an exonuclease that creates single-stranded overhang. Once 
established the overhang may loop back and invade the sub-telomeric DNA. 
Then the looped DNA can be processed by endonucleases, which generate the 5' 
overhang. The resulting overhang can then fuse to another telomere or a double 
strand break [Figure 4.7; (Letsolo et al. 2009)].
4.3.5 Complex events involving documented fragile sites.
The fusion events that involved non-telomeric loci (2ql4, 7p22.1, Xp22.1 and 
8q24.3) were identified near the known fragile sites; 2ql3 (FRA2B), 7p22 
(FRA7B), Xp22.3 (FRAXB) and 8q24.3 [FRA8D; (Buttel et al. 2004)]. Fragile 
sites are generally stable in normal cells; however, in tumours they can be 
involved in chromosomal aberrations such as deletions and translocations. For 
instance, terminal deletion involving 7p22 is reported in 22% of endomentrial- 
derived tumours (Gogusev et al. 1999). Similarly, an increase in copy number at 
8q24 (c-myc gene; an oncogene mapped within 8q24) is frequent in human 
tumours. It has been shown that telomerase activity is correlated with gains of 
this locus, which support the fact that c-myc induces telomerase in human cells. 
Indeed Wang and colleagues have shown that c-myc induces telomerase activity 
in normal human mammary epithelial cells and human diploid fibroblasts, by 
increasing the expression of hTERT, a catalytic subunit of telomerase (Wang et 
al. 1998). Further support comes from the report that the promoters of hTERT 
have c-myc binding sites (Wu et al. 1999). The involvement of the locus in 
fusion events in cells undergoing crisis could suggest that the cells are activating 
a telomere maintenance mechanism and thus will become immortal. Indeed 
studies have shown that in mammals, telomere dysfunction can activate 
senescence, however cells that bypass senescence through oncogenic 
transformation continue dividing until they reach crisis, the mortality stage II that 
is characterised by large-scale chromosome instability and death (Wright and 
Shay 1992). However, cells that survive, activate a telomere maintenance
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Figure 4.7. Illustrating a model, for the sequence of events, that may account 
for intra-allelic event in which Insertion of same allelic DNA in inserted in 
reverse orientation. (A-B) Unprotected, short telomeres are susceptible to 
nycleolytic attack that generates a 3'-overhang within the telomere-adjacent 
DNA. (C) The 3'-end of the overhang (— 111) folds back upon itself and 
anneals adjacent to the -596 position, this is ligated and endonucleolytic 
cleavage creates a 5'-overhang structure which can be rendered double­
stranded by strand extension (D). Further resection (E) to the -356 position 
creates a substrate (F) for annealing and ligation of the lp sub-telomere at 
position -1260 (G). Endonucleolytic cleavage removes the unpaired 3'- 
overhang from XpYp (G), strand extension and ligation complete the fusion 
(H-I). [reproduced from Letsolo et al 2009 with permission from producer, 
DMB]
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mechanism notably telomerase, 90% of the time and continue dividing 
indefinitely. Thus, the cells containing these fusion events near the myc site 
could activate c-myc, which in turn would activate its target genes including 
telomerase and thus bypass crisis and continue proliferating. However, it is not 
obvious if this event represents the terminal deletion at 8q, which result in 
telomere instability thus fuelling large-scale genome instability.
Several translocations near 8q24.3 locus and terminal amplifications involving 
the locus 8q24.3 have been reported in breast cancer (James et al. 1997) and 
other malignancies. For example, the locus 8q24.21 which is adjacent to the 
fusion detected here is associated with B-CLL risk plausibly through differential 
expression of c-myc. If similar type of fusions occurs in vivo, this could lead to 
larger scale rearrangements and hence genomic instability that could drive 
tumour progression in susceptible individuals (Crowther-Swanepoel et al.). 
While being of clinical significance in several other lymphomas, the locus 8q24 
poses a cancer risk in several solid cancers including hereditary and non- 
hereditary prostate, colorectal, endometrial (Setiawan et al. 2007) and breast 
cancers (Schumacher et al. 2007; Fletcher et al. 2008).
Thus, whatever the mechanism that underlies these events, it is apparent that 
short dysfunctional telomere can initiate large-scale rearrangements that may 
extend to non-telomeric loci.
4.3.6 Mutational spectrum with the TVR region
The proximal part of the human telomere consists of complex patterns of 
TTAGGG repeats interspersed with telomere variant repeats (TVR) such as 
TGAGGG, TCAGGG, TTGGGG (Allshire et al. 1989; Brown et al. 1990; Baird 
et al. 1995; Coleman et al. 1999; Varley et al. 2002).
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The large dataset derived from direct sequence analysis of telomere fusion events 
at the single cell level enabled the alignment of TVR-maps for each allele within 
the same cell strain. The data has also revealed inter-allelic variation at the same 
telomere within the same cell strain. This is consistent with previous studies in 
which several alleles at the XpYp, 16p and 12q have been described (Baird et al. 
1995; Coleman et al. 1999; Baird et al. 2000). In HEK293, two XpYp alleles 
were associated with a specific haplotype, consistent with previous studies in 
human populations (Baird et al. 1995).
The analysis of the TVR distribution from separate cells within same cell strain 
has revealed intra-allelic variation arising from duplications, expansion or 
contraction of repeat blocks as well as single nucleotide deletions and insertions 
resulting in expansions and contractions of individual repeats. Thus, similar 
intra-allelic processes are operating at these sequences. In addition, transversions 
and transitions, which change one repeat type to another, were observed. These 
events are consistent with intra-allelic processes such as errors arising during 
replication such as slippage (Weber and Wong 1993; Richards and Sutherland
1994), as well as the intra-molecular recombination such as unequal sister 
chromatid exchange [review in (Britt-Compton and Baird 2006)]. Similar events 
which included variant repeat-type switching and intra-allelic events involving 
deletions and insertions have been described in ALT+ cells as well as in human 
populations (Baird et al. 1995; Coleman et al. 1999; Baird et al. 2000; Varley et 
al. 2002). In addition, the mutational processes that underlie the variability of the 
TVR region are similar to those described at other tandem repeat loci (Mahtani 
and Willard 1993; Weber and Wong 1993).
In addition to simple events, two fusion events in which the blocks of repeats 
with no obvious origin were inserted adjacent to the fusion junction were 
observed. This could represent the insertion of additional DNA from another 
telomere. The observed levels of variability within the telomere variant region 
may be a consequence of telomere fusion process. However, it is highly likely
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that the repeat changes occurred prior to fusion events as the mutations were 
observed in more than one independent fusion events. In addition, such events 
were seen in more than one event from same sample as well as from different PD 
samples in MRC5. However, it was noted that in MRC5, a cell line grown under 
controlled conditions, the variability in the variants at early PD32.2 was rare 
while in fusion events occurring later on as in PD52, the events were occurring 
and becoming stable overtime. The mutations within the TVR at regions adjacent 
to the fusion point could be a result of processing during fusion event. Whilst, 
those occurring distal to the fusion point could have arisen prior to fusion event 
and thus, were stably maintained through cell division.
Recent work has shown that one of the N-type repeats CTAGGG are highly 
unstable in male germ-line (Lim et al. 2009; Mendez-Bermudez et al. 2009). By 
aligning the different TVR maps within the same cell strain, no particular repeat 
type seemed to be replaced or added more often than others. Thus, I concluded 
that in this study no telomere variant repeat was more unstable.
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4.4 Key findings
• Using the extended and improved assay, I have isolated and characterised 
the telomere fusion event in telomerase-positive HEK293 and in 
telomerase-negative human fibroblast (MRC5) that have bypassed 
senescence.
• I have shown that fusion of short telomeres in human cells are 
characterised by large deletion extending close to the limit of the assay 
(6kb), short patches of microhomologies, insertions and complex 
rearrangements regardless of the telomerase status of the cells (Letsolo et 
al. 2009).
• This dataset is consistent with the notion that in addition to repair through 
chromosome healing, telomere loss can be restored through mechanism 
that form chromosome fusions resulting in translocations, dicentric 
chromosomes and ring chromosomes. Although the mechanism of 
chromosome fusions generated by dysfunction telomeres in human cells is 
not yet known, it is consistent with some form of error-prone ku- 
independent mechanism, which creates large deletions and utilises micro­
homologies.
• Analysis of the proximal part of the telomere has revealed that the 
mutational processes that underlie variant repeats are intra-allelic. The 
single-cell data described here is consistent with previous studies in 
human populations.
• The data will be used to compare fusion profiles generated from human 
tissues, in normal and specific disease situation and importantly in 
experimental systems testing the mechanistic basis of fusion.
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5 Chapter 5: Telomere dynamics in normal human 
skin
5.0 Summary
Normal somatic tissues exhibit low-level or undetectable telomerase activity. 
Consequently, their telomeres erode as a function of age due to “end-replication” 
problem (Harley et al., 1990). Telomere erosion can trigger replicative 
senescence, an irreversible growth arrest that cells have to bypass to progress to 
malignancy, thus senescence represents a potential tumour suppressive 
mechanism (Allsopp et a l,  1995; Allsopp et a l, 1992; Campisi et a l, 2001).
In vitro studies have demonstrated that telomeres are subjected to processes 
which generate short telomeres that are capable of fusion (Baird et a l, 2003; 
Britt-Compton et a l, 2006; Capper et a l,  2007). The objective of this study was 
to translate this knowledge of telomere dynamics in vitro to human tissues in 
vivo. To accomplish this, the high-resolution single-molecule approaches; 
STELA and the improved telomere fusion assays were utilised to investigate 
telomere length erosion, instability and fusion in normal human tissues. The 
samples derived from human skin of nineteen (19) individuals which included 
melanocytic naevi and the adjacent tissue, were subjected to telomere length and 
fusion analysis. The study revealed that the mean telomere length at XpYp and 
17p was significantly shorter in melanocytic naevi than in adjacent tissue across 
the sample collection (P<0.05). In addition, the mean telomere length at 17p in 
naevi and associated adjacent tissue was shorter than that of XpYp (P<0.05).
Analysis of the fusion events between the telomeres of XpYp, 17p and 21 q 
family revealed large sub-telomeric deletions, short patches of micro-homologies 
at the fusion point and complex events involving loci near fragile-sites known to 
confer increased susceptibility to skin cancer. Consistent with in vitro data, 
normal skin tissues are subjected to telomere erosion, instability and fusion.
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5.1 Introduction
The human skin is the largest organ in the body that forms a barrier between 
internal and external environment. It is divided into two layers, the dermis and 
the epidermis (Figure 5.1). The dermis consists of the extracellular matrix 
components, the hair follicles, sweat glands, sebaceous glands, apocrine glands, 
lymphatic and blood vessels. The dermis consist of various types of cells such as 
endothelial cells, inflammatory cells and fibroblasts, which constitutes the larger 
source of dermal DNA (Sugimoto et a l , 2006). Whilst the epidermis is a self- 
renewing tissue that proliferates from the basal layer at the turnover of up to 45 
days throughout lifetime (Hoath and Leahy, 2003). It consists largely of basal 
and squamous keratinocytes (95%), interspersed with melanocytes (melanin- 
producing cells), Merkels cells (sensory receptors) and Langerhans cells 
[dentritic cells; Figure 5.1; (Gilchrest et al., 1999; Hoath and Leahy, 2003)]. The 
discussion on this chapter is limited to the brief description of keratinocytes, 
melanocytes and related skin cancers.
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Figure 5.1. The anatomical cross-section o f human skin illustrating different layers of 
the skin; epidermis, dermis with associated compartments and subcutaneous fat tissues 
(top right). Magnifying through section illustrates different cells that reside in the 
epidermis as well as part o f the dermis (bottom left).
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5.2 Skin cancer
Skin cancer is one of the most common forms of cancer in western countries 
(Brewster et al., 2007; Hussain et al.; Jung et al., 2010). This study is limited to 
brief discussion on basal and squamous cell carcinoma [also known as non­
melanoma or Keratinocyte carcinoma] and melanoma.
5.2.1 Non-Melanoma/ keratinocyte carcinoma
Basal cell carcinoma (BCC) is the most common but least deadly form of skin 
cancer especially in men than women (Armstrong and Kricker, 2001; Brewster et 
al., 2007). It arises from the basal keratinocytes, cells lining the deepest layer of 
the epidermis (Blanpain et a l , 2007; Janes et a l , 2002). Most if not all BCC 
occur on sun-exposed areas such as face, neck, scalp, shoulders and back. Thus, 
major risk factor for BCC is chronic UV-exposure such as short intense episodes 
of sunlight (Armstrong and Kricker, 2001; English et a l , 1997). Other risk 
factors are outlined in Table 5.1 A. The clinical features include nodules, plaques, 
ulcers etc (Rubin et a l , 2005). Although easily treated at early stages, advanced 
tumours can damage the adjacent tissue causing considerable destruction and 
disfigurement. However, BCC rarely metastasises to vital organs (Albert and 
Weinstock, 2003; Lear et al., 1998; Rubin et al., 2005).
Squamous cell carcinoma (SCC) is the second most common type of skin cancer 
in Caucasians, Asians and Hispanics, and most commonly diagnosed type in 
black populations (Alam and Ratner, 2001). SCC arises from uncontrolled 
proliferation of squamous keratinocytes of the epidermis (Gilchrest et al., 1999; 
Nemes and Steinert, 1999). It often develops in sun exposed areas (Armstrong 
and Kricker, 2001; Hussain et al., 2010), thus major risk factors include 
cumulative chronic exposure to UV radiation from the sunlight and artificial 
tanning lamps (English et al., 1998; Karagas et al., 2002). Like BCC, it is curable 
at early stages but can spread to other tissues if not treated (Alam and Ratner, 
2001; Gloster and Neal, 2006). Although common, keratinocyte carcinomas 
account for fewer fatalities compared to melanoma.
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Table 5.1A. Risk factors associated with Non-melanoma skin cancers
Cancer-type Risk factors References
Basal and
Squamous
cell
carcinoma
• Fairer skin,
• Blond or red hair
• Blue, green or grey eyes
(Armstrong and Kricker, 2001; 
English et al., 1998).
• Immuno-suppression and 
chronic infections as in HIV 
or HPV infection, after 
chemotherapy and anti­
rejection drugs-treatment.
(Albert and Weinstock, 2003; 
Moloney et al., 2006)
• Genetic disorders 
o xeroderma 
pigmentosum 
o nevoid basal cell 
carcinoma syndrome
(Albert and Weinstock, 2003; 
Giannotti et al., 2003)
• Risk is positively associated 
with age and being male, 
however women are also 
affected
(Albert and Weinstock, 2003; 
Rubin et al., 2005)
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Table 5.1B. Risk factors associated with Melanoma
Cancer-type Risk factors References
Melanoma • Chronic exposure to UVA and 
UVB rays from the sun and/or 
UV tanning booths.
• Fairer skin, green, blue or grey 
eyes, and red or blonde hair
(Armstrong and Kricker, 2001; 
Gilchrest et al, 1999; Han et al, 
2009; Tucker and Goldstein, 
2003) (Thompson et al, 2005).
• Compromised immune system 
as in:
o lymphoma, HIV 
infection 
o After chemotherapy or 
radiation-treatment and 
in patients taking anti- 
rejection drug after 
organ transplant.
(Armstrong and Kricker, 2001; 
Chin et al., 1998a; Thompson et 
al., 2005)
• Family and personal risks
• A personal history of any of 
the skin cancers such as 
keratinocyte carcinomas.
• Personal history of melanoma 
is associated with increased 
risk of recurrence.
• First-degree (50% increased 
risk) and Second-degree 
relatives of melanoma patients
• Familial atypical multiple mole 
melanoma syndrome 
(FAMMM)-[also known as 
dysplastic naevus syndrome 
(DNS)], a condition in which 
atypical melanocytic naevi are 
detected in a melanoma-prone 
individual, are at greater risk 
of developing melanoma
(Li et al, 2006) 
(Chaudru et al., 2004)
t
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5.2.2 Melanoma
Cutaneous melanomas are the rare but most aggressive and fatal forms of skin 
cancer (Armstrong and Kricker, 2001; Jemal et al., 2003). They are curable when 
detected early, however, untreated, they can metastasise to other parts of the body 
and cause serious illness and death (Chin et al., 1998a). Melanomas are malignant 
tumours that originate in the melanocytes; the cells that produce a pigment 
(melanin) that gives the skin, hair and eyes their colour (Gilchrest et al., 1999). 
They are usually black or brown and rarely skin-coloured, pink, red, purple, blue or 
white (Chin et a l , 1998a; Gloster and Neal, 2006). Every individual is at risk of 
melanoma however certain factors such as melanocytic naevi, genetics and others 
(Table 5.IB), increases the risk of developing melanoma. The incidences of 
melanomas are on the rise in western countries, with an approximate increase rate 
of 5% reported in the past four-to-five decades (Armstrong and Kricker, 2001; 
Thompson et al., 2005). Therefore, there is considerable interest in understanding 
the genetic and environmental mechanisms that drive disease risk, initiation and 
progression.
5.2.3 Melanocytic naevi
Melanocytic naevi (also known as moles) are benign tumours, which arise from 
uncontrolled proliferation of melanocytes (Robinson et al., 1998; Skender-Kalnenas 
et al., 1995). They consist of functionally viable melanocytes (Bandyopadhyay et 
a l , 2001; Bennett, 2003; Bennett and Medrano, 2002; Mooi and Peeper, 2006) 
which have undergone senescence following oncogenic mutations (Davies et a l , 
2002; Ichii-Nakato et a l , 2006; Michaloglou et a l , 2005; Pollock et a l , 2003). 
Although they predispose to melanoma in susceptible individuals, melanocytic 
naevi can remain dormant for many years (Bennett and Medrano, 2002; Hayward,
2000). Common naevi are small brown blemishes, out-growths or beauty marks that 
appear at early childhood or adolescent (acquired) or are present at birth 
(Congenital). They may also be caused by chronic UV exposure especially before 
the age of 20 (Takata and Saida, 2006).
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Colour DiameterSymmetry
Benign
Symmetrical
Borders
Even Smaller than Vi inch
Uneven Two/m ore shades Larger than V* inch
Malignant
Asym m etrical
Adapted from: www.skincancer.org/m elanom a 
Figure 5.2. Benign and Malignant melanocytic naevi. Changes in size, symmetry,
appearance and colour o f moles can signify that moles could be cancerous.
The definition of the dysplastic naevi (also known as atypical mole) is still 
controversial but they represent naevi that have a distinct appearance from the 
common mole. The risk of developing melanoma is directly proportional to the 
number of atypical (dysplastic) moles (>100) i.e. the more moles an individual 
possesses, the higher the risk of developing melanoma (Skender-Kalnenas et al.,
1995). In addition, the changes in atypical mole such as symmetry, colour, borders 
and size can suggest the development o f cancer (Figure 5.2). In support of this, 
primary melanomas are associated with pre-existing dysplastic naevi (Kraemer et 
a l, 1983).
5.2.3.1 Genetics
The melanoma tumour suppressor gene, CDKN2A is mapped to 9p21. It encodes 
for the two cell cycle inhibitors, p l6 INK4a, (referred to hereafter as p i6) and p l4 ARF 
(referred to hereafter as ARF) which are transcribed from separate promoters and 
read into different reading frames (Bennett, 2003; Sharpless, 2005). Germ-line and 
somatic CDKN2A mutations or deletions have been linked to familial and sporadic
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melanoma respectively (Harland et a l , 1997; Hayward, 2000; Hewitt et a l , 2002; 
Hussussian et a l , 1994; Newton Bishop et a l ,  1999). Furthermore, about 100% of 
all melanoma cell lines have an altered CDKN2A gene, through either deletions or 
promoter methylations, which all affect the p i 6 and ARF proteins (Harland et al., 
1997; Walker et al., 1998; Zuo et al., 1996).
The cell cycle protein, p l6  binds to cyclin-dependent kinases 4/6 and prevents 
phosphorylation of retinoblastoma proteins (pRb); thus inhibiting cell proliferation 
(Sherr and Roberts, 1999; Weinberg, 1995). Thus, the loss of p i 6 function results in 
active CDK4/6 and hyper-phosphorylation of pRb and hence unscheduled entry into 
S-phase (Chin et a l ,  1998a; Chin et a l ,  1998b). The germ-line mutations in p i6 are 
associated with multiple large or dysplastic naevi and melanoma (Hayward, 2000; 
Thompson et a l ,  2005).
ARF on the other hand, is a potent tumour suppressor that induces G\ and G2 cell 
cycle arrest through its interaction with MDM-2, a protein that degrades p53 to 
inhibit cell cycle arrest. Thus, ARF binds to MDM-2 and blocks p53 degradation 
thereby stabilising p53, and hence allows cell cycle arrest (Kamijo et a l ,  1997; 
Zhang et a l ,  1998). In addition, ARF can block uncontrolled cell proliferation 
independent o f p53 pathway (Ha et a l ,  2007).
Another melanoma susceptibility gene is the gene for CDK4 located on 12ql3. The 
germ-line mutations in CDK4 gene have also been reported in melanoma-prone 
families (Soufir et a l ,  1998; Zuo et a l ,  1996).
An additional tumour suppressor gene, phosphatase PTEN, a protein-lipid that 
inhibits AKT activation by Phosphatidylinositol 3' kinase (PI3K) is mapped to lOq. 
The loss of heterozygosity at the locus 10q23 and somatic mutations at PTEN have 
been reported in melanomas (Isshiki et a l ,  1993; Wu et a l ,  2003).
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Finally, NRAS is a proto-oncogene often mutated in melanomas (Polsky and 
Cordon-Cardo, 2003) through mutations that result in p21RAS onco-protein. This 
hybrid protein remains bound to GTP and active. This activates downstream RAF, a 
protein that has three isoforms; A-, B- and C-RAF. Interestingly B-RAF mutations 
are common in melanocytic naevi, regardless of whether acquired, congenital or 
dysplastic and melanomas (Pollock et al., 2003). Importantly BRAFV600E, a mutant 
which induces senescence, is expressed in 69-88% of melanocytic naevi, both 
acquired and congenital regardless of their location, i.e. regardless of whether they 
were located on sun-exposed or non-exposed areas (Davies et al., 2002; Ichii- 
Nakato et al., 2006; Michaloglou et al., 2005; Pollock et al., 2003).
5.2.3.2 Cellular senescence in melanocytic naevi (Moles)
Cellular senescence is the loss of ability to proliferate after a finite number of cell 
divisions (Hayflick and Moorhead, 1961). It is considered a crucial barrier that cells 
have to bypass to allow continued cell division required for progression to 
malignancy, thus senescence represents a potential tumour suppressive mechanism 
(Campisi, 2001; Sharpless and DePinho, 2004; Wright and Shay, 2001). Two main 
pathways effecting normal cellular senescence in culture have been reported, the 
well-known pathway is that first described in fibroblasts. In culture, human 
fibroblasts cease to divide after 40-70 population doublings and undergo pRb and 
p53 dependent growth arrest (M l). M l can be bypassed through oncogenic 
transformation of cells with viral oncoproteins such as HPV16 E6 E7 or SV40 large 
T antigen (Crook et al., 1991; Ducray et a l , 1999; Shay et al., 1993). Significantly, 
expression of the catalytic subunit of telomerase (hTERT), an enzyme that 
maintains telomere length can also circumvent M l (Counter et al., 1992). Thus in 
most normal somatic cells that lack hTERT, telomere erosion triggers p53/pRb 
dependent cell cycle exit called replicative senescence (Allsopp et al., 1992; Harley 
et al., 1990).
An alternative route that occurs earlier than M l has been described in keratinocytes 
and epithelial cells. This cell cycle exit referred to as M0 appear to be pRb-
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dependent but p53-independent (Kiyono et a l, 1998; Ramirez et a l, 2001). In 
support of this, immortalisation of these cells requires both HPV16 E6E7 and 
hTERT, implicating that culture stress may play an important role in cell cycle 
arrest of these cells (Kiyono et a l,  1998). Indeed, improvement of culture 
conditions, such as growing the cells with fibroblast “feeder” cells, extended the life 
span of these cells until they undergo the p53 and pRb senescence and are 
immortalised through forced expression of hTERT alone (Ramirez et a l, 2001).
Similarly, culture conditions play an even more significant role in the timing of cell 
cycle arrest in melanocytes, which vary from 8-90pd in neonatal cells to 2.4-40pd in 
adult melanocytes (Bennett, 2003; Bennett and Medrano, 2002). Several studies 
have indicated that senescence in melanocyte cultures is accompanied by 
upregulation of p i6, dephosphorylation of pRb and down regulation of CDK2 and 
CDK4 among others (Bandyopadhyay and Medrano, 2000; Bandyopadhyay et a l,
2001) .i.e. unlike senescence in fibroblast cultures, p21/p53 pathway appears to play 
little or no role in melanocyte senescence (Ha et al., 2007; Serrano et al., 1996; 
Sviderskaya et al., 2002) . This view is backed by studies in human melanocytes 
carrying wild type ARF but non-functional p i6, which exhibited elevated levels of 
p21 and p53 proteins which are often not upregulated in normal melanocytes 
(Bandyopadhyay et al., 2001; Sviderskaya et al., 2003), indicating that senescence 
of normal melanocytes is similar to the M0 cell cycle arrest (Kiyono et a l, 1998; 
Ramirez et a l , 2001).
It is possible that normal melanocytes senesce through the mechanism that act 
against the BRAFV600E mediated oncogenesis. The expression of such mutated gene 
has been reported to induce cell cycle arrest in human melanocytes, with cells 
expressing senescence-associated beta—galactosidase, a senescent marker,
accompanied by p i 6 expression. However, 25-30% of such senescent cells did not 
express any p i 6, implicating that other factors may be driving senescence in these 
melanocytes (Bennett, 2003; Davies et a l,  2002; Michaloglou et a l, 2005).
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Another genetic change that drives senescence is telomere dysfunction (Campisi et 
al., 2001; Herbig et al., 2004; Karlseder et al., 2002). However, the role of telomere 
biology in melanocytic naevi senescence is controversial. As discussed above, it is 
believed that senescence of normal melanocytes in culture is dependent on pi 6 [M0; 
(Bennett, 2003)]. However, improvement of culture conditions can extend the life 
span of melanocytes to another growth arrest (Bandyopadhyay et al., 2001) that is 
dependent upon p53 and pRb, which is also triggered by telomere dysfunction 
(Herbig et al., 2004), suggesting that telomere biology may play a role in 
senescence of melanocytes. In support of this, some studies have demonstrated that 
indeed progressive telomere attrition triggers human melanocytic senescence. In 
addition, ectopic expression of hTERT did extend the life span of melanocytes 
(Bandyopadhyay etal., 2001; Bennett, 2003).
5.3 Telomere biology in Skin
Human skin exhibits low-level telomerase activity (Bacchetti, 1996). When the skin 
was dissected high levels o f telomerase activity were detected in the basal layer of 
the epidermis while the dermis was telomerase-negative (Harle-Bachor and 
Boukamp, 1996; Yasumoto et al., 1996). In addition, immortalised skin 
keratinocytes are telomerase-positive regardless of their immortalisation method 
(Harle-Bachor and Boukamp, 1996). However, the normal skin fibroblasts do not 
express any detectable telomerase activity (Kim et al., 1994).
Telomerase activity varies among different skin conditions and cancer types. 
Previous studies have demonstrated that melanoma cell lines are telomerase- 
positive (Kim et al., 1994). In addition, low or undetectable telomerase activity has 
been reported in benign melanocytic proliferations, while high telomerase activity 
was detected in cells at S-M phases within the dysplastic naevi (Rudolph et a l , 
2000). Furthermore, all skin cancer samples are telomerase-positive regardless of 
the skin cancer type. However, BCC exhibits a high relative telomerase activity 
compared to SCC and melanoma. Moreover, telomerase activity is increased in 
aggressive melanoma being highest in tumours with deepest invasion, i.e.
192
Chapter 5: Skin
Telomerase activity in melanomas increases with disease progression to metastatic 
melanoma (Rudolph et a l , 2000; Taylor et al., 1996). In addition to skin cancer, 
telomerase activity has also been reported in some non-malignant skin conditions 
such as UV-damaged skin, hyper-proliferative skin diseases; psoriasis and poison 
ivy dermatitis, peritumoural samples and actinic keratoses (Sugimoto et al., 2006; 
Taylor et al., 1996). It was however, not clear in these studies whether telomerase 
activity was exhibited by skin cells or infiltrating lymphocytes, which are known to 
be telomerase-positive (Hiyama et al., 1995; Igarashi and Sakaguchi, 1997).
Telomere erosion plays contradicting role in different skin cancers, i.e. The shorter 
telomere lengths are associated with decreased risk of melanoma (Han et al., 2009) 
and an increased risk of basal cell carcinoma while there is no association between 
the telomere length and squamous cell carcinoma risk. Furthermore, there is no 
association between the number of moles and telomere length on the skin cancer 
risk while short telomeres in peripheral blood are associated with decreased mole 
counts and size (Bataille et al., 2007).
5.4 This study
In normal cells, telomeres erode as a function of age due to “end-replication” 
problem (Harley et a l , 1990; Watson, 1972). Progressive telomere erosion has been 
implicated as mitotic “clock” that limits cell proliferation in the absence of 
telomerase activity (Allsopp et a l , 1995; Allsopp et a l , 1992; Harley et a l , 1990). 
Eroded telomeres can initiate chromosome instability resulting in large-scale 
rearrangements similar to those observed in epithelial cancers (Artandi et a l , 2000; 
Mumane, 2006; Mumane and Sabatier, 2004; Rudolph et a l , 2001).
Several studies have demonstrated that telomeres are subjected to stochastic 
deletion events resulting in shorter telomeres than those in senescence cells in vitro 
(Baird et al., 2003; Britt-Compton et al., 2006); these short telomeres are 
dysfunctional and are capable of fusion (Capper et a l , 2007; Letsolo et al., 2009). 
We have further demonstrated that telomere length and frequency of telomere
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fusion correlated with severity o f the disease in human blood malignancy, chronic 
lymphocytic leukaemia (Lin et al., 2010). Thus, this work was undertaken to 
investigate if such events were occurring in normal and senescent human tissues in 
vivo.
Telomere length instability and fusion were investigated in melanocytic naevi and 
adjacent tissue. Melanocytic naevi provide an important model for cell senescence 
as cells undergo oncogene-induced senescence and remain dormant for long periods 
even though they pose an increased risk to melanoma development in susceptible 
individuals (Robinson et a l , 1998). This study will enable the investigation of 
whether telomere dynamics is implicated in the senescence of melanocytes. In 
addition, it will indicate whether telomere dynamics plays a significant role in 
progression of benign naevi to malignancy. Furthermore, defining the fusion 
frequency in normal tissues will serve as a reference when determining if frequency 
of these events is elevated in pre-malignant conditions such as Barrett’s oesophagus 
(chapter 6).
5.5 Sample Collection, Preparation and Statistical analysis
The naevi samples were obtained from 19 females bom between 1955 and 1974 
who volunteered for adult twin study registry at St Thomas hospital, London. The 
ethical approval for use of these samples was granted by Guy's and St Thomas NHS 
Trust ethics committee (Bataille et al., 2007). Using a clean scalpel, the naevi 
samples were macro-dissected and separated from adjacent tissue (DMB personal 
comm.). Thus the DNA extracted from either the naevi or adjacent tissues may 
contain the traces of DNA from other cells of the skin such as keratinocytes of the 
epidermis and any cells of the dermis.
DNA was then extracted by standard Phenol/Chloroform methods (Sambrook et a l , 
1989). Samples used for STELA and telomere fusion assays were diluted as 
described in (Baird et a l , 2003; Letsolo et al., 2009).
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The DAgostino & Pearson omnibus normality test was used to assess if the data 
was normally distributed. For pair-wise comparison, Mann-Whitney test (for 
medians) and unpaired t-test (for means) were used with F-test (for variance) to 
analyse not-normally-distributed and normal distributed data respectively. The two- 
tailed P-value, P<0.05 was considered statistically significant while P<0.001 was 
considered extremely significant.
5.6 Results
Here, I describe work undertaken to investigate telomere length instability and 
fusion in normal skin samples consisting of melanocytic naevi and the adjacent 
tissue. STELA was used to determine the telomere length at telomeres of XpYp and 
17p. The telomere fusion events were investigated between telomeres of XpYp, 17p 
and 21 q family: lq, 2q, 5q, 6p, 6q, 8p, lOq, 13q, 17q, 19p, 19q, 21q, 22q and 
interstitial 2ql3.
Data was derived from the analysis of the nineteen [19] individuals, consisting of 17 
melanocytic naevi and 19 naevi-adjacent tissue samples.
5.6.1 Telomere length distributions in Melanocytic naevi
The analysis of the seventeen [17] melanocytic naevi revealed considerable 
telomere length heterogeneity within each sample at both XpYp and 17p, with 
variation of up to 12.3kb [17p; 20562M] and 12.4kb [XpYp; 32811AM; Figure 5.3; 
Table 5.2]. This is consistent with the variation that has been observed in senescent 
populations (Baird et al., 2003; Britt-Compton et al., 2006). Similarly, large inter­
individual variation in mean telomere lengths was observed with maximum 
variation of 3.9kb at XpYp and 2.18 kb at 17p telomeres [combined mean telomere 
lengths (±SD), XpYp=4.85±0.90kb; 17p=4.3±0.7kb].
The telomere of 17p has been implicated as one of the shortest in human genome 
(Martens et a l , 1998). Using STELA, 17p telomere was typically the shortest in 
some senescent clones (Britt-Compton et al., 2006). Consistent with this, 17p
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Table 5.2. Summary of the telomere length data from melanocytic naevi at XpYp telomere. Range is the difference between the shortest and the 
longest telomere. The shortest telomeres (blue bolded font) and the biggest difference between the telomeres (red bolded) across the sample
collection are indicated. Standard deviation measures how widely the values are dispersed from the mean telomere length.
Sample id
XpYp mean 
telomere 
length (kb)
Standard
Deviation
Shortest
telomere
(kb)
Longest
telomere
(kb) Range
17p mean 
telomere 
length (kb)
Standard
Deviation
Shortest
telomere
(kb)
Longest
telomere
(kb) Range
98592M 5.42 2.09 1.90 13.32 11.42 4.57 1.58 2.45 9.19 6.73
95981M 4.22 2.17 1.39 9.26 7.87 5.45 2.16 1.28 11.72 10.45
32811AM 4.13 2.75 0.21 12.60 12.39 3.27 2.31 0.14 8.96 8.83
3281 IBM 5.10 2.70 0.44 11.67 11.23 3.37 2.27 0.14 9.74 9.60
20561M 5.45 3.11 1.92 10.97 9.06 4.10 2.26 1.09 7.69 6.60
20562M 5.06 2.90 0.68 12.00 11.32 5.20 2.78 1.23 13.48 12.25
52984M 5.84 2.61 2.15 11.65 9.50 4.92 2.55 1.36 11.46 10.10
93942M 3.57 1.93 1.43 10.71 9.29 4.37 1.83 0.41 8.73 8.32
2492M 4.35 2.58 0.73 11.67 10.94 3.96 1.81 0.97 7.83 6.86
2493M 4.79 2.64 0.55 10.52 9.97 4.42 1.88 1.05 9.30 8.26
94041M 3.15 2.03 0.32 10.04 9.72 4.09 1.85 1.59 9.40 7.81
97051M 5.00 2.63 1.68 11.99 10.31 5.05 2.45 1.38 11.72 10.35
18261M 5.13 2.77 1.36 11.63 10.27 4.34 1.38 2.10 7.78 5.68
93983M 5.12 2.37 2.17 9.37 7.19 3.33 1.05 1.48 5.71 4.23
06651M 4.14 2.09 1.35 9.45 8.10 4.15 2.23 1.41 8.96 7.55
06652M 4.94 2.22 1.20 11.66 10.46 3.45 1.80 0.97 8.69 7.72
98591M 7.05 3.03 2.13 14.04 11.91 4.76 1.60 1.52 8.51 6.99
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Figure 5.3. Summary of the telomere length distributions as determined by STELA at telomeres 
of XpYp (open boxes) and 17p (blue boxes) in 17 melanocytic naevi samples. The boxes represent 
lower and upper quartiles of the telomere measurements with the telomeres <5% and >95% percentile 
measurements considered outliers (indicated by dots). The line inside the box represents the mean 
telomere lengths.
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Figure 5.4. Histograms summarising the telomere length distributions at telomeres of XpYp (open bars) 
and 17p (blue bars) in tissues derived adjacent to melanocytic naevi from 19 individuals (identified by a 
number). Telomere length was determined by STELA in which products were detected by Southern 
hybridisations with a TTAGGG-containing probe. The line in the middle of the bar is the mean, while the 
top and bottom of the bars represents the largest and shortest telomere respectively.
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telomere was shorter than XpYp in 65% [11/17; Figure 5.3) of the melanocytic 
naevi samples analysed. Although 17p telomere appeared to display the shortest 
telomere length distributions, this was not significant (chi square, P=0.22).
5.6.2 Telomere length in tissue adjacent to the naevi
Telomere length analysis at XpYp and 17p telomeres was undertaken in nineteen 
tissue samples derived adjacent to the melanocytic naevi. Again the telomere length 
distributions at XpYp and 17p telomeres were heterogeneous displaying variation of 
up to 13.3kb [06652; Figure 5.4Q] and 13.6kb [93941; Figure 5.41] at XpYp and 
17p respectively [Table 5.3; Figure 5.4; Figure 5.4A-5.4S and 5.5A] in some 
individuals. Similarly, large variation in mean telomere length was observed 
between individuals in these samples (Figure 5.4A-S), with the combined means 
(±SD) of 5.3±1.2 (XpYp) and 4.9±0.7 (17p).
In addition to large inter-individual variation in mean telomere distributions, XpYp 
displayed more heterogeneous profiles than those of 17p (P=0.047). This was more 
apparent in individual 32812 [XpYp, mean±SD=3.1±2.2; 17p, mean±SD=4.2±1.7; 
PO.OOOl; Figure 5.4F and 5.5B].
Furthermore, 74% (14/19) of the samples exhibited shorter 17p mean telomere 
length profiles than XpYp, and the telomere of 17p displayed more homogeneous 
distributions (P=0.047). These observations are consistent with previous 
observation on the analysis of 17p telomere length and stability in vitro (Britt- 
compton 2006). The observations are also consistent with the notion that 17p tends 
to be one of the shorter telomere among human telomeres [(Martens et al., 1998); 
chi-square, P=0.039).
Outlying short or long telomeres than the rest of the telomeres were also apparent in 
these distributions; these events are consistent with sporadic telomere events 
resulting in elongation or deletion of telomeres [Figure 5.5B; (arrow-headed)].
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Figure 5.5. Examples of the STELA gels illustrating the telomere length data of XpYp 
and 17p telomeres from tissues derived adjacent to the melanocytic naevi from nine 
individuals. The zero limits of the distributions for each telomere are indicated by 
dashed horizontal line at the bottom of the gels. The molecular weight marks are 
shown on the left. The telomeres typical of stochastic deletion/ elongation events are 
indicated (arrow-headed).
199
Table 5.3. Summary of the telomere length data derived from XpYp and 17p telomeres in tissues adjacent to the melanocytic naevi. Range is the 
difference between the shortest and the longest telomere. The shortest telomeres (blue bolded font) and the biggest difference between the telomeres 
(red bolded) across the sample collection are indicated. Standard deviation measures how widely the values are dispersed from the mean telomere
length.
Sample id XpYp telomere 17p telomere
Mean
(kb)
Standard
Deviation
Shortest 
telomere (kb)
Longest 
telomere (kb)
Range Mean
(kb)
Standard
Deviation
Shortest 
telomere (kb)
Longest 
telomere (kb)
Range
98592 6.50 2.65 2.18 11.98 9.80 4.86 0.86 3.50 6.87 3.38
95981 5.53 3.09 1.29 11.69 10.40 6.21 2.15 3.33 11.60 8.27
3281 IB 5.80 3.60 0.22 13.26 13.05 5.46 2.29 1.62 11.77 10.16
20561 5.70 2.89 1.21 11.73 10.53 5.23 2.52 0.72 11.79 11.08
20562 6.66 3.59 2.07 10.77 8.70 3.32 1.86 0.87 7.59 6.72
32812 3.13 2.15 0.30 11.67 11.37 4.16 1.66 1.95 9.34 7.39
52894 6.18 2.69 0.71 11.80 11.09 5.44 2.31 1.08 12.30 11.22
17442 5.25 2.83 0.48 11.72 11.24 4.34 2.24 0.49 10.51 10.02
93941 4.89 2.63 0.93 11.14 10.22 4.56 2.11 0.48 14.11 13.63
93942 4.25 1.98 1.09 10.01 8.92 4.37 2.33 0.98 11.59 10.62
2492 6.09 1.93 1.82 9.39 7.57 5.38 2.33 2.15 10.34 8.19
2493 5.90 3.16 0.54 11.68 11.14 4.94 2.20 0.89 11.30 10.41
94041 5.97 3.02 1.04 14.05 13.00 5.91 2.39 2.93 9.20 6.27
97051 5.40 2.84 1.97 12.19 10.22 5.29 2.57 0.93 11.76 10.83
18261 5.04 2.70 0.61 11.69 11.08 5.42 2.24 1.23 11.21 9.98
93983 4.30 1.97 1.47 8.17 6.70 3.75 1.55 1.37 6.95 5.57
0665 ID 3.50 2.10 0.31 8.99 8.69 4.91 2.78 0.98 11.76 10.79
06652D 6.71 3.24 1.39 14.71 13.32 4.92 2.78 1.21 11.75 10.54
98591 7.49 3.06 2.24 13.36 11.13 5.12 2.60 0.66 13.84 13.18
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At the XpYp telomere, 25% (4/16) of individuals exhibited telomere length 
distributions that were significantly shorter and different from those of the dermis 
(Figures 5.6, 5.7A and 5.7B). For example, individual 06652, displayed a bimodal 
distribution in the melanocytic naevi sample but a single distribution in the dermis 
(Figure 5.6A and 5.7A; P=0.0001). Similarly, individual 95981 displayed 
heterogeneous telomere profiles in melanocytic naevi and what appeared like 
bimodal distribution in dermis (Figures 5.6A and 5.7D; P<0.05). In addition, in two 
other individuals 2492 and 94041, both tissues exhibited, heterogeneous profiles 
(Figures 5.6A, 5.7B and 5.7C; P<0.001).
The analysis of the 17p telomere revealed that in 56% (9/16) of the individuals, 
melanocytic naevi exhibited shorter telomere length profiles than the adjacent 
tissues (Figures 5.6B). Interestingly, a subset (3/9) of those individuals displaying 
shorter 17p telomeres also displayed shorter telomere profiles at XpYp; namely 
06652 (Figures 5.7A, 5.6B; P=0.001); 2492 (Figure 5.7B; 5.6B; P=0.018) and 
94041 (Figures 5.7C, 5.6B; P=0.013). The polymorphism at the 17p telomere was 
observed in one individual; individual 94041 exhibited fewer (<95%) 17p 
molecules compared to XpYp telomere (Figure 5.7C); this is consistent with large- 
scale structural polymorphism at chromosome ends which was observed previously 
[Chapter 3 of this thesis; (Britt-Compton et al., 2006)].
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Figure 5.6. Illustrates the telomere distribution at XpYp (A) and 17p (B) telomeres for 
melanocytic naevi (red bars)-adjacent tissue (blue bars) matched samples. Unpaired t-test (Pi) 
and F-test (P2) were used to compare means (line inside the bar) and variances respectively. 
*denotes the individualswho display different telomere distributions between melanocytic naevi 
and adjacent tissue.
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In summary, this analysis has revealed shorter telomere length profiles in naevi than 
the adjacent tissue in a subset of individuals regardless of the telomere being 
investigated. In addition, the similar pattern was maintained across the sample 
collection such that overall mean telomere lengths were shorter in melanocytic 
naevi than in dermis (Figure 5.8A and 5.8B). The highest frequency (mode) of the 
mean telomere lengths in melanocytic naevi was 5kb and 6kb in the adjacent tissue 
at both 17p and XpYp (Figures 5.8C and 5.8D). It was however not known if the 
difference in telomere length distributions between the two tissues was reflective of 
the difference in telomere length distribution during development. In addition, the 
apparent heterogeneity in telomere length within the adjacent tissue was expected as 
the tissues were macro-dissected and thus may consist of several cell types with 
different replicative history and telomere distributions.
5.6.4 Telomere fusion frequencies
It was clear from the telomere length analysis that normal skin samples from both 
melanocytic naevi and adjacent tissues, contained cells which exhibit telomere 
length distributions within the range at which fusion had previously been detected 
[(Capper et al., 2007; Letsolo et al., 2009); Figure 5.9]. I have therefore examined 
these samples for evidence of telomere fusion. The telomere fusion assay that 
detects fusion events between telomeres of XpYp, 17p and/ or 21q family was 
undertaken with multiple reactions [typically 7-8] containing lOOng each (1.67xl04 
molecules). The amplified products were then detected by sequential Southern 
hybridisations with XpYp, 17p and 21q probes. As explained in chapter 3 and in 
(Letsolo et a l , 2009), hybridisation with 21q probes produced several non-specific 
bands thus the telomere fusion frequencies were estimated from molecules detected 
with XpYp or 17p probes. The number of molecules analysed per reaction was 
estimated from the weight of a single diploid genome equivalent (6pg) relative to 
the amount of input DNA. A total of 1.02xl08 diploid cell equivalents were 
analysed using multiple reactions. In melanocytic naevi, the data was collected for 
15 samples only as naevi from two individuals did not yield sufficient DNA for
204
Chapter 5: Skin
B
P=0.0080
8.On
4.0-
• • •
& 2 . 0 -
Ajacent tissue Melanocytic 
naevi
_Q 8
0)6c0
&  A0 4
Eo
0
c 2(0
0
01
0.
0-
0-
0.0
P=0.0234
• • •
*•••
•# • • •
 1 1---------
Adjacent tissue Melanocytic 
naevi
60'60
50'50
40
30
2020
10
0
8 100 0 2 4 6102 4 6 8
17p Mean telomere Length (kb) XpYp Mean Telomere length (kb)
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telomere fusion analysis (Table 5.4), whilst, fusion frequency for the dermal tissue 
was determined for 19 samples (Table 5.5).
Telomere fusion molecules could readily be detected in the samples derived from 
melanocytic naevi, where the fusion frequency was slightly higher between XpYp 
and other telomeres than between 17p and other telomeres (P=0.03). There was no 
direct relationship between shortest telomere, mean telomere length at XpYp or 17p 
or the lower 20 percentile of the telomere distribution and the frequency of the 
fusions detected with either probe (Figure 5.10 A; 5.10B; Table 5.4). The average 
telomere fusion frequency in melanocytic naevi was 3x1 O'6 and 4.21 xlO'6 with 17p 
and XpYp probes respectively [Figure 5.11]; this is comparable to the fusion 
frequency detected in normal MRC5 cells in vitro (section 3.3.4.2 in chapter 3). In 
the sub-set of samples where telomere fusions were detected, the frequency of 
fusion was comparable to that observed in post-senescence cells in culture (Letsolo 
etal., 2009). However, fusion events were not detected in most of the individuals at 
both XpYp (9/15) and 17p (9/15) telomeres (Table 5.4).
Both melanocytic naevi and adjacent tissues exhibited shorter telomeres that are 
capable of fusion. In this study, the average telomere fusion frequency in all naevi 
was lower (1.9x) than in all dermal tissue (XpYp=8.21xl0‘6; 17p 5.6xl0‘6) however 
this difference was not statistically significant (P>0.05). In addition, the analysis of 
the naevi-dermal matched samples has revealed that the frequency of fusions in 
melanocytic naevi was comparable to that observed in adjacent tissues (P=0.25; 
Tables 5.4 and 5.5). One individual (32812), exhibited exceptionally high frequency 
of fusions in tissues derived adjacent to naevi [3.61xl0‘5 (17p); 6.22xl0’5 (XpYp); 
Figure 5.11] compared to the other individuals (Table 5.5). Whilst the tissues 
analysed consisted of several cell types, the fusion frequency in dermal tissue was 
comparable to that observed in the normal lung fibroblast cell line MRC5 [chapter 
3; (Letsolo et al., 2009)].
Consistent with shorter telomeres observed at telomere of XpYp than at 17p in 25% 
of individuals, the frequency of fusions detected with XpYp probe was higher than
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those detected with 17p probe (Table 5.5). This was more apparent in 32812, an 
individual that exhibited exceptional heterogeneous telomeres with very short 
distributions at XpYp (20th percentile, l.Okb) compared to 17p (20th percentile 
2.7kb); with fusion frequency reflecting this difference (Figure 5.11; Table 5.5).
Table 5.4. Summarising the frequency of fusion events involving telomere of XpYp or 17p 
in melanocytic naevi. The fusion frequency is based on analysis of 5.8x103 to 1.3xl06 
diploid genome equivalents per sample (4-5 experiments of 8 reactions each). N represents 
the number of telomere repeats (assuming hexanucleotide repeat) estimated from the 
shortest telomere.
Sample
XpYp 17p
Mean 
telomere 
length (kb) N
Fusion
Frequency
(x l0°)
Mean 
telomere 
length (kb) N
Fusion
Frequency
(xlO'6)
98592M 5.42 316.7 1.13 4.57 408.3 7.50
95981M 4.22 231.7 0 5.45 213.3 1.86
32811A-M 4.13 35.0 1.50 3.27 23.3 0.779
32811B-M 5.10 73.3 0 3.37 23.3 0
20561M 5.45 320.0 0 4.10 181.7 0
20562M 5.06 113.3 0 5.20 205.0 0
52894M 5.84 358.3 0 4.92 226.7 0
93942M 3.57 238.3 0 4.37 68.3 0
2492M 4.35 121.7 0.375 3.96 161.7 0
2493M 4.79 91.7 0 4.42 175.0 0
94041M 3.15 53.3 0 4.09 265.0 0
97051M 5.00 280.0 0.156 5.05 230.0 1.56
93983M 5.12 361.7 2.25 3.33 246.7 0
06652M 4.94 200.0 0.911 3.45 161.7 9.11
98591M 7.05 355.0 0 4.76 253.3 7.50
Total fusion Frequency 6.32x10° 4.5x10°
Average fusion Frequency 4.21 xlO'6 3x10°
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Table 5.5. Summarising the frequency o f fusion events involving telomeres of XpYp or 
17p in tissues derived adjacent to melanocytic naevi. The fusion frequency is based on 
analysis of 5 .8xl05 to 1.3xl06 diploid genome equivalents per sample (4-5 experiments of 
8 reactions each). N represents the number of telomere repeats (assuming hexa-nucleotide 
repeat) estimated from the shortest telomere.
Sample
XpYp 17p
Mean 
telomere 
length (kb) N
Fusion
Frequency
(xlO'5)
Mean 
telomere 
length (kb) N
Fusion 
Frequency 
(xlO’5)
98592 6.5 363.3 3.93 4.86 583.3 2.75
95981 5.53 215 0 6.21 555 0
3281 IB 5.8 36.6 0 5.46 270 0
20561 5.7 201.6 0 5.23 120 0
20562 6.66 345 0 3.32 145 0
32812 3.13 50 6.22 4.16 325 3.61
52894 6.18 118.3 0 5.44 180 0
17442 5.25 80 1.53 4.34 81.6 0.613
93941 4.89 155 1.12 4.56 80 1.12
93942 4.25 181.6 0.678 4.37 163.3 0.678
2492 6.09 303.3 0 5.38 358.3 0
2493 5.9 90 0 4.94 148.3 0
94041 5.97 173.3 0 5.91 488.3 0
97051 5.4 328.3 0.313 5.29 155 0
18261 5.37 296.6 1.45 5.42 205 1.07
93983 4.3 245 0 3.75 228.3 0
06651 3.5 51.6 0 4.91 163.33 0
06652 6.71 231.6 0.311 4.92 201.6 0
98951 7.49 373.3 0 5.12 110 0.75
Total fusion frequency 1.56x10‘4 1.06x10‘4
Average fusion frequency 8.21xl0"6 5.6x1 O'6
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J 5.6.5 Molecular structure of telomere fusions
We have previously characterised telomere fusion events between telomeres of 
XpYp, 17p and 21q family in vitro (Letsolo et a l , 2009). Thus, I have extended that 
study to investigate telomere fusion events between these telomeres in vivo. The 
molecular structure of the fusion events was determined from putative fusion events 
by semi-nested PCR amplification and direct sequencing analysis. However, the 
fusion assay techniques cannot re-amplify the sister-chromatid type fusions as these 
have potential to form palindromic structures that can be refractory to PCR. Thus 
putative sister chromatid-type fusion events detected during this study could not be 
verified as true fusion by direct sequence analysis.
Forty-five putative fusion molecules were successfully isolated and reamplified for 
characterisation with direct sequence analysis. Of the 45 isolated putative fusion 
events, seven did not produce readable sequences while 14 were sequenced 5-6 
times but appeared too large to obtain the fusion junction, thus require additional 
sequencing reactions for future analysis.
Consistent with our in vitro (Capper et al., 2007; Letsolo et al., 2009) and other in 
vivo studies (Lin et al., 2010), all of the twenty-four fusion events that were fully 
sequenced involved the deletion of at least one of the telomeres. The deletion events 
involved the l-2kb proximal part of the telomere that contained telomere variant 
repeats interspersed with TTAGGG repeats (Baird et a l , 1995), and extended into 
the subtelomeric DNA close to the limit of the assay at telomeres of 21 q family 
(3.5kb).
The sub-telomeric deletion size for all the telomeres involved was plotted together 
due to small sample size [n=24; Figure 5.12]. The mean deletion size was 1253bp, 
whilst the smallest and largest deletion were 91 bp (XpYp) and 3436bp (21q) from 
the start of the repeat arrays respectively (Figure 5.12A). Interestingly, 65% of the 
deletion events were clustered within 1.2kb of the telomere repeat array, with the 
distribution beyond 1.2kb being random. However, these data should be interpreted
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with caution, as the small sample size (n=24) might not be an accurate 
representation of the distribution of deletion events. Consistent with our previous 
studies (Capper et al., 2007; Letsolo et al., 2009; Lin et al., 2010), these data 
indicate that the telomeric deletion can be very extensive.
In addition to sub-telomeric deletions, 72% of the fusion events were characterised 
by short patches of micro-homology (1-6 nucleotides) at fusion point [Figures 
5.12B and 5.13A-D; Mean=2.3 nucleotides]. Although the data did not reveal a 
clear GC bias (chi-square, P=0.07), analysis of a large sample collection could 
reveal the GC bias similar to that we observed in the large (n=308) dataset of fusion 
sequences obtained from cells in culture [(Letsolo et al., 2009); chapter 4].
Furthermore, 20% of the fusion events were characterised by lack of telomere 
(TTAGGG) repeats but contained extensive number of telomere variant repeats at a 
fusion junction (Figure 5.12C). Although these events lacked TTAGGG repeats at 
fusion point, the telomere variant repeats at the fusion junction were preceded by 
long tracts of TTAGGG repeats (Figure 5.13A). The remaining 80% of fusion 
events contained TTAGGG repeats at the fusion point that were longer than those 
we have observed in cells in vitro with the mean number of TTAGGG repeats in 
skin samples being 3.3x [mean 19; chi square, P=0.004] that we observed in 
HEK293 [mean, 5.2] and MRC5 cells that have bypassed senescence [mean 5.2]. In 
addition, the largest number of telomere repeats at the fusion point was 67.18 
(403bp) perfect TTAGGG repeats. This is the largest number of repeats we have 
detected so far with these assays [except for MCF7 TRF2 knockdown; (Figures 
5.12C and 5.13B)]; indicating that in vivo, longer telomeres may become uncapped 
and initiate fusion compared to that observed in vitro.
The fusion molecules are sequenced from individual cells, therefore sequencing of 
the same-sized fusion molecule which displays same DNA sequence more than 
once from the same individual (Figure 5.1 IB and 5.1 ID; 06652M), would imply 
that the fusion event is clonal. Of the 24 fusion events, six fusion events represented
Chapter 5: Skin
three different clonal fusion events; one clonal event detected in 06652M [Figure 
5.13C] while two were detected in 32812, an individual that exhibited exceptionally 
short telomere profiles at XpYp such that 20% of the distributions lie within the 
TVR region [20th percentile (lkb); Figures 5.11 and 5.13D).
In addition, these events and other events that involved XpYp and 17p telomeres, 
were characterised by a deletion of the XpYp telomere fused to long tracts of 
telomere repeats from 17p. Consistent with our study with MRC5 clone 1 that 
displayed loss of XpYp allele prior to loss of 17p (Capper et a l , 2007), these events 
were derived from individuals in which 17p exhibited longer telomere length 
profiles than XpYp telomere (Figures 5.13A and 5.13C). This was more apparent in 
32812, where XpYp telomere distributions were significantly shorter than those of 
17p telomere [P<0.001; 20th percentile, (XpYp, lkb; 17p, 2.7kb); Figures 5.11A and 
5.11C, rightmost gels].
A subset of fusion events (3/24) contained an insertion of sequences from elsewhere 
in the human genome. One of these events contained simple insertion comprising 
three nucleotides (ACA; Figure 5.13E). The other two events involved an insertion 
of sequences near documented fragile sites [14q32 (280bp); 9q22.3 (367bp); Figure 
5.13F]. Importantly, the locus 9q22.3 is often deleted in sebaceous naevi which 
have potential to develop into basal skin carcinoma (Xin et al., 1999). These fusion 
events were both derived from naevi.
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CCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAACCCTAApCCCTAAgCCTAACCCTAACCCTAAC...,
D*.CACAGCTCAGAAAGGCAGTGTGGACCCAAAGAGTGAGCAGTAGCAAGATTTATTGCAAAGAGTGAAAAGAACGAAGCTTC 
CACAGTATGGAA;-.GGGACCCTA,'-.CCCT/-./-.CCCT/'.:-.CCCT.'-.-'-CCCT . CCC. . C C C  ■ -.CCCTTAACCCTTAACCTTACC -
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c c t a g g t g g c t c a g g c c t g t a c c a c a g a c a t a c c c c g t c c t c c c t g t g g c a g t c t g t c a g t g g g g t a g g g t c c a c a a t c c t
g g a a c c a t t a c t t g g a t t c c t t g a g g a t t t t a a t t c t c t a c t g c c a g a t a t g t g t c t g a t g t g a a t t g g c t t c c a c a t a c c
t g c c c t t c a t t c t t c c c a c c c t a g a t t c c a a g a c c c t c c c a c c t g c a c c c a g c c t c a a a g a a g c a g t t g t g t g g a g c a c t c
t t a g g a g a a g c t g a a a t c t t t g c t g t c a t t a c c c t g t a t t c a t g g a g g c t t t g g a a a c c c g g g a a a g t g c t g a a t c c c t t t
TATAAATTGCGCCT GGGGAGCGCGGGGGGGTGGCGCGGTGC, GCCCAGAGAC ACACG'T...
1 » 1 >
Insertion lq : A-780bp
 14nt?________________________________________________________________________________
Figure 5.13. Example of DNA sequences for telomere fusion events in melanocytic
naevi and associated dermis. A. lq:XpYp fusion, involving the telomere variant repeats
(denoted V: TVRs) and long tracts of TTAGGG (T) prior to TVRs at the fusion junction.
B. lq:XpYp fusion with the longest TTAGGG repeat array so far. C-D. XpYp:17p fusion
events which were detected twice in same individual, thus represent 2 different clonal
events (*). Short patches of micro-homology (underlined and bolded). E. 21q:XpYp
fusion event, with insertion of three nucleotides at fusion point (black emboldened font).
F. Complex fusion event involving lq:XpYp and insertion of 9q22.32. The deletion size
as estimated from start of telomere repeat array is indicated by delta (A).
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5.7 Discussion
In this study, I have described telomere length dynamics and rates of telomere 
fusion events in human melanocytic naevi and tissues derived adjacent to naevi. 
Melanocytic naevi represents clonal, benign tumours composed of senescent 
cutaneous melanocytes (Robinson et al., 1998). Naevi can progress to melanoma, a 
deadly form of skin cancer, however this is rare and thus the features that 
distinguish naevi that will progress from those that will not are the subject of 
research. In culture, melanocytes undergo pi 6-dependent (M0) cell cycle arrest 
induced by culture conditions (Bandyopadhyay et a l , 2001; Bennett, 2003), which 
is abrogated in p i 6-deficient melanocytes [Hme-1] extending the lifespan of 
melanocytes until they undergo p53 and pRb dependent senescence [Ml; 
(Sviderskaya et al., 2003)] which is also triggered by telomere uncapping (Karlseder 
et a l , 2002) or erosion (Herbig et al., 2004). In addition, over-expression of hTERT 
is sufficient to immortalise these pi 6-deficient melanocytes (Sviderskaya et al.,
2003). Considering these observations, we hypothesised that telomere biology could 
predict those naevi that will progress to malignancy. Melanocytic naevi harbors 
oncogenic BRAF mutations that are associated with increased p i6 expression but 
no significant upregulation of p53 or p21 (Michaloglou et al., 2005). There are 
contradicting reports regarding the role to telomere biology in melanocytic 
senescence in vivo. Michaloglou and colleagues found no evidence of telomere 
attrition in melanocytic naevi derived from individuals in their first year of life 
(Michaloglou et a l , 2005). Other studies have reported increasing levels of 
telomerase activity during progression from normal melanocytes to melanoma, i.e. 
Normal melanocytes are telomerase-negative, while a small fraction of normal 
naevi are telomerase-positive. All atypical naevi and melanomas exhibit elevated 
telomerase activity (Glaessl et a l , 1999; Parris et a l , 1999; Taylor et a l , 1996). It 
has been demonstrated that progressive telomere attrition did indeed trigger 
senescence in normal melanocytes and the ectopic expression of the telomerase 
catalytic subunit extended the lifespan of melanocytes (Bandyopadhyay et al., 2001; 
Sviderskaya et al., 2003). Thus the role that telomere biology plays in the 
progression of melanoma is still unclear.
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5.7.1 Large Variation in telomere length
In this study we have utilised our high resolution technologies to re-address the role 
of telomere dynamics in melanocytic naevi. Using STELA, I have demonstrated 
that telomere lengths in naevi are shorter than those described in some senescent 
fibroblasts (Britt-Compton et a l , 2006) and telomerase-negative melanocytes in 
culture (Bandyopadhyay et al., 2001).
The telomere lengths in melanocytic naevi were shorter than those observed in 
adjacent tissue. These differences could be explained by inherent telomere length 
difference within each cell type as majority of common naevi and associated peri- 
lesion tissues are telomerase-negative (Glaessl et al., 1999; Parris et al., 1999). 
Indeed, several studies have demonstrated that telomere length in epidermis is 
shorter than in the dermis but both erode with chronological age at the similar rate 
of 9-75bp/year (Friedrich et al., 2000; Lindsey et al., 1991; Nakamura et al., 2002; 
Sugimoto et a l , 2006). These differences may also be due to differences in the 
replicative histories of the different cells constituting these tissues (Allsopp et al., 
1992).
In addition, large variation in telomere length was observed in both tissues 
implicating that the telomere length variation at each telomere may be due to inter­
individual variation which is probably predetermine in the zygote and maintained 
throughout life (Graakjaer et a l , 2006). Indeed, in vitro and in vivo studies have 
revealed inter-allelic variation at the same telomere as well as inter-individual 
variation across the telomeres of different individuals (Baird et a l , 2006; Baird et 
a l , 2003; Britt-Compton et a l , 2009; Britt-Compton et a l , 2006).
All naevi (except for one sample) exhibited heterogeneous telomere length similar 
to adjacent tissue. Considering the clonal nature of melanocytic naevi, one would 
expect that the telomere length profiles would be homogeneous, typical of those of 
clonal senescent cells in culture. These differences could be accounted for by 
presence of several sub-clones within the melanocytic naevi that display different
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telomere length profiles. In support of this view, other studies have reported the 
existence of mosaicism in the expression of other genetic markers such as p i6 
within the same naevi. In addition the fact that some melanocytes that express 
BRAFE60° do not exhibit any detectable p i6, in spite of cells having undergone 
senescence (Michaloglou et a l , 2005), could indicate that other factors such as 
telomere dysfunction could induce senescence in a subset of melanocytes. 
Furthermore, the presence of normal melanocytes within the naevi could account 
for longer telomere lengths. Another possible explanation could be the quality of 
the sample analysed. The naevi were macro-dissected, thus it is possible that 
samples contained significant proportion of other cell types either from the 
epidermis such as keratinocytes or dermis (DMB personal comm.), all contributing 
to the apparent heterogeneity in telomere lengths. Thus for future investigation, the 
pure melanocytic naevi preparations would reveal if the large heterogeneity is due 
to existence of several sub-clones with each naevi.
A subset of individuals exhibited shorter telomere lengths at 17p compared to 
XpYp. The short arm of chromosome 17 (17p) carries p53, a tumour suppressor 
protein, which is often deleted in human cancers, including skin cancer and its 
telomere is one of the shorter in human genome (Martens et al., 1998; Zou et a l , 
2004). The fact that 17p telomere was longer than XpYp in some individuals 
suggest that 17p telomere being shorter is not absolute but a random event, 
consistent with previous studies in vitro (Britt-Compton et a l , 2006). LOH at 17p 
has been reported in dysplastic naevi, the naevi which carry increased risk to 
melanoma (Healy et al., 1995; Park et al., 1998). We have also demonstrated that 
LOH at 17p telomere was linked to LOH at p53 in B-cells of CLL patients (Lin et 
al., 2010). The loss of p53 function allows cells to bypass cell cycle arrest and 
continued telomere erosion, which could generate large-scale rearrangements 
typical of cancers (Artandi et a l , 2000; Rudolph et a l , 2001). Thus if telomere 
dysfunction triggers cell cycle exit in melanocytes in vivo, the cells that have lost 
p53 may exhibit a growth advantage and escape senescence and through 
accumulation of additional mutations become malignant.
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5.7.2 Telomere fusion in normal tissues is similar to that
observed in vitro.
We have demonstrated that the shortest telomeres are subjected to fusion in cells 
undergoing crisis in culture and in chronic lymphocytic leukaemia [(Capper et al., 
2007; Letsolo et al., 2009; Lin et al., 2010)]. This study has revealed that short 
telomeres in normal and senescent cells in vivo are subjected to fusion. Telomere 
fusion represents a significant mutational event that has potential to fuel large-scale 
rearrangements that can lead to deactivation of tumour suppressor gene or 
oncogenic activation (Artandi et a l , 2000; Mumane, 2006; Mumane and Sabatier,
2004).
The study revealed no significant difference in fusion frequencies between the naevi 
and adjacent tissues; suggesting that the same background rates of fusion occur in 
both tissues and that this may be independent of replicative telomere erosion but 
instead more consistent with sporadic telomere deletion. Indeed as illustrated in 
Figure 5.10, there was no association between shortest telomere, mean telomere 
length or lower distribution of the telomere profile and fusion frequency. The 
telomere fusion events that were consistent with sporadic deletion events have been 
described in Chapter 4 of this thesis as well as in our recent publications in which 
fusion events that involve longer and shorter length alleles could be distinguished 
(Capper et al., 2007; Letsolo et al., 2009).
In this study, the frequency of fusion events in dermis (tissue adjacent to naevi) was 
comparable to that documented from lung fibroblast cell line, MRC5. The dermis 
consists of several cell types of which fibroblasts constitute the larger portion. Thus 
the observed fusions could be contributed mainly by the fibroblasts.
The molecular structure of the fusion events was similar to that we have described 
in human cells in vitro (Capper et al., 2007; Letsolo et al., 2009) and in vivo (Lin et 
al., 2010), characterised by large deletions extending into sub-telomeric DNA, 
patches of DNA sequence homology and a lack on TTAGGG on one side of the
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fusion junction. Although the mechanism that underlies these events is not known, 
it is error-prone and may be indicative of the DNA PKcs/ku independent end- 
joining processes (Maser et a l , 2007; Wang et a l , 2003; Yu and Gabriel, 2003) as 
discussed in chapter 4.
The fusion events that display longer arrays of TTAGGG than those described in 
cells undergoing crisis were detected. It is possible that different cell types cannot 
withstand the telomere uncapping to a specific length. Indeed in fibroblast cells that 
have just bypassed senescence, we observed longer tracts of repeats compared to 
crisis cells, which indicate that the in vitro analysis is physiologically relevant. 
Another explanation for long tracts of repeats in fusion events that are consistent 
with sporadic deletion would be the mutational mechanism that the skin is exposed 
to. First, skin is exposed to UV radiation which is known to target the dithymidines 
causing breakage, thus it is possible that the UV radiation induces telomere breaks 
resulting in uncapped telomeres that are capable of fusion (Jin and Ikushima, 2004; 
Kawanishi and Oikawa, 2004). Similarly UV radiation could create reactive oxygen 
species which target the triguanine structures and induce telomere erosion 
(Kawanishi and Oikawa, 2004; Oikawa and Kawanishi, 1999). In support of this, 
oxidative stress has been implicated as one of the mechanisms that has potential to 
accelerate telomere erosion (Houben et al., 2008; Kurz et al., 2004; von Zglinicki,
2002). Another possible explanation could be telomere uncapping due to 
insufficient telomere binding proteins such that certain cell types may harbour 
mutations in shelterin components. It has been demonstrated that disruption of the 
shelterin components such as loss of TRF2, Rapl and Potl result in telomere 
fusions while loss o f TRF1 function result in telomere deletion (Bae and Baumann, 
2007; He et al., 2006; Sarthy et al., 2009; Sfeir et al., 2009; van Steensel et al.,
1998). It is therefore possible that any mutations that results in tethering of shelterin 
components may generate telomeric deletions resulting in telomere capable of 
fusion.
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Similar to our previous studies (Capper et al., 2007; Letsolo et al., 2009; Lin et al., 
2010), there was evidence of clonal fusion events, characteristic of solid tumours 
(Gisselsson et al., 2001). This data indicates that some of these lesions occur early 
in premalignant tissues. Clonal events have potential to dominate the cell population 
and result in clonal expansion, thus creating an environment in which more 
abnormalities that could drive malignant progression may arise. Clonal expansion 
has been reported in early-stage, premalignant conditions (Galipeau et al., 1999; 
Maley et al., 2006).
The telomere fusion analysis also revealed insertion of non-telomeric sequences, 
two of which were close to fragile sites. The involvement of loci near fragile sites 
that are often deleted in basal skin cancer could indicate that telomere biology may 
play a role in chromosome instability that could drive progression to malignancy. 
Of these fragile sites, 9q22.3 was of interest because LOH at 9q22.3 is frequent in 
sporadic basal cell carcinoma (Xie et a l , 1998). Within 0.3Mb of the fusion 
junction, lies the PTCH, a gene responsible for nevoid basal cell carcinoma 
syndrome, a condition that predisposes to basal cell carcinoma. Interestingly, the 
properties of the naevi are some of the important features in nevoid basal cell 
carcinoma syndrome (Xin et al., 1999). Thus, the involvement of this locus in 
telomere fusion in an early premalignant lesion is tantalising. However it is not 
known if terminal deletion involving 9q22.3 that is frequent in skin cancer is a 
result o f telomere dysfunction. It is thus a subject of next investigation through 9q 
telomere-specific length analysis in these samples.
In conclusion, the data described in this chapter is consistent with previous studies 
from human cells in culture which revealed that telomere dysfunction may generate 
uncapped telomeres that are capable of fusion. It is therefore exciting to observe 
that telomere erosion, instability and fusion observed in vitro is physiologically 
relevant.
I
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5.8 Key findings
• Telomere length at 17p telomere was shorter than that of XpYp in 65% of 
melanocytic naevi.
• Similarly, 17p telomere is shorter than XpYp in 74% of skin adjacent to 
melanocytic naevi.
• In addition, 17p telomere is shorter in naevi than adjacent tissue (56% of 
individual).
• In a subset of individuals, both XpYp and 17p telomeres were shorter in 
naevi than adjacent tissue.
• Clonal telomere length distributions at 17p were observed in both naevi and 
adjacent tissue in different individuals, i.e. homogenous telomere length in 
one tissue and heterogeneous in another.
• Although the telomere length profiles were shorter in melanocytic naevi 
compared to the adjacent dermis, there was no difference in the frequency of 
fusion events using our assays that detect fusion events between telomeres of 
XpYp, 17p and 21q family.
• For those individuals whose 17p telomere was longer than XpYp, the fusion 
events involving the two telomeres contained a deletion from XpYp and long 
arrays of telomere repeats from 17p.
• Clonal telomere lengths and fusion events were observed in naevi and 
adjacent tissue.
i
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• Fusion frequencies in both naevi and adjacent tissue were similar to those 
estimated from normal cells in vitro. However, the frequency was lower than 
estimated from cells undergoing crisis. '
• Consistent with studies in cells undergoing crisis, the telomere fusion events 
were characterised by deletions extending into the sub-telomeric DNA, short 
patches of micro-homologies and lack of TTAGGG repeats on one side of 
the fusion events.
• In addition, complex fusion events involving insertion of DNA sequences 
near documented fragile sites were observed. Interestingly, some of these 
sites are often deleted in skin cancer.
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6 Chapter 6: Telomere instability and fusion in 
Barrett’s oesophagus
6.0 Summary
The aim of the work described in this chapter was to investigate telomere 
dynamics in Barrett’s oesophagus. Barrett’s oesophagus is a premalignant 
metaplastic condition in which the normal squamous epithelium lining the distal 
oesophagus is replaced by columnar epithelium with goblet cells due to chronic 
reflux disease (Haggitt, 1994; Spechler, 2002). Although, it predisposes patients 
to development of adenocarcinoma of the oesophagus, only a fraction of 
Barrett’s oesophagus patients progress to adenocarcinoma (Flejou and Svrcek, 
2007). Thus, it is essential to determine bio-molecular markers that may predict 
those individuals that will progress.
A detailed analysis of telomere length at the telomeres of XpYp, 17p, 1 lq  and 9p 
has revealed that the transformation of native squamous tissue into Barrett’s 
metaplasia is accompanied by telomere erosion (P0.001). In addition, telomere 
length dynamics was related to zonal segments of oesophageal tissues derived 
from Barrett’s oesophagus patients, such that segments physically separated by 
distance of 2cm displayed large variation in telomere length (P<0.01). Some 
segments displayed short telomere profiles with narrow variance characteristic of 
clonal cell populations in culture [(Baird et al., 2003; Britt-Compton et al., 2006); 
P<0.0001)]. The cells displaying such clonal telomere length profiles have 
potential to dominate the tissue and result in clonal expansion, which could 
confer selective advantage for other abnormalities that may drive progression to 
oesophageal adenocarcinoma.
Preliminary analysis of telomere fusion events between telomeres of XpYp, 17p, 
16p and 21q families revealed that tissue samples that displayed short telomere 
length profiles also displayed increased frequency of telomere fusions, 
characterised by large deletions extending into the sub-telomeric DNA and DNA 
sequence homology at the fusion point. This mutational profile is similar to that 
we described in human cells in vitro and in vivo.
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6.1 Terminology
Z-line is the oesophageal squamo-columnar junction: an arbitrary line at which 
the columnar epithelium changes to squamous epithelium in Barrett’s 
oesophagus [Figure 6.1; (Spechler, 2004)].
Gastro-oesophageal junction [also known as cardia-oesophageal junction (C-O) 
or oesophago-gastric (O-G) junction is an anatomical region that marks the end 
of the oesophagus and the start of the stomach. It is often characterised by gastric 
fold during upper endoscopy [Figure 6.1; (Hayward, 1961; Wild and Hardie, 
2003)].
Upper Endoscopy is the procedure in which a flexible fibre-optic lens or a thin 
scope with a light and camera is passed through the mouth to visualise the upper 
gastrointestinal tract, oesophagus, stomach or upper part of small intestines (Wild 
and Hardie, 2003).
Native squam ous 
oesophagus 
Z-line
Proximal
B arrett's
oesophagus/m etap lasia
Distal
O esophago-gastric junction
Gastric reflux
_ Duodenum
D uodeno-gastro
reflux
Stomach
Figure 6.1. Diagrammatic outline of the part of the human digestive system illustrating 
the normal oesophagus, Barrett’s oesophagus, stomach and duodenum.
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6.2 Brief introduction
Oesophageal cancer is the eighth [8th] most common cancer worldwide (Parkin, 
2001; Parkin et al., 2005). The two types, squamous cell carcinoma and 
adenocarcinoma of the oesophagus differ histologically but are diagnosed, 
treated and managed in the similar way. Squamous cell carcinoma tends to occur 
on proximal part of the oesophagus (Parkin, 2001; Parkin et al., 2005) and its 
geographical distribution varies widely with exceptionally high occurrences of 
the malignancy in the Shanxi province of north central china, whose cause is not 
known (He et al., 2008; He et al., 2003).
Oesophageal adenocarcinoma, on the other hand is found at the lower/distal part 
of the oesophagus [Figure 6.1 for distal oesophagus]. It is the predominant form 
of oesophageal cancer in western countries (Parkin, 2001; Parkin et al., 2005). 
This study will be limited to the discussion of oesophageal adenocarcinoma with 
little reference to squamous cell-carcinoma whenever required. The incidence of 
oesophageal adenocarcinoma has been increasing dramatically over the past three 
decades in the western world (Devesa et al., 1998; Newnham et al., 2003). The 
risk factors include: age of 65 or older, being male, smoking, heavy alcohol 
consumption, poor nutrition that is low in vitamins and mineral but high in fats 
and salts, obesity, acid reflux disease and Barrett’s oesophagus (Devesa et al., 
1998; Lagergren et al., 1999; Wild and Hardie, 2003).
6.2.1 Barrett oesophagus and Gastro-oesophageal reflux 
disease (GORD)
Gastro-oesophageal reflux disease (GORD; referred to hereafter as reflux 
disease) is a complication due to reflux of stomach and possibly duodenual 
contents into the oesophagus causing symptoms or damage to the mucosa [Figure 
6.1; (Fox and Forgacs, 2006)]. The most commonly recognised manifestation of 
reflux is frequent heartburn or a burning sensation in the chest after meals and/or 
on bending (Klauser et al., 1990; Lagergren et al., 1999). Other symptoms
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include regurgitation, hoarseness, chronic cough, bleeding and weight loss 
(Klauser et al., 1990).
The progression from reflux disease to cancer is believed to be a stepwise 
(Flejou, 2005; Miros et al., 1991) process arising from the prolonged exposure of 
oesophageal tissue to duodena-gastric contents (bile, acid, pepsin) thus damaging 
the oesophageal tissue. The damaged tissue then heals possibly through a 
metaplastic replacement of native squamous epithelium by columnar intestinal- 
like epithelium with goblet cells, a condition termed Barrett’s oesophagus. Such 
intestinal metaplasia can then progress through accumulation of genetic 
abnormalities to dysplasia and ultimately cancer (Flejou, 2005; Jenkins et al., 
2002; Spechler, 2002).
Barrett’s oesophagus is an acquired, hyper-proliferative and premalignant lesion 
that predisposes to oesophageal and oesophago-gastric adenocarcinomas; the 
malignancies on the increase in western world (Blot et al., 1991; Drewitz et al., 
1997). It is defined as a change of any length [long segment (>3cm) or short 
segment (<3cm)] that can be observed during endoscopy (Sampliner, 2002; 
Sharma et al., 1998). However, it excludes internal metaplasia of the cardia but 
includes any intestinal metaplasia at the oesophagus (Sampliner, 2002).
The risk of developing cancer in Barrett’s oesophagus patients is estimated to be 
30-125 times more than the general population (Cameron et al., 1985; Jenkins et 
al., 2002); whilst the incidences of adenocarcinoma are 0.5-1% per patient year 
i.e. 1 incidence per 100-200 patient years of observation (Koppert et al., 2005; 
Shaheen et al., 2000). However, the prevalence of Barrett’s oesophagus in the 
general population is not known, as some patients are asymptomatic (Gerson et 
al., 2002; Shalauta and Saad, 2004). Nonetheless, those individuals with 
symptomatic Barrett’s oesophagus, exhibit symptoms, typical of reflux disease. It 
is not known whether reflux disease predisposes to Barrett’s oesophagus or 
whether it promotes carcinogenesis in patients with Barrett’s oesophagus.
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Nevertheless, it is estimated that 5-15% of patients with gastro-oesophageal 
reflux disease also have Barrett’s oesophagus (Flejou, 2005; Lagergren et al.,
1999).
Like oesophageal adenocarcinoma, risk factors for Barrett’s oesophagus include 
being a Caucasian male, alcohol and drug-abuse, obesity and older age greater 
than 60 years (Cameron and Lomboy, 1992; Prach et al., 1997). It is uncommon 
in Asia and Far east, with an estimated 0.3-0.6% cases reported in Japan 
(Nakamura et al., 1999). The mean age at diagnosis is 55-60 years, however, 
studies have reported the increasing risk of Barrett’s oesophagus with 
progressive increase in age from 30 to 70 years (Conio et al., 2001). Nonetheless, 
Barrett’s oesophagus is rarely diagnosed during childhood. In addition, 
individuals with family history of Barrett’s oesophagus, oesophageal or 
oesophago-gastric junction adenocarcinoma are likely to have Barrett’s 
oesophagus (Chak et al., 2004; Chak et al., 2002; Chak et al., 2006). However, 
no specific gene has been identified so far that predisposes individuals to either 
Barrett’s oesophagus or oesophago-gastric cancers.
6.2.2 Common genetic changes in Barrett’s oesophagus
Several genetic changes have been associated with clonal evolution in 
precancerous Barrett’s metaplasia and hence neoplastic progression (Jankowski 
et al., 1999; Reid et al., 2003). However, this discussion will be limited to tumour 
suppressor loci and some of the important cell cycle proteins.
The CDKN2A gene, located at 9p21 encodes for a CDK inhibitor, p i6. Loss of 
p i6 (a product of CDKN2A) function, is reported in 85% of Barrett’s 
oesophagus patients and is detectable very early in Barrett’s oesophagus (Maley 
et al., 2004b; Wong and Fitzgerald, 2005). The allelic losses of p i6 through 
promoter hyper-methylation, loss of heterozygosity and/or sequence mutations in 
metaplastic and dysplastic Barrett’s tissue are more prevalent than losses of p53,
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and precedes aneuploidy (Barrett et al., 1996a; Galipeau et al., 1999; Hardie et 
a l, 2005).
The TP53 gene at chromosome 17pl3, encodes for a cell cycle protein p53, 
which monitors the integrity o f the genome. The loss of p53 function through 
mutations and LOH is a common feature of human cancers (Hollstein et a l, 
1991; Lane, 1994). Similarly, losses of p53 appear to be an early event during 
oesophageal carcinogenesis, with losses of p53 reported in 60% of metaplastic 
and 40-66% of dysplastic Barrett’s tissues and 40-88% of oesophageal 
adenocarcinomas. However, in Barrett’s metaplasia, loss of p53 is preceded by 
loss of p i6 thus exhibiting selective advantage for clones that have lost p l6 
(Doak et a l, 2003; Jenkins et a l, 2003). Indeed, loss of p53 has been associated 
with increased risk of progression to cancer. For instance, according to Reid and 
colleagues, patients with inactive p53 have 16x increased risk of progressing to 
cancer than their counterparts with functional p53 (Reid et a l, 2000; Reid et a l,
2003).
Allelic losses at the adenomatosis polyposis coli gene (APC; 5q21), loci for 
deleted in colorectal cancer (DCC;18q) and deleted in pancreatic cancer 
(DPC4;18q) tumour suppressor genes are all common in Barrett’s oesophagus 
(Barrett et a l, 1996b; Bektas et a l, 2000; Zhuang et a l, 1996).
Cyclin D l, which is located on 11 q l3 is a cell cycle protein that phosphorylates 
pRb thereby inactivating it and thus facilitating G]-S phase cell cycle progression 
(Lukas et a l, 1996). Cyclin D l is often over-expressed in Barrett’s oesophagus 
and has been reported to be associated with increased risk of disease progression 
to cancer (Arber et a l, 1996; Bani-Hani, 2000). In contrast, the loss or alteration 
in function of pRb genes occurs late during oesophageal carcinogenesis, with no 
losses detected in Barrett’s metaplasia (Maley et a l, 2006; Sarbia et a l, 2001).
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6.2.3 Clonal evolution
Neoplastic progression is an evolutionary process characterised by genomic 
instability. During progression, cells in neoplasm acquire heritable genetic and 
epigenetic lesions that affect their survival and reproduction, typically generating 
clonal heterogeneity (Barrett et al., 1999). If these cells are selected for during 
evolution, they could dominate the population and lead to clonal expansion. 
Barrett’s metaplasia is recognised as a neoplasm (Maley et al., 2004b; Wong et 
al., 2001) as clones carrying CDKN2A mutation and methylation, 9p LOH, TP53 
mutations and 17p LOH are usually highly selected for clonal expansion during 
oesophageal carcinogenesis (Galipeau et al., 1999). Evidently, the sizes of clones 
with 17p LOH or DNA content tetraploidy and aneuploidy increases the risk of 
progression from Barrett's oesophagus to oesophageal adenocarcinoma (Maley et 
al., 2006; Maley et al., 2004a).
6.2.4 Telomere dynamics in Reflux disease and Barrett’s 
oesophagus
The gastro-oesophageal reflux disease is known to increase the proliferation of 
squamous cells lining the oesophagus. In addition, contents of reflux could 
produce reactive oxygen species, which also cause oxidative DNA damage, 
which is believed to accelerate telomere shortening (Olliver et al., 2003; von 
Zglinicki, 2002; Zhang et al., 2001). It would be expected that telomeres in reflux 
disease undergo progressive telomere shortening. Indeed Souza and colleagues 
have reported short telomeres in tissues derived from the distal oesophagus of 
reflux disease sufferers (Souza et al., 2007). In addition, telomere erosion has 
been implicated in the evolution of chromosome instability in Barrett’s 
oesophagus, resulting in gains and losses of specific chromosomes (Finley et al., 
2006; Meeker et al., 2004). Telomere erosion has also been detected in tissue 
samples derived from Barrett’s oesophagus patients, with telomere erosion being 
associated with increased chromosome instability (Finley et al., 2006). In 
contrast, the inverse association between the frequency of chromosome anaphase
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bridges, surrogate markers o f chromosome instability induced by telomere 
dysfunction and telomere lengths have been reported in tissues derived adjacent 
to Barrett’s metaplasia (Kammori et al., 2006; Kammori et al., 2007). Short 
telomeres in leucocytes blood from Barrett’s oesophagus patients have also been 
reported to predict risk of oesophageal cancer (Risques et al., 2007). Whilst 
increasing levels of hTERT expression are associated with progression to cancer, 
such that minimal telomerase activity is detectable in Barrett’s metaplasia with a 
further increase in high-grade dysplasia (HGD) and adenocarcinoma (Going et 
al., 2004).
It is clear from these studies, cited previously that telomere shortening and 
chromosome instability occur early in neoplastic progression of reflux disease 
and Barrett’s metaplasia. However, these studies have not defined the actual 
telomere length in tissues derived from corresponding patients. Similarly, the 
molecular structure of telomere-related chromosome fusions has not been 
studied. Thus, this study will investigate these aspects; telomere length and 
telomere fusions in details.
6.3 This study
Barrett’s oesophagus is a good model for human neoplastic progression, as 
progression from Barrett’s oesophagus is believed to follow multi-step, 
histological stages of metaplasia, low-grade and high-grade dysplasia to cancer, 
with high-grade dysplasia carrying the elevated risk of progression (Barrett et al., 
1999; Flejou, 2005; Jankowski et al., 1999). However, inter-observer variation 
during diagnosis (Reid et al., 1988) coupled with difficulty in identifying stages 
due to chronic inflammation and possibility of regression in putative high-risk 
dysplasia (Conio et al., 2003; Weston et al., 2000), complicates the prediction for 
those individuals who will progress. Thus, there is a need for development of 
reproducible biomarkers that could identify those individuals that will progress.
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The development of Barrett’s oesophagus involves the hyper-proliferative and 
chronic inflammatory state (Spechler, 2002), thus we considered that the 
generation of reactive oxygen species (ROS) from acid and bile could drive 
telomere attrition and dysfunction in Barrett’s metaplasia, resulting in evolution 
of clones with increased chromosome instability and hence initiation of 
oesophageal cancer. This study was therefore aimed at investigating the role of 
telomere biology in the transformation of normal squamous oesophageal 
epithelium to Barrett’s metaplasia.
In addition, chromosome instability has been implicated to initiate and drive 
genomic instability in pre-neoplastic diseases such as ulcerative colitis (Chin et 
al., 2004; Meeker et al., 2004; O’Sullivan et al., 2002). Similarly, chromosome 
instability is one of the common events during progression from Barrett’s 
metaplasia to adenocarcinoma (Finley et al., 2006; Jenkins et al., 2002). The 
chromosome instability could be a result of telomere dysfunction which has been 
shown to drive tumour progression through among others breakage-fusion-bridge 
cycles (Artandi et al., 2000; Rudolph et al., 2001). Therefore, another objective 
of the study was to investigate the telomere instability and fusion in tissues 
derived from Barrett’s oesophagus patients.
To achieve these objectives, STELA and telomere fusion assays were employed 
to study telomere length distribution at the telomeres of XpYp, 17p, l lq  and 9p; 
these were selected because LOH at 17p, and 9p, and gains of 11 q are frequent 
events in Barrett’s oesophagus (section 6.2.2). Telomere fusion events between 
telomeres of XpYp, 17p, 21q and 16p family were investigated in patient- 
matched samples consisting of gastric tissues, Barrett’s metaplasia and native 
squamous epithelium. These data will define the extent of the telomere erosion, 
instability and dysfunction. In addition, whilst the chromosome instability is 
common in Barrett’s oesophagus during disease progression, the data collected 
from this study will provide insights into the nature of telomere-induced 
chromosome instability (in the form of telomere fusion sequences).
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6.4 Sample collections and Statistical tests
Tissue biopsies, obtained from 14 patients undergoing periodic endoscopy at the 
Morrison’s hospital in Swansea were treated with the tissue rupture homogeniser 
(Qiagen) prior to DNA extraction with standard methods (Sambrook et al., 
1989). The tissue samples were composed of 14 gastric mucosae, 13 Barrett’s 
metaplasia and 9 squamous epithelia. It is worth noting that biopsies derived 
from only eight individuals consisted of all the three tissues.
Another set of tissue biopsies was obtained from patients undergoing periodic 
endoscopy for Barrett’s oesophagus at Glasgow Royal Infirmary (Going et al.,
2004). Tissues samples were supplied from 24 patients consisting of samples cut 
every 2cm from the normal squamous epithelium of the oesophagus, oesophageal 
squamo-columnar junction (“Z line”); through Barrett’s metaplasia, cardia or 
oesophago-gastric (O-G) junction, then the gastric body and antrum (Figure 6.2). 
Of these, two were classified as minimal and severe dysplasia respectively (Table 
2.3 in chapter 2). An additional two sets of samples (making a total of 26 
patients) were obtained from one patient in which the gastric and oesophageal 
tumours were detected as well as another patient that had an unclassified tumour 
(by collaborators). The telomerase activity of these samples was documented 
previously (Going et al., 2004); telomerase activity was absent in the gastric 
tissues; body and antrum. Whereas, all the oesophageal mucosa samples were 
telomerase-positive and this increased moving distally within the Barrett’s 
mucosa (Going et al., 2004).
The tissue biopsies derived from patients at Swansea and Glasgow were analysed 
independently as biopsies collected from each individual comprised of different 
number of samples.
Statistical methods employed were as described in chapter 5 of this thesis.
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Figure 6.2. Anatomy of the oesophagus and Stomach, with biopsy sites indicated by 
grey dots. The normal oesophagus is lined by the squamous epithelium, however when 
the distal oesophagus become damaged partly due to gastric reflux the cells changes to 
columnar-like, a condition called Barrett’s oesophagus/metaplasia. The end of 
oesophagus and start of the stomach is characterised by the folds, made of cardia tissue 
and is termed the oesophago-gastric (EG) junction. The proximal and distal parts of the 
stomach are called gastric body and gastric antrum respectively [obtained from (Going 
et al., 2004)].
6.5 Results
6.5.1 Telomere length in Squamous, Barrett’s and Gastric 
Mucosa.
The telomere length was investigated at the telomeres o f XpYp, 17p, l lq  and 9p 
in squamous epithelium, Barrett’s and gastric tissues collected from patients at 
Morrison hospital Swansea (referred to hereafter as first dataset). The analysis of 
all samples revealed no difference in mean telomere length distributions at all the 
four telomeres in squamous tissues of the nine individuals (P=0.36). However, 
within each individual, the XpYp telomere was the shortest in 4 out of 9 
individuals (P<0.05; Figure 6.3i). Similarly, the mean telomere lengths were not 
different in Barrett’s (P=0.96; Figure 6.3ii) and gastric mucosa (P=0.64; Figure
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Figure 6.3. Summary of the mean telomere length at telomeres of XpYp, 17p, 9p, 1 lq 
in normal squamous oesophagus (i), Barrett’s metaplasia (ii) and gastric mucosa (iii). 
The mean telomere length distributions were not different in any of the individuals.
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Figure 6.4. Summary of mean telomere lengths of XpYp, 17p, 9p and 11 q 
telomeres in eight individuals comprising Gastric mucosa (blue dots), Barrett’s 
mucosa (red dots) and Squamous epithelium (black dots). Mean of all the mean 
within sample population are indicated (Green line).
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6.3iii), with no apparent telomere being the shortest. Interestingly there was large 
inter-individual variation in mean telomere length in Barrett’s mucosa in all 
telomeres; with variation of up to 4.8kb (difference between smallest and longest 
means) at XpYp telomeres. Whilst there is considerable variation in telomere 
length among individuals, each individual displayed similar telomere length 
profiles at all the ends analysed [Figures 6.3i-iii].
6.5.2 Telomere length dynamics in Barrett’s oesophagus
6.5.2.1 XpYp telomere
The changes in telomere length during transformation of normal oesophagus to 
Barrett’s metaplasia were apparent at the XpYp telomere. Within individuals, 
large variation in telomere lengths of up to 4.8kb (difference between smallest 
and longest telomere) in metaplasia were observed in all the three tissues. Similar 
variation was reflected in mean telomere lengths [Figure 6.4i].
There was also clear evidence of telomere erosion during the transformation of 
the oesophageal tissues as observed in 50% (4/8) of the individuals showing P- 
value of 0.05 or less [P<0.05 ; Figures 6.5i-ii, 6.5iv]. Some individuals displayed 
substantial differences in telomere length between the squamous epithelium and 
the Barrett’s mucosa, for example in 814850 (Figures 6.5ii, 6.5vi), 70% of 
telomeric molecules lie below the mean (4.6kb) in Barrett’s metaplasia compared 
to 45% of molecules greater than 6.4kb (mean) in squamous epithelium (Figure 
6.5ii).
It was also apparent that telomere erosion could result in severe telomere 
shortening with telomere profiles extending close to the length range at which 
telomere fusion has previously been detected (Capper et al., 2007). The evidence 
for this came from the analysis of the telomere variant region (TVR) using TVR- 
PCR [Figures 6.5i-vi; (Baird et al., 1995)] where telomere length data was 
corrected for the presence of the non-functional telomere variant repeat region. It 
was clear that telomere length in Barrett’s oesophagus were similar to that
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Figure 6.5 Telomere distribution at XpYp telomere in squamous (S, black bars), gastric 
(G, blue bars) and Barrett’s mucosae (B, red bars). STELA products were detected by 
Southern hybridisation with TTAGGG-containing probe, i Bimodal telomere 
distribution in Barrett’s and gastric tissue, ii. Individual with two alleles could be 
distinguished by allele-specific STELA (vi). iv. Telomeres in Barrett’s metaplasia are 
shorter than squamous, iii, v. Barrett’s oesophagus length is longer than in squamous 
tissue. Mean telomere length and standard deviations (SD) are shown below each 
distribution vii. Summary of the mean telomere distributions in eight individuals. For 
P<0.0001 [***] and P<0.05 [*] are indicated. Viii. Summary of the mean distributions 
at XpYp between gastric (blue bars) and Barrett's mucosae (red bars). The individuals 
in which there was no significant difference between the mean telomere distributions 
are shown by #. Error bars (green) represent 95% confidence intervals.
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observed in cells undergoing crisis, with 60% of telomeres in some individuals 
clustered below 2kb of perfect TTAGGG repeats [Figure 6.5ii].
In addition, some individuals displayed bimodal distributions with one of the two 
distributions consisting of telomeres clustered below 2kb [30th percentile; e.g. 
172729; Figure 6.5i]. To determine if these bimodal distributions and telomere 
erosion represented evolution of clones with short telomeres, or the presence of 
allelic variation, direct sequence analysis of the well-documented SNPs within 
the 850bp sequences adjacent to the XpYp telomere was carried out (Baird et al., 
1995). This analysis revealed that all the eight individuals [except individual 
814850; Figure 6.5vi] were homozygous at the SNPs comprising two XpYp 
alleles (-427G/-415C or GC allele and -427A/-415T or AT allele). Thus, the 
telomeric alleles could not be separated in seven individuals and hence it was not 
possible to determine the possibility of clonal evolution based on the SNP data. 
In one individual that was heterozygous, the two alleles were analysed with the 
allele-specific STELA. It was clear that there was no difference in the telomere 
length distributions derived from the two alleles. This data indicates that at least 
in this individual the shorter of the two telomere length distributions could 
represent clonal evolution and not allelic telomere length variation. However, 
analysis of telomere distribution revealed that all the tissue samples displayed 
heterogeneous (wide variance) telomere profile distinct from the homogenous 
(narrow variance) distributions observed in clonal cell population in culture 
[(Baird et al., 2003; Britt-Compton et al., 2006); Figures 6.6i, 6.6ii and 6.6iii].
Twenty-five percent of individuals exhibited longer telomere lengths in Barrett’s 
mucosa than squamous (P<0.01), suggesting the selective growth of cells with 
long telomeres (Figures 6.5iii and 6.5v). This was more apparent in patient 
867688, in which mean telomere lengths in Barrett’s tissue was 1.5x that of 
squamous epithelium, with telomere distributions shifted towards the upper range 
relative to squamous epithelium (Figure 6.5v; P<0.05). It is possible that these
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Figure 6.6. Summary of mean telomere length distribution (middle bar) and Standard 
deviations (error bars), (i) Mixed population and clonal (Cl.) cell proliferations 
derived from human lung fibroblast MRC5. Y and S represents young and senescent 
cells respectively (data derived from Baird et al 2003, supplementary data), (ii) and 
(iii) distributions in gastric (blue), Barrett’s (red) and squamous epithelium of the 
oesophagus (black) in XpYp (i)and 17p (ii) telomeres respectively.
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individuals were exhibiting histological stage dysplasia, which is often associated 
with increased telomerase activity and telomere elongation.
Telomere length in Barrett’s mucosa was compared to that of gastric mucosa, 
with the assumption that if Barrett’s mucosa are composed of same cell type and/ 
or are exposed to similar environment, they may exhibit similar telomere length 
instability. The mean telomere length between gastric mucosa and Barrett’s 
metaplasia was not significantly different in 46% [6/13; P>0.05; Figure 6.5viii], 
suggesting that telomerase activity in Barrett’s oesophagus may be insufficient to 
counteract telomere loss. The cells of the gastric mucosa and Barrett’s 
oesophagus undergo rapid proliferation to replace cells lost due to DNA damage 
resulting from acid damage, thus telomeres are lost each time cells divide.
Although the telomeres were maintained at a specific length, the telomeres that 
were within the length range at which fusion can occur were detected. These 
events are consistent with sporadic telomeric deletion events (Figure 6.5, 
indicated with red marks).
6.5.2.2 17p, 9p and llq  telomeres
Similar to telomere length profiles at XpYp telomere, large variation in telomere 
length at telomeres of 17p, 9p and l lq  were observed in all tissues [S; Figure 
6.4ii-ivj. Again there was evidence of telomere erosion in Barrett’s mucosa 
compared to native squamous at 17p [62.5% (5/8); P<0.001; Figure 6.7i; 6.7ii; 
6.7iv; 6.7v and 6.7vi]. For example, in 172729: telomere length profiles at 17p in 
Barrett’s metaplasia are shorter than those at squamous (P<0.001) and not 
different from the gastric tissue (P=0.64). In addition, there was clear presence of 
short telomeres; however, it was not possible to include the TVR region at these 
telomeres.
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Figure 6.7. Telomere length analysis at 17p telomere in squamous (S, black bars), 
gastric (G, blue bars) and Barrett’s mucosae (B, red bars). STELA products were 
detected by Southern hybridisation with TTAGGG-containing probe, i-ii, iv-v. Barrett’s 
oesophagus telomere lengths are shorter than those of native squamous epithelium, iii. 
Telomeres are longer in Barrett’s oesophagus than squamous. Mean telomere lengths 
and standard deviation (SD) are shown for each distribution vi. Summary of the mean 
telomere distributions in eight individuals. For P<0.0001[***] and P<0.05 [*] are 
indicated, vii. Summary of the mean distributions at XpYp between gastric (blue bars) 
and Barrett’s mucosae (red bars). The individuals in which there was no significant 
difference between the mean telomere distributions are shown by #. Error bars (green) 
represent 95% confidence intervals.
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Similar to XpYp analysis, the telomere length distribution were elongated in 2/8 
in Barrett’s metaplasia (PO.OOl; Figures 6.7vi). In addition, at 17p telomere, 
there was no evidence of telomere length profiles that were as homogeneous as 
those that characterise clonal cell populations (Figure 6.6iii).
Again, in those individuals that also had squamous oesophageal tissue, 62.5% 
(5/8) individuals exhibited shorter telomeres in Barrett’s metaplasia than gastric 
mucosa (P<0.01; Figures 6.7vi). Similar pattern was also observed in additional 
(3 out of 5) individuals in which the squamous was not provided, adding up to 
the total of 8 out of 13 (62%; P<0.001; Figure 6.7vii) suggesting that telomere 
erosion is elevated in Barrett’s oesophagus and is independent of that of the 
gastric mucosa.
Like XpYp and 17p telomere profiles, short telomere profiles were observed in 
Barrett’s mucosa of 75% (6/8) of individuals analysed at telomeres of 9p 
[PO.Ol; Figure 6.8i-v] and l lq  (P<0.01; Figure 6.9i-v). Again the Barrett’s 
tissue was shorter in 8/13 individuals compared to gastric mucosa at both 
telomeres. Likewise, telomere profiles at 9p and l lq  did not reveal distributions 
consistent with clonal expansion [Figures 6.8i-iv and 6.9i-iv; (narrow variance)]. 
Moreover, individuals that displayed longer telomere profiles in Barrett’s tissue 
at XpYp and 17p telomeres also displayed longer telomere profiles at 9p and 1 lq 
[Figures 6.8i, 6.8v, 6.9i, 6.9v].
6.5.3 Summary from first data set
It was apparent that telomere erosion was occurring in Barrett’s metaplasia 
regardless of the telomere being studied (Figure 6.10; top panel). However, 
biopsies derived from two individuals exhibited elongated telomeres in Barrett’s 
metaplasia compared to squamous epithelium (6.10; top panel). Of most interest 
was one individual in whom all telomeres were extremely longer in Barrett’s 
oesophagus compared to the native squamous [individual 867688, Figure 6.10;
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Figure 6.8. Telomere length analysis at 9p telomere in squamous (S, black bars), gastric 
(G, blue bars) and Barrett’s mucosa (B, red bars). STELA products were detected by 
Southern hybridisation with TTAGGG-containing probe, i-ii Barrett’s oesophagus length 
longer than in squamous epithelium, iii-vi. Barrett’s oesophagus telomere lengths are 
shorter than those of native squamous epithelium. Mean telomere lengths and standard 
deviation (SD) are shown for each distribution v. Summary of the mean telomere 
distributions in eight individuals. For P<0.III 1 ”***], PO.Ol [**] and P<0.05 [*] are 
indicated. Error bars (green) represent 95% confidence intervals.
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Figure 6.9. Telomere length analysis at llq  telomere in squamous (S, black bars), 
gastric (G, blue bars) and Barrett’s mucosae (B, red bars), i. Barrett’s oesophagus 
length longer than in squamous epithelium, ii-iv. Telomere length shorter in Barrett’s 
oesophagus than in squamous. Mean telomere lengths and standard deviation (SD) are 
shown for each distribution v. Summary of the mean telomere distributions in eight 
individuals. For P<0.III1'***], PO.Ol [**] and P<0.05 [*] are indicated. Error bars 
(green) represent 95 % confidence intervals
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top panel; P<0.01]. In addition, in 3 out of 8 individuals the telomere length 
distributions were comparable to those observed in gastric tissues (Figure 6.10; 
middle panel) and the mean telomeres between such Barrett’s and gastric tissues 
were not statistically different (P>0.05; Figure 6.10; bottom panel).
Thus, the preliminary data indicates that during metaplastic change of distal 
oesophageal tissue, the telomeres are subjected to processes that could result in 
rapid telomere erosion relative to the adjacent squamous tissue. Similarly, the 
evolution of cells with longer telomeres was observed consistent with clonal 
evolution during the transformation. However, the data did not reveal any clear 
evidence of clonal telomere distributions.
Given the existence of zonal segmentation in telomerase expression within the 
Barrett’s mucosa (Galipeau et al., 1999; Going et al., 2004), it is possible that 
these tissues contained several clones that could not be distinguished. Thus to 
investigate this possibility, telomere length was analysed in 2cm zonal segments 
derived from normal oesophagus down to the gastric antrum. The data is 
discussed in the next section.
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Figure 6.10. Illustrating the difference in mean telomere length at XpYp, 17p, 9p and 
llq  between: Barrett’s and squamous oesophageal tissues (top panel), gastric and 
squamous mucosa (middle panel); gastric and Barrett’s mucosa (bottom panel). The 
positive number shows an increase in telomere length while negative number shows 
decline in telomere length in the two tissues under comparison.
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6.5.4 Telomere variation is related to zonal segments in 
Barrett’s metaplasia
It was apparent from the first data set that all the four telomeres exhibited similar 
telomere length profiles and therefore it was not necessary to analyse all 
chromosome ends. Thus for the second data set (biopsies from Glasgow), 
telomere length distributions were analysed at the telomeres of XpYp and 17p 
only.
Consistent with the first data set, the telomere lengths in normal oesophageal 
tissues were longer than those of the gastric tissues (PO.OOOl). In addition, it 
was evident that the telomere distributions in normal squamous epithelium of the 
oesophagus were longer than those of the Z-line and O-G junction [ANOVA; 
PO.OOOl; Figure 6.11 A]. However, large variability in mean telomere lengths 
was observed within the Barrett’s oesophagus segments across the population 
(Figure 6.1 IB). This made it difficult to draw conclusion based on the population 
as a whole; however, inspection of the telomere profiles at the individual level 
revealed often considerable differences in telomere length profiles within 
adjacent tissue samples, sometimes only physically separated by 2cm. For 
instance, shortest telomere profiles were observed in distal, proximal and 
intermediate segments such that it was difficult to relate the telomere 
distributions relative to the Z-line and/ or O-G junction (Figure 6.12A, 6.12B; 
PO.Ol). However, it was clear that telomere length profiles within some tissue 
segments were more homogeneous [with narrow variance] and similar to that 
observed in clonal cell populations in culture. This was more apparent in Z-line, 
and segment 2cm from it (Figure 6.12C, 6.12D; P<0.001). Similarly, the 
segments that exhibited the clonal telomere profiles were randomly distributed 
within the Barrett’s oesophagus with no clear relation between distance from Z- 
line and/ or O-G junction and the telomere length distribution. These clonal 
distributions consisted of short telomere profiles some of which were within the 
range at which fusions can occur (Figure 6.13; PO.OOl). These clonal 
distributions were observed at both XpYp and 17p, indicating that evolution of
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clones with short telomeres is not dependent on the erosion of a specific 
telomere. In addition, the telomere distributions were statistically different 
between segments of the Barrett’s metaplasia (P<0.001; Figure 6.1 IB, 6.12A, 
6.12B).
These observations contrasted with the long heterogeneous telomere length 
distributions observed in the native squamous tissues of the oesophagus [Figures 
6.12A-D, 6.13; P<0.001). It was interesting that all the segments of Barrett’s 
metaplasia were not statistically different from the C-0 junction and the body but 
they were all longer or comparable to those of the antrum, the telomerase- 
negative distal segment of the stomach [Figures 6.12, 6.13; PO.OOl].
6.5.4.1 Telomere length in Barrett’s metaplasia with 
histological stage, dysplasia
The progression from Barrett’s metaplasia to cancer is believed to follow a multi- 
step process; metaplasia-low-grade dysplasia-high-grade dysplasia-carcinoma in 
situ (Flejou, 2005; Sampliner, 1998). High-grade dysplasia is a risk factor for 
subsequent development of cancer. Two out of the 24 individuals analysed were 
characterised as having histological stages, low (minimal) and high (severe)- 
grade dysplasia. Although subtle differences could be detected between adjacent 
sections (Figure 6.14), no information was available as to the specific location, if 
any, of the dysplastic histology. Therefore, it was not clear if telomere length 
correlated with the extent of dysplasia.
Like all the 24 individuals without dysplasia, in these two individuals with 
histological dysplasia, longer telomere distributions were observed in 
oesophageal tissues than in gastric tissues [t-test, PO.OOOl; Figure 6.14A-B]. In 
addition, zonal telomere length differences between segments of the Barrett’s 
metaplasia with random changes in mean telomeres as well as changes in the 
distributions between segments separated by 2cm was observed (Figure 6.14). In 
all the segments, the mean telomere lengths in Barrett’s segments were
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significantly shorter than those of the normal oesophagus, an observation 
inconsistent with the report that telomerase over-expression in Barrett’s 
oesophagus with dysplasia was accompanied by telomere elongation [(Finley et 
al., 2006); PO.OOOl]. However, this data is uninformative as it is based on two 
individuals. It is therefore possible that analysis of several individuals with 
histological stage dysplasia could yield informative telomere length profiles.
6.5.5 Telomere distributions in Tumours
In a sample of three tumours comprising oesophageal and gastric from one 
individual and an unclassified tumour from another individual, there was no 
consistent pattern in telomere distributions between the tumour and adjacent 
tissue at both XpYp (P=0.51) and 17p (P=0.96; Figure 6.15). In an individual 
with two tumours, the telomere length in normal oesophagus was longer than that 
of the tumour at both XpYp and 17p (P<0.001; Figure 6.15). Whilst telomeres in 
the gastric tumour were longer than those of gastric body (t-test, P=0.006; F-test, 
P=0.002; Figure 6.15), the mean telomeres in the gastric body were also shorter 
than those of the antrum (t-test, P=0.001; F-test, PO.OOOl; Figure 6.15).
6.5.6 Telomere fusions in premalignant Barrett’s oesophagus
Telomere dysfunction can promote chromosome instability through anaphase 
bridge-breakage-fusion cycles in ulcerative colitis (O'Sullivan et al., 2002), and 
mouse models (Artandi et al., 2000). In addition, increased levels of aneuploidy 
have been reported in Barrett’s oesophagus (Jenkins et al., 2002; Koppert et al., 
2005). It was clear from the telomere length analysis, that short telomeres within 
the length range at which fusion can occur were readily detected in these 
samples. Thus, to examine if telomere dysfunction could contribute to 
chromosome instability observed in Barrett’s oesophagus, the frequency of 
telomere fusion events was investigated in patient-matched oesophagus and 
gastric tissues derived from Barrett’s oesophagus patients. This was facilitated by 
using the more sensitive telomere fusion assay between the telomeres of XpYp,
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17p, 21q family and/ or 16p family described in chapter 3. Multiple reactions 
(typically 7-8) containing 50-100ng per reaction were carried out with each DNA 
sample derived from Barrett’s oesophagus patients consisting of normal 
squamous oesophageal tissue, Barrett’s metaplasia and gastric tissues. Whilst 
putative fusion molecules could be detected during analysis of the first data set 
(biopsies from Swansea), it was not possible to characterise these molecules by 
DNA sequence analysis and thus they could not be confirmed as genuine fusion 
events. Thus in these samples, no telomere fusion events could be verified in an 
analysis of 9.33x106 diploid genome equivalents.
In contrast, analysis of the samples that consisted of the segments derived every 
2cm from normal oesophagus to antrum [second data set; n=2.73xl07), did reveal 
telomere fusion events in those samples that contained very short telomeres with 
the average fusion frequency of 3.8x1 O'6 in normal oesophagus and 2.5x1 O'6 in 
antrum. In other tissues, the fusion frequency was either undetectable or low 
(xlO'7). In Barrett’s oesophagus, there was no evidence of increase in telomere 
fusion events compared to the normal oesophagus with the highest fusion 
frequency being 7.5x1 O’6 in Barrett’s segments (Figure 6.16A, B).
An increased fusion frequency was observed in tumours, with the highest 
frequency detected in oesophageal tumour (XpYp=3.0xl0‘5; 17p=2.25xl0‘5) 
compared to gastric tumours (XpYp=2.25xl0‘5; 17p=7.5xl0'6). These fusion 
frequencies were higher than those of adjacent tissues (P<0.05), being 
undetectable in normal oesophagus and 7.5x1 O'6 in normal gastric tissues (data 
not shown).
As explained in chapter 3 and 4, putative fusion molecules were isolated using 
nested PCR primers and molecular structure confirmed by direct sequence 
analysis. Whilst 98 putative telomere fusion events could be readily re-amplified 
prior to sequencing, only six of these could be fully characterised. The remaining 
92 could not be fully characterised because they were either too large (23) and it
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was not possible to identify the fusion point or in others, the involvement of 
related telomeres created inverted repeats that resulted in uninterpretable 
sequence information (69).
The preliminary data indicated that the fusion events were characterised by large 
sub-telomeric deletions, a lack of TTAGGG repeats at the fusion point as well as 
short patches of microhomology, similar to those described in cells in vitro and 
human tissues in vivo (Chapter 4-5; Figure 6.17 A-D).
6.6 Discussion
6.6.1 Telomere length distribution
Barrett’s oesophagus is a complex premalignant condition in which the cells of 
the distal oesophagus are subjected to physical, thermal and chemical trauma, 
which could result in rapid cell proliferation and accumulation of genetic changes 
such as inactivation of tumour suppressor genes in particular pi 6, p53 and over­
expression of cyclin D1 (Arber et al., 1996; Bani-Hani, 2000; Galipeau et al., 
1996; Hardie et al., 2005; Jenkins et al., 2002). These events could allow cells 
with damaged DNA to progress through the cell cycle and facilitate progression 
to cancer. Loss of p i6 function is associated with late Gi cell cycle arrest and is 
one of the early events during Barrett’s oesophagus progression thus could confer 
selective advantage (Barrett et al., 1996a; Galipeau et al., 1999; Wong et al.,
2001). Additional loss of p53, the multifunctional protein that mediates cell cycle 
arrest or apoptosis in response to several cellular and environmental stresses 
could facilitate the bypassing of checkpoints such as senescence and apoptosis 
that may be induced by telomere attrition (Galipeau et al., 1996; Galipeau et al., 
1999).
In this study, telomere length analysis at telomeres of XpYp, 9p, 1 lq  and 17p has 
been described. Three telomeres of 1 lq, 9p and 17p were selected for analysis 
because these chromosome arms are known to be involved in the early stages of 
Barrett’s oesophagus, i.e. losses of p l6 (Barrett et al., 1996a; Maley et al., 2004b;
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Figure 6.17. Examples of the sequences of the fusion events detected in tissues derived 
from Barrett's oesophagus patients. A. 17p: 1 p fusion event illustrating large deletion 
size B. XpYp:XqYq fusion events, has potential to form ring chromosomes. C. 
21q:XpYp fusion event. D. 13q:XpYp fusion showing deletion on both sides of the 
fusion point. The short patches of micro-homology nucleotides are boldened and 
underlined while deletion (A) from start of telomere tracts are shown in base pairs (bp), 
V represents telomere variant repeats while T represents TTAGGG repeats.
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Wong et al., 2001) and p53 (Blot et al., 1991; Galipeau et al., 1996) and over­
expression of cyclin D1 are frequent (Bani-Hani, 2000). The analysis of telomere 
length at XpYp, 17p, 9p and 1 lq  telomeres using STELA revealed that the 
telomeres of the oesophageal epithelial cells are shortened in Barrett’s 
oesophagus compared to normal squamous epithelium. One mechanism by which 
telomeres may be eroded in Barrett’s oesophagus is through oxidative damage. 
Barrett’s oesophagus is characterised by chronic inflammatory which is 
associated with oxidative damage and increased levels of double stranded breaks 
(Reid et al., 1993). In addition chronic exposure to acids and bile salts (Jolly et 
al., 2004), could generate reactive oxygen species which may cause oxidative 
damage to telomeric DNA. Indeed elevated levels of reactive oxygen species has 
been demonstrated in oesophageal squamous epithelium of patients with other 
oesophageal disease such as reflux oesophagitis (Wetscher et al., 1995); 
oesophageal squamous epithelium of patients with severe gastro-oesophageal 
reflux disease (Olliver et al., 2003) and Barrett’s metaplasia (Farhadi et al.,
2002). In addition, telomeres have been suggested to be preferential sites for 
oxidative damage (Oikawa and Kawanishi, 1999; von Zglinicki, 2002), thus 
combination of chronic inflammation and effects of gastric acids and bile salts 
could result in accelerated telomere erosion.
Another possible mechanism is the rapid cell proliferation, which is known to be 
elevated in damaged oesophageal mucosa of reflux disease laboratory rat models 
(Zhang et al., 2001) and Barrett’s oesophagus in humans (Ouatu-Lascar et al., 
1999). Telomeres shorten as a function of cell division in vivo and in vitro 
(Allsopp et al., 1995). Thus rapid cell proliferation in the absence of sufficient 
telomerase activity would be expected to result in rapid decline in telomere 
lengths in Barrett’s oesophagus. Consistent with this view, large variation in 
mean telomere length of up to 4.8kb, was observed between Barrett’s mucosa 
and squamous epithelium. Assuming that end-replication losses are the only 
factor that results in such difference, 4.8kb difference will be equivalent to 48 
population doubling (PD) difference [based on lOObp loss per PD; (Harley et al.,
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1990)] in the absence of telomerase activity. Since both tissues express 
telomerase activity, such differences in mean telomere lengths could represent 
many more PDs.
Consistent with other studies, telomeres in Barrett’s oesophagus are eroded 
(Finley et al., 2006; Meeker et al., 2004; Souza et al., 2007) despite expression of 
telomerase (Going et al., 2004; Lord et al., 2000; Morales et al., 1998; Souza et 
al., 2007). In addition, it has been reported by others that telomerase expression 
increases with increasing histological grade during oesophageal carcinogenesis 
resulting in increased telomere length within the high-grade dysplasia (Finley et 
al., 2006; Lord et al., 2000). Telomerase expression compensates for telomere 
loss that could activate DNA damage checkpoints (Blackburn, 1990). However, 
it appears that the telomerase activity in Barrett’s metaplasia is insufficient to 
counteract telomere erosion. In support of this, it has been shown that telomerase 
extends the lifespan of human cells without net telomere lengthening (Zhu et al.,
1999) and inhibition of telomerase in Barrett’s cancer cells in vitro leads to 
senescence and apoptosis (Shammas et al., 2005; Shammas et al., 2004).
In a subset of individuals, the telomere lengths in Barrett’s oesophagus were 
similar to those in gastric mucosa, suggesting that the damage to telomeres by 
gastric contents result in cells of the oesophagus mimicking those of the gastric 
mucosa. In addition, shorter telomere length profiles than those of the gastric 
tissues were observed. These observations are of interest because oesophageal 
tissues are telomerase-positive but gastric tissues are not, thus it would be 
expected that despite increased proliferation, the telomere erosion could be 
counteracted by telomerase. However, given the rapid turnover in both gastric 
and Barrett’s metaplasia, it is possible that telomerase expression in Barrett’s 
oesophagus allowed the extended proliferation and thus further erosion. An 
alternative explanation could be the differences in apoptotic ability of the cells in 
these tissues, i.e. apoptosis is less frequent in Barrett’s metaplasia compared to 
gastric tissues (Chen et al., 2002), thus, it is possible that whilst cells with short
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) telomeres exit cell cycle through apoptosis to maintain tissue homeostasis, high 
proliferation in Barrett’s metaplasia is not counteracted by cell death thus 
resulting in further telomere erosion, and possibly clonal growth.
There was evidence of clonal telomere length profiles in some segments of 
Barrett’s oesophagus at all telomeres analysed. It has been suggested that clonal 
expansion of cells that have lost p53 and p i6 could subvert cell cycle 
checkpoints, thus conferring selective advantage for these clones to divide 
uncontrollably (Barrett et al., 1999; Galipeau et al., 1999; Maley et al., 2006). 
Loss of p i6 function could confer selective advantage to cells during neoplastic 
progression while loss of p53 gives cells the proliferative advantage by bypassing 
cell cycle checkpoints such as senescence and apoptosis that can be activated by 
short telomeres (Jenkins et al., 2002). Thus it is possible that the clonal 
proliferation could lead to telomere attrition in Barrett’s metaplasia, consistent 
with this and other studies (Finley et al., 2006), which could in turn initiate 
chromosome instability once telomeres have eroded to critical lengths. Once 
telomeres have eroded to within length ranges at which telomere fusion can 
occur, they may initiate large-scale chromosome instability, a hallmark of human 
cancers. However, substantial variation among individuals in telomere lengths 
coupled with the small samples made it difficult to conclude whether telomere 
biology can be used to predict those individuals that will progress. It will be 
interesting to observe how these telomere length distributions correlate with 
genomic complexity.
As described in Chapter 5, there was a subset of telomeres that were several 
orders of magnitude shorter than the bulk of the distribution. These telomere 
profiles are consistent with stochastic telomere deletions that generate truncated 
telomeres, which are capable of fusion. These events could drive background 
chromosome instability, which would activate onco-proteins or inactivate tumour 
suppressor proteins (Callen et al., 2002; Capper et al., 2007; Mumane et al., 
1994).
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Evidence of telomere elongation in cells of Barrett’s oesophagus were also 
observed in a subset o f biopsies analysed implicating that in these individuals 
other factors that select for cells with longer telomeres could play a role in 
Barrett’s oesophagus. This may be a consequence of the over-expression of 
telomerase resulting in telomeric elongation. Indeed, elevated telomerase 
expression during oesophageal carcinogenesis as early as in Barrett’s metaplasia 
being highest in dysplasia and adenocarcinoma has been documented (Lord et al.,
2000). Although these individuals were not characterised as having histological 
stage, dysplasia, it is possible that dysplasia was present at the distal oesophagus. 
In support of this, several studies has demonstrated that increase in telomerase 
expression in dysplastic biopsy of Barrett’s oesophagus is associated with 
telomere elongation (Finley et al., 2006; Lord et al., 2000; Morales et al., 1998).
6.6.2 Telomere fusion events
It was clear from both data sets that, the telomeres can erode to within the length 
range at which fusion was detected. Fusions could readily be detected in all the 
samples analysed in the zonal samples [second dataset]. However, there was no 
apparent increase in telomere fusion frequencies in Barrett’s oesophagus. It is not 
known whether the absence of fusions is a reflection of a low-level of telomere- 
driven chromosome instability or whether the chromosomes being targeted with 
our assays were not subjected to fusion in Barrett’s oesophagus. In their study, 
Finley and colleagues reported increased levels of chromosome fusion in high- 
grade dysplasia, the histological stage that is believed to have elevated risk of 
progressing to cancer (Finley et al., 2006), as well as in other hyper-proliferative 
conditions such as ulcerative colitis (O'Sullivan et al., 2002). Thus the 
preliminary results described in this thesis are in contrast to that study in which 
they observed an increased fusion frequency at 17p, 1 lq and 9p using FISH 
(Finley et al., 2006). In this study, the telomere fusion frequency in Barrett’s 
mucosa of the two individuals that were diagnosed as having dysplasia, there was 
no significant difference in telomere fusion frequency. Considering the fact that 
only 10% of Barrett’s oesophagus progress to cancer (Koppert et al., 2005), the
266
I
I Chapter 6: Barrett's oesophagus
f.
data reported here may not provide sufficient representation of those individuals 
that will progress. In addition, the fusion frequencies in different tissues may be 
too low to make a meaningful comparison and thus these data are uninformative 
for understanding disease progression in Barrett’s oesophagus.
Preliminary fusion data has revealed that the molecular structure of the fusion 
events consists of large deletions extending into the sub-telomeric DNA, short 
patches of micro-homology nucleotides and lack of TTAGGG repeats at fusion 
junction. This profile is similar to that we have reported in cells in culture 
[chapter 4; (Capper et al., 2007)], as well as in normal cells (chapter 5). The 
occurrence of such fusion events even though at low frequency could initiate 
chromosome instability during successive cell division.
6.6.3 Telomere instability and fusion in tumours.
Telomere shortening has been reported to be one of the earliest and most 
prevalent alterations in epithelial carcinogenesis (Meeker et al., 2004) 
contributing to the acquisition of chromosomal instability (Finley et al., 2006; 
O'Sullivan et al., 2002), which in turn may promote tumour evolution (Feldser et 
al., 2003; Gisselsson et al., 2001). In addition, during oesophageal 
carcinogenesis, telomerase activity is elevated in dysplasia and adenocarcinomas 
(Lord et al., 2000; Morales et al., 1998). Consistent with this, increased telomere 
lengths and chromosome instability in the form of telomere fusion events were 
observed in the oesophageal tumours analysed here. It has been shown that for 
cancer cells to continue proliferating they require the telomere maintenance 
mechanism such as telomerase, which is expressed in 85-90% of human 
epithelial cancers (Kim et al., 1994). However, telomerase expression in tumours 
is known to be insufficient to completely stabilise the telomeres and prevent 
chromosome instability (Gisselsson et al., 2001). This is evident from the three 
tumours analysed here, where telomere lengths were longer in tumours than 
adjacent normal tissues.
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6.7 Conclusion
In this study, telomere erosion, instability and fusion have been described. It is 
clear that telomere erosion occurs very early in premalignant condition, Barrett’s 
oesophagus. In addition, like other biomarkers such as LOH at p53 and p i6, 
evolution of clones with short telomeres that are capable of fusion was evident. It 
is clear that Barrett’s oesophagus is a very complex condition consisting of 
multiple clones some of which carry the features that may drive neoplastic 
progression. However, it remains to be determined if telomere erosion and 
telomere-driven chromosome instability can predict individuals at risk of 
progression.
6.8 Key findings:
• Telomere attrition is apparent in 75% of Barrett’s oesophagus individuals, 
regardless of the telomere under-investigation. However, telomeres were 
longer in Barrett’s oesophagus in two individuals [first data set].
• Although it was apparent that telomeres in Barrett’s tissues were shorter 
than those o f the normal squamous epithelium, large variation in telomere 
distributions was observed within segments of Barrett’s oesophagus 
within each individual as well as across the whole sample collection 
[second data set].
• The large telomere variation in segments separated by 2cm was evident 
with evidence of clonal expansion in some segments, as described by 
homogeneous telomere distributions similar to those described in analysis 
of clonal cell populations in culture.
• Preliminary data has revealed that the molecular structure of the telomere 
fusion events observed in these tissue samples is similar to those described 
in cells in culture (chapter 3 and 4) and other normal human cells (Chapter
5).
• In tumours, telomere elongation was accompanied by increase in telomere 
fusion frequency.
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7 Chapter 7: Final Discussion and Future Work
7.1 Summary of key results
Much of the work described in this thesis has been discussed in the relevant 
chapters. Therefore, in this chapter, a general overview of the results, possible 
limitations and future directions will be considered. First, the key findings of the 
study are outlined:
• The telomere fusion assays have been expanded to cover at least 43% of  
the human genome. This will allow the understanding of the mechanistic 
basis of telomere fusion and how this may impact upon genomic 
instability.
•  Using the extended and improved assays, telomere fusion events have 
been isolated and characterised in cells in culture, as well as in human 
tissue biopsies, derived from normal and diseased tissues including 
normal dermis, melanocytic naevi, Barrett’s metaplasia, normal 
oesophageal and gastric tissues.
•  The analysis of the molecular structure of fusion events has revealed that 
fusion of short dysfunctional telomeres is accompanied by large deletions 
extending into the sub-telomeric DNA up to 5.6kb (close to the limit of 
the assay at 6kb). The fusion events were also characterised by short 
patches of homology nucleotides with a GC bias at the fusion junction. In 
addition, complex fusion events involving insertion of DNA sequences 
near loci that have been implicated in human cancers were detected.
• Clonal telomere length distributions and fusion events were observed in 
vitro and in vivo. These events may suggest that genomic rearrangements 
arising as a consequence of telomere erosion, instability and fusion could
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confer selective advantage for other abnormalities that may drive 
neoplastic progression.
• The telomere length profiles were shorter in melanocytic naevi compared 
to the adjacent dermis; however there was no difference in the frequency 
of fusion events using our assays that detect fusion events between 
telomeres of XpYp, 17p and 21q family.
• For those tissue samples in which 17p telomere length distributions were 
longer than those observed at XpYp telomere, the fusion events involving 
the two telomeres contained a deletion from XpYp and long arrays of 
telomere repeats from 17p.
• The fusion frequencies in both melanocytic naevi and adjacent tissue were 
comparable to those of normal cells in vitro. However, the frequency was 
lower than estimated from cells undergoing crisis in culture.
• Telomere attrition was apparent at all telomeres analysed in Barrett’s 
mucosa. Telomere erosion was also related to zonal segments of Barrett’s 
oesophagus such that large variation in telomere length profiles was 
evident in segments that are physically separated by only 2cm.
• In tumours, telomere elongation was accompanied by increase in telomere 
fusion frequency.
7.2 Technological development of STELA and Fusion assay
The data described in this thesis examines telomere erosion, instability and 
fusion in human cells and tissues using single-molecule approaches, STELA 
(Baird et al., 2003) and telomere fusion assays (Capper et al., 2007).
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The sequence composition of the sub-telomeric DNA immediately adjacent to 
the telomeres is highly variable consisting of duplications, low-copy number 
repeats as well as multiple repeat families (Brown et al., 1990; Mefford and 
Trask, 2002; Riethman et al., 2005). The repetitive nature of the sub-telomeric 
DNA has allowed the development of the telomere fusion assays that detect 
fusion events between multiple chromosomes simultaneously. The telomere 
fusion assay has been extended to include additional telomeres comprising at 
least 43% of the human telomeres (Letsolo et al., 2009). The improved assays 
have enabled the detection and isolation of fusion events in human cells in vitro 
and tissues in vivo. It has also been employed by colleagues to study telomere 
instability and fusion in solid and haematological tumours as well as in 
experimental systems testing the mechanistic basis of fusion of short 
dysfunctional telomeres [DMB personal comm.]. The development of this assay 
has revealed that telomere instability and fusion that we previously described 
between XpYp and 17p (Capper et al., 2007) was not unique to these ends but a 
feature of critically eroded, uncapped telomeres.
Development of STELA assays at additional telomeres proved to be technically 
challenging due to high sequence homology between the sub-telomeric DNA of 
multiple chromosomes (Brown et al., 1990). Nevertheless, STELA could still be 
developed at additional telomeres using the single nucleotide differences. These 
STELA assays revealed that properties of XpYp and other four autosomal 
telomeres analysed previously were not unique (Baird et al., 2003; Britt- 
Compton et al., 2006). Thus taking advantage of the single nucleotide sequence 
differences, STELA can potentially be extended to other chromosome ends.
7.2.1 Possible limitations
Current fusion assays are restricted to detection of fusion events between 
heterologous chromosomes as well as sister-chromatid type fusion events that 
involved the deletion of one of the participating telomeres. However, sister-
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chromatid fusions that include long arrays of telomere repeats on both sides of 
the fusion junction cannot be detected as these have potential to form 
palindromic structures that may be refractory to PCR (Capper et al., 2007; 
Letsolo et al., 2009). If these types of events occur they would not be represented 
in these telomere fusion assays. However, fusion analysis following the 
knockdown of TRF2 revealed telomere fusion events between heterologous 
chromosomes that contained long arrays of TTAGGG on either side o f the fusion 
junction (Capper et al., 2007), indicating that these types of events could be 
detected with our fusion assays. However, as it was apparent from the data 
presented in this thesis, the telomere fusion containing TTAGGG repeats on 
either side of the fusion point is rare. It is possible that this also applies to sister 
chromatid-type fusion events. It would be informative to develop the fusion 
assay to allow the detection of sister chromatid fusion events that contain 
TTAGGG repeats on either side of the fusion point. This would allow an 
assessment to be made about contribution that these events make to telomere 
mutation.
The presence of repetitive sequences such as satellites immediately adjacent to 
the telomere (Blouin et al., 1995; Brown et al., 1990; de Lange et al., 1990), also 
limits the detection of fusions within those regions, as repetitive DNA sequences 
may be refractory to PCR.
Despite the mentioned limitations, the current telomere fusion assay appeared to 
be a robust methodology. Unlike other technologies that can detect large 
deletions and complex chromosomal fusions (Gisselsson et al., 2000; Takubo et 
al., 2010), the telomere fusion assay cannot detect fusion events comprising 
larger deletions than those detected with our assays (maximum deletion of 6kb). 
However, the assay is robust in giving the actual molecular structure of the 
fusion events. The study of the molecular structure of fusion events will give 
inside into the mechanistic basis of telomere fusion of critical dysfunctional 
telomeres. Again, unlike other methods that could not be utilised for analysis of
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tissue biopsies as the method requires proliferating cells for metaphase spreads 
(McNeil and Ried, 2000), the telomere fusion assay has been used in this study 
and by colleagues to study telomere-related chromosome instability in human 
tissues. Furthermore, unlike other methods that study frequency of anaphase 
bridges which may not be a consequence of telomere dysfunction (Gisselsson et 
al., 2000), the telomere fusion assay detects fusion events between the 
dysfunctional telomeres (Capper et al., 2007; Letsolo et al., 2009).
The sequence homology within sub-telomeric DNA poses a challenge for 
development of STELA at specific telomeres. This makes it difficult to identify 
sufficient sequence difference to differentiate one telomere within the family 
from its close relatives. Indeed it has been reported that some chromosome ends 
such as 6p contain telomere adjacent repeat sequences that hybridise to more 
than one repeat family, telbam 11 and telbam 3.4 (Brown et al., 1990). However, 
it has become increasingly apparent from the data presented in this thesis, as well 
as that from this laboratory, that telomere length dynamics appeared to be 
conserved within the cell strain analysed (Baird et al., 2003; Britt-Compton et al., 
2006). Thus it may not be necessary to develop STELA at additional 
chromosome ends. To compensate for above limitations, the STELA technique 
has been improved by others in a method called “universal STELA.” The 
“universal STELA” estimates telomere length from almost all telomeres 
simultaneously. Although robust for detecting very short telomeres, “universal 
STELA” may not be widely applicable as it suffers the amplification efficiency 
for detection of molecules greater than 7kb (Bendix et al., 2010). In contrast 
chromosome-specific STELA can detect the full spectrum of human telomeres 
[0-25kb; (Baird et al., 2006)]. Again like TRF analysis, telomere length estimated 
by “universal STELA” contains unknown and varying length of subtelomeric 
DNA. Furthermore, Unlike chromosome-specific STELA which displays linear 
correlation [r=0.91; (Baird et al., 2003)] with mean telomere lengths estimated by 
TRF analysis, “universal STELA” shows non-linear correlation with TRFs 
(Bendix et al., 2010). Thus chromosome-specific STELA is the ideal method for
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detecting telomere length at specific telomeres as it does not suffer hybridisation 
threshold like TRF analysis and also does not give the mean telomere length or 
ratio like other methods described in chapter 1 of this thesis (Baird, 2005; 
Saldanha et al., 2003).
7.3 Telomere dynamics i n  v i t r o  is a reflective of that i n  v i v o .
Human malignancies are characterised by complex cytogenetic profiles typically 
highlighted by presence of complex rearrangements such as non-reciprocal 
translocations that occur early in tumour development (Hanahan and Weinberg, 
2000; Maser and DePinho, 2002). One of the mechanisms that may initiate 
genomic instability is the state of the telomere, which if “uncapped”, could 
initiate genomic instability during early stages of carcinogenesis (Artandi et al., 
2000; Rudolph et al., 2001). Whilst in advanced stages the genome is partially 
stabilised by reactivation of telomere maintenance mechanism such as telomerase 
(Kim et al., 1994; Meyerson et al., 1997). Telomere function depends on the 
telomere length and intact telomere binding proteins which forms a scaffold that 
protect the chromosome ends (de Lange, 2005). However, dysfunctional 
telomeres are detected as double stranded breaks and activate DNA damage 
response checkpoints including ATM, CHK2 which induce p5 3-dependent cell 
cycle exit through cascade of events (d'Adda di Fagagna et al., 2003; Karlseder et 
al., 1999). If DNA checkpoints are defective as in terc'A p53'/_ mice, progressive 
telomere erosion leads to end-to-end fusions, which during subsequent cell 
division could fuel large-scale genomic instability through cycles o f breakage- 
fusion-bridging and result in rearrangements such as non-reciprocal 
translocations, that typify epithelial cancers (Artandi et al., 2000; Mumane and 
Sabatier, 2004). The role of telomere instability in generating genomic instability 
and carcinogenesis is further supported by studies with late generation telomere 
knockout mice (terc‘A) which show that mice displaying telomere loss and 
genomic instability also display an increased rate of tumour formation very early 
in life (O'Hagan et al., 2002; Rudolph et al., 1999).
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The work described in this thesis has addressed the role of telomere erosion, 
instability and fusion in vitro and in vivo in human cells and tissues, and their 
possible role in driving malignant progression. Previous studies with mouse 
models have shown that fusion occur between chromosome arms bearing shortest 
telomeres (Hemann et al., 2001). Similarly in this study and other recent studies 
we have demonstrated that in human cells fusion occur between critically short 
telomeres in vitro (Capper et al., 2007; Letsolo et al., 2009). Likewise recent 
studies using other methods of analysis have revealed that short telomeres 
accumulate in senescent cultures (Bendix et al., 2010) and chromosome 
instability is increased in cells displaying short telomeres but not in young 
proliferating cells (Takubo et al., 2010; Zou et al., 2009). We have also 
demonstrated that telomere dysfunction is physiologically relevant as telomere 
instability and fusion could be detected in normal and diseased human tissues in 
vivo (chapters 5 and 6 of this thesis) and was correlated with disease progression 
in chronic lymphocytic leukaemia (Lin et al., 2010). Whilst, telomere erosion, 
instability and fusion have been described extensively in humans, our studies 
provide some of the first insights into the nature (DNA sequence arrangement) of 
the telomere-related chromosomal fusions. It would be interesting to investigate 
how our dataset correlates with genome-wide chromosome instability. The data 
will also provide a reference for experimental settings investigating the 
mechanistic basis of fusion of critically short dysfunctional telomeres.
Telomere fusion between sister chromatids can create inverted repeat structures 
which may in turn create fragile sites which can break at adjacent loci to original 
fusion (Lo et al., 2002) resulting in broken chromosomes and amplified 
segments; thus possibly leading to localised deletions and amplifications 
(Mumane, 2006). Indeed this study and our recent publications have described 
fusion events that are consistent with sister chromatid-type fusion in which one 
telomere is fused to telomere-adjacent DNA of same telomeric allele in the 
reverse orientation (Capper et al., 2007; Letsolo et al., 2009).
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We have also described fusion events that involve interstitial loci near sites 
implicated in cancer, some of which are located near documented fragile sites. 
Fragile sites are gaps or breaks in chromosomes that may be induced by 
environmental mutagens (Sutherland et al., 1998). They are classified according 
to their chemistry of induction and their frequency in the population. The rare 
fragile sites are found in 5% of the population and are induced by folic acid- 
deficiency or bromodeoxyuridine (BrdU) or distamycin A (Schwartz et al.,
2006). Whereas common fragile sites are found in all individuals and are induced 
by aphidicolin or 5-azacytidine (Schwartz et al., 2006). The interstitial loci 
detected in fusion during this study, were near documented common fragile sites, 
8q24.3 (FRA8D), 7p22 (FRA7B), 9q22.1 (FRA9D) and Xp22.31 [FRAXB; 
(Debacker and Kooy, 2007)]. Common fragile sites are involved in sister 
chromatid exchange, deletions and translocations in human malignancies 
(Debacker and Kooy, 2007; Glover, 2006). If such events occur near growth 
control genes, they may result in rearrangements and amplification which could 
result in tumour suppressor gene inactivation or oncogene activation (Maser and 
DePinho, 2002). Indeed, common fragile site, FRA3B spans over putative 
tumour suppressor genes (FHIT) and is implicated in human diseases, for 
example, FHIT gene is often deleted in premalignant conditions such as Barrett’s 
oesophagus [81-86%] and oesophageal adenocarcinoma (Lai et al., 2010; 
Michael et al., 1997).
The data presented here is consistent with the view that telomere dysfunction 
leads to the different types of large-scale genomic mutation (Mumane, 2006). 
These types of mutations have the potential to drive disease progression in early 
stages of cancer. This view is consistent with many studies in the field 
implicating telomere dysfunction in tumour progression. These include early 
studies showing telomere erosion in human tumour tissues compared to adjacent 
normal tissue (Hastie et al., 1990; Nakamura et al., 2000). In addition the 
adenoma-carcinoma transition is characterised by increased frequency of 
anaphase-bridges, surrogate marker of telomere fusion in colorectal carcinoma,
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breast and oral squamous cell carcinomas (Chin et al., 2004; Gordon et al., 2003; 
Rudolph et al., 2001), further implicating that telomere dysfunction may drive 
genomic instability during progression in human cancers.
The end-to-end fusions can be induced by loss of telomere protection due to loss 
of TTAGGG repeats or titration of telomere binding proteins, especially TRF2 
from telomeres (van Steensel et al., 1998). Several experiments have reported 
that telomere dysfunction resulting from loss of telomere capping activates DNA 
repair mechanisms that are employed for repair of double stranded breaks, non- 
homologous end-joining [NHEJ; (Karran, 2000)], and homologous 
recombination [HR; (Denchi and de Lange, 2007; Wu et al., 2006)]. NHEJ is 
employed at any stage of the cell cycle to repair uncapped telomeres that contain 
long tracts of telomere repeats (Yang et al., 2005) whilst HR is the main method 
for repair of sister chromatid telomeres (Rudd et al., 2007).
However, the fusion events characterised by large sub-telomeric deletions (up to 
5.6kb) and short patches of homology DNA sequences at the fusion junction 
described in the thesis, as well as other data from the laboratory (Capper et al.,
2007) implicate additional end-joining mechanisms in facilitating fusion of 
dysfunctional telomeres. Similarly others have shown that the fusion of 
dysfunctional telomeres in human fibroblasts is independent of the activity of 
Ligase IV, a protein involved in non-homologous recombination (Zou et al., 
2009). This may include Ku-independent error-prone end-joining mechanisms 
such as micro-homology mediated end-joining or alternative NHEJ. MMEJ is 
distinguished from the other Ku/DNA-PK independent error-prone mechanisms 
by its utilisation of 5-25 base pair micro-homology DNA sequences to align and 
join the broken strands (Bentley et al., 2004; McVey and Lee, 2008). However, 
our dataset comprising fusions containing less that 5bp DNA sequence homology 
are inconsistent with micro-homology mediated end-joining described in yeast 
(Ma et al., 2003), plants (Heacock et al., 2007) and some human cancers (Bentley 
et al., 2004).
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The alternative NHEJ method of repair employs shorter homology sequences. An 
example o f the use o f this mechanism is in mammalian cells during class 
switching recombination in the absence of NHEJ. Class switch recombination 
(CSR) is a biological mechanism that changes a B cell's production of antibody 
from one class to another. During this process, double-stranded breaks are 
generated in DNA at two switch (S) regions, which are upstream from gene 
segments that encode for the constant regions of antibody heavy chains 
(Stavnezer, 1996). After the removal of the intervening DNA between the S- 
regions, the free ends of the DNA are rejoined by NHEJ (Lieber et al., 2006; Ma 
et al., 2002). In the absence of non-homologous end joining components, free 
ends of DNA may be rejoined by an alternative pathway which is biased toward 
micro-homology and is independent of NHEJ-factors such as ku and ligase iv 
(Boboila et al., 2010; Yan et al., 2007).
Clonal expansion has been implicated as one of the early lesions that may predict 
progression to malignancy (Maley et al., 2006). During this study, clonal fusion 
events and telomere length profiles that were consistent with clonal growth, were 
described both in vitro and in vivo. Clonal events have potential to dominate the 
cell population and provide selective advantage for accumulation of other 
abnormalities that could drive neoplastic progression. Indeed clones that have 
lost p i6 and/or p53 function through mutations or LOH, pose an increased risk of 
progression to malignancy from premalignant conditions such as Barrett’s 
oesophagus (Galipeau et al., 1999; Maley et al., 2006; Maley et al., 2004a; Maley 
et al., 2004b). In addition, consistent with the data described in this thesis (clonal 
telomere lengths), clones expanding in multiple 2-cm intervals in the Barrett's 
segment were detected with 9p LOH only, or 17p LOH only or both 9p and 17p 
LOH (Galipeau et al., 1999). Similarly, frequent clonal expansion of p53 mutant 
cells occurs in the epidermis adjacent to basal cell carcinomas (BCCs) during 
skin carcinogenesis (Urano et al., 1995). This data is consistent with the 
observation that non-reciprocal translocations in carcinomas and early stage
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neoplasia are clonal (Artandi et al., 2000) and could be initiated by telomere 
dysfunction.
The inspection of telomere length in human tissues comprising patient-matched 
melanocytic naevi and Barrett’s metaplasia revealed extensive telomere erosion 
in these tissues compared to adjacent normal tissues. Loss of pi 6 function is very 
common in melanocytic naevi (Bennett, 2003; Michaloglou et al., 2005) and 
Barrett’s metaplasia (Galipeau et al., 1999; Jenkins et al., 2002). Thus it is 
possible that the loss of p i6 confers an advantage for accumulation of more 
abnormalities such as the loss of p53 function, extensive telomere erosion and 
chromosome instability. Indeed telomere-driven genomic instability is associated 
with transition from benign lesions to malignancy (Chin et al., 2004; Meeker et 
al., 2004). In addition, pl6INK4a has been reported to contribute to the p53- 
independent response to telomere damage (Jacobs and de Lange, 2004); thus loss 
of p i6 function can allow cells with damaged telomeres to bypass senescence 
and allow further telomere attrition and instability.
The telomere erosion observed in the skin and Barrett’s metaplasia samples could 
arise from oxidative stress which in skin may be due to chronic UV exposure 
while in Barrett’s metaplasia it may be due to gastro-duodenal acids and salts. 
Telomeres are prone to UV damage which generates UVB-induced pyrimidine 
especially at dithymidine sites (Jin and Ikushima, 2004). In addition, oxidative 
damage due to either metabolism or UV is predominant at guanine sites 
(Kawanishi and Oikawa, 2004; Oikawa and Kawanishi, 1999). Since the repair 
of these lesions is less effective at telomeres, their existence at telomeres may 
result in substantial loss of telomere repeats and thus telomere erosion. Indeed, 
oxidative stress and/or UVA exposure has been reported to compromise the 
telomere integrity in cultured fibroblasts (Houben et al., 2008; Kawanishi and 
Oikawa, 2004; Oikawa et al., 2001; Oikawa and Kawanishi, 1999; von Zglinicki, 
2002) and endothelial cells (Kurz et al., 2004). Thus oxidative stress (see section 
on oxidative damage in Chapter 1 of this thesis) could result in telomere
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breakages generating short uncapped telomeres which have potential to fuse and 
leads to genomic instability through anaphase-bridging-breakage-cycles (Maser 
and DePinho, 2002). Consistent with telomere breakage rather than telomere 
erosion, telomere fusion events that contain long arrays of telomere repeats on 
one side were detected in normal skin samples (chapter 5 of the thesis).
The difference in telomere length between metaplasia, naevi and adjacent tissues 
could also have been due to replicative history of the cells (Martin-Ruiz et al., 
2004). Indeed, it has been demonstrated that the replicative life span of human 
primary cells in culture is highly heterogeneous such that even within the same 
clone different cells display different telomere length profiles and each dividing 
cell population contain a fraction of senescing cells [possibly telomere-induced 
senescence; (Kill et al., 1994)]. In addition, the rate of telomere erosion varies 
greatly in cultured fibroblasts and generates large heterogeneity in telomere 
length (Martin-Ruiz et al., 2004). Moreover, telomere erosion varies in different 
fibroblasts depending on age of donor, such that reduced telomere loss is 
reported in foreskin fibroblasts from young donors compared to fibroblasts from 
older donors (Figueroa et al., 2000; Takubo et al., 2010). Thus it is possible that 
different cell types within these tissues had different rates of telomere loss. The 
replicative history can also account for the large heterogeneity in telomere 
distributions of these tissues. It is also possible that different cell populations 
could be subjected to end-replication losses as a consequence of cell 
proliferation, whilst in others shortening at an increased rate is due to other 
factors such as oxidative stress from the microenvironment as well as stochastic 
deletion/breakage events within the telomeres. Indeed work in our laboratory 
(Baird et al., 2006) and others laboratories (Callen et al., 2002; Mumane et al., 
1994) have demonstrated that superimposed on end-replication losses, telomeres 
are subjected to events that generate short telomeres.
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7.4 The mutational changes within telomere variant repeat 
arrays
Telomeric DNA sequences share some properties with simple tandem repeat 
(STRs) sequences such as length variation between unrelated individuals (Dib et 
al., 1996; Kong et al., 2002). In humans, the proximal part of the telomere is 
marked by interspersion of the canonical TTAGGG repeats with variant repeats 
such as TCAGGG, TGAGGG, TTGGGG etc (Allshire et al., 1989; Baird et al., 
1995; Coleman et al., 1999; Letsolo et al., 2009). The role of telomere variant 
repeats in telomere function is not known, however it is assumed that due to large 
variability as well as lack of binding to telomere proteins, they do not play an 
essential role, if  any, in telomere function. However, recently it has been 
demonstrated that some of the variant repeats, notably CTAGGG arrays are 
bound weakly by TRF1 and 2, and strongly by POT1 (Mendez-Bermudez et al., 
2009). In addition, like (TTAGGG)2 (Tsolou et al., 2008), telomere variants, 
(TCAGGG)2 and (CTAGGG)2 induced DNA damage reponse in fibroblasts 
(Mendez-Bermudez et al., 2009). Considering these recent findings, it is possible 
that TVR may play some role in telomere function which is yet to be determined.
The pattern of interspersion of telomere variant repeats has been examined by 
Telomere Variant Repeat mapping by PCR, TVR-PCR (Baird et al., 1995). The 
analysis of the repeats in human populations revealed that these repeats are 
extremely variable and display 98% heterozygosities (Baird et al., 2000; Baird et 
al., 1995; Coleman et al., 1999). In addition, inspection of different telomeric 
alleles using the specific primers in the telomere-adjacent DNA revealed that the 
mutational mechanisms underlying the variability in interspersion of the variant 
repeats was predominately intra-allelic such as replication slippage, and unequal 
sister chromatid recombination resulting in expansions or contractions of the 
repeat blocks (Baird et al., 2000; Baird et al., 1995). Replication Slippage is a 
mutational process in which repetitive sequences expand or contract by addition 
or subtraction of the simple tandem repeat unit (Viguera et al., 2001). The data 
described in this thesis was collected by direct sequence analysis of TVR region
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from single fusion molecules. This revealed similar mutation pattern to that 
described for human population studies consisting of contractions and expansions 
of repeat blocks as well as contractions and expansions of TTAGGG repeat unit 
[e.g. TTTTAGGG; TTAGGGG; TTA-GG, TT-GGG, T-AGGG, etc] coupled 
with transversions or transitions changing TTAGGG to another type. E.g. 
TTAGGG to TTCGGG or TTGGGG or CTAGGG or TCAGGG or TGAGGG 
etc. Superimposed on simple events, a fraction of complex events that involved 
insertion of block of repeats with no obvious origin were also detected. It is not 
known whether these infrequent events arise through inter-allelic recombination or 
through gene conversion-like processes similar to those known to generate 
diversity at minisatellites in germ-line (Jeffreys et al., 1994; Monckton et al., 
1993). However, unlike minisatellites, there are no known recombination hotspots at 
telomeres. It is clear from this data, that telomere repeat arrays are unstable structures in 
somatic cells, if this instability is reiterated in the rest of the telomere repeat array that is 
composed of homogenous TTAGGG repeats, could lead to loss of telomere function. 
This mechanism has the potential to create telomere length instability, which has the 
potential to lead to telomere dysfunction and fusion.
7.5 Conclusion
In conclusion, this thesis has assessed different aspects of telomere dysfunction 
in human cells and tissues. The knowledge of telomere dynamics in vitro has 
been translated to human tissues in vivo. This study has demonstrated that 
telomere erosion, instability and fusion previously studied in human tissues in 
vitro are physiologically relevant as these events were detected in human tissues. 
The telomere erosion, instability and fusion were apparent in melanocytic naevi 
and Barrett’s oesophagus. However, from the data described in this thesis it was 
difficult to determine if telomere dynamics play any role in melanocytic 
senescence in vitro or if telomere dynamics could be used as a prognostic 
biomarker that will predict those individuals that will progress to melanoma or 
oesophageal adenocarcinoma. However, our data has provided direct (molecular 
structure) evidence of telomere-induced chromosome fusions.
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7.6 Future work
This study has revealed very interesting findings some of which may be pursued 
further. For instance, involvement of interstitial loci near sites implicated in 
malignancies could suggest that telomere instability may be more extensive. To 
explore this possibility, development of STELA at those ends that we have 
detected fusion events involving their interstitial loci especially those implicated 
in certain cancer could indicate whether these telomeres behave differently from 
other telomeres studied so far. If these telomeres are more unstable their 
involvement in telomere fusion events could eventually result in terminal 
deletion creating double stranded breaks that could fuse with dysfunctional 
telomeres. Alternatively, the analysis would indicate whether the involvement of 
such interstitial loci is a result of telomere dysfunction at associated telomeres 
initiating chromosome instability. Whatever, the mechanism that result in these 
events, it is clear that telomere instability and fusion can be catastrophic. In 
chapter 4 of this thesis, I have hypothesised that telomere instability and fusion 
may induce activity of telomerase, if fusion occurs adjacent to genes involved in 
regulation of telomerase. For example fusion events involving the c-myc locus at 
8q24.3 could activate this oncoprotein, which in turn can activate transcription of 
the hTERT gene (Wang et al., 1998; Wu et al., 1999) on chromosome 5p. 
Although this locus (8q24.3) is often deleted in human cancers, the increase in 
copy number of 8q arm has been reported in tumours [reviewed in (Cao et al.,
2008)]. Similarly, telomere fusions involving 5p may result in activation of  
hTERT, probably through localised amplification of the terminally located 
hTERT locus [5p 15.33]. In support of this view, an increase in copy number of 
the hTERT locus has been reported in human tumours [13%; reviewed in (Cao et 
al., 2008). I therefore hypothesise that telomere fusion-breakage-bridging cycles 
involving 5p telomere could result in increased copy number at the hTERT locus 
and thus increased telomerase activity. Indeed the increase in copy number of the 
hTERT locus has been correlated with telomerase expression and activity in
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neuroblastoma (Zhang et al., 2000) and lung carcinoma cell lines (Saretzki et al., 
2002).
Evidence of telomere dysfunction resulting from hTERT deletions comes from 
the infant conditions called Cri du chat syndrome in which terminal deletion of 
5p encompassing hTERT locus is responsible for the characteristic cat-like cry in 
this condition (Laczmanska et al., 2006). Here, I hypothesise that loss of 
telomere function may lead to misregulation of telomerase activity and extended 
proliferation for cells with eroded telomeres and hence accumulation of more 
abnormalities that may drive neoplastic progression. Thus assays that target these 
loci may give insights into the mechanistic activation of telomerase, in cells that 
have bypassed senescence.
In addition, the improved telomere fusion assay appears to be a robust analysis of 
telomere-related chromosome instability at multiple chromosomes. Thus, the 
assay could further be extended to detect the fusion events involving short 
dysfunctional telomeres with fragile sites and/or other repetitive unstable loci 
within the human genome. In addition, the assay could be expanded to include 
other ends that are not detected with the current assays.
Analysis of melanocytic naevi has indicated that short telomeres are subjected to 
fusion. Thus for future investigations, the telomere length and fusion could be 
investigated in dysplastic naevi and melanoma. This would indicate the role of 
telomere biology in melanoma development. The role of telomere biology in 
Barrett’s oesophagus progression could be extended by studying telomere 
dynamics in dysplastic and carcinoma in situ tissue samples. In addition, the 
telomere length dynamics and fusion can be correlated with telomerase 
expression in different tissue segments derived from Barrett’s oesophagus 
patients. Furthermore, telomere dynamics can also be correlated with genome- 
wide chromosome instability using comparative genomic hybridisation (CGH) 
and other biomarkers such as loss of p53, pl6, FHIT deletions etc. It would be
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interesting to investigate whether the clones that display short telomeres and 
increased chromosome instability also display loss of p l6  and or p53 function. 
Thus LOH and methylation patterns can be investigated in these genes.
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Appendix
Box 2.1
The frequency of telomere fusions for each experiment was calculated as follows: 
Number of fragments on the gel detected by either the XpYp or 17p probes, 
divided by the number of input diploid genome equivalents.
[Number of input diploid genome equivalents=input DNA per reaction 
(picograms) x number of reactions (typically 6-18, rarely 36-38)/6 picograms 
(diploid genome equivalents)]. Then the average fusion frequency was estimated 
from the average of all frequencies per experiment (based on 3-5 experiments 
depending on the sample concentration).
362
Table 3A-1B. Illustrates the experiments carried out for determining the fusion frequency in MRC5 with XpYp, 17p, 21 q and/or 16p primers
XpYp:17p:21q (3 primers) XpYp:17p:21q:16p (four primers)
Amplified
bands Fusion Frequency Amplified bands Fusion Frequency
Number of 
Reactions per 
experiment
Concentration 
per reaction 
(ng)
Input
genome
equivalents
XpYp
17p XpYp 17p XpYp 17 p XpYp 17p
18 300 900000 0 3 0 3.33 xlO'6 0 5 0 5.56 xlO'6
6 300 300000 0 2 0 6.67 xlO'6 1 1 3.33 xlO'6 3.33 xlO'6
MRC5
6 300 300000 0 0 0 0 2 2 6.67 xlO'6 6.67 xlO'6
Total
frequency 0 1.00 xlO'5 1.00 xlO'5 1.56 xlO'5
Average
Fusion
frequency 0 3.33 xlO'6 3.33 xlO'6 5.19 xlO'6
A p p en d ix
3 5 9 4 1  CCATGCATTC TCCATTGATA AGACTCTTCA GTGATTTAGT TATCCTTCTC TTCTTGGTGI
3 6 0 0 1  CGAGAGAGGT AGCTTTTAAA GG. G C C G G C C C C G
3 6 0 6 1  C C C C C CC G GC C TATTA
3 6 1 2 1 GCTTGGAATA ATTCTTAAGC CAAAGGGACA TATTTTGGGG TTGCATATTC TGGTTTCCTA
3 6 1 8 1 CCATTATATT t : g g g g t g g c ATAGTTTGGT CTTATACACT GTGTTCCACT GGCAATGAAA
3 6 2 4 1 AGAGTTCTTG TTTTTCCTCC AGCAATTTGT CATTTGTTA7 AGAGCTTAGC AGTTCTAAGA
3 6 3 0 1 GATATAGACC AGCTGTGCTA TCTTTTTGTG GTTTTCAGTT CTCTAGTATG TTGAGCATCT
3 6 3 6 1 TTTTGTAAGT GTACTTGCCA TCTGTAGATC C GG G AAGTGTCTGT TCAGATCTGT
3 6 4 2 1 GTGCATTTTT .TTGGGTTG TTTAACTTAT TGTTTAGTTT TAACAATTTT TTATATATTT
3 6 4 8 1 TGAATACAAA TTCTCAGATC TGTATTTTGC AAATATTTTC TTCAATATGT GGCTTGTCTT
3 6 5 4 1 TTTGTTCTCT TGACAAGGTC TCTTCCAGAG TATAAACTGT AAATATTAAG AAATCCACAT
3 6 6 0 1 TGTCATTTCT TCTGTGTATA TCAACCTTCT GTGTCATTTG TTAAAATTCA TTACCAAACG
3 6 6 6 1 CAAAGGCACA CAGCTTTTCC TCTATAGTTT CTTCTAGAAA G G TTGCATTTTT
3 6 7 2 1 AGTGTAAGGA TGATTTTGAG G G TGTAAGTTGT AAAGTTTTCA TCTACATGCA
3 6 7 8 1 TATCATTTCT TATGGTTTCC AATTAATCAT TCCCTCACTA TTTTTGGG AGACACAGGA
3 6 8 4 1 TAGTGGGCTC TGTTAGAGTA GATAGCTAGC TAGACATGAA CAGGAGGGGG AGCTCCTGGA
3 6 9 0 1 AAAGGGAAAG TCTGTGAAGG CTCACCTGGA GGGACCACCA AAAATGCACA TATTjAGTAGC
3 6 9 6 1 ATCTCTAGTG CTGGAGTGGA TGGGCACTTG TCAATTGTGG TTAGGAGGGA GAAGAGGTAC
Line LI
3 7 0 2 1
3 7 0 8 1
3 7 1 4 1
3 7 2 0 1
3 7 2 6 1
3 7 3 2 1
21Q 2
CTACGCAGAA ACACCC GA ACTTCTCTTA 
CACGCCTGTA ATCCCAGCAC TTTGGGAGGC 
CGAGACCATC CTGGCTAACA AGGTGAAACC 
CGGGCGCGGT GGCGGGCGCC TGTAGTCCCA
AGGTGCCCCA ATCGGATGGG CGCGGTGGCT 
CGAGGCGGGT GGATCATGAG GTCAGGAGAT 
CCGTCTCTAC TAAAAATACA AAAAATTAGC 
GCTCTTCGGG AGGCTGAGGC AGGAGAATGG
Sine/Alu
CGTGAACCCG GGAAGTGGAG CTTGCATTGA GCCGAGATTG CGCCACTGCA GTCCGCAGTC 
CGGCCTGGGC GACAGAGCGA GACTCCGTCT CAAAAAAAAA AAAAAAAAAA AGATGCCCCA
3 7 3 8 1 ATCATCATTC ACTCTGCAAT AAAAATGTCA GAATATTGCT AGCTACATGC TGATAAGAAG
3 7 4 4 1 GACAAAGGGG ACATTTTTAA GAGAAACCTG GCACCATAAG TACAGATTAG GGCAGAGAAA
3 7 5 0 1 GACATTCAAA AGAGGCAGCT GCAGTAGATA CAAACGTGAC TGCTGTCAGC CTGCCTGGTA
3 7 5 6 1 TGGCGGGAAG GAGGCTGGTG CCAGAGTGGA TTCGGATTGA TCACCACACA TGTACCTCAA
3 7 6 2 1 TCAACAGTGA GGAGGTCCCA CAAGGCTAAG TGGGGCAAGT CGGGGACCTA TGGCAGTAGC
O O
3 7 6 8 1
3 7 7 4 1
3 7 8 0 1
3 7 8 6 1
3 7 9 2 1
3 7 9 8 1
3 8 0 4 1
3 8 1 0 1
3 8 1 6 1
3 8 2 2 1
3 8 2 8 1
3 8 3 4 1
3 8 4 0 1
3 8 4 6 1
3 8 5 2 1
3 8 5 8 1
3 8 6 4 1
3 8 7 0 1 .
3 8 7 6 1
3 8 8 2 1
3 8 8 8 1
3 8 9 4 1
3 9 0 0 1
3 9 0 6 1
3 9 1 2 1
3 9 1 8 1
3 9 2 4 1
3 9 3 0 1
3 9 3 6 1
3 9 4 2 1
3 9 4 8 1
CAGGAATGTG AAGAAGTCCA 
GCACTATCAG CCTACTCCTC 
TATCTTCCAT 
CATCAGCTCT 
GATGGGGATT AATAACTGGC
AGGAAAACGA AAGAAAACAG GCGGAGACTT GAGACAGAGG
AAATAAAAAT CCCTGCACAG GACTCTTAGG CTGTTTTCAT
CCTATTTTTG TACTATAAGC TCTTTACTCT GTATTTCTTT TCAATGAAGT
CTTTGTACTG CCTCTTGGTG AAAAGCTGTC TTCCAAGTTA ATAACTGGGA
CCGCAGTAAT AGCTCCTTTT CAGTTTTAAT TTACAGAACT
GCTCTGACTT TAAGTGGTGC AGGAGGTGGC CAGTAGGGGA CGGCAGCCGT CACACCGGGA
GCAAGAGGGC CCTGCGTAGT CCCCATGTGC CTGCATGTGG CGTGCAGCCA CGACAATGCC
AGCAAGAGGG CCCGGCACTG TGCCCAGCTG CCAGCAGGCG GGTGTGCTGC CACTACAATG
TGAGGAAGAG GGCTCTGCAA TGTCCCTAGC TGCCAGC -GG CGGCGTGCCA CCACTATACT
1 0q 2
GCGAGCAAGA GAGCCCTGCC GTGCCCCGGC GCTAGCAGGG GGCGGTGGAC ACCACTGTAA
ACAAGAGGGC CCTGCAGTTG TCCTAGTCGC CAGTAGGGGG CGCAATGGCA GAGCACCGTG
2 1 q 3
GGCAAGCTGG TCCTGTAGTG CCCGGCTGCA AGCAGGGGGC 
ATTACTCAGG TTCCACTCGT CTCTGCGCCG CCGGGGACGT
GCCTCACTCC CGCCCGCCCA 
GCCCIGTGCC GCGTCTCCCC
GCCCAAAACG GGCTTTTCAG 
GTGTCTCTGC GCGTGCACCG 
GCGCTCCCCG CCCGGCGGCG CGCGACTGTG CGACTGCAAC ACTCCCCGCC 
GAGCGACGTG CGTCTCTGCG CCTGCGCCGC 
CCCTCCGGGG AGGCGCCGGC GTGCGTCTAT 
CGCCTCTCTG CGCCTGCGCC GGCGCGCCGC GCCTCTCTGC GCCTGCGCCG 
CCTCTCTGCG CCTGCGCCGG CGCGCCGCGC 
TCTCTGCGCC TGCGGCGGCG CGCCGCGCCT 
TCTGCGCCTG CGCCGGCGCG CCGCGCCTCT 
GCGCCTCTCT
CGCCACCCCC 
ACCCTCAGCC 
GCGACCCCTC 
AACAGCGCCG 
GCGCGCCGCG 
GCGCCGCGCC 
GCCGCGCCTC 
CGCGCCTCTC TGCGCCTGCG CCGGCGCGCC
CTCTCTGCGC CTGCGCCGGC 
CTCTGCGCCT GCGCCGGCGC 
CTGCGCCTGC GCCGGCGCGC 
GCGCCT GCGC CGGCGCGCCG
CGCCTCTCTG CGCCTGCGCC GGCGCGCCGC GCCTCTCTGC GCCTGCGCCG GCGCGCCGCG
CCTCTCTGCG CCTGCGCCGG CGCGCCGCGC 
TCTCTGCGCC TGCGCCGGCG CGCCGCGCCT 
TCTGCGCCTC CGCCGGCGCG CCGCCTTTGC 
ACCCGGAGAG CATCGCCAGG GCGGAGCTGC
CTCTCTGCGC CTGCGCCGGC GCGCCGCGCC
CTCTGCGCCT CCGCCGGCGC GCCGCGCCTC^
GAGGGCGGAG TTGCGTTCTC TTTAGCACAC
GTTCTTCTCT GCACAGACTT CGGGGGTATT
GCGAAGGCGG AGCAGAGTTC TTCTCAGGTC AGACCTGGGC GGGCGGGCTG AGGGCACTGC
GAGGGCGGAG CTGTGTTCTG TTCAGCACAG ACCTGGGGGG TACCGTAAAG GCGGAGCAGC
ATTCTTCTCA GCACAGACGT TGGGGGTACT
CGACGGTGAA TAAAATCTTT CCCGGTTGCT
AGAATGGTTT AGTGTGGAAA GCGGGAAACG AAAAGCCTCT
Satellite
GCATGGCTTT GGGACAACTC 
GCCCTGAATA ATCAAGGTCA
3 9 5 4 1  T . CTCCCAAG 
3 9 6 0 1  ATGCAGCATT 
3 9 6 6 1  GG
GCAAGGCGAG GGGCTGTATT 
CCTAATGCAC ACATGACACC CAAAATATAA
GGGGCTGCAT 
CAGACCAGTT 
CTGAATCCTG CGCACCGAGA 
S u b t e l2
GCACGGTTCA ACTGCAGCGT CGCAACTCAA 
CAGACATATT ACTCATGGAG
Start o f telomere 365
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Figure 3A-1: Telomere adjacent DNA of 21q telomere. The primers are indicated 
with grey highlighting and underlining. Different repeat regions are indicated. The 
numbering of the nucleotide is based on accession number (AP001761).
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. GGG ; GGG • GGG ' GGG ' GGG ' G G G . ' GGG : GGG GGG ' G G G . GGG ■ .G 
G • GGG • GGG GGG ' G- G:  ' GGG GGG G GGG GGG ' GGG GGG G GGG '
GGG- GGG G GGG ' GGG G GGG GGGG GGG GGG GG G GGG G G GG G
GG GGG ' GGG GG GGG GGG GGG ' GGG . GGG G G G . ' GGG GGG 
GGG ' GGG G G G .': GGG. GGG ' GGG GGG ’ GGG GGG G GGG GGG
TC A G G G : G GGACCCTI G C- G GG G G G G GG G G GGG -
G G : GGCCCCGCTTCCTCACTGGAAGGAGATGGTGCTCTTCTTTTTTCTTTCTGAATTGTGGCCACCTTCA  
TACCAGTCTGTCATGGAACACTTAAGCCGCTTGAGTGTCTGCTGGTACTCCCAGCCCTGCCATGCCTGAG  
CCCCCTGCACACAAGGAGCCAGGAGTAATCAGGGCAGACCCATTAGGGCACGGGGACTTCTGGATTGTGA  
AATTGGCTCTCTGGGGGCCAAGGCCTTCTAACGTTGGTGGAAGTGGCTTTGGCTTATTGGGTCGGATTCT  
AGGCCATTCGTTCCAACCTTTAGAGACATCCCAGCTTTCCCTAGCCCAGAGTCTGCAGCCCCTCCACCAT  
CCCACATCCTCCCCCTCCCTTTCCTCATGAACCCCAGTCGCGCCTCTGCCTTCTCAAACCCCTCCACCAT  
CCCACACCCTCCTCCTGCCCTTCCTCATGAACCCCAGTCGCGCCTCTGCCTTCTCATCCCTGCGCACCAC  
ACAGGCTCGCTCGTGCCCGGTGAATGCTGAGGCTGCTCTGCACGTGGAGTGTGGCCCTGTGGGCAAGGGC  
: GGGCTCTTGGAGGTAGGGGAGCTACAGGGGCGACTGGGAGGAGGATGTTGTGTTACACACGCATCAGAG  
TTAACTTTGCAGTGAGAGCGGCCTTGCTGCGGCCAAAGAACATGGAAAAGCATGAGTGGGGTGATGTGCC  
TTAAAGCATCAGACACTTGGGCCTCGGGCATCAGGAGCCAGCCACAGGGATGTCTGGGGAAATGGCGTTC  
CAT GAGAT GC AAGC ACAC AAGAAT GCACT T GGC ACAT CT GGGGAAC AGC AGGC AGCT GAT AT CACT GGGC 
CCACCCCGCACCAGGGAGGATGGAAGCAGGTGAGGAGCTAGACCACACTGAGGCGGTGGTCGGGACTCAG  
AGTTTGCTCAGTGAGCCGTTCACTAGGTGCAGGGGCAGTTCCCCGTCTGAATTTAGGTGACGACACTCAG  
GTCCAGCCTTGCCAGTCTCAGCCTCCGGTCTCCGTTCCCCCTCTGCAGAGGTCACTTTGTCTGCTGCACG  
TGATCATGAGGGGTTGTGAAGTGCTTGCCCCATCAGTAGCCATGTGTGCATGTGTAAATACCATCCTCTG  
TGTGCCCTGGAGGCTGTCCTTCAGATAGCATGTACAGGTGGCAGCATAGGGCCTGTCCCTAGTGAGAGTG  
CAGGGAACTCAGCACCGTCAACTCCTCGACCCTGCAGGTCAGATTATCCTTGTAGAGGCCCCCTGGATGG  
CACCAAGATCGGCCCTGGCAAGCAGGTGACCCTGACTTCAGAGCCCTTGCCTGAGGGCCTGGCCTGGCAG  
CTCTGCTGTTAGAAGCAGGAGGTGTGCAGGGGGTGGGGAGCAGCCCAGCCTCTGTGATCTTCTCCATGGC  
AGGATCTCCCAGCAGGTAGAGCAGAGCCGGAGCCAGGTGCAGGCCATTGGAGAGAAGGTCTCCTTGGCCC 
AGGCCAAGATTGAGAAGATCAAGGGCAGCAAGAAGGCCATCAAGGTAGTCCCCATGCCCCTGTGTCCTGA  
GGCTACTGGGCAGTCCCTCTATTTCCCCGTGCCTCTGAGGCTGCCCAGTCTCTGCCCTGCTGCCCACCTG  
TACCTTGGGCTTTCTTCTCGCCCAGGCTTCCAACTCCACCCTCTCCTGCCAAGCAATCCTAGCCCTCTGA  
GCCTCTTGGGGCCCCCTCAGACTTGTCCCTGTGTCCACAGGTGTTCTCCAGTGCCAAGTACCCTGCTCCA  
GAGCGCCTGCAGGAATATGGCTCCATCTTCACCGACGCCCAGGACCCTGGCCTGCAGAGACGCCCCCGCC  
ACAGGATCCAGAGCAAGCAGCGCCCCCTGGACGAGCGGGCCCTGCAAGTCTGCTGGCTGCGCACATAACT  
TAGCCTGTCACACACCAGGAGGACTGGATACTGGGGAGGAGCCGGGGCCACCAAGGGTTCTGTCCCCCAG  
AGGAGGCTGACTGGGATGGGGTGGCAGCTGATTAGGCCCAGCACCAAATATTCACCATCCCTTGGCCATC  
CTGGCCCTCCCAGGAGAAGCTGAAGGACTTTCCTGTGTGCGTGAGCACCAAGCCAGAGCCCGAGGACGAT  
GCAGAAGAGGGACTTGGGGGTCTTCCCAGCAACATCAGCTCTGTCAGCTCCTTGCTGCTCTTCAACACCA  
CCGAGAACCTGTATGGCCAGAAGGCAGGGCCGAGGGGTGTGGGCGGTAGGCCCGGCCTGGCTTAGTGGGG  
ACCCAGGGCATCAGACACAGGTACAGCACATAGCCCAGGAGCCAGGGGGTGACTGGGGTGGCTCGGCTCG  
GGAGGCCTGGGACCCCAC AGT GCACAC T GTGCCCCT GAT GAT GT GGGAGAGGAAC ATGGGCT CAGGACAG  
CGGGTGTCAGCTTGCCTGACCCCCATGTCGCCTCTGTAGGTACAAGAAGTATGTCTTCCTGGACCCCCTG  
GCTGGTGCTGTAACAAAGACCCATGTGATGCTGGGGGCAGAGACAGAGGAGAAGCTGTTTGATGCCCCCT  
TGTCCATCAGCAAGAGAGAGCAGCTGGAACAGCAGGTGGGAGGGGCGGGACAGAGGTGGAGATAGGTGCA  
6 8 2 5  GTGGCCCAGGGCCTTGCCAGAGCTCCTCTCCAGTCAAGGCTGTTGGGCCCCTTATTCCACCCATGGGAGG  
6 7 5 5  TGCACACAAGGTCTTGTTGGCTGCCCCTGCAGGTCCCTGTCACCTCTCACATGTCCCTGCCTAATCTTGC  
6 6 8 5  AGGTCCCAGAGAACTACTTCTATGTGCCAGACCTGGGCCAGGTGCCTGAGATTGATGTTCCATCCTACCT  
6 6 1 5  GCCTGACCTGCCCGGCATTGCCAACGACCTCATGTACATTGCCGACCTGGGCCCCGGCATTGCCCCCTCT  
6 5 4 5  GCCCCTGGCACCATTCCAGAACTGCCCACCTTCCACACTGAGGTAGCCGAGCCTCTCAAGGTAGGTGAGC  
6 4 7 5  TGGGTTCTGGGATGGGAGCTGGGCCGGGGACCTCCCTGCTCACACACCTTCTTCCCTAGACACCCCACAC  
6 4 0 5  TTTGTGTTTCAGACCTACAAGATGGGGTACTAACACCACCCCCACCGCCCCCACCACCACCCCCAGCTCC  
6 3 3 5  TGAGGTGCTGGCCAGTGCACCCCCACTCCCACCCTCAACCGCGGCCCCTGTAGGCCAAGGCGCCAGGCAG  
6 2 6 5  GACGACAGCAGCAGCAGCGCATCTCCTTCAGGTGGGAGCAGCTCTTTGAGGCCACCTGATTTCTGGCGTG  
6 1 9 5  CTCAGTGCACTCGGGTGGATTTTCTGTGGGTTTGTTAAGTGGTCAGAAATTCTCAATTTTTTGAATAGTT
6 1 2 5  t c c a t t t c a a a t a t c t t g t t c t a c t t g g t t c a t a a a a t a g t g g c t t t c a a a c t g t a g a g c t c t g g a c t t c
6 0 5 5  TCACTTCTAGGGC 15 GGGAGCCTG^CAAGTGAGGCTCTGGGTTCCTCATTCCTAATTAA.ACCAATGGA  
1 6 p l
5 9 8 5  AAGAAGGGGTCTAATAACAAACTACAGCAACACATTTTTCATTTCAGCTTCACTGCTGTATCTCCCAGTG  
5 9 1 5  TAACCCTAGCATCCAGAAGTGGCACAAAACCCCTCTGCTGGCTCATGTGTGCAACTGAGACTGTCAGAGC
1 6 p 2 ___________________________
5 8 4  5 ATGGCTAGCTCAGGGGTCCAGCTCTGCAGGGTG.-'-.GGGCT; G -G GG - G" GGG G T A T C : GCACACAGG 
5 7 7 5  ATGCCCGCGCTCAGGTGGTTGCCGAAGTCAGTGCCCGGGCCCCACACAGTCTCCAAAGGTCCGGCCTCCC
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5 7 0 5  CAGCGCGGGGCTCCTCGTTTGAGGGGAGGTGACTTCCCTCCCAGCAGGCTCTTGGACACAGTAAGCTTCC  
5 6 3 5  CCAGCCCTGCCTGAGCAGCCTTTCCTCCTTGCCCTGTTCCCCACCTCCCGGCTCCAGTCCAGGGAGCTCC  
5 5 6 5  CAGAGAAGTGGTCGACCCCTCCGGTGGCTGGGCCACTCTGCTAGAGTCCATCCGCCAAGCTGGGGGCATC  
5 4 9 5  GGCAAGGCCAAGCTGCGCAGCATGAAGGAGCGAAAGCTGGAGAAGCAGCAGCAGAAGGAGCAGGAGCAAG  
5 4 2 5  GTGAGCGGGCCCTGGAGCCTGCGGTCGGAGGGCCTTTGGGCAAGATCGCCTCCTCCCCTCCAGCCCTGAG  
5 3 5 5  TCCACCGGGTGCTTTCTGCCCACCCCCTGCTCCTGCCAGCTGGCCCCTGCTTCCCCTAGGGCACATGCTG  
5 2 8 5  GAAGCCCTGGGCCGCCACCAGAGGTCCTCAGCCCTCCTGCCTGGGCTATGGCTCCTTCCTGGTTTGGGM
__________ 1 6 p s e q l r e v ___________
5 2 1 5  CCATAGTGGAGCTTTCCTCTCTAAGCTCACCCAGCTCAAACTGTGACAGGAGAATCTTCTTCGACTGCCA  
5 1 4 5  AGAGCGGTCCAAGGCAATGGTCAGCCACTGCAGCCTCCTGAGATATTTTTAGAGACTGGACCTGAGGCCT  
5 0 7 5  CTGGAGGCTACTGATGATGCCTGCTGTGAACGCAGACACTGGTGTGATGCGATGCCTGCGCCTGCAGCGG  
5 0 0 5  CAGTGCCCTGGGCACTATGGTTTTGAGCTTGTACCCAGCGCTGCTTTTGCCTTGCTCTGTGACCCCAGGC
1 6 p s e q l _______________________
4 9 3 5  AAGCTGCCTCACCTCTCTGGGCCAGTTTCCCCATCGTACAGTGGTGCTGCACACCCTGGCCCTGTCCCCG  
4 8  6 5  AGGTGGCTGGGAGGTGGCTCCTCAAACAGCCACTTTCTCATCAGTGCCCGGTGCTGGGTCAGGCATCGAC  
4 7 9 5  TGAGGCTCTGAGCTAACTAGGAAACACAGTGGCCTTGGAGGGCTGGGGAGTGTCATGGGGGTGGGGACAG  
4 7 2 5  GGAGCCACCGGTCGCATGTGACTGAACTCTTCACCCCAGTCTGTGGCTTTCCCGTTGCAGTGAGAGCCAC
1 5 q s e q l __________
4 6 5 5  GAGCCAAGGTGGGCAC . : G. TG GG TCTCTTCAACAAGCTGGTCATGAGGCGCAAGGGTAGGAGGCAG  
4 5 8 5  GGCCGCTGCCCACCCTGGGCCGGCACATTGTAATTCTGTCCTGCCTTTTTCTTCCTGTATTTAAGTCTCC  
4 5 1 5  GGGGGCTGGGGGAACCAGGGTTTCCCACCAACCACCCTCACTCAGCCTTTTCCCTCCAGGCATCTCTGGG  
4 4  4 5  AAAGGACCTGGGGCTGGTGACGGGCCCGGAGGAGCCTTTGCCCGCGTGTCAGACTCCATCCCTCCTCTGC  
4 3 7 5  CGCCACCGCAGCAGCCACAGGCAGAGGACGAGGACGACTGGGAATCGTAGGGGGCTCCATGACACCTTCC
 X q Y q s e q 2 ____________
4 3 0 5  CCCCCAGACCCAGACTTGGCCGTTGCTCTGACATGGACACAGCCAGGACAAGCTGCTCAGACCTGCTTCC  
4 2 3 5  CTGGGAGGGGGTGACGGAACCAGCACTGTGTGGAGACCAGCTTCAAGGAGCGGAAGGCTGGCTTGAGGCC  
4 1 6 5  ACACAGCTGGGGCGGGGACTTCTGTCTGCCTGTGCTCCATGGGGGGACGGCTCCACCCAGCCTGCGCCAC  
4 0 9 5  TGTGTTCTTCTCTTAAGAGGCTTCCAGAGAAAACGGCACACCAATCAATAAAGAACTGAGCAGAAACCAA  
4 0 2 5  CAGTGTGCTTTTAATAAAGGACCTCTAGCTGTGCAGGATGCAAACGTCTCGGGGTCAGTGACTGCCTCCT  
3 9 5 5  GCCCCTGTTGGTCCCTAGGCAGTGGGGGCAGAAGCTCCCAGCTGACCTGTTTCTCTGGGATGAGAGGG G
l p s e q l A
3 8 8 5  G G G . GGG G -G . ' G ' GGGG -.GCTGTTGCAGATGGGAGGAATAGTCTCCCACAAAAAAGGTT|CAG  
3 8 1 5  TGACAGAC/.CGGGGTCTCTAAAAATAGTCATGCTGAGAGCCTAATGGCCCTTGGCACAATTGCTGGTGTT  
3 7  4 5 GGGG G G G  GG AGTTTGCTCACGTGGTTGAGAGGGAGGGAGGTGCCATCGACTTGGAGGAAC
3 6 7 5  TGGCACCAAGCCAGGGAGATAGAAATCCAGGCAAGGCTGTGGGGCAGGTTAGGGAGCAAGGCTGCAGGAG  
3 6 0 5  TGACTCAGGAAGAAGGTGGGGGAGGTGACAAGCCCCCAGGCAGGGGCCCTGTGGCCATGGGGATCTTTTT 
3 5 3 5  AAATGGAGACTAGGGGGTGAATAGTCCAGGGCAGCTAACTTTAGTTATTATAGAAAGGGCAGTAGCAGAT  
3 4  6 5  GGGTCTGCTCCGTCTCGCTTCTAAGAAGGTGGGCAGGACAAATGGCAGCCTCCTGCAGAGGCCCAGTGAG
3 3 9 5  a a g c c t g g c c c t c g g c c a c g c a g g a t g g a a g a c a g a t t g g a t t c c a c a g a g g g g a g c t g c c c t g g g a a g a  
3 3 2 5  TCTCACGGATGGCCAGGACCCACCATTTCTTCGGGATTCCCCTGTTTTCTCCAACGGGCACTAATGCCTG
1 6 p s e q 4 _____________________
3 2 5 5  TGCCTGGGTCCTGGCAACACTCTGGATTCCACACTCTCCTGGGTTTCACCTTTGTAGCAGGATCCCTGCA  
3 1 8  5 GACCAGGCCCA G ''GTCTCCAGCGGGCAGAGCAAAGGAAGGGCGCAGCGCCAGGCAGTGGTG
3 1 1 5  CAGCTGCCTGTCAGGAAGAGGCCTACTTCTGGTGAAACTGGGCAGACAAAAGGCAGTGAGAAATGTGATC  
3 0 4  5 TCGGGGTGGTGGAGGCTCTAGGGAAAGGAAAAGGCAGGAGTGAACTTCCACACAGCAGCAATGGCAGAAC  
2 9 7 5  CAAAGGTTGCTTTGACCTCCACGAGGGCTCAGATTCAGGCCAACAGCCTGTCCAGGACAGGGTGCCGGGT 
2  9 0 5  g t a t c a c t g g t c c a g g a g c a c t a t g c t g g c a g a a t c c c t t t g g t g c c t g a t g g c c c t g c c t t c a t g g g a a  
2 8 3 5  CAGAGGCTAAGGCTTTGAGTTACAGCTGCCTCCCCAACAGTGCATCCCCTTCTCCTTCCTCAGCCTCAGG  
2 7  6 5  TAGGAGACAGGGCAGGCAACTCCCCTTTCCTCTTCTCCCCTTCTCCAGCCCCTGTCTGTCCACCCAGCTG  
2  6 9 5  GAGGCAGCCAGGCTTGCCTATGGACTGGTTGACAGCCTTCATGCACAGGTTCTCCACCAGAGCCTTTCTT  
2  6 2 5  GGGGGCCCCTGGCCTGGGCTCTGAGCTGGGAGTGAAGGGGATGACCCATGCGGACTGTTTGCTGCTTATA  
2 5 5 5  GCTTTCCCTGGGAAAGACTCTGCCAGGCCTTGGAGCCAGACCAGGAGGCTTTATAGGCCACCGCAAGCAG
________ 1 6 p 2 s e q 2 B ______^
2 4  8 5  CAGGGCTCCAGATGACATCACAGGG GAGCAAGAGGGTGTGGAGGGGCATCGAAGCCTCTCCAGGAGAC 
2  4 1 5  AGGAGACGCCGGCCCAGTAGAGCCCTAGGGGTGACGCCACTCCCACTCACTGTCGACTCTCCTCTCACCT  
2 3 4 5  CTGCAACACTGGGGACACTCACAAGAGTGTGATCCAAGTCGGCCGTCGTCTTCTGCAGCTCTGGAGACCT  
2 2 7 5  GATGCTGGGGAAGGGCATGCCTGGCATCACCACACACCTGGGGGGAGACAGGAGCCTGGGGCCGGTGGGC 
2 2 0 5  CCACACATCACCAGCTGCTCCGTTCTACCATTTCTTCAGCCCTCTTGGCTGTGCCTGCGGCTCTGCCCCT
<4__ 1 6 p s e a 4 r e v ________
2 1 3 5  CCCCTCTCTGCACCTACCACCCAGAGAGGGCrr G : G. GCTCAGAGATCCCACCTAGGCCAATCCACTGG  
2 0 6 5  GTTCTGCGGCAGCGATGGCCTGCCTGATCTTCCACCTGCTCTCCCAGGGCCAAAGCCAGACCTGCTGAGC
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1 9 9 5  CCCTCCCTCCAGCCGGCTGGTCTGAGCAGTCACAGCTCGGCTTTGGGCTCCGATGGCAGCAGACGGCAGG
^ _________ 1 6 p s e q 5 r e v __________
1 9 2 5  TAGGGGTCCAGCTGCTGGAGCGAGGGCCGGCCACGTATCACAGCCAAGGAGATGAGCACAAGCACTACTT 
1 8 5 5  ACTGGCCTAGGTTGTCAGAGAAGTTGATGCTCTCACTCATCTTTCCTCCAATCTTTCCCGTATGCCTGGT  
1 7 8 5  TGTGGTATTAAGTTACATGCAGACAACAGGGGCCAGAAGATGAACAATGGCCCATCCCACTCTAGGCATG
_____________ 1 6 p 6 ____________________ ^
1 7 1 5  GCTCCTCTCCACAGGAA.AACTCCACTCCAGTGCTCAGCTTGCACCCTGGCACAGGCCAGCAGTTGCTGGA  
1 6 4 5  AGTCAGACACCTGCAGATCAAGACCACAGCATCAAGACCCTGTGACCTCTCAAAGGCCCGGTGGAAAGGA  
1 5 7  5 CACGGGAAGTCTGGGCTAAGAGACAGCAAATACACATGAAGAGAAAGAAGAGGTCAAAGAAAAGGCTGAC  
1 5 0 5  GGCAAGTTAACAAAAAGAAAAATGGTGAATGATACCCGGTGGTGGCAATCTCGTTTAAACTACATGCAGG  
1 4 3 5  AACAGCAAAGGAAATCCGGCAAATTTGCGCAGTCATTCTCAACACCGGCCATGCAGCAAAATCATCAGTG
1 6 p s e q 3 _________
1 3 6 5  GAAATTTAAAAAAATACACATGGCCAGGCCCCAGCCCAAATGACTAATAAGAATCTCCAGGGCTTCACCT  
1 2  9 5  GCTAGACTGGCAAAAATCCAAAAGTAAACACTTTGTGGAGAAACAGGTATTCCTAGACATTGCTGGTGGG  
1 2 2 5  AT AC AGAAC AGTATAAT T CT GAT GGTAAT CAGT T AAC AAATT AAACAT AT T T AT T T T AT ACT TT T AAAC C 
1 1 5 5  CAGGAATCCCATATTTAGGAGTCTACTGAGACCAAACAGCATATGCTCCGGGTGTTTCCCTATAATCCGC  
1 0 8 5  CACTACTGTTGGAGCAAGAGGGCCCGGCAGTGTCCCCAGCTGCCAGCAGGCGGGCGTGCTGCCACTACAC
 1  ►
1 0 1 5  2 rTGAGCAAGAGGAGCCTGCAATGTCCCTAGCTGCCAGCAGGCGGCGTGCCACCACTATACAGTAAGC.-. 
9 4  5 G.- .GGGCCCTGCAGTGCCCCGGCGCC.- -GCAGGGGG'-'GCTGGCCACC/.C' C G . G G -.GCCCTGCAG".
T 2 1 q 3
8 7 5  TGCCC G CGCCAGCAGGGGGCGCCC: GGCACA GCACCG. GAGCAAGCGGGICCTGTAG GCCCGGCTG 
8 0 5  ■■.■-.GC.-.. GGGGCGGl CGATCCCGGCTTTTCGGATTACTGAGGTTCCACCCGTCTCTGCGCCGCGCCACCG
7 3 5  TGACGTGAGTTTCTGCGCGTGCAACGGCGCCCCCCACCCCCCGCCCCCAGGCCGGCGCCGTGCGACTTTG
6 6 5
5 9 5
CTCCTGCAACACACGCCCCCCCAACCCCCGCCCGTAGGCGTGCGTCTCTGCGCCTGCGCCACGCCTCCAC
1 6 p 5
CCCTGGACGCGCT G GTGTCTC" GCGCC" GCGCCGGCGCGGCGCGCCCCTCTGCGCCTGCGCCGGCG
29bp
repeat
5 2 5 GG G G G ’ ’ G G 3GGCGGAGTTGCG7 ."CTCCTCAGCACAGACGCGGAG-'-.GCACCGCGAGGGCGG
4 5 5
X q Y q s e q l
AG CTGCGTTCTCC11TGCACAGA1 : : CGGTGG A 'C  7GCGAAGGCAGAGCAGAGTTCTGCTCAGGTCAGAC
37 bp 
repeat
3 8 5 CCGGGCGGGCGGGCTGAGGGTACTGCGAGGGCGGAGCTGCGTTCTGCTCAGCACAGACCTGGGGGTCACC
3 1 5 GTAAAGGTGGAGCAGCATTCTGCTAAGCACAGACGTTGGGGGCACTGCCTGGCTTTGGGACAACTCGGGG
2 4 5  CGCATTGACAGTGAATAAAATCTTTCCCGGTTGCAGCCGTGAATAATCAAGGTCAGAGACCAGTTAGAAC
S u b t e l 2 __________________ ^
1 7 5  GGTTCAGTGTGGAAAATGGGAAACTAAAAGCCCCTCTGAATCCTGGGC-CCGAGATTCTCCCAAGGCAAG
___________ 1 5 q A ( p o s i t i o n )
1 0 5  GCGAGGGGCTGCATTGCAGGGTCCAGTTGCAGCGTTGAAACACAAATGCAGCATTCCTAATGCACCCATG  
3 5  ACAGCTAAAATATAACACCCACATTGCTCATGTGGT 1 GGG. G GGG G .GGG GG GGG GGG 
___________ GGG V GGG GGG
Figure 3A-2. The telomere adjacent DNA of one allele of 16p, accession number 
(NT 037887.4). The oligonucleotide primers used for telomere fusion assay and sequencing 
are orientated 5'-3' towards the telomere (highlighted in grey), the arrows indicates the 5'-3' 
orientation of the reverse primers. The position for the STELA primer for 15q telomere is 
highlighted in yellow. The distance of nucleotide from the start o f the telomere array is shown 
on the left. The position of the repeat region is shown with underlining.
1 5 q A : A T C GGAAC GCAAAT GCAGCAG
2 9 b p : CTCTGCGCCTGCGCCGGCGCGGCGCGCCC
3 7 b p : ACTGCGAAGGCAGAGC. GAGTTCTGCTCAGGTCAGAC
6 l b p : GCCACTACTGTTGGAGCAAGAGGGCCCGGCAGTGTCCCCAGCTGCCAGCAGGCGGGCGTGC
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21 :X
XpYp
probe
: !
Subtel2:X Subtel1:X 16:X
:-8 kbw
:#
9
9
9
*-2kb
Frequency 5.25x10*5 3x10*5 1.5x10*5 1.5x10*5
B
21:17
f I
17p
probe
Subtel2:17 Subtel1:17 16:17
-8kb
P
0  -2kb
Frequency 7.13x10*5 2.25x10*5 1.13x10*5 1.5x10*5
Figure 4A-1. Examples of single molecule telomere fusion gels in HEK293 for 
detecting fusion events between XpYp (A) or 17p (B) telomere and telomeres of 2 1 q 
(panels 1, 2) and 16p (panels 3, 4) families. Each reaction contains lOng o f DNA, 
fusion products were detected with XpYp, and 17p probes respectively. The oligo­
nucleotide primers used for each assay are shown above each gel, 21 represents 
21 q l, 16 represents 16pl. The frequency at which fusion was detected is indicated 
below each gel. Molecular weight markers are indicated on the right.
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Figure 4.A-2. Extensive DNA sequences for the telomere fusion events. A) XpYp:21q 
fusion showing long arrays of TTAGGG repeats at fusion junction. B ) 17p:10q showing 
fusion with TTAGGG on either side of the fusion point. C) fusion of 17p to the intestitial 
locus 2ql4. D) XqYq:8p fusion. E) XpYp:8p showing fusion at the proximal part of the 
telomere. F) 6p:XpYp, an example of an event with insertion from intestitial locus of same 
telomere (Xp22.1) in reverse orientation.
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TAG G TCCA CTTTC AG AG G G TTAG G G TTA G G G TTAG G G TTA G G G TTAG G G TTTA G G G TCAG G G TTA
GGGGTTAGGGTCAGGGTCAGGGTCAGGGTCAGGGTCAGGGTCAGGGTCAGGGTCAGGGTCAGGGTC
AGGGTCAGGGTCAGGGTCAGGGTTAGGGTCAGGGTTAGGGTTTGGGTCAGGGTTAGGGTTAGGGTT
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT
AGGGTTAGGGTTAGGGTTTGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT
AG G G TTAGG G TTAG G GACATG G CAG ACCCTCTTCCTCACATTGTAG TGG CAGCACACG CG CCTG CT
T x 4 3  X p Y p  +— —r  *  A -1 4 8 4  b p :2 1 q  
_ -1  17p tel start
GCTGAGGTGGGTTAGGGTTAGGGTTCGGGTTCGGGGTTCGGGTTCGGGGTTCGGGTTCGGGTTCGG
T x 2
G TTCGGGGTTCGGGTTCGGGGTTCGGGTTCGGGTTCGGGTTCGGGTTCGGGTTCGGGTTCGGGTTC
GGGTTCGGGTTCGGGTTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGCTAGGGGTT
T
AG G G TTA G G G TTAG G G TTA G G G TTAG G G TTA G G G TTAAC CCTA ACC CTAA CCC TAAC CCTTA ACC C
Tx63/6 m ^  * Tx33/6
17p 10q
T T A A C C C TTAAC CCTT AAC CCTA ACC CTTAA CCC TTAAC CCTA ACC CG AAC CCG AA CCC G A CCC CG
v---------------------   '  T
AACCCGACCCCTAGCCCTAACCCGAACCCG AACCCG AACCCGAACCCG AACCCG AACCTG AACCCT
T  ' '  ^
AACCC TCCA TG A G TA ATATG CC TG TTATATTTA G G G TG TCATG TG TG C ATTA G G AA TG C TG C ATTG  
-1
 10q  tel s tart______________________________________________________________________
C)
. . . G TCCTG CCTTTTTCTTCCTG TATTTAAG TCTCCG G G G G CTG G G G G AACAG G G TTTCCCACCAA  
CC A C C C T C A C T C A G C C T T T T C C C T C C A G G £T A A C C C T A A gC T A A C C T A A ,C C C T A A C C C T A A C C C T A
A -4 0 7 1  b p :2 q 1 4  intestitial < * T x  1 a / q  ^ ^  T x 7 ~
AC CCTA ACC CTAA CCC TAAC CCTA ACC CCTA G C CCTA G C CCTA G C CCTA G C CCTA G C CCTA G C CCT  
AGCCCTAACCCGAACCCGAACCCGAACCCGAACCCGAACCCGAACCCGAACCCGAACCCGAACCCG  
AACCCCGAACCCGAACCCCGAACCCGAACCCGAACCCGAACCCCGAACCCGAACCCCGAACCCGAA  
C C C T A A C C C T A A C C C T A C T C A G C T T T C A A T T C T T A A G T A G C C . . .t
1 7p  tel start
P i  . TGATGTCGGATCTCTTCAACAAGCTGGTCATGAGGCACAAGGGTAGGAGGCAGGGCCGCTGCC  
CG CCCTG GG CCGG CACCTTG TAATTCTG ACGG G GCACG G CAG G GCTCTCTTG CTCG CAG TATACTG
A-4737 b p :  XqYq *  * -974  b P : 8P
G CG GCACG CCGCCTG CTG ACAGCTAG GG ACATTG CAGG G CCCTCTTG CTCACATTG TAG TG G C. . .
E ) .  . CAAAG G GG ACATTCCTAAG AG AA ACCCTAAACCCAACCCCAACCCCAACCCTG ACCCTG ACCT
A-2 0 5 4  bp: 8p  w V x 1 0 3/ 7
X p Y p
TG ACC CCG AC CCC TAAC CCTA AAC CCTA ACC CCTA ACC CTAA CCC TACC CCTA G C CCA AAC CCG AA
T  V  T
C C CG AAC CCTA A C C C TA A C C C C TA A C C C TA A C C C TA A C C C TA A C C C TA A C C C TC A C C C TA A C C C TA  
A C C C T C A C C C T A A C C C T A A C C C T C A C C C T A A C C C T A A C C C T A A C C C T A A C C C T A A C C C T A A C C C T C  
A C CCTA A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC A C C C TC  
A C CCTC ACC C TA A C C C TC A C C C TA A C C C TA A C C C TA A C C C TA A C C C TA A C C C TC A C C C TC A C C C TC  
A C C C T C A C C C T C A C C C T C A C C C T C A C C C T C A C C C T C A C C T T C A C C C T C T G A A A G T G G A C C A A T . . .
+  s tart of X p Y p  te lo m e re
F)
. . . C A G T G TC C TTA G C TA C TTA TTTC A A TC A C TG TTC A TA A G A G A TG TTTT C C A A A G G  CACTTCAAG
A -9 0 0  bp: 6 p  *  X p 2 2 .1
CA TCG TTTAG AG G AAG TG G TA G C CCA G A TG TTA TG G AA G TCTCG G TTAAC AAC AAC TTAG AAA TG TC A
G C T A C TTA G TG C TC A TC C TC A G A G A A C TTG G TG TC A T TTG A A TG C C TTG A C C TC TC C TTC C TG TA TC C
CTCATG CCTACCACACAGAACAGACACTGGAGACAGAGTAGCGACGCCAAGACTCCAGTGTAGCCTAA
^ —►Tx11/6
CC CCTG AC CCTG ACCCTG ACCCTG ACCCTG ACCCTG ACCCTG ACCCTG ACCCTG ACCCTG ACCCTG AC
CCTG A CCC TG A CCC TG A CCC TAAA CCC TAAC CCTG AC CCTA ACC CTAA CCC TAAC CCTC TG AAA G TG G
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XpYp
l 10 20 30 40 50 60 70
DG6G6G
DGSGSGGGGGTTTTT-T
DGGGGGGGGGTTTTTGTGGGGGGGG
d g g g g g g g g g t ttt tg tg g g g g g g g g g
DGGGGGGGGGTTTTTGTGGGGGGGGGGG
DGGGGGGGGGTTTTTGTGGGGGGGGGGGT
d g g g g g g t g g ttt ttg t g g g g g g g g g g g tg ...
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGT
DGGGGGGTGGTTTTTGTGGGGGGGGGGGTGTT
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTT
DGGGGGGTGGTTTTTGTGGGGGGGGGGGTGTTTTTTGT
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGT
D GGGGGGT GGT T T T T GT GGGGGGGGGGGT GT T T T T TGT
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGT
D GGGGGGGGGT T T T T G T GGGGGGGGGGGT G T T T T T T G T T
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T G)
DGGSGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTT
dq g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t g t t g t t g
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T G T T G T 
D GGGGGGGGGT T T T TG T GGGGGGGGGGGT G T T T T T T GT T GT T GT T 
D GG GGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T G T T G T T 
D GGGGGGGGGT T T T T G T GGGGGGGGGGGT GT T T T T TGT TGT TGT T T T 
DGGGGGGGGGT T T T TGTGGGGGGGGGGGTGT T T T T TGT TGT TGT T T T 
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTTTT... . 
D(|S^GGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTTTT|
D GGGGGGGGGT T TT TGTGGGGGGGGGGGTGT T TT T TGT TGT TGTT TT T TB T T
d g g g g g g g g g t t t t tGt g g g g g g g g g g g t g t t t t t t g t t g t t g t t t t t t b t t
d g g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t g t t g t t g t t t t t tBt t t
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T G T T G T T T T T T B T T T 
D GGGGGGGGGT T T T TGTGGGGGGGGGGGT GT T T T T TGT T GT TGT T T T T T B T T T T T 
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T T G T T G T T T T T T B T T T T T T 
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTTTTBTTTTgT 
D GGGGGGGGG T T T T T G T GGGGGGGGGGG T G T T T T T T G T IpG T T 6  T T T T KX-B T T T T T T
d g g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t g t t g t t g t t t t t t b t t t t t t
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTTTTTTT--------------BTTTTTT....
d g g g g g g g g g t t t t t g t g g g g g g g g g g t t Gt t t t t t g t t g t t g t t t t t t b t t t t t t t
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTTTTfTTTTTTTTTTTTT
d g g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t6 t t g t t g t t t t t t | t t t t t t t t t t t t | t t | t t t t
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTT— ^TTAALWETKTVKKD^YJJYW
d g g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t b t t b t t g t t t t t t b t t t t t t t t t t t t t t t t t t t t t
DGGGGGGGGGTTTTTGTGGGGGGGGGGGTGTTTTTTGTTGTTGTTTTTTBTTTTTTTTTTTTjS1]
d g g g g g g g g g t t t t t g t g g g g g g g g g g g t g t t t t t t Gt t g t t g t t t t t t b t t t t t t t t t t t t § t t J t t ^
DGGGGGGGGGTTTTTGTGGGGGG&AAAj|SSTT©i§E®TTTTT§TTSTTTTTfiT...
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Figure 4.A-3. T e lo m e re  v a ria n t re p e a t (T V R ) s truc tu re  d e rived  fro m  te lo m e re s  o f X p Y p  
and 1 7 p  in H E K 2 9 3  an d  M R C 5  E 6 E 7  cells . T h e  ke y  co nsis ts  o f le tte r used  to d e n o te  
th e  d iffe ren t re p e a ts  typ es, th e  g a p s  (-) w e re  in tro du ced  to im p ro ve  th e  a lig n m e n t and  
thus re p re s e n t pu tative  e x p a n s io n s  an d  co n trac tio n s  in re p e a ts  b locks. T h e  du p lica tion  
is sh o w n  by arro w s.
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